"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Humana Fourth Quarter 2020 Earnings Call. [Operator Instructions] With that, I would now like to hand the conference over to Amy Smith, Vice President of Investor Relations. Thank you,",45,"Ladies and gentlemen, thank you for standing by, and welcome to the Humana Fourth Quarter 2020 Earnings Call. [Operator Instructions] 
With that, I would now like to hand the conference over to Amy Smith, Vice President of Investor Relations. Thank you, and please go ahead."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Chief Financial Officer, will discuss our fourth quarter 2020 results and our updated financial outlook for 2021. Following these pr",461,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Chief Financial Officer, will discuss our fourth quarter 2020 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Our Chief Legal Officer, Joe Ventura, will also be joining Bruce and Brian for the Q&A session. We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. Additionally, we have posted supporting materials to our Investor Relations page for reference during Brian's prepared remarks. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. 
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission our fourth quarter 2020 earnings press release as they relate to forward-looking statements. And to note, in particular, that these forward-looking statements could be impacted by risks related to the spread of and response to the COVID-19 pandemic, including the potential impacts to us of: One, actions taken by federal, state and local governments to mitigate the spread as COVID-19 and in turn, relax those restrictions; two, actions taken by us to expand benefits for our members and provide relief for the health care provider community in connection with COVID-19; three, disruptions in our ability to operate our business effectively; and four, negative pressure in economic employment and financial markets, among others, all of which creates additional uncertainties and risks for our business. Our forward-looking statements should therefore be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results. 
Today's press release, our historical financial news releases and our filings with the SEC are also available on our Investor Relations site. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Finally, any references to earnings per share, or EPS, made during this conference call refer to diluted earnings per common share. 
With that, I'll turn the call over to Bruce Broussard."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Thank you, Amy, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $18.75 for 2020, consistent with our commentary throughout the year as expected, reflecting a loss in the fourth quarter, largely driven by o",1595,"Thank you, Amy, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $18.75 for 2020, consistent with our commentary throughout the year as expected, reflecting a loss in the fourth quarter, largely driven by our investments in programs to support members, patients employers, providers and the communities we serve. Our fourth quarter results were impacted by the continued waiver of Medicare Advantage cost-sharing, including for primary care and COVID-19 treatment, delivery of meals, mask and prevented tests to our members, in-home assessments investments and programs to assist underserved communities and efforts to ease the financial burden for our provider partners. For the full year, these initiatives, among others, exceeded $2 billion. Defined by the worldwide pandemic, 2020 was an unprecedented and challenging year. I'm proud of the resilience and response of our associates, putting our members, patients and providers holistic health at the forefront, while continuing to advance our strategy. Despite the pandemic, Humana continued to accelerate on all fronts in 2020, including our short-term operating and financial performance, our ability to drive and invest in our long-term strategic objectives and in our customer-centric efforts. The strength of our underlying core business is compelling. In our Healthcare Services business, we delivered double-digit percentage growth and adjusted EBITDA year-over-year in 2020 with our pharmacy, provider and home business all performing well. In our Pharmacy business, we processed 478 million scripts and drove mail order penetration of over 37% in MAPD. Today, our Pharmacy business has organically grown to the fourth largest pharmacy benefit manager, or PBM. In our Provider business, we ended the year with 156 wholly owned primary care centers after opening 15 new centers in 2020, including expanding to Louisiana and Nevada. In addition, our Conviva primary care clinics delivered significant clinical and financial improvement as the turnaround in the business continued, including a 5% reduction in admissions per 1,000. In the Home, we've made important investments in our strategy to offer primary care and post-acute services in the home through minority investments in Heel, a pioneer of in-home primary care and dispatch health, a provider of emergent in-home medical care. In addition, Kindred at Home successfully managed the transition to the new CMS payment model, while also implementing a new operating system in 2020, setting it up to drive further operating model advancement in 2021. 
We demonstrated an over 50,000 home episodes integrated new proactive clinical models within the Nurse's workflow significantly reduces downstream emergency room visits and hospital admissions. The success of these clinical test and learns provides the confidence, scaling these programs will provide meaningful quality and cost improvements in 2021 and beyond. We also delivered strong fundamental results in our core insurance business while investing for the long term. We remain very focused on the consumer experience broadly across all platforms and are proud to have driven an overall 670 basis point increase in our Net Promoter Score, or NPS, in 2020, with a meaningfully higher increase in our NPS for our commercial group business. We also announced that 92% of our MA members are in plans rated 4 star or higher, leading the public traded MA companies. We ended the year with approximately 4.6 million total Medicare Advantage members, reflecting year-over-year growth of 11%, fueling consolidated revenue growth of 19% in 2020. The positive momentum continued in 2021 Medicare Advantage Annual Election Period, or AEP. For the full year, we are expecting individual MA growth of approximately 425,000 to 475,000 members or 11% to 12%. Importantly, as in prior years, our robust growth is balanced across multiple MA plan types as a result of the strength of our clinical programs, provider partnerships and distribution channels as well as our broad offerings that allow for deeper personalization to meet the member's needs. In the AEP, we led the industry in each of HMO, special needs plans, or D-SNP and MA-only membership growth and continue to grow our LPPO membership. We also launched Author by Humana in South Carolina in January, managing 5 Medicare Advantage plans with approximately 13,500 members. Author is designed to meet the emerging expectations of digital savvy seniors aging into Medicare, leveraging health coaches, digital and artificial intelligence, to create a simplify and integrated experience for consumers. We plan to scale Author by delegating more MA lives overtime and look forward to sharing our learnings. 
We continue to focus on how we can expand our presence with underserved populations, an effort to drive improved clinical outcomes and reduce health disparities. In Medicare Advantage, we experienced industry-leading growth in D-SNPs in 2020, increasing D-SNP's membership approximately 41% year-over-year. We expect another year of robust D-SNP membership growth in 2021. Our Medicaid strategy is predicated on the core strengths of our Medicare chassis, including our clinical programs, provider relationships, focus on value-based care and commitment to investments in the communities we serve. We are able to offer state individualized approach to care that considers the physical and mental well-being of beneficiaries as well as the critical social determinants that impact the population. We began serving Medicare members in Kentucky in 2020 and recently announced our entry into the South Carolina Medicaid program as well as the acquisition of Eye Care in Wisconsin. We firmly believe organic growth is the most efficient use of capital for our shareholders and remain committed to further organic Medicaid growth supplemented by smaller tuck-in acquisitions. We have a long history of success growing our Medicare Advantage and pharmacy businesses organically, and in just the last week, we were awarded the Managed Medicare Contract in Oklahoma, a state that previously did not offer Managed Medicaid. I would like to thank the Medicaid team for their tireless efforts and congratulate them on these key wins. 
As I reflect on what we've learned from the pandemic, I am energized by the way the collective health care system responded to the crisis and how actions taken to combat pandemic strengthened and accelerated critical tenets of the system. As an industry, in partnership with policymakers, we took deliberate and sustain actions to remove financial barriers and enhance access to care in response to the pandemic, easing some of the burden on our nation's most vulnerable population at a time when they need it most. Supported by CMS, health plans and providers proactively address social determinants of health that were exacerbated by the pandemic and quickly pivoted to the telephonic and in-home care, advancing in a matter of months what may have taken years absent the pandemic. Our combined actions underscore the strength of the Medicare Advantage program as an enduring public-private partnership that puts seniors and their holistic health at the forefront. Humana's pandemic response continues to evolve, and we are actively engaged with the Biden administration, including HHS and CMS as well as state and local governments regarding our role in the vaccination process as both a primary care provider and as a health plan, representing a significant portion of the nation's most vulnerable population. As such, our role is multifaceted, and we stand ready to assist further as the nationwide distribution progresses to later phases and more and more individuals become eligible for the vaccine. Driven by our strong care coordination capabilities, our role includes identification of eligible members utilizing our analytics, vaccination education and concierge services, second dose reminders and ensuring we follow-up on any complications. We are also engaged in industry-wide efforts to conduct vaccine surveillance, identify regions where vaccinations are lagging and intervene to help our members access vaccine. By collaborating with other health insurances, we can align regionally communication efforts to educate and engage members and reduce disparities in vaccine use across the U.S.  Equity and health care is an area that we are particularly focused on, recognizing that we must play a critical role, working closely with our industry and governmental partners to address the imbalance that exists today. Data shows that Medicare Advantage is continuing to grow as the preferred option for those who are low income and for racial and ethnic minorities. Of the nearly 26 million Advantage -- Medicare Advantage members, there is a growing diversity and enrollment with more than 28% of the beneficiaries being racial and ethnic minor orders as compared to 21% at traditional Medicare. This day demonstrates that as we think about disparities in health care for underserved populations, Medicare Advantage plans are uniquely positioned to address the needs of these members. Humana is committed to leverage our business platforms to support local communities and their efforts to lower social and health disparities. This includes enhancing access to care by continuing to expand and build primary care centers in underserved markets, offering supplemental benefits, including over-the-counter medication coverage, transportation, dental and vision as well as taking the leadership role in enhancing innovative solutions aimed at addressing social determinants for both Medicare and Medicaid. In addition, we recently named Dr. Land Aloha to the newly created position of Senior Vice President and Chief Equity Officer effective in April of this year. Dr. Aloha will set direction and establish strategy to promote health equity across all Humana lines of business, including our care delivery assets while working collaboratively with the broader health care community to advance health equity so health care can work better for everyone, regardless of background, age or economic status. 
In closing, we remain committed to public-private partnerships that are solution orient and drive results that will meaningfully benefit the health care system in the coming years. With that, I'll turn the call over to Brian."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Thanks, Bruce, and good morning, everyone. Today, we reported full year 2020 adjusted earnings per share of $18.75, consistent with our guidance commentary throughout the year. As Bruce described in detail, despite the unique challenges we faced in 2020 d",3019,"Thanks, Bruce, and good morning, everyone. Today, we reported full year 2020 adjusted earnings per share of $18.75, consistent with our guidance commentary throughout the year. As Bruce described in detail, despite the unique challenges we faced in 2020 due to the pandemic, our fundamentals remain very strong. With the underlying core business delivering compelling results for the full year, including a 19% increase in consolidated revenue and an 11% increase in our total Medicare Advantage membership. We were also pleased to be able to maintain stable benefits and premiums for our members, despite the return of the $1.2 billion health insurance fee, or HIF, which was not deductible for tax purposes and disproportionately impacted our business relative to the competition. In addition, I would like to echo Bruce's congratulations to our Medicaid team for our recent contract awards in Oklahoma and our announced expansion in South Carolina. These awards further demonstrate our ability to drive organic Medicaid growth, and together with our Eye Care acquisition in Wisconsin, expand our Medicaid presence from 3 states to 6. 
I will turn now to our fourth quarter results and underlying trends, which provide important context for our initial 2021 guide. As expected, we reported an adjusted loss per share of $2.30 for the first -- for the fourth quarter of 2020 on account of the significant investments made in all of our constituents because of the pandemic. Further, as disclosed in our 8-K, filed January 8, we experienced a significant increase in COVID treatment and testing costs across the nation in November and December. For full year 2020, we incurred $1.5 billion in gross COVID treatment costs, $1.3 billion of which were related to Medicare or $825 million net of capitation to providers in risk arrangements. As a result of the dramatic increase in COVID during these months, we also experienced a decline in non-COVID utilization in the fourth quarter, particularly for Medicare, as fewer people sought nonemergent care. As a result, non-COVID Medicare utilization was approximately 15% below baseline in November and December after having yearly returned to baseline levels in October. Overall utilization in the quarter, including COVID costs, was a bit below baseline for Medicare and above for commercial. While the magnitude of these changes was unexpected, the decline in non-COVID utilization in the quarter relative to our prior expectations more than offset the increase in COVID treatment and testing costs. We were, therefore, able to increase our spending for ongoing pandemic relief efforts and investments to advance the company's strategy. It is important to note that investments in the group and specialty segment in the quarter, particularly those intended to ease financial stress for providers while positioning the business for long-term success, were disproportionate relative to the reduction in non-COVID utilization levels for the company's commercial group medical and specialty members, significantly increasing the segment's benefit ratio. In addition, as it's customary, marketing costs associated with the Medicare Advantage Annual Election Period, along with COVID-related investments, were heavily weighted to the fourth quarter in our retail segment as reflected in our operating cost ratio. 
I will now speak to our expectations and related assumptions for 2021. Today, we are providing adjusted EPS guidance for 2021 of $21.25 to $21.75, reflecting approximately 16% growth off of our $18.50 2020 baseline at the midpoint. While this guidance is consistent with our previous high level 2021 commentary from our third quarter earnings call, the embedded COVID assumptions in today's guidance have changed materially since that time, with largely offsetting headwinds and tailwinds in revenue and benefits expense. This is consistent with our previous commentary that there are natural countervailing forces between trends in COVID treatment costs and trends in non-COVID utilization. Importantly, in an effort to simplify any explanations we are going to provide, we have included a slide on our Investor Relations website, which summarizes the expected full year impact of the various material headwinds and tailwinds to our guidance today, rather than discussing any incremental changes since the third quarter conference call. At the time of that call, we reflected both revenue and expense puts and takes into our high-level commentary about expected 2021 financial performance. Since that time, the magnitude of the COVID-related impacts have increased significantly. Therefore, as I said, we will provide full year estimates, inclusive of where we stood at the time of the third quarter call  so as to provide our investors with a comprehensive assessment of our latest estimates. I would note that this heightened level of transparency, whereby we provide granular assumptions on a number of variables, is necessitated by the unique the unique uncertainties that the pandemic creates for our 2021 financial outlook. I would also note that the numbers we are providing today are for individual and group Medicare Advantage only as the net impact of a pandemic on our other lines of business is currently expected to be relatively immaterial. Additionally, it is important to note that we are providing reasonably wide ranges, given the inherent uncertainty of our estimates for each line item. And finally, so as to make it easier for investors to understand the full financial picture, all the COVID-related figures we are discussing today are net numbers. After taking into account, our capitation agreements in which provider groups take risk in whole or in part on the member. 
With that context, I will now discuss the material COVID-related headwinds and tailwinds and facing our Medicare business in 2021. I will begin with Medicare Risk Adjustment, or MRA. We now expect an MRA revenue headwind of approximately $700 million to $1 billion, representing 1% to 1.5% of Medicare premium for the full year. As a reminder, Humana's 2021 Medicare Advantage revenue is primarily driven by the risk assumed care for our membership, established through conditions documented by providers within the 2020 calendar year. While we know the 2021 prospective payment amounts from CMS based on diagnosis codes incurred through June of 2020 and submitted by the first Friday in September, over the coming months, these payments will be adjusted to reflect additional conditions documented for claims incurred within the 2020 calendar year. While we estimate and accrue for the incremental revenue from anticipated submissions as the year progresses, there is a higher degree of uncertainty in our revenue projections compared to a normal year. 
Let me spend a few minutes addressing the drivers of this increased uncertainty. First, while we worked tirelessly throughout 2020 to ensure members had access to and we're receiving the appropriate level of care, including by significantly increasing outreach and availability of in-home care and providing access to video telehealth clinician visits, the meaningful drop in non-COVID medical utilization in November and December was not expected. Those are important months as they round out our ability to drive meaningful clinical interactions with our members, and therefore, the unexpected decline in utilization affected our ability to appropriately document their conditions. Second, the mix of utilization was very different in 2020 relative to prior years. For example, the dramatic increase in the number of telehealth visits from 2019 to 2020, although critical in allowing our members to access care, while affording us the opportunity to document their conditions, nonetheless, creates greater uncertainty around the type and volume of diagnoses codes collected. Separately, utilization for in-patient and non-in-patient continued to increase for COVID diagnosis throughout the year. Accordingly, within the mix of submissions from 2020 that drive our 2021 revenue, we also expect organic diagnosis code submissions tied to COVID claims for which we have limited visibility at this time. These are just 2 examples of how emerging experience in 2020 creates more uncertainty in our MRA revenue projections for 2021 because we are not able to place the same level of reliance on historical trends as compared to a normal year. 
I will now discuss COVID-related utilization. As a general rule, we have seen an inverse relationship between COVID treatment costs and levels of non-COVID utilization as surges in the pandemic led to less nonessential care being sought by our members. While the ratio of COVID treatment to non-COVID depressed utilization has varied, to date, we have seen in our Medicare book that the level of depressed utilization has more than offset the treatment cost. The shape of the COVID case curve is one of the largest drivers of these 2 related factors, and as such, they remain the 2 largest sources of uncertainty for 2021, given the unprecedented nature of the pandemic. To set a bit more context around what we are seeing currently, the COVID and non-COVID utilization trends we saw in the fourth quarter persisted throughout January. Medicare in-patient non-COVID utilization is running approximately 20% below baseline. With non -- in-patient reduction percentages in the low teens, with a significant caveat that we have a much better view of inpatient emissions for which we receive weekly authorization data than we do for non in-patient utilization. Importantly, the increased COVID treatment costs incurred in November and December 2020 ramped up quickly with the reduction in non-COVID utilization initially lagging that ramp as would be expected. We expect the inverse to occur in 2021, such that when COVID treatment costs begin to decline, the rate of decline will likely be steeper than the bounce back in non-COVID utilization, potentially creating a favorable impact for a more prolonged period of time. This is consistent with what we saw throughout 2020 as COVID cases ramped up and then declined in various markets. As a result, we now expect Medicare COVID treatment and testing costs of $525 million to $925 million, which when combined with the Medicare physician fee schedule increase that I will discuss in a minute, represents approximately 1.9% to 3.1% of normalized Medicare claim costs. This is similar to what we experienced in 2020 and is consistent with the expectation that the pandemic will begin to subside as more people get vaccinated through the first and second quarters. 
In addition, subsequent to the third quarter call, a net claims headwind of $175 million to $200 million resulted from the increase to the physician fee schedule rates for 2021 as part of the December stimulus bill, partially offset by a net $80 million to $90 million impact from the Medicare sequester relief extension through March 31. Our guidance to date does not assume that the sequester relief will be extended for the rest of the year. Finally, for full year 2021, we currently expect a reduction of $1.3 billion to $2 billion in Medicare non-COVID utilization off a normalized claims pattern, including lower flu costs, which are significantly reduced compared to normal seasonal patterns. This reflects overall non-COVID annual reductions of approximately 3.6% to 5.5% of a normalized claim pattern, and inclusive of COVID treatment costs, a reduction of approximately 1.7% to 2.4%. For full year 2020, the all-in reduction with and without COVID was approximately 5.9% and 8.6%, respectively. We, of course, acknowledge that the ranges we are providing are wide and are a consequence of the continued heightened uncertainty surrounding the ongoing pandemic. We recognize that it will take at least several months to both ascertain from CMS, the negative impact to our 2021 revenue growth expectations, resulting from decreased utilization experience in 2020, including, in particular, the unanticipated depression in non-COVID utilization in the final 2 months of 2020 and to the extent to which this reduction in utilization and associated medical cost impact net of COVID-related expenses persists into 2021. With respect to quarterly utilization patterns, our guidance ranges assume that we will experience non-COVID utilization levels that reflect double-digit percentage reductions to baseline levels throughout the first few months of 2021, before ramping back up and running slightly above baseline levels towards the end of the year. Similarly, we assume COVID testing and treatment costs will continue to run at the higher levels experienced in November and December in the first quarter of 2021 and trend down as the vaccine becomes more widely available in the second quarter. 
With that said, there are a range of potential scenarios, and we would expect any variance in our assumptions around COVID treatment costs to be more than offset by a change in non-COVID utilization. As I said before, we expect that COVID and non-COVID utilization are driven by naturally countervailing forces. Also as a reminder, we believe capacity constraints in the health care system will prevent non-COVID utilization from running materially above baseline and also limit the amount of time a modest increase above a normal baseline could continue. Therefore, given the deviation from historical patterns we will experience in 2021, forecasting quarterly EPS split is much more difficult than usual, but we do expect a meaningfully higher portion of our earnings coming in the first quarter that we typically see. As such, we expect the first quarter to contribute just below 1/3 of the annual total versus a more typical first quarter, which will contribute 800 to 1,000 basis points less. As an important aside, while utilization patterns will be most significantly affected in the first quarter of the year, we expect the negative impact on revenue to be more equally split throughout the year. 
Now that I've walked you through the material Medicare headwinds and tailwinds, I'm going to turn to our expected operating performance by segment. I encourage you to reference the waterfall slide provided on our Investor Relations website with the webcast materials. As outlined in the waterfall, given the pandemic, we must first reset the baseline off of which to grow 2021 adjusted EPS. As discussed previously, our starting point is $18.50, which represents the midpoint of our initial adjusted EPS guide for 2020 and effectively neutralizes for any COVID impacts throughout 2020. Importantly, we believe we struck the appropriate balance in our pricing between top and bottom line growth while investing for long-term sustainability, contemplating both the permanent repeal of the health insurance industry fee and the significant impact of the pandemic, which creates more uncertainty than we would experience in a typical year. Our 2021 consolidated revenue guidance of $80.3 billion to $81.9 billion at the book midpoint reflects year-over-year growth of approximately 8% from adjusted 2020 consolidated revenue. This growth is primarily driven by our expected 11% to 12% individual MA membership growth, partially offset by anticipated declines in group MA and standalone PDP membership. The revenue is also adversely impacted by the MRA headwind previously discussed as well as fewer months of sequester relief in 2021 versus 2020. Additionally, and as previously discussed, the after-tax benefit of the hit was worth approximately $2 in EPS, and we took a balanced approach in increasing our benefits to our members while providing enhanced earnings to our shareholders. We have incorporated the hints impact in the segment waterfall bars. 
In our Retail segment, we are excited about the balanced Medicare growth we have seen, in particularly our industry-leading D-SNP growth. Our Medicaid business also continues to perform very well, and we are excited about the opportunities ahead for this growing business. Taken together, the Retail segment is expected to show strong operating improvement as demonstrated in the waterfall, contributing an incremental $1.21 to adjusted EPS. With respect to our Group and Specialty segment, while we are facing some pressures on account of the pandemic, specifically as it relates to actions by our competitors to retain membership, the business continues to execute on its growth strategy, and we are excited about the prospects for our major medical, specialty and military businesses. We expect the segment to contribute approximately $0.05 of incremental adjusted EPS to the enterprise for 2021. For Healthcare Services, we experienced double-digit adjusted EBITDA percentage growth from 2019 to 2020 and expect high-teens growth year-over-year in 2021. Accordingly, we expect the increase in Healthcare Services adjusted EBITDA to contribute an incremental $1.72 to adjusted EPS. In our Pharmacy business, we anticipate continued momentum, primarily driven by our strong Medicare Advantage membership growth and continued increased mail order penetration. Likewise, our Home business is anticipated to perform well, led by Kindred at Home, and our wholly owned provider businesses continue to improve core operating performance while meaningfully expanding our primary care center footprint, as Bruce described. In summary, our 2021 adjusted EPS guidance of $21.25 to $21.75 reflects growth of 16% from the 18.50 baseline at the midpoint, modestly above our long-term target of 11% to 15%. Since 2017, following the termination of the Aetna merger, the company has achieved an adjusted EPS compounded annual growth rate of 16.4%, which is above the top end of our 11% to 15% long-term growth commitment we have made to our investors. 
While it's very early, I want to close with some preliminary thoughts on our current view of 2022. Our expectation is that 2022 will be a more normal year, and as we get into the spring and summer, we expect the vaccine to take hold and COVID utilization to decline, allowing non-COVID utilization to trend back to more normal levels, enabling providers to see our members in the ordinary course and appropriately document their clinical conditions, resulting in more normalized medical costs and revenue expectations for 2022. Therefore, barring any major unforeseen circumstances or significant changes in the course of the pandemic, the midpoint of the 2021 adjusted EPS guidance that we provided today were 21.50 is the baseline off of which investors should think about growing earnings for 2022. As we do every year, we will consider a variety of factors as we approach our bids in the spring, including any lingering impacts of a pandemic either on revenue or utilization relative to baseline as well as other external dynamics. 
Before I open up the line for questions, I also wanted to announce that we plan to host an Investor Day on Tuesday, June 15, 2021. Please save the date. With that, we will open the lines up for your questions. In fairness to those waiting in the queue, we ask that you limit yourself to a question. Operator, please introduce the first caller."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","We have our first question from the line of Kevin Fischbeck from Bank of America.",15,"We have our first question from the line of Kevin Fischbeck from Bank of America."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Great. Maybe just following up on that last point about kind of how you guys are viewing this year's guidance as a baseline. I guess when you guys submitted your bids back in June, obviously, there's been some legislative changes, things like that, that h",119,"Great. Maybe just following up on that last point about kind of how you guys are viewing this year's guidance as a baseline. I guess when you guys submitted your bids back in June, obviously, there's been some legislative changes, things like that, that have happened. So basically, what you're saying is that COVID has completely offset all of the kind of external legislative changes and everything else. I just want to make sure that I'm understanding that correctly, and that I guess, everything can be ""repriced"". I guess I'm just struggling a little bit with the $2 HIP, and how to think about that over a multiyear period? It feels like it's a relatively low net addition overtime?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Kevin, let me just try to provide some context on our bids and how we roll forward today. When we approached our bids in the spring and early summer, this past year. We obviously knew we had a significant pandemic that we had to contend with. And we ran a",614,"Kevin, let me just try to provide some context on our bids and how we roll forward today. When we approached our bids in the spring and early summer, this past year. We obviously knew we had a significant pandemic that we had to contend with. And we ran a host of scenarios on the revenue and the cost side to putting the pricing what we felt was an appropriate adjustment, and there were certainly countervailing forces. We anticipated that there could be a revenue headwind. We ran various utilization scenarios to see whether there would be any offsets, and we put our assumption into our pricing. Rolling forward to the third quarter when we gave guidance, obviously, a lot of things by definition changed since pricing and the sort of the high-level guidance we gave at the time reflected our current view of those headwinds and tailwinds that we would face. I would also remind you that as we've said multiple times throughout the year that our operators are spending a significant amount of time working to try to mitigate any of those revenue headwinds by really trying to see our members, which was really important to get into their homes, visit them either in-person or via telehealth, where we would also have the benefit of being able to document their conditions. And so we took a really significant effort, invested a lot of dollars to be able to do that. And so as we approach the third quarter, we understood where we were relative to those expectations and obviously, updated our utilization expectations for 2021. And in that context, we provided 2021 guidance or high level guidance. November, December happened, a lot changed, significant decrease in utilization, which was unexpected as the COVID pandemic really took off and hit levels that really exceeded any expectations, and we're much higher levels that were even hit in the spring and was nationwide. And so that clearly impacted our perspective. And so as we approach the JPMorgan Conference in January, we felt it was important to get out to our investors to provide some high-level commentary on what we are seeing of potential countervailing headwinds and tailwinds.  So we've done that. Here, we provided, obviously, a lot of granular detail on that, but there is a lot of variation in these numbers. I mean, you can see there are wide ranges, and we've deliberately provide those wide ranges. We think what's on this page is obviously reasonable. There is nothing that we're seeing that suggest that these numbers aren't reasonable, but where we fall in these ranges on all these variables matters a lot. And that's something, obviously, that we're going to continue to watch closely, and as appropriate, we would update investors on that. But I would just say, as we said in our remarks that 2021 has heightened uncertainty relative to what we thought coming into the year into your question on the HIF. We actually feel we achieved an appropriate balance between giving dollars back to our members through higher benefits, which we did, and giving higher EPS growth to our shareholders where we're exceeding our typical 11% to 15% growth. And at our midpoint, notwithstanding all the COVID headwinds and tailwinds, we're still able to guide to a midpoint that's above that range. So we think we've achieved the right balance. There is no doubt that 2021 has a heightened level of uncertainty, and we're going to be monitoring it very closely and keep you updated, which is why we've also, I think, anchored investors on 2022 with the hope and expectation that, that will be a much more normal year."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Kevin, just to add a little bit on the HIF side. Our historical practice has been passing the pretax onto that to our members, both the cost and the benefit, as you know, is come and gone during the year. So this past bid season was very consistent with w",115,"Kevin, just to add a little bit on the HIF side. Our historical practice has been passing the pretax onto that to our members, both the cost and the benefit, as you know, is come and gone during the year. So this past bid season was very consistent with what we've done on the pre-tax side. And then the post-tax side, the tax benefit, we've always tried to be fair as to both our members and shareholders. And we typically divided that 50-50, both on the cost side and on the kind of the benefit side there. So I think what we've done this year is pretty consistent from  our historical treatment of the HIF."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Rivka Goldwasser from Morgan Stanley.",13,"Our next question comes from the line of Rivka Goldwasser from Morgan Stanley."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","So just couple of questions of clarification. When we think about your guidance and sort of to balance the cadence between first half and second half, what are the embedded assumptions for return of utilization for the Medicare population versus baseline?",111,"So just couple of questions of clarification. When we think about your guidance and sort of to balance the cadence between first half and second half, what are the embedded assumptions for return of utilization for the Medicare population versus baseline? Or at least what is the range? And then secondly, when we think about 2022, to your point we want to anchor in 2022 of that starting part of [21.50], but when you think about the 2021 COVID-related headwinds, could you maybe help us quantify what is reasonable for us to back out of the 2021 number? Do you think for more normalized 2022? I think truly onetime in nature."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. Yes. Let me start with utilization patterns and then try to address 2022, recognizing we just gave 2021 guidance. So we're not going to provide a lot of details on 2022, obviously. With respect to the utilization patterns, as we mentioned in our rema",251,"Yes. Yes. Let me start with utilization patterns and then try to address 2022, recognizing we just gave 2021 guidance. So we're not going to provide a lot of details on 2022, obviously. With respect to the utilization patterns, as we mentioned in our remarks, we expect the first quarter to see the most depressed utilization and certainly, the highest COVID treatment cost. And so those, as I mentioned, offset one another, but again, we expect that most sort of utilization depression will occur in the first quarter. We expect the utilization to remain depressed in the second quarter, although not as much, and then we expect it to ramp up more towards normal than a bit above normal as we approach the back half of the year and the end of the year. So that's how we're broadly thinking about it, which we think is consistent with what we're seeing with the vaccinations and the progress there. As that impacts 2022, it's really hard to give specifics at this point. Again, we'll have to decide when we get to the spring, what's appropriate to reflect in our bids. We'll be very mindful of what we're seeing in terms of headwinds and tailwinds with respect to COVID and revenue and utilization like we were this year. But beyond that, I wouldn't want to comment other than to say, we do think 21.50 is a reasonable baseline off of which to think about 2022 without providing any more specifics beyond that today."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Josh Raskin from Nephron Research.",13,"Our next question comes from the line of Josh Raskin from Nephron Research."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","So I know you guys have spoken in the past about new members in MA coming in at higher MLRs in that first year. Could you just give us a sense as to what the typical first year MLR looks like for an MA member? And then this inability to risk code, is that",149,"So I know you guys have spoken in the past about new members in MA coming in at higher MLRs in that first year. Could you just give us a sense as to what the typical first year MLR looks like for an MA member? And then this inability to risk code, is that affecting new lives at all? Or is that really just an existing book that typically sees the revenue improvement? And then apologies, but I just clearing, I know 2022 isn't -- we're not looking for guidance here, but is it correct to think that there'll be kind of a bolus of premium benefit? You'll have all of the older members that have been with you for a couple of years that get coded correctly as well as the new cohort in 2021. Is that a fair way to think about the MRA benefit in 2022?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. So the way I would think about it, rather than focusing on MRs, I would rather just focus on pretaxes, what we've discussed in the past. I think it's fair to say that new members tend to be breakeven. If these steps may run a little bit better out of",306,"Yes. So the way I would think about it, rather than focusing on MRs, I would rather just focus on pretaxes, what we've discussed in the past. I think it's fair to say that new members tend to be breakeven. If these steps may run a little bit better out of the gate, but not a lot of profitability in the first year. Certainly, as we get to the second and third year, we start getting to more of our normalized margins as we're able to document our members' conditions and also get them in our clinical programs and that really hasn't changed. I think that's consistent with what we've seen, and certainly, that's what we typically plan for in our bids. We think without providing too much detail on 2022, I think it's fair to say that you might see effectively a catch-up in 2022. So any MRA revenue headwind we've seen in 2022, which is a function of sort of our existing membership base. And remember, it's not just the members that we have, but it's also the new members that we got, particularly if they were in other Medicare plans. So if they're a switcher, they would also have sort of -- we'd have less of their documentation than normal for the same reasons because our competitors weren't able to get those conditions documented either. And so you will see sort of the -- for us, the 2021 cohort as well as, frankly, some of our other cohorts where we weren't able to redocument their conditions, you will see more of a sort of an increase in 2022. And that will be something that we planned for in our bids as we figure out what percent of normal do we expect to be for 2022 based on 2021 utilization. Hopefully, that was clear."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Ralph Giacobbe from Citi.",14,"We have our next question comes from the line of Ralph Giacobbe from Citi."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I just wanted to go back and understand the assumptions on the core again or the non-COVID utilization. I think, on the slide, it said minus 3.6% to minus 5.5%. It sounded like that was off of a 2021 normalized baseline. I just want to make sure that's ri",96,"I just wanted to go back and understand the assumptions on the core again or the non-COVID utilization. I think, on the slide, it said minus 3.6% to minus 5.5%. It sounded like that was off of a 2021 normalized baseline. I just want to make sure that's right. And I guess it'd be helpful to understand what you normally assume for utilization increases? Or maybe even just how it compares to kind of 2019? And then it sounds like the first quarter is running down 20% on the non-COVID. Did I hear that right?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Sure. Yes. So Ralph, so we don't -- we're not going to give you specific sort of utilization assumptions that we're very transparent, but we can't be that transparent on some of our core stuff on that regard. But I would just say, as it relates to utiliza",338,"Sure. Yes. So Ralph, so we don't -- we're not going to give you specific sort of utilization assumptions that we're very transparent, but we can't be that transparent on some of our core stuff on that regard. But I would just say, as it relates to utilization, we've been thoughtful about sort of normalized trends and then think about what the impact might be when we did our pricing for 2021 and all these various variables that we've talked about. Really, what we mean by normalized baseline is actually, really straightforward, which is to say if you were -- if you just stripped out COVID entirely, what would the claims assumption be, based on sort of the normal inflators we would use from 2021 over 2020. And so whatever sort of secular trends and other things that we build in, trend vendors and other things, we get to sort of a net trend ex-COVID and that's really the baseline. Just to give you a -- make it easier for you to compare relative to, say, on 2020 ex-COVID and what the baseline reduction is. And that's why I tried to say sort of ex-COVID for Medicare, it was, call it, 8.5%, 8.6% down for 2020 relative to the 3.6% to 5.5% that we guided today. So again, we think that number is reasonable. Again, we could be wrong. That's -- there's just a wide range here. And I guess, I just emphasize that there is more uncertainty around this 2021 number than we would typically have because when we formulate those trend assumptions that you were asking about, we have a lot of historical experience. We have hundreds of actuaries, very smart people working on our trend assumptions. It's something that we think we're very good at and ensuring we baked in the appropriate levels of potential tread variances. We're dealing here in a whole new world with a pandemic where we have no historical experience. And so that creates some of the challenges in our forecasting."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of A.J. Rice from Crdit Suisse.",14,"Our next question comes from the line of A.J. Rice from Crdit Suisse."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Just to drill down a little bit on the '21 outlook. So you've got the COVID testing and treatment headwind is substantially less than the tailwind for depressed COVID utilization, but you're talking about the interplay there. And I think, in the prepared",183,"Just to drill down a little bit on the '21 outlook. So you've got the COVID testing and treatment headwind is substantially less than the tailwind for depressed COVID utilization, but you're talking about the interplay there. And I think, in the prepared remarks, you said as a vaccine gets widely disseminated, you'd expect the COVID testing and treatment to come off quicker than the utilization of non-COVID or come back. So long-winded setting the stage for the question. So if you -- if the vaccine gets widely distributed quicker than you think or later than you think, does that move the assumptions around within the range? Or could that throw you outside the range? And I guess, I'd also ask, you've talked a lot about the investments that you made this year. I know a lot of that investment was just giving help to your constituents, but does that give you any flexibility within this guidance range because you pull forward investments in 2020 that would have otherwise can happened in '21. How much flexibility does that give you in your range?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","A.J., I would say on the first question, there's a lag really because as people are not so seeing their doctor and going to the hospital. They're not able to schedule the surgeries, for example, it just takes time for the system to ramp back up. So there",331,"A.J., I would say on the first question, there's a lag really because as people are not so seeing their doctor and going to the hospital. They're not able to schedule the surgeries, for example, it just takes time for the system to ramp back up. So there is just sort of a natural trail off that -- just given the volumes we're talking about, they're not insignificant. And it's one of the reasons why we had the tailwinds we had in 2020 was that delay. It just takes time to get the gears cranking again, and they will crank again. And we certainly forecast that, but there is that delay. To the extent the vaccine rolls out more slowly or there is a variance in the virus that we've heard and that they're not as effective. That, for sure, can affect our ranges here. We try to capture what we think are reasonable ranges based on today's sets of facts and circumstances. To the extent those facts and circumstances change, it's conceivable that some of these sort of COVID treatment versus non-COVID cost, that could be impacted. Again, it's likely that because there is a -- there is that inverse correlation. They will offset one another. Though in the Medicare business, it tends to lead to a tailwind, as we mentioned. The commercial business is not as clear. As you mentioned, in the fourth quarter, we are running a little bit above par all-in, but for the Medicare business, we were below. 
The investments, to your question there, we really, I would say, pull all those out for 2021. So there is really not any additional flexibility there. We were very clear to confine those investments in 2020, and as we've described, we benefit all of our constituents and really gave back a lot of those dollars, which is important to do, but that was not baked in in any way into our 2021 pricing or to our guide."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Robert Jones from Goldman Sachs.",15,"We have our next question comes from the line of Robert Jones from Goldman Sachs."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Great. I mean, maybe just to go back to the MRA headwind. I know it's a tricky thing to get your arms around, but maybe just more of a tactical question. If you are, in fact, expecting non-COVID utilization to be down again because of -- obviously, becaus",137,"Great. I mean, maybe just to go back to the MRA headwind. I know it's a tricky thing to get your arms around, but maybe just more of a tactical question. If you are, in fact, expecting non-COVID utilization to be down again because of -- obviously, because of COVID. Obviously, the risk adjustment was an issue coming into this year. I guess, just tactically speaking, what things specifically are you thinking about doing differently in '21 as it relates to getting the appropriate risk coding, given that there's probably going to be a similar dynamic, at least for part of the year that made it a challenge coming into this year? Just curious if there is a different approach, maybe you're taking or more aggressive approach you're taking this year as it relates to risk coding."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes, Brian, I'll take that to give you a little break. Just on the -- we -- in the really the third and fourth quarter, we're fairly aggressive in trying to ensure that our members were utilizing the health system, and in addition that we are being able t",310,"Yes, Brian, I'll take that to give you a little break. Just on the -- we -- in the really the third and fourth quarter, we're fairly aggressive in trying to ensure that our members were utilizing the health system, and in addition that we are being able to provide in-home assessments, and other areas where documentation was appropriate. And I would say we would continue to carry that forward in the first part of this year and continuing throughout the year. Because I would -- we did readdress where we're at and begin to really become aggressive and use all of availability. I do believe the biggest area that we -- our challenge with this is just the normal course of people not using the health care system. We are very active both with our value-based providers and in addition, with our outbound engagement with our members to ensure that they are going to the physician office or utilizing the health care system. We'll continue to do that. We have a team of people that are focused on this every day to try to really help, whether it's lining up transportation to the ability to -- for us to provide telehealth to them, to the ability to have an in-home assessment. And I really would say, we'll just continue to do what we did in the third and fourth quarter. But getting people into the health care system is our biggest both opportunity and challenge. And as a health care system readjust itself to really treating COVID and social isolation becomes more and more of an issue and where the markets are spiking, that really gives us the largest challenge. I think it was just COVID-related and stable in the marketplace, we would be able to navigate through this in a fairly effective fashion of the programs we have."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Justin Lake from Wolfe Research.",13,"Our next question comes from the line of Justin Lake from Wolfe Research."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Just a couple of questions here on numbers. First, you -- can you -- you've given us a lot of detail here. Can you tell us what the total Medicare risk adjustment impact was for 2021 on a gross basis, meaning how big of an impact is it to your yields over",105,"Just a couple of questions here on numbers. First, you -- can you -- you've given us a lot of detail here. Can you tell us what the total Medicare risk adjustment impact was for 2021 on a gross basis, meaning how big of an impact is it to your yields overall? And what do you expect your yields to be for 2021 on a year-over-year basis? And then just on Medicare Advantage margins, it looked like your retail margins are about 3% in the -- within guidance. Can you confirm that's kind of where you expect individual Medicare Advantage margins to be in 2021?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Sure. Justin, so on the MRA side, what we're showing here effectively is the total headwind net of mitigation. And so as Bruce just described, we did a lot to really try to get our members into the health care system and make sure we can see them. And so",643,"Sure. Justin, so on the MRA side, what we're showing here effectively is the total headwind net of mitigation. And so as Bruce just described, we did a lot to really try to get our members into the health care system and make sure we can see them. And so this is the sort of the full headwind that we currently face, and again, we want to be very transparent, but this is net of our mitigation efforts. As it relates to yields, we typically don't, as you know, guide to PMPMs, but just to help you out, I would say, it sort of flat, maybe modestly up is the way I would describe our  individual MA PMPM expectations, and we'll see where that ultimately goes. But there are a lot of things that impact that, Justin, as you know. Obviously, MRA is one of them. The rate notice is another. Sequester is another. Remember, there is fewer months of sequester relief this year. Business mix is a very significant driver because there are pretty disparate rates around the country. So depending on where you grow, that can impact it. So there are a host of things that impact yields, but it's a fair question and understand where you're going. 
Now I would be disappointed if you didn't ask us about the margin question. So I'm glad you took the opportunity, and I know it's a fair question. I think it's important when you look at the overall retail margin is to -- remember that there are multiple businesses inside the Retail segment. First off, the margin has been impacted by the HIF and the fact that it was nondeductible. So there is a lot of geography going on there, and certainly, we thought about after tax. I mean we sort of managed to pretax, but think about the after-tax impact as we thought about our pricing, et cetera. As we just discussed, we balance giving back some of the tax benefit, both to our members in the form of higher benefits as well as to our shareholders. So there is some geography issues that will impact and depress the margin. There are also, as we've discussed on the PDP side, a lot of the margin has come out of that product. And in fact, most of the margin today, if not all, the margin today is in the pharmacy for us. We've talked about how that product has become much more of a commodity product at these levels of premium. It's hard to make money on the insurance side, and so we're doing nicely on the Pharmacy side. And so we want to -- we'll continue to be aggressive in this business. And as Bruce commented in his remarks, our mail order penetration continues to -- we can reach very, very high levels both on the MA side, but also on the PDP side. So -- but again, that's a geography issue. So as you think about individual MA margins, you need to take that into account. Also, just to be transparent here, group MA has seen some margin impacts from some of the larger accounts that have been shifting back and forth between major competitors. When there is margin to those accounts when they get rebid, sometimes takes a few years to recover that margin. And so that's also driving some of the impact there, too. So it is, for sure, in the case that we are below our 4.5% to 5% target. I would say you're reasonably below that target. We are committed to that over the longer term to get back to that 4.5% to 5%, but I would just say there are a lot of things impacting that number, and there is a lot of sort of variables embedded in that retail overall guide that you're looking at."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Lance Wilkes from Bernstein.",12,"Our next question comes from the line of Lance Wilkes from Bernstein."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Can you talk a little bit about the investments in provider assets? In particular, I was interested in, what you're seeing as far as MLR differential and growth rate differential for members and the lines of business that are in value-based care partner o",48,"Can you talk a little bit about the investments in provider assets? In particular, I was interested in, what you're seeing as far as MLR differential and growth rate differential for members and the lines of business that are in value-based care partner or owned primary care assets?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes, I'll take that. We see great results in the primary care clinics, both in the ones we owned and the affiliated ones. We see and we -- we've started a slide for a number of years as physicians continue to evolve deeper value-based relationship model,",300,"Yes, I'll take that. We see great results in the primary care clinics, both in the ones we owned and the affiliated ones. We see and we -- we've started a slide for a number of years as physicians continue to evolve deeper value-based relationship model, we see superior performance and the STAR scores typically greater than 4 to 4.5. We see great MLR significantly below what the average is in the industry, and we also see great Net Promoter Score. All that combined, that's why you see us aggressively pursuing on both our affiliated relationships and in addition, building our primary care clinics to place our members in those clinics. The challenge with the clinic side is just the organic. There is not enough capacity in the marketplace to fill the demand. So you see a lot of start-up clinics -- from a start-up point of view being invested into to build the capacity there, and so for us, for more capacity constraint as opposed to -- for our growth. Our growth traditionally has been at equal to and greater than what you see in the traditional 10% to 12% growth that you've seen over the last few years in these clinics and getting more and more members in those clinics. And I think you'll see that growth accelerate as the capacity becomes more and more available for us. On the value-based provider side of the business, outside of the ones that are clinic oriented, we continue to see really, really great -- good results from that. Those results are a little less than the clinic results. We see good STAR scores. We see 4 and above, and we see good Net Promoter Scores, but it does not compare to the outcomes that we see in the clinic side."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Scott Fidel from Stephens.",12,"Our next question comes from the line of Scott Fidel from Stephens."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I wanted to ask just about maybe an update on how you're thinking about some of the puts and takes with the ESRD coverage expansion that played out in MA. Obviously, that was already one of the big changes for MA in 2021 before COVID kicked in. So just in",120,"I wanted to ask just about maybe an update on how you're thinking about some of the puts and takes with the ESRD coverage expansion that played out in MA. Obviously, that was already one of the big changes for MA in 2021 before COVID kicked in. So just interested, maybe first, if you could -- if you have an estimate of how much your MA membership for ESRD actually changed for 2021? And then as we think about the impacts of the pandemic on that population and then try to overlay that into the rates that you have, how you're thinking about sort of the overall margin profile expectations that you had for that population now versus prepandemic?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","I'll have to start and Bruce can put color on any of the strategic side here. But I would say, just from a share numbers perspective, we got about, call it 10,000 or so, plus or minus, lives from ESRD in the AEP, which puts us to around 29,000, 30,000 mem",190,"I'll have to start and Bruce can put color on any of the strategic side here. But I would say, just from a share numbers perspective, we got about, call it 10,000 or so, plus or minus, lives from ESRD in the AEP, which puts us to around 29,000, 30,000 members, which is really right in line with our expectations. What we expect is, as we've said for a number of quarters here, we think it's going to take several years to get up to the Medicare Advantage penetration. We think that continues to be the case, and so again, I'd say right in line with our expectations. These are not profitable members. I think overtime, as we continue to manage them and work with partners and really try to get them before they get the ESRD and slow their disease progression. We think there is real opportunities to drive profitability, but I would say, we're getting to a point where it's more or less breakeven as opposed to having any meaningful losses on these members. But Bruce, I don't know if you want to add anything on that?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","I would just add, Scott, I know this was an active conversation for us in 2020, and how we were going to deal with it. And I really have to hats off to the team and how they've been able to really develop some deep partnerships with the 2 major dialysis p",223,"I would just add, Scott, I know this was an active conversation for us in 2020, and how we were going to deal with it. And I really have to hats off to the team and how they've been able to really develop some deep partnerships with the 2 major dialysis providers and really be able to evolve the relationships to a value-based payment model that shares the risk. And that has helped us in being able to effectively manage the clinical side -- of the and the cost side, but the clinical side of the ESRD. And then the second thing is we continue to invest in innovative models, both around the the coordination of care and then also where the care is provided in the home. And those 2 strategies really have given us more confidence in the ability to manage these patients. As Brian said, the patients will continue to be costly and continue to be -- to low margin or very, very low margin business for us going forward. So again, I think we're in a great shape from where we were a year ago when we began talking about this, and as Brian also said, is that we do see this will be years in the making to see the penetration to the average penetration of MA overall."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","And Bruce, do you think that the pandemic itself has much impact on this population? I know that some of the providers here have talked -- given some updates recently, just thinking about that population as it relates to pandemic itself?",41,"And Bruce, do you think that the pandemic itself has much impact on this population? I know that some of the providers here have talked -- given some updates recently, just thinking about that population as it relates to pandemic itself?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. Typical to any vulnerable population, whether it's ESRD or other chronic conditions, you do have a higher likelihood of having a more similar cases in those populations. And for us, we are very active in managing the populations that have those vulne",108,"Yes. Typical to any vulnerable population, whether it's ESRD or other chronic conditions, you do have a higher likelihood of having a more similar cases in those populations. And for us, we are very active in managing the populations that have those vulnerable conditions. So I would say, they are different than the average population because of their conditions, but they are not different than our other chronic members, and how we effectively reach out to them and manage them, and they are reflected, obviously, in the results that Brian was talking about in our -- and where we look at COVID being more costly in our forecast."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Matt Borsch from BMO Capital Markets.",14,"Our next question comes from the line of Matt Borsch from BMO Capital Markets."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Maybe I could ask about on Medicaid. What you are assuming or how you're thinking about the Medicaid rate process, given the action states took in the second half of last year? And then maybe also what you're assuming on the resumption of redeterminations",50,"Maybe I could ask about on Medicaid. What you are assuming or how you're thinking about the Medicaid rate process, given the action states took in the second half of last year? And then maybe also what you're assuming on the resumption of redeterminations? If you can just address that."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Sure. I'm happy to take that. So just on the rate side, we're waiting to see in our major states or Kentucky and Florida. I think we expect some rate adjustments, and we're waiting to see, and we certainly bake what our expectations might be into our sort",220,"Sure. I'm happy to take that. So just on the rate side, we're waiting to see in our major states or Kentucky and Florida. I think we expect some rate adjustments, and we're waiting to see, and we certainly bake what our expectations might be into our sort of in our Medicaid budget. And so we're waiting to see the impact there. With respect to redeterminations, you see -- we've got a pretty wide guidance range on Medicaid membership. Effectively, the assumption is the public health emergency ends in April will -- if that happens, then we expect to lose some lives because we saw a nice increase this past year, but as the redeterminations happen, that will cause that membership to decline. And so I would say that's sort of our base case expectation as we think about our overall guidance and revenue, et cetera. To the extent that the public up emergency is extended, the redeterminations don't happen, that will cause the increase in membership to continue, which -- again, I think would be relatively immaterial to the overall enterprise, but would cause us to have a higher membership at the end of the year, and that, of course, excludes anything from South Carolina or Oklahoma, which will kick in later this year, and our guide excludes that."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Stephen Willoughby from Barclays.",12,"Our next question comes from the line of Stephen Willoughby from Barclays."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Maybe just a question for Bruce, just on the COVID cost risk. As we do think about your ability to control the medical cost in '21 versus 2020, specifically for COVID, has there been any evolution on the provider side for '21 where value-based provider go",91,"Maybe just a question for Bruce, just on the COVID cost risk. As we do think about your ability to control the medical cost in '21 versus 2020, specifically for COVID, has there been any evolution on the provider side for '21 where value-based provider go at risk for any sort of episodic bundled payments related to COVID patients? Or is that not really evolved? And if not, are there any other evolving payment arrangements with providers you can talk about, specifically tied to COVID that's different for '21 versus '20?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. Great question. We don't have a bundled type of payment model for COVID. I mean we have many bundles and other conditions and -- but not for COVID. And we haven't seen that really any uptake with physicians on that. Keep in mind a lot of the COVID co",180,"Yes. Great question. We don't have a bundled type of payment model for COVID. I mean we have many bundles and other conditions and -- but not for COVID. And we haven't seen that really any uptake with physicians on that. Keep in mind a lot of the COVID cost is on a DRG basis and incorporated in the DRG side. The testing is something of a lesser magnitude here. So going at risk for that, I think is fairly small and aerial kind of kit. I think to broaden your question a little bit, what we do see is that when we do have value-based relationships and the proactiveness really helping the member in this time is so important for us, especially as you think about downstream cost and other conditions that could occur, if not properly maintained and traded. So to answer your question, we don't see much in COVID bundling the type of payment, but we do see very different proactive care models in our value-based payment relationships in this time, especially with the more vulnerable populations."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of George Hill from Deutsche Bank.",13,"Our next question comes from the line of George Hill from Deutsche Bank."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Bruce, I just wanted to circle back and make sure I heard you right to say that pharmacy mail penetration was 37%. Was that for the quarter or for the year? I assume, it was for the quarter. And I guess, is it your expectation that, that kind of comes dow",86,"Bruce, I just wanted to circle back and make sure I heard you right to say that pharmacy mail penetration was 37%. Was that for the quarter or for the year? I assume, it was for the quarter. And I guess, is it your expectation that, that kind of comes down a bit as things return to normal? And would love to hear you talk a little bit more about the strategies that you guys have used to drive mail penetration to such a high level."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Okay. Great. Yes, that's right. I would -- that is actually for the year. We did see an increase in mail penetration as we looked for the -- in the early part of the COVID pandemic. We saw it in the March and April timeframe as people were really concerne",395,"Okay. Great. Yes, that's right. I would -- that is actually for the year. We did see an increase in mail penetration as we looked for the -- in the early part of the COVID pandemic. We saw it in the March and April timeframe as people were really concerned about the lockdown that was happening, and therefore, we're taking 90-day prescriptions and really utilizing the mail order along with the fact that they couldn't get to the drug stores if they were normal users and became more active users of the mail order. What we have seen is as a result of the convenience of mail order and really, I would say, as a result of our service improvement we've seen, more and more people really converting to mail order as a result of that. And so the pandemic we have seen has helped educate individuals of the benefit of may order and the ability to continue to utilize it on an ongoing basis as opposed to just through the pandemic and some of the shutdown periods. So we look at it first as really an accelerator for us in that. The second thing is that we have a very active investment going in into making it much more consumer friendly on the mail order side, all the way from the digital platforms that are being used to the turnaround time of delivery to be able to ensure that we can meet the the expectations and the changing expectations of customers today on when they expect deliveries to happen. And I would say that our goal is to really grow the penetration of mail order in our existing book of business. 
You asked why sort of high the penetration, I would say it's been a very concentrated effort by our management team and really all the way from our service centers on the insurance side to our providers that we have relationships with to our specialty pharmacy area continuing to remind our members of the benefits of the mail order. And that continued use of throughout the organization of being -- bringing the mail order conversation then at the appropriate period of time has really assisted us being able to increase that rate from a much different rate that is the average in the industry to really a superior rate that you see having."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Dave Windley from Jefferies.",12,"Our next question comes from the line of Dave Windley from Jefferies."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I wanted to ask about telehealth, Bruce. You've mentioned it a couple of times during the call. How is Humana incentivizing telehealth? How are you looking at it as a facilitator to whether it's the primary care effort that you're putting forth, home heal",67,"I wanted to ask about telehealth, Bruce. You've mentioned it a couple of times during the call. How is Humana incentivizing telehealth? How are you looking at it as a facilitator to whether it's the primary care effort that you're putting forth, home health and extension there. I guess, I'm just wondering where are you using it aggressively? And how are you incentivizing and reimbursing its use."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","We're big believers in telehealth for -- all the way from the convenience of the member to really being able to have a channel that is actively engaging with the member at -- especially, the more vulnerable members where transportation is always a limiter",302,"We're big believers in telehealth for -- all the way from the convenience of the member to really being able to have a channel that is actively engaging with the member at -- especially, the more vulnerable members where transportation is always a limiter for them. Answer your question about how do we incentivize them. We're really doing it on 2 slides: First on, we did carry over the Co Pay, the 0 Co Pay this year telehealth and carried that on going forward; and then the second thing that we've also done is, we continue to pay equal to our member -- I mean, our providers visit versus a telehealth visit. And both of those have been, I think, reducing the barriers and really creating, as you said, on incentives to use use telehealth. We really have a few different strategies of using telehealth. I mean one is around really helping our providers if they don't have telehealth and providing them some some technology that would offer them to utilize it. That's in a small need for external providers as they have all sort of become very acquainted with telehealth and being able to use it. Our internal -- our own providers, we offer them a very sophisticated telehealth platform that they can outreach on the telehealth side. And then the third area that we look at is continuing to work with hospital systems, especially in the specialty area, where we can have an outreach where specialists might be in and short supply in certain markets and being able to offer that at a convenience in the local marketplace. So we do see it to help members, I mean health providers, but more importantly, we do see us partnering with especially the hospital systems to offer specialty and remote areas."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Can I clarify real quickly, is that reimbursement at parity, is that in your commercial book as well as Medicare?",20,"Can I clarify real quickly, is that reimbursement at parity, is that in your commercial book as well as Medicare?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","I don't know if what I get for -- Amy, are we giving the different payment by the different divisions.",21,"I don't know if what I get for -- Amy, are we giving the different payment by the different divisions."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","I don't think we're providing that. I would just say, in general, I know, in general, we're providing, but I wouldn't want to get into the specifics.",28,"I don't think we're providing that. I would just say, in general, I know, in general, we're providing, but I wouldn't want to get into the specifics."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","[indiscernible] the distinction it also is -- if it's in the office that we're -- we can follow-up, but to the office, we're doing full reimbursement. If it's not, then it gets more of a reduced rate, but we can get you all the details.",45,"[indiscernible] the distinction it also is -- if it's in the office that we're -- we can follow-up, but to the office, we're doing full reimbursement. If it's not, then it gets more of a reduced rate, but we can get you all the details."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Gary Taylor from JPMorgan.",12,"Our next question comes from the line of Gary Taylor from JPMorgan."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I just want to maybe just go back big picture just for a second. Brian, you had talked about a lot of the MRA, COVID-related headwinds normalizing as you move into in 2022, using the 21.50 a jumping off point. So when we think about '22, given we've got a",87,"I just want to maybe just go back big picture just for a second. Brian, you had talked about a lot of the MRA, COVID-related headwinds normalizing as you move into in 2022, using the 21.50 a jumping off point. So when we think about '22, given we've got a an early and known final rate notice above historic rate increase, is there any reason from this distance that we shouldn't be thinking about the the long-term 11% to 15% growth off of that 21.50 in 2022."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Well, again, I really don't want to be giving guidance on this call for 2022. I would say, at the highest level, certainly, our our goal is to deliver that 11% to 15% growth. And that's a long-term growth rate, and sometimes we're above. There are some ti",84,"Well, again, I really don't want to be giving guidance on this call for 2022. I would say, at the highest level, certainly, our our goal is to deliver that 11% to 15% growth. And that's a long-term growth rate, and sometimes we're above. There are some times from when we've been below. But certainly, our goal is to to hit that 11% to 15%, and we always have to take the facts and circumstances at the time when we price. So hopefully that."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Charles Rhyee from Cowen.",12,"Our next question comes from the line of Charles Rhyee from Cowen."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I just wanted to follow-up about telehealth. I think in the prepared comments, you spoke about how documentation with using telehealth create some uncertainty around coding. I think, later on, Bruce, you talked about #1 issues, trying to get people back i",130,"I just wanted to follow-up about telehealth. I think in the prepared comments, you spoke about how documentation with using telehealth create some uncertainty around coding. I think, later on, Bruce, you talked about #1 issues, trying to get people back into the health care system itself. It sounds like -- is there a disconnect then that when telehealth is used to accurately kind of code people to understand sort of their actual health status? And is that a fundamental problem with the way telehealth is set up today? I know in just the previous question, you talked about how you're trying to incentivize your -- or all providers to use it is this an integration issue? Or is this an issue itself with how telehealth is being deployed?"
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","No, it's really more on the member side, what we find. First, telehealth, if you use audio and video today can support documentation. So that is possible and regulatorily came into place the latter part of last year. So it is a way to be able to bring doc",225,"No, it's really more on the member side, what we find. First, telehealth, if you use audio and video today can support documentation. So that is possible and regulatorily came into place the latter part of last year. So it is a way to be able to bring documentation. The problem is that what we see is, once there is -- when someone uses telehealth, then use it more frequently. And so we see a significant use of telehealth, but the members that are using it are more contained, I should say, are more refined, and it's not across all our membership. So we could see a significant increase in telehealth, but that increase in telehealth will be over a confined membership base as opposed to across our membership base. And that really comes to one of the barriers we're working with in the communities we serve is that not everyone to access either [indiscernible] is comfortable with telehealth as a result of some of the technology limitations there or just needs to be educated more. They might have the technology, but it might not be integrated. And that's where we see a lot of work needs to be had is the ability for telehealth to be used in a more broad membership base as opposed to the narrower membership base that it has today."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","If I could follow-up, does that mean when you guys talked earlier then about going into 2021. Is it that just the usage of telehealth itself. You're uncertain whether the coding that your -- the documentation that you're getting is going to persist at tha",54,"If I could follow-up, does that mean when you guys talked earlier then about going into 2021. Is it that just the usage of telehealth itself. You're uncertain whether the coding that your -- the documentation that you're getting is going to persist at that kind of level? Was that more to a..."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. And Brian can add to this, but the really, the telehealth is -- let me give you an example. We have members today that are using telehealth. We are receiving documentation from -- on those members. The next visit could be a telehealth visit, and ther",165,"Yes. And Brian can add to this, but the really, the telehealth is -- let me give you an example. We have members today that are using telehealth. We are receiving documentation from -- on those members. The next visit could be a telehealth visit, and therefore, we're not going to -- there is not going to improve our documentation any better. We would love to see another member that hasn't been documented as being able to receive telehealth, but they're not comfortable with using telehealth for whatever the reasons I attributed to. So our penetration is more in a narrower membership base. We are working hard to try to broaden that, but there is a lot of barriers that require that, whether it's access to the technology itself or the ability to educate people on that on use telehealth. And that's really what we're talking about. It's a barrier because it is narrowing the membership. We only are penetrating a smaller membership for [indiscernible]."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","And we have no questions at this time. I will now turn the call back to Bruce Broussard. Sir, please go ahead.",22,"And we have no questions at this time. I will now turn the call back to Bruce Broussard. Sir, please go ahead."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Well, thanks, everyone. Again, we continue to thank you for your support and our -- and especially in this time of complexity and through the pandemic and through 2021. As you can see, the organization is performing quite well and -- at all levels, strate",104,"Well, thanks, everyone. Again, we continue to thank you for your support and our -- and especially in this time of complexity and through the pandemic and through 2021. As you can see, the organization is performing quite well and -- at all levels, strategically, from our consumer point of view and from our financial performance there. And as we -- in 2020, I think it's a great thank you to our 50,000 employees that have been dedicated to really delivering these results on behalf of all our constituencies. So thank you again, and I hope everyone is safe, and have a great day."
29618,700196136,2189790,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, that does conclude our conference for today. Thank you all for participating, and you may now disconnect. Have a great day.",24,"Ladies and gentlemen, that does conclude our conference for today. Thank you all for participating, and you may now disconnect. Have a great day."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Humana Fourth Quarter 2020 Earnings Call. [Operator Instructions] With that, I would now like to hand the conference over to Amy Smith, Vice President of Investor Relations. Thank you,",45,"Ladies and gentlemen, thank you for standing by, and welcome to the Humana Fourth Quarter 2020 Earnings Call. [Operator Instructions] 
With that, I would now like to hand the conference over to Amy Smith, Vice President of Investor Relations. Thank you, and please go ahead."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Chief Financial Officer, will discuss our fourth quarter 2020 results and our updated financial outlook for 2021. Following these pr",463,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Chief Financial Officer, will discuss our fourth quarter 2020 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Our Chief Legal Officer, Joe Ventura, will also be joining Bruce and Brian for the Q&A session. We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. Additionally, we have posted supporting materials to our Investor Relations page for reference during Brian's prepared remarks. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today.  
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission and our fourth quarter 2020 earnings press release as they relate to forward-looking statements and to note, in particular, that these forward-looking statements could be impacted by risks related to the spread of and response to the COVID-19 pandemic, including the potential impacts to us of: One, actions taken by federal, state and local governments to mitigate the spread of COVID-19 and in turn, relax those restrictions; two, actions taken by us to expand benefits for our members and provide relief for the health care provider community in connection with COVID-19; three, disruptions in our ability to operate our business effectively; and four, negative pressure in economic, employment and financial markets, among others, all of which creates additional uncertainties and risks for our business. 
Our forward-looking statements should therefore be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results.  
Today's press release, our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Finally, any references to earnings per share, or EPS, made during this conference call refer to diluted earnings per common share.  
With that, I'll turn the call over to Bruce Broussard."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Thank you, Amy, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $18.75 for 2020, consistent with our commentary throughout the year as expected, reflecting a loss in the fourth quarter, largely driven by o",1593,"Thank you, Amy, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $18.75 for 2020, consistent with our commentary throughout the year as expected, reflecting a loss in the fourth quarter, largely driven by our investments in programs to support members, patients, employers, providers and the communities we serve. Our fourth quarter results were impacted by the continued waiver of Medicare Advantage cost-sharing, including for primary care and COVID-19 treatment, delivery of meals, mask and prevented tests to our members, in-home assessments, investments in programs to assist underserved communities and efforts to ease the financial burden for our provider partners. 
For the full year, these initiatives, among others, exceeded $2 billion. Defined by the worldwide pandemic, 2020 was an unprecedented and challenging year. I'm proud of the resilience and response of our associates, putting our members, patients and providers' holistic health at the forefront, while continuing to advance our strategy. Despite the pandemic, Humana continued to accelerate on all fronts in 2020, including our short-term operating and financial performance, our ability to drive and invest in our long-term strategic objectives and in our customer-centricity efforts. 
The strength of our underlying core business is compelling. In our Healthcare Services business, we delivered double-digit percentage growth in adjusted EBITDA year-over-year in 2020 with our pharmacy, provider and home business all performing well. In our Pharmacy business, we processed 478 million scripts and drove mail order penetration of over 37% in MAPD. Today, our Pharmacy business has organically grown to the fourth largest pharmacy benefit manager, or PBM. In our provider business, we ended the year with 156 wholly owned primary care centers after opening 15 new centers in 2020, including expanding to Louisiana and Nevada. 
In addition, our Conviva primary care clinics delivered significant clinical and financial improvement as the turnaround in the business continued, including a 5% reduction in admissions per 1,000. In the Home, we've made important investments in our strategy to offer primary care and post-acute services in the home through minority investments in Heal, a pioneer of in-home primary care; and DispatchHealth, a provider of emergent in-home medical care. In addition, Kindred at Home successfully managed the transition to the new CMS payment model, while also implementing a new operating system in 2020, setting it up to drive further operating model advancement in 2021.  
We demonstrated an over 50,000 Home episodes, integrated new proactive clinical models within the nurses' workflow significantly reduces downstream emergency room visits and hospital admissions. The success of these clinical test and learns provides the confidence scaling these programs will provide meaningful quality and cost improvements in 2021 and beyond. We also delivered strong fundamental results in our core insurance business while investing for the long term. We remain very focused on the consumer experience broadly across all platforms and are proud to have driven an overall 670 basis point increase in our Net Promoter Score, or NPS, in 2020, with a meaningfully higher increase in our NPS for our commercial group business. 
We also announced that 92% of our MA members are in plans rated 4 star or higher, leading the public-traded MA companies. We ended the year with approximately 4.6 million total Medicare Advantage members, reflecting year-over-year growth of 11%, fueling consolidated revenue growth of 19% in 2020. The positive momentum continued in 2021 Medicare Advantage Annual Election Period, or AEP. For the full year, we are expecting individual MA growth of approximately 425,000 to 475,000 members or 11% to 12%. Importantly, as in prior years, our robust growth is balanced across multiple MA plan types as a result of the strength of our clinical programs, provider partnerships and distribution channels as well as our broad offerings that allow for deeper personalization to meet the member's needs. 
In the AEP, we led the industry in each of HMO, special needs plans or D-SNP, and MA-only membership growth and continue to grow our LPPO membership. We also launched Author by Humana in South Carolina in January, managing 5 Medicare Advantage plans with approximately 13,500 members. Author is designed to meet the emerging expectations of digital savvy seniors aging into Medicare, leveraging health coaches, digital and artificial intelligence, to create a simplify and integrated experience for consumers. We plan to scale Author by delegating more MA lives over time and look forward to sharing our learnings.  
We continue to focus on how we can expand our presence with underserved populations, an effort to drive improved clinical outcomes and reduce health disparities. In Medicare Advantage, we experienced industry-leading growth in D-SNPs in 2020, increasing D-SNP membership approximately 41% year-over-year. We expect another year of robust D-SNP membership growth in 2021. Our Medicaid strategy is predicated on the core strengths of our Medicare chassis, including our clinical programs, provider relationships focused on value-based care and commitment to investments in the communities we serve. We are able to offer states individualized approach to care that considers the physical and mental well-being of beneficiaries as well as the critical social determinants that impact the population. 
We began serving Medicare members in Kentucky in 2020 and recently announced our entry into the South Carolina Medicaid program as well as the acquisition of iCare in Wisconsin. We firmly believe organic growth is the most efficient use of capital for our shareholders and remain committed to further organic Medicaid growth supplemented by smaller tuck-in acquisitions. We have a long history of success growing our Medicare Advantage and pharmacy businesses organically, and in just the last week, we were awarded the Managed Medicare contract in Oklahoma, a state that previously did not offer Managed Medicaid. I would like to thank the Medicaid team for their tireless efforts and congratulate them on these key wins. 
As I reflect on what we've learned from the pandemic, I am energized by the way the collective health care system responded to the crisis and how actions taken to combat the pandemic strengthened and accelerated critical tenets of the system. As an industry, in partnership with policymakers, we took deliberate and sustained actions to remove financial barriers and enhance access to care in response to the pandemic, easing some of the burden on our nation's most vulnerable population at a time when they need it most. Supported by CMS, health plans and providers proactively addressed social determinants of health that were exacerbated by the pandemic and quickly pivoted to the telephonic and in-home care, advancing in a matter of months what may have taken years absent the pandemic. 
Our combined actions underscore the strength of the Medicare Advantage program as an enduring public-private partnership that puts seniors and their holistic health at the forefront. Humana's pandemic response continues to evolve, and we are actively engaged with the Biden administration, including HHS and CMS as well as state and local governments regarding our role in the vaccination process as both a primary care provider and as a health plan, representing a significant portion of the nation's most vulnerable population. 
As such, our role is multifaceted, and we stand ready to assist further as the nationwide distribution progresses to later phases and more and more individuals become eligible for the vaccine. Driven by our strong care coordination capabilities, our role includes identification of eligible members utilizing our analytics, vaccination education and concierge services, second dose reminders and ensuring we follow-up on any complications. We are also engaged in industry-wide efforts to conduct vaccine surveillance, identify regions where vaccinations are lagging and intervene to help our members access vaccine. By collaborating with other health insurances, we can align regionally communication efforts to educate and engage members and reduce disparities in vaccine use across the U.S.  
Inequity in health care is an area that we are particularly focused on, recognizing that we must play a critical role, working closely with our industry and governmental partners to address the imbalance that exists today. Data shows that Medicare Advantage is continuing to grow as the preferred option for those who are low income and for racial and ethnic minorities. Of the nearly 26 million Advantage -- Medicare Advantage members, there is a growing diversity in enrollment with more than 28% of the beneficiaries being racial and ethnic minorities as compared to 21% in traditional Medicare. This data demonstrates that as we think about disparities in health care for underserved populations, Medicare Advantage plans are uniquely positioned to address the needs of these members. 
Humana is committed to leverage our business platforms to support local communities in their efforts to lower social and health disparities. This includes enhancing access to care by continuing to expand and build primary care centers in underserved markets, offering supplemental benefits, including over-the-counter medication coverage, transportation, dental and vision as well as taking a leadership role in enhancing innovative solutions aimed at addressing social determinants for both Medicare and Medicaid. In addition, we recently named Dr. Nwando Olayiwola to the newly created position of Senior Vice President and Chief Equity Officer effective in April of this year. Dr. Olayiwola will set direction and establish strategy to promote health equity across all Humana lines of business, including our care delivery assets, while working collaboratively with the broader health care community to advance health equity so health care can work better for everyone, regardless of background, age or economic status.  
In closing, we remain committed to public-private partnerships that are solution oriented and drive results that will meaningfully benefit the health care system in the coming years. With that, I'll turn the call over to Brian."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Thanks, Bruce, and good morning, everyone. Today, we reported full year 2020 adjusted earnings per share of $18.75, consistent with our guidance commentary throughout the year. As Bruce described in detail, despite the unique challenges we faced in 2020 d",2998,"Thanks, Bruce, and good morning, everyone. Today, we reported full year 2020 adjusted earnings per share of $18.75, consistent with our guidance commentary throughout the year. As Bruce described in detail, despite the unique challenges we faced in 2020 due to the pandemic, our fundamentals remain very strong with the underlying core business delivering compelling results for the full year, including a 19% increase in consolidated revenue and an 11% increase in our total Medicare Advantage membership. We were also pleased to be able to maintain stable benefits and premiums for our members, despite the return of the $1.2 billion health insurance fee, or HIF, which was not deductible for tax purposes and disproportionately impacted our business relative to the competition. In addition, I would like to echo Bruce's congratulations to our Medicaid team for our recent contract awards in Oklahoma and our announced expansion in South Carolina. These awards further demonstrate our ability to drive organic Medicaid growth, and together with our iCare acquisition in Wisconsin, expand our Medicaid presence from 3 states to 6.  
I will turn now to our fourth quarter results and underlying trends, which provide important context for our initial 2021 guide. As expected, we reported an adjusted loss per share of $2.30 for the first -- for the fourth quarter of 2020 on account of the significant investments made in all of our constituents because of the pandemic. Further, as disclosed in our 8-K filed January 8, we experienced a significant increase in COVID treatment and testing costs across the nation in November and December. For full year 2020, we incurred $1.5 billion in gross COVID treatment costs, $1.3 billion of which were related to Medicare or $825 million net of capitation to providers in risk arrangements. As a result of the dramatic increase in COVID during these months, we also experienced a decline in non-COVID utilization in the fourth quarter, particularly for Medicare, as fewer people sought nonemergent care. As a result, non-COVID Medicare utilization was approximately 15% below baseline in November and December after having nearly returned to baseline levels in October. 
Overall utilization in the quarter, including COVID costs, was a bit below baseline for Medicare and above for commercial. While the magnitude of these changes was unexpected, the decline in non-COVID utilization in the quarter relative to our prior expectations more than offset the increase in COVID treatment and testing costs. We were, therefore, able to increase our spending for ongoing pandemic relief efforts and investments to advance the company's strategy. It is important to note that investments in the Group and Specialty segment in the quarter, particularly those intended to ease financial stress for providers while positioning the business for long-term success, were disproportionate relative to the reduction in non-COVID utilization levels for the company's commercial group medical and specialty members, significantly increasing the segment's benefit ratio. In addition, as is customary, marketing costs associated with the Medicare Advantage Annual Election Period, along with COVID-related investments, were heavily weighted to the fourth quarter in our retail segment as reflected in our operating cost ratio.  
I will now speak to our expectations and related assumptions for 2021. Today, we are providing adjusted EPS guidance for 2021 of $21.25 to $21.75, reflecting approximately 16% growth off of our $18.50 2020 baseline at the midpoint. While this guidance is consistent with our previous high level 2021 commentary from our third quarter earnings call, the embedded COVID assumptions in today's guidance have changed materially since that time, with largely offsetting headwinds and tailwinds in revenue and benefits expense. This is consistent with our previous commentary that there are natural countervailing forces between trends in COVID treatment costs and trends in non-COVID utilization. 
Importantly, in an effort to simplify any explanations we are going to provide, we have included a slide on our Investor Relations website, which summarizes the expected full year impact of the various material headwinds and tailwinds to our guidance today, rather than discussing any incremental changes since the third quarter conference call. At the time of that call, we reflected both revenue and expense puts and takes into our high-level commentary about expected 2021 financial performance. Since that time, the magnitude of the COVID-related impacts have increased significantly. Therefore, as I said, we will provide full year estimates, inclusive of where we stood at the time of the third quarter call so as to provide our investors with a comprehensive assessment of our latest estimates. I would note that this heightened level of transparency, whereby we provide granular assumptions on a number of variables, is necessitated by the unique uncertainties that the pandemic creates for our 2021 financial outlook. 
I would also note that the numbers we are providing today are for individual and group Medicare Advantage only as the net impact of the pandemic on our other lines of business is currently expected to be relatively immaterial. Additionally, it is important to note that we are providing reasonably wide ranges, given the inherent uncertainty of our estimates for each line item. And finally, so as to make it easier for investors to understand the full financial picture, all the COVID-related figures we are discussing today are net numbers after taking into account our capitation agreements in which provider groups take risk in whole or in part on the member.  
With that context, I will now discuss the material COVID-related headwinds and tailwinds facing our Medicare business in 2021. I will begin with Medicare Risk Adjustment, or MRA. We now expect an MRA revenue headwind of approximately $700 million to $1 billion, representing 1% to 1.5% of Medicare premium for the full year. As a reminder, Humana's 2021 Medicare Advantage revenue is primarily driven by the risk assumed to care for our membership, established through conditions documented by providers within the 2020 calendar year. While we know that 2021 prospective payment amounts from CMS based on diagnoses codes incurred through June of 2020 and submitted by the first Friday in September, over the coming months, these payments will be adjusted to reflect additional conditions documented for claims incurred within the 2020 calendar year. While we estimate and accrue for the incremental revenue from anticipated submissions as the year progresses, there is a higher degree of uncertainty in our revenue projections compared to a normal year.  
Let me spend a few minutes addressing the drivers of this increased uncertainty. First, while we worked tirelessly throughout 2020 to ensure members had access to and were receiving the appropriate level of care, including by significantly increasing outreach and availability of in-home care and providing access to video telehealth clinician visits, the meaningful drop in non-COVID medical utilization in November and December was not expected. Those are important months as they round out our ability to drive meaningful clinical interactions with our members, and therefore, the unexpected decline in utilization affected our ability to appropriately document their conditions. 
Second, the mix of utilization was very different in 2020 relative to prior years. For example, the dramatic increase in the number of telehealth visits from 2019 to 2020, although critical in allowing our members to access care while affording us the opportunity to document their conditions, nonetheless, creates greater uncertainty around the type and volume of diagnoses codes collected. Separately, utilization for in-patient and non-in-patient continued to increase for COVID diagnosis throughout the year. Accordingly, within the mix of submissions from 2020 that drive our 2021 revenue, we also expect organic diagnosis code submissions tied to COVID claims, for which we have limited visibility at this time. These are just 2 examples of how emerging experience in 2020 creates more uncertainty in our MRA revenue projections for 2021 because we are not able to place the same level of reliance on historical trends as compared to a normal year.  
I will now discuss COVID-related utilization. As a general rule, we have seen an inverse relationship between COVID treatment costs and levels of non-COVID utilization, as surges in the pandemic led to less nonessential care being sought by our members. While the ratio of COVID treatment to non-COVID depressed utilization has varied, to date, we have seen in our Medicare book that the level of depressed utilization has more than offset the treatment cost. The shape of the COVID case curve is one of the largest drivers of these 2 related factors, and as such, they remain the 2 largest sources of uncertainty for 2021, given the unprecedented nature of the pandemic. To set a bit more context around what we are seeing currently, the COVID and non-COVID utilization trends we saw in the fourth quarter persisted throughout January. Medicare in-patient non-COVID utilization is running approximately 20% below baseline, with non-in-patient reduction percentages in the low teens, with a significant caveat that we have a much better view of inpatient admissions for which we receive weekly authorization data than we do for non-in-patient utilization. 
Importantly, the increased COVID treatment costs incurred in November and December 2020 ramped up quickly with the reduction in non-COVID utilization initially lagging that ramp as would be expected. We expect the inverse to occur in 2021, such that when COVID treatment costs begin to decline, the rate of decline will likely be steeper than the bounce back in non-COVID utilization, potentially creating a favorable impact for a more prolonged period of time. This is consistent with what we saw throughout 2020 as COVID cases ramped up and then declined in various markets. As a result, we now expect Medicare COVID treatment and testing costs of $525 million to $925 million, which when combined with the Medicare physician fee schedule increase that I will discuss in a minute, represents approximately 1.9% to 3.1% of normalized Medicare claim costs. This is similar to what we experienced in 2020 and is consistent with the expectation that the pandemic will begin to subside as more people get vaccinated through the first and second quarters. 
In addition, subsequent to the third quarter call, a net claims headwind of $175 million to $200 million resulted from the increase to the physician fee schedule rates for 2021 as part of the December stimulus bill, partially offset by a net $80 million to $90 million impact from the Medicare sequester relief extension through March 31. Our guidance to date does not assume that the sequester relief will be extended for the rest of the year. Finally, for full year 2021, we currently expect a reduction of $1.3 billion to $2 billion in Medicare non-COVID utilization off a normalized claims pattern, including lower flu costs, which are significantly reduced compared to normal seasonal patterns. This reflects overall non-COVID annual reductions of approximately 3.6% to 5.5% off a normalized claim pattern, and inclusive of COVID treatment costs, a reduction of approximately 1.7% to 2.4%. For full year 2020, the all-in reduction with and without COVID was approximately 5.9% and 8.6%, respectively. 
We, of course, acknowledge that the ranges we are providing are wide and are a consequence of the continued heightened uncertainty surrounding the ongoing pandemic. We recognize that it will take at least several months to both ascertain from CMS the negative impact to our 2021 revenue growth expectations, resulting from decreased utilization experience in 2020, including, in particular, the unanticipated depression in non-COVID utilization in the final 2 months of 2020 and to the extent to which this reduction in utilization and associated medical cost impact, net of COVID-related expenses, persists into 2021. With respect to quarterly utilization patterns, our guidance ranges assume that we will experience non-COVID utilization levels that reflect double-digit percentage reductions to baseline levels throughout the first few months of 2021, before ramping back up and running slightly above baseline levels towards the end of the year. Similarly, we assume COVID testing and treatment costs will continue to run at the higher levels experienced in November and December in the first quarter of 2021 and trend down as the vaccine becomes more widely available in the second quarter.  
With that said, there are a range of potential scenarios, and we would expect any variance in our assumptions around COVID treatment costs to be more than offset by a change in non-COVID utilization. As I said before, we expect that COVID and non-COVID utilization are driven by naturally countervailing forces. Also as a reminder, we believe capacity constraints in the health care system will prevent non-COVID utilization from running materially above baseline and also limit the amount of time a modest increase above a normal baseline could continue. Therefore, given the deviation from historical patterns we will experience in 2021, forecasting quarterly EPS splits is much more difficult than usual, but we do expect a meaningfully higher portion of our earnings coming in the first quarter than we typically see. As such, we expect the first quarter to contribute just below 1/3 of the annual total versus a more typical first quarter, which will contribute 800 to 1,000 basis points less. As an important aside, while utilization patterns will be most significantly affected in the first quarter of the year, we expect the negative impact on revenue to be more equally split throughout the year.  
Now that I've walked you through the material Medicare headwinds and tailwinds, I'm going to turn to our expected operating performance by segment. I encourage you to reference the waterfall slide provided on our Investor Relations website with the webcast materials. As outlined in the waterfall, given the pandemic, we must first reset the baseline off of which to grow 2021 adjusted EPS. As discussed previously, our starting point is $18.50, which represents the midpoint of our initial adjusted EPS guide for 2020 and effectively neutralizes for any COVID impacts throughout 2020. Importantly, we believe we struck the appropriate balance in our pricing between top and bottom line growth while investing for long-term sustainability, contemplating both the permanent repeal of the health insurance industry fee and the significant impact of the pandemic, which creates more uncertainty than we would experience in a typical year. 
Our 2021 consolidated revenue guidance of $80.3 billion to $81.9 billion at the book midpoint reflects year-over-year growth of approximately 8% from adjusted 2020 consolidated revenue. This growth is primarily driven by our expected 11% to 12% individual MA membership growth, partially offset by anticipated declines in group MA and standalone PDP membership. The revenue is also adversely impacted by the MRA headwind previously discussed as well as fewer months of sequester relief in 2021 versus 2020. Additionally, and as previously discussed, the after-tax benefit of the hit was worth approximately $2 in EPS, and we took a balanced approach in increasing our benefits to our members while providing enhanced earnings to our shareholders. We have incorporated the HIF's impact in the segment waterfall bars. 
In our Retail segment, we are excited about the balanced Medicare growth we have seen, and particularly our industry-leading D-SNP growth. Our Medicaid business also continues to perform very well, and we are excited about the opportunities ahead for this growing business. Taken together, the Retail segment is expected to show strong operating improvement as demonstrated in the waterfall, contributing an incremental $1.21 to adjusted EPS. With respect to our Group and Specialty segment, while we are facing some pressures on account of the pandemic, specifically as it relates to actions by our competitors to retain membership, the business continues to execute on its growth strategy, and we are excited about the prospects for our major medical, specialty and military businesses. We expect the segment to contribute approximately $0.05 of incremental adjusted EPS to the enterprise for 2021. 
For Healthcare Services, we experienced double-digit adjusted EBITDA percentage growth from 2019 to 2020 and expect high-teens growth year-over-year in 2021. Accordingly, we expect the increase in Healthcare Services adjusted EBITDA to contribute an incremental $1.72 to adjusted EPS. In our Pharmacy business, we anticipate continued momentum, primarily driven by our strong Medicare Advantage membership growth and continued increased mail order penetration. Likewise, our Home business is anticipated to perform well, led by Kindred at Home, and our wholly owned provider businesses continue to improve core operating performance while meaningfully expanding our primary care center footprint, as Bruce described. 
In summary, our 2021 adjusted EPS guidance of $21.25 to $21.75 reflects growth of 16% from the $18.50 baseline at the midpoint, modestly above our long-term target of 11% to 15%. Since 2017, following the termination of the Aetna merger, the company has achieved an adjusted EPS compounded annual growth rate of 16.4%, which is above the top end of our 11% to 15% long-term growth commitment we have made to our investors. 
While it's very early, I want to close with some preliminary thoughts on our current view of 2022. Our expectation is that 2022 will be a more normal year, and as we get into the spring and summer, we expect the vaccine to take hold and COVID utilization to decline, allowing non-COVID utilization to trend back to more normal levels, enabling providers to see our members in the ordinary course and appropriately document their clinical conditions, resulting in more normalized medical costs and revenue expectations for 2022. Therefore, barring any major unforeseen circumstances or significant changes in the course of the pandemic, the midpoint of the 2021 adjusted EPS guidance that we provided today of $21.50 is the baseline off of which investors should think about growing earnings for 2022. As we do every year, we will consider a variety of factors as we approach our bids in the spring, including any lingering impacts of the pandemic either on revenue or utilization relative to baseline as well as other external dynamics. 
Before I open up the line for questions, I also wanted to announce that we plan to host an Investor Day on Tuesday, June 15, 2021. Please save the date. With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","We have our first question from the line of Kevin Fischbeck from Bank of America.",15,"We have our first question from the line of Kevin Fischbeck from Bank of America."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Great. Maybe just following up on that last point about kind of how you guys are viewing this year's guidance as a baseline. I guess when you guys submitted your bids back in June, obviously, there's been some legislative changes, things like that, that h",120,"Great. Maybe just following up on that last point about kind of how you guys are viewing this year's guidance as a baseline. I guess when you guys submitted your bids back in June, obviously, there's been some legislative changes, things like that, that have happened. So basically, what you're saying is that COVID has completely offset all of the kind of external legislative changes and everything else. I just want to make sure that I'm understanding that correctly, and that I guess, everything can be ""repriced"". I guess I'm just struggling a little bit with the $2 HIF, and how to think about that over a multiyear period? It feels like it's a relatively low net addition over time?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Kevin, let me just try to provide some context on our bids and how we roll forward today. When we approached our bids in the spring and early summer this past year, we obviously knew we had a significant pandemic that we had to contend with. And we ran a",620,"Kevin, let me just try to provide some context on our bids and how we roll forward today. When we approached our bids in the spring and early summer this past year, we obviously knew we had a significant pandemic that we had to contend with. And we ran a host of scenarios on the revenue and the cost side to put in a pricing what we felt was an appropriate adjustment. And there were certainly countervailing forces. We anticipated that there could be a revenue headwind. We ran various utilization scenarios to see whether there would be any offsets, and we put our assumption into our pricing. 
Rolling forward to the third quarter when we gave guidance, obviously, a lot of things by definition changed since pricing and the sort of the high-level guidance we gave at the time reflected our current view of those headwinds and tailwinds that we would face. I would also remind you that, as we've said multiple times throughout the year that, our operators are spending a significant amount of time working to try to mitigate any of those revenue headwinds by really trying to see our members, which was really important to get into their homes, visit them either in-person or via telehealth, where we would also have the benefit of being able to document their conditions. And so we took a really significant effort, invested a lot of dollars to be able to do that. 
And so as we approached the third quarter, we understood where we were relative to those expectations and, obviously, updated our utilization expectations for 2021. And in that context, we provided 2021 guidance -- or high level guidance. November and December happened, a lot changed, significant decrease in utilization, which was unexpected, as the COVID pandemic really took off and hit levels that really exceeded any expectations and were much higher levels than were even hit in the spring and was nationwide. And so that clearly impacted our perspective. 
And so as we approached the JPMorgan Conference in January, we felt it was important to get out to our investors and provide some high-level commentary on what we are seeing of potential countervailing headwinds and tailwinds. And so we've done that. Here, we provided, obviously, a lot of granular detail on that, but there is a lot of variation in these numbers. I mean you can see there are wide ranges, and we've deliberately provided those wide ranges. We think what's on this page is obviously reasonable. There is nothing that we're seeing that suggests that these numbers aren't reasonable, but where we fall in these ranges on all these variables matters a lot. And that's something, obviously, that we're going to continue to watch closely, and as appropriate, we would update investors on that. 
But I would just say, as we said in our remarks, that 2021 has heightened uncertainty relative to what we thought coming into the year. And to your question on HIF, we actually feel we achieved an appropriate balance between giving dollars back to our members through higher benefits, which we did, and giving higher EPS growth to our shareholders where we're exceeding our typical 11% to 15% growth. And at our midpoint, notwithstanding all of the COVID headwinds and tailwinds, we were still able to guide to a midpoint that's above that range. So we think we've achieved the right balance. There is no doubt that 2021 has a heightened level of uncertainty, and we're going to be monitoring it very closely and keep you updated, which is why we've also, I think, anchored investors on 2022 with the hope and expectation that, that will be a much more normal year."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Kevin, just to add a little bit on the HIF side. Our historical practice has been passing the pretax on to the -- to our members, both the cost and the benefit, as you well know, has come and gone during the year. So this past bid season was very consiste",119,"Kevin, just to add a little bit on the HIF side. Our historical practice has been passing the pretax on to the -- to our members, both the cost and the benefit, as you well know, has come and gone during the year. So this past bid season was very consistent with what we've done on the pretax side. And on the post-tax side, the tax benefit, we've always tried to be fair as -- to both our members and shareholders. And we typically divided that 50-50, both on the cost side and on the kind of the benefit side there. So I think what we've done this year is pretty consistent from our historical treatment of the HIF."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Ricky Goldwasser from Morgan Stanley.",13,"Our next question comes from the line of Ricky Goldwasser from Morgan Stanley."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","So just couple of questions of clarification. When we think about your guidance and sort of to balance the cadence between first half and second half, what are the embedded assumptions for return of utilization for the Medicare population versus baseline?",112,"So just couple of questions of clarification. When we think about your guidance and sort of to balance the cadence between first half and second half, what are the embedded assumptions for return of utilization for the Medicare population versus baseline? Or at least what is the range? And then secondly, when we think about 2022, to your point, we want to anchor in 2022 of that starting point of $21.50, but when you think about the 2021 COVID-related headwinds, can you maybe help us quantify what is reasonable for us to back out of the 2021 number as we think of a more normalized 2022? I think truly onetime in nature."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. Yes. Let me start with utilization patterns and then try to address 2022, recognizing we just gave 2021 guidance. So we're not going to provide a lot of details on 2022, obviously. With respect to the utilization patterns, as we mentioned in our rema",253,"Yes. Yes. Let me start with utilization patterns and then try to address 2022, recognizing we just gave 2021 guidance. So we're not going to provide a lot of details on 2022, obviously. With respect to the utilization patterns, as we mentioned in our remarks, we expect the first quarter to see the most depressed utilization and certainly, the highest COVID treatment cost. And so those, as I mentioned, offset one another. But again, we expect that the most sort of utilization depression will occur in the first quarter. We expect the utilization to remain depressed in the second quarter, although not as much, and then we expect it to ramp up more towards normal and then a bit above normal as we approach the back half of the year and the end of the year. 
So that's how we're broadly thinking about it, which we think is consistent with what we're seeing with the vaccinations and the progress there. As that impacts 2022, it's really hard to give specifics at this point. Again, we'll have to decide when we get to the spring, what's appropriate to reflect in our bids. We'll be very mindful of what we're seeing in terms of headwinds and tailwinds with respect to COVID and revenue and utilization like we were this year. But beyond that, I wouldn't want to comment other than to say, we do think $21.50 is a reasonable baseline off of which to think about 2022 without providing any more specifics beyond that today."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Josh Raskin from Nephron Research.",13,"Our next question comes from the line of Josh Raskin from Nephron Research."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","So I know you guys have spoken in the past about new members in MA coming in at higher MLRs in that first year. Could you just give us a sense as to what the typical first year MLR looks like for an MA member? And then this inability to risk code, is that",149,"So I know you guys have spoken in the past about new members in MA coming in at higher MLRs in that first year. Could you just give us a sense as to what the typical first year MLR looks like for an MA member? And then this inability to risk code, is that affecting new lives at all? Or is that really just an existing book that typically sees the revenue improvement? And then apologies, but I'm just clearing, I know 2022 isn't -- we're not looking for guidance here, but is it correct to think that there'll be kind of a bolus of premium benefit? You'll have all of the older members that have been with you for a couple of years that get coded correctly as well as the new cohort in 2021. Is that a fair way to think about the MRA benefit in 2022?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. So the way I would think about it, rather than focusing on MERs, I'd rather just focus on pretaxes, what we've discussed in the past. I think it's fair to say that new members tend to be breakeven. These steps may run a little bit better out of the g",304,"Yes. So the way I would think about it, rather than focusing on MERs, I'd rather just focus on pretaxes, what we've discussed in the past. I think it's fair to say that new members tend to be breakeven. These steps may run a little bit better out of the gate, but not a lot of profitability in the first year. Certainly, as we get to the second and third year, we start getting to more of our normalized margins as we're able to document our members' conditions and also get them in our clinical programs, and that really hasn't changed. I think that's consistent with what we've seen. And certainly, that's what we typically plan for in our bids. 
We think without providing too much detail on 2022, I think it's fair to say that you might see effectively a catch-up in 2022. So any MRA revenue headwind we've seen in 2022, which is a function of sort of our existing membership base, and remember, it's not just the members that we've had, but it's also the new members that we got, particularly if they were in other Medicare plans. So if they're a switcher, they would also have sort of -- we'd have less of their documentation than normal for the same reasons because our competitors weren't able to get those conditions documented either. And so you will see sort of the -- for us, the 2021 cohort as well as, frankly, some of our other cohorts where we weren't able to redocument their conditions, you will see more of a sort of an increase in 2022. And that will be something that we plan for in our bids as we figure out what percent of normal do we expect to be for 2022 based on 2021 utilization. Hopefully, that was clear."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","We have our next question, comes from the line of Ralph Giacobbe from Citi.",14,"We have our next question, comes from the line of Ralph Giacobbe from Citi."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I just wanted to go back and understand the assumptions on the core again or the non-COVID utilization. I think, on the slide, it said minus 3.6% to minus 5.5%. It sounded like that was off of a 2021 normalized baseline. I just want to make sure that's ri",96,"I just wanted to go back and understand the assumptions on the core again or the non-COVID utilization. I think, on the slide, it said minus 3.6% to minus 5.5%. It sounded like that was off of a 2021 normalized baseline. I just want to make sure that's right. And I guess it'd be helpful to understand what you normally assume for utilization increases? Or maybe even just how it compares to kind of 2019? And then it sounds like the first quarter is running down 20% on the non-COVID. Did I hear that right?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. So Ralph, so we don't -- we're not going to give you specific sort of utilization assumptions that -- we're very transparent, but we can't be that transparent on some of our core stuff on that regard. But I would just say, as it relates to utilizatio",343,"Yes. So Ralph, so we don't -- we're not going to give you specific sort of utilization assumptions that -- we're very transparent, but we can't be that transparent on some of our core stuff on that regard. But I would just say, as it relates to utilization, we've been thoughtful about sort of normalized trends and then think about what the impact might be when we did our pricing for 2021 on all these various variables that we've talked about. Really, what we mean by a normalized baseline is actually, really straightforward, which is to say if you are -- if you just stripped out COVID entirely, what would the claims assumption be, based on sort of the normal inflators we would use from 2021 over 2020. And so whatever sort of secular trends and other things that we build in, trend vendors and other things, we get to sort of a net trend ex COVID and that's really the baseline. Just to give you a -- make it easier for you to compare relative to, say, our 2020 ex COVID what the baseline reduction is. And that's why I tried to say sort of ex COVID for Medicare, it was, call it, 8.5%, 8.6% down for 2020 relative to the 3.6% to 5.5% that we guided today. 
So again, we think that number is reasonable. Again, we could be wrong. That's -- there's just a wide range here. And I -- again, as I just emphasized, that there is more uncertainty around this 2021 number than we would typically have because when we formulate those trend assumptions that you were asking about, we have a lot of historical experience. We have hundreds of actuaries, very smart people working on our trend assumptions. It's something that we think we're very good at in ensuring we bake in the appropriate levels of potential trend variances. We're dealing here in a whole new world with a pandemic where we have no historical experience. And so that creates some of the challenges in our forecasting."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of A.J. Rice from Crdit Suisse.",14,"Our next question comes from the line of A.J. Rice from Crdit Suisse."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Just to drill down a little bit on the '21 outlook. So you've got the COVID testing and treatment headwind, is substantially less than the tailwind for depressed COVID utilization, but you're talking about the interplay there. And I think, in the prepared",184,"Just to drill down a little bit on the '21 outlook. So you've got the COVID testing and treatment headwind, is substantially less than the tailwind for depressed COVID utilization, but you're talking about the interplay there. And I think, in the prepared remarks, you said as the vaccine gets widely disseminated, you'd expect the COVID testing and treatment to come off quicker than the utilization of non-COVID to come back. So long-winded, setting the stage for the question. So if you -- if the vaccine gets widely distributed quicker than you think or later than you think, does that move the assumptions around within the range? Or could that throw you outside the range? And I guess, I'd also ask, you've talked a lot about the investments that you made this year. I know a lot of that investment was just giving help to your constituents, but does that give you any flexibility within this guidance range because you pulled forward investments in 2020 that would have otherwise kind of happened in '21. How much flexibility does that give you in your range?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","A.J., I would say on the first question, there's a lag really because as people are not, of course, seeing their doctor and going to the hospital. They're not able to schedule the surgeries, for example. It just takes time for the system to ramp back up.",331,"A.J., I would say on the first question, there's a lag really because as people are not, of course, seeing their doctor and going to the hospital. They're not able to schedule the surgeries, for example. It just takes time for the system to ramp back up. So there is just sort of a natural trail off that, just given the volumes we're talking about, they're not insignificant. And it's one of the reasons why we had the tailwinds we had in 2020, was that delay. It just takes time to get the gears cranking again, and they will crank again. And we certainly forecast that, but there is that delay. 
To the extent the vaccine rolls out more slowly or there is a variant in the virus that we've heard and that they're not as effective, that, for sure, can affect our ranges here. We've tried to capture what we think are reasonable ranges based on today's sets of facts and circumstances. To the extent those facts and circumstances change, it's conceivable that some of these sort of COVID treatment versus non-COVID cost, that could be impacted. Again, it's likely that because there is a -- there is that inverse correlation, they will offset one another, though in the Medicare business, it tends to lead to a tailwind, as we mentioned. The commercial business is not as clear. As you mentioned, in the fourth quarter, we are running a little bit above par all-in, but for the Medicare business, we were below. 
The investments, to your question there, we really, I would say, pulled all those out for 2021. So there is really not any additional flexibility there. We were very clear to confine those investments to 2020. And as we've described, we benefit all of our constituents and really gave back a lot of those dollars, which was important to do, but that was not baked in, in any way into our 2021 pricing or to our guidance."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","We have our next question, comes from the line of Robert Jones from Goldman Sachs.",15,"We have our next question, comes from the line of Robert Jones from Goldman Sachs."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Great. I mean, maybe just to go back to the MRA headwind. I know it's a tricky thing to get your arms around, but maybe just more of a tactical question. If you are, in fact, expecting non-COVID utilization to be down again because of -- obviously, becaus",137,"Great. I mean, maybe just to go back to the MRA headwind. I know it's a tricky thing to get your arms around, but maybe just more of a tactical question. If you are, in fact, expecting non-COVID utilization to be down again because of -- obviously, because of COVID, obviously, the risk adjustment was an issue coming into this year. I guess, just tactically speaking, what things specifically are you thinking about doing differently in '21 as it relates to getting the appropriate risk coding, given that there's probably going to be a similar dynamic, at least for part of the year that made it a challenge coming into this year? Just curious if there is a different approach, maybe you're taking or more aggressive approach you're taking this year as it relates to risk coding."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes, Brian, I'll take that to give you a little break. Just on the -- we, in really the third and fourth quarter, were fairly aggressive in trying to ensure that our members were utilizing the health system, and in addition that we are being able to provi",312,"Yes, Brian, I'll take that to give you a little break. Just on the -- we, in really the third and fourth quarter, were fairly aggressive in trying to ensure that our members were utilizing the health system, and in addition that we are being able to provide in-home assessments and other areas where documentation was appropriate. And I would say we would continue to carry that forward in the first part of this year and continuing throughout the year. Because I would -- we did readdress where we're at and began to really become aggressive and use all availability. I do believe the biggest area that we -- our challenge with this is just the normal course of people not using the health care system. 
We are very active both with our value-based providers and, in addition, with our outbound engagement with our members to ensure that they are going to the physician office or utilizing the health care system. We'll continue to do that. We have a team of people that are focused on this every day to try to really help, whether it's lining up transportation, to the ability to -- for us to provide telehealth to them, to the ability to have an in-home assessment. And I really would say, we'll just continue to do what we did in the third and fourth quarter. But getting people into the health care system is our biggest both opportunity and challenge. And as the health care system readjusts itself to really treating COVID and social isolation becomes more and more of an issue in -- where the markets are spiking, that really gives us the largest challenge, I think. If it was just COVID-related and it was fairly stable in the marketplace, we would be able to navigate through this in a fairly effective fashion with the programs we have."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Justin Lake from Wolfe Research.",13,"Our next question comes from the line of Justin Lake from Wolfe Research."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Just a couple of questions here on numbers. First, you -- can you -- you've given us a lot of detail here. Can you tell us what the total Medicare risk adjustment impact was for 2021 on a gross basis, meaning how big of an impact is it to your yields over",105,"Just a couple of questions here on numbers. First, you -- can you -- you've given us a lot of detail here. Can you tell us what the total Medicare risk adjustment impact was for 2021 on a gross basis, meaning how big of an impact is it to your yields overall? And what do you expect your yields to be for 2021 on a year-over-year basis? And then just on Medicare Advantage margins, it looked like your retail margins are about 3% in the -- within guidance. Can you confirm that's kind of where you expect individual Medicare Advantage margins to be in 2021?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Sure. Justin, so on the MRA side, what we're showing here effectively is the total headwind net of mitigation. And so as Bruce just described, we did a lot to really try to get our members into the health care system and make sure we can see them. And so",641,"Sure. Justin, so on the MRA side, what we're showing here effectively is the total headwind net of mitigation. And so as Bruce just described, we did a lot to really try to get our members into the health care system and make sure we can see them. And so this is the sort of the full headwind that we currently face. And again, we want to be very transparent, but this is net of our mitigation efforts. As it relates to yields, we typically don't, as you know, guide to PMPMs, but just to help you out, I would say, is sort of flat, maybe modestly up is the way I would describe our individual MA PMPM expectations, and we'll see where that ultimately goes. 
But there are a lot of things that impact that, Justin, as you know. Obviously, MRA is one of them. The rate notice is another. Sequester is another. Remember, there is fewer months of sequester relief this year. Business mix is a very significant driver because there are pretty disparate rates around the country. So depending on where you grow, that can impact it. So there are a host of things that impact yields, but it's a fair question and understand where you're going. 
Now I would be disappointed if you didn't ask us about the margin question. So I'm glad you took the opportunity, and I know it's a fair question. I think it's important when you look at the overall retail margin, is to -- remember that there are multiple businesses inside the Retail segment. First off, the margin has been impacted by the HIF and the fact that it was nondeductible. So there is a lot of geography going on there, and certainly, we thought about after tax. I mean we sort of managed the pretax, but think about the after-tax impact as we thought about our pricing, et cetera. 
As we just discussed, we balance giving back some of the tax benefit, both to our members in the form of higher benefits as well as to our shareholders. So there is some geography issues that will impact and depress the margin. There are also -- as we've discussed on the PDP side, a lot of the margin has come out of that product. And in fact, most of the margin today, if not all the margin today, is in the pharmacy for us. We've talked about how that product has become much more of a commodity product at these levels of premium. It's hard to make money on the insurance side, and so we're doing nicely on the pharmacy side. And so we want to -- we'll continue to be aggressive in this business. 
And as Bruce commented in his remarks, our mail order penetration continues to, we think, reach very, very high levels both on the MA side, but also on the PDP side. So -- but again, that's a geography issue. So as you think about individual MA margins, you need to take that into account. Also, just to be transparent here, group MA has seen some margin impacts from some of the larger accounts that have been shifting back and forth between major competitors. When there is margin to those accounts when they get rebid, sometimes takes a few years to recover that margin. And so that's also driving some of the impact there, too. So it is, for sure, the case that we are below our 4.5% to 5% target, I would say, reasonably below that target. We are committed to that over the longer term to get back to that 4.5% to 5%, but I would just say there are a lot of things impacting that number, and there is a lot of sort of variables embedded in that retail overall guide that you're looking at."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Lance Wilkes from Bernstein.",12,"Our next question comes from the line of Lance Wilkes from Bernstein."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Could you talk a little bit about the investments in provider assets? And in particular, I was interested in what you're seeing as far as MLR differential and growth rate differential for members and the lines of business that are in value-based care part",49,"Could you talk a little bit about the investments in provider assets? And in particular, I was interested in what you're seeing as far as MLR differential and growth rate differential for members and the lines of business that are in value-based care partner or owned primary care assets?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes, I'll take that. We see great results in the primary care clinics, both in the ones we own and the affiliated ones. We'd see, and we've showed a slide on for a number of years. As physicians continue to evolve to deeper value-based relationship model,",299,"Yes, I'll take that. We see great results in the primary care clinics, both in the ones we own and the affiliated ones. We'd see, and we've showed a slide on for a number of years. As physicians continue to evolve to deeper value-based relationship model, we see superior performance and the star scores typically greater than 4 to 4.5. We see great MLR, significantly below what the average is in the industry, and we also see great Net Promoter Score. All that combined, that's why you see us aggressively pursuing on both our affiliated relationships and in addition, building our primary care clinics to place our members in those clinics. 
The challenge with the clinic side is just they're organic. There is not enough capacity in the marketplace to fill the demand. So you see a lot of start-up -- clinics from a start-up point of view being invested in to build the capacity there. And so for us, for more capacity constraint as opposed to for our growth. Our growth traditionally has been at equal to and greater than what you see in the traditional 10% to 12% growth that you've seen over the last few years in these clinics and getting more and more members in those clinics. And I think you'll see that growth accelerate as the capacity becomes more and more available for us. On the value-based provider side of the business, outside of the ones that are clinic oriented, we continue to see really, really great -- good results from that. Those results are a little less than the clinic results. We see good star scores. We see 4 and above, and we see good Net Promoter Scores, but it does not compare to the outcomes that we see in the clinic side."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Scott Fidel from Stephens.",12,"Our next question comes from the line of Scott Fidel from Stephens."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I wanted to ask just about maybe an update on how you're thinking about some of the puts and takes with the ESRD coverage expansion that played out in MA. Obviously, that was already one of the big changes for MA in 2021 before COVID kicked in. So just in",119,"I wanted to ask just about maybe an update on how you're thinking about some of the puts and takes with the ESRD coverage expansion that played out in MA. Obviously, that was already one of the big changes for MA in 2021 before COVID kicked in. So just interested, maybe first, if you could, if you have an estimate of how much your MA membership for ESRD actually changed for 2021? And then as we think about the impacts of the pandemic on that population and then try to overlay that into the rates that you have, how you're thinking about sort of the overall margin profile expectations that you had for that population now versus prepandemic?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","I'm happy to start and Bruce can put color on any of the strategic side here. But I would say, just from a sheer numbers perspective, we got about, call it, 10,000 or so, plus or minus, lives from ESRD in the AEP, which puts us to around 29,000, 30,000 me",191,"I'm happy to start and Bruce can put color on any of the strategic side here. But I would say, just from a sheer numbers perspective, we got about, call it, 10,000 or so, plus or minus, lives from ESRD in the AEP, which puts us to around 29,000, 30,000 members, which was really right in line with our expectations. What we expect is, as we've said for a number of quarters here, we think it's going to take several years to get up to the Medicare Advantage penetration. We think that continues to be the case. And so again, I'd say right in line with our expectations. These are not profitable members. I think over time, as we continue to manage them and work with partners and really try to get them before they get the ESRD and slow their disease progression, we think there is real opportunities to drive profitability. But I would say, we're getting to a point where it's more or less breakeven as opposed to having any meaningful losses on these members. But Bruce, I don't know if you want to add anything on that?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","I would just add, Scott, I know this was an active conversation for us in 2020, and how we were going to deal with it. And I really have to take the hats off to the team on how they've been able to really develop some deep partnerships with the 2 major di",221,"I would just add, Scott, I know this was an active conversation for us in 2020, and how we were going to deal with it. And I really have to take the hats off to the team on how they've been able to really develop some deep partnerships with the 2 major dialysis providers and really be able to evolve the relationships to a value-based payment model that shares the risk. And that has helped us in being able to effectively manage the clinical side of this and the cost side, but the clinical side of ESRD. 
And then the second thing is we continue to invest in innovative models, both around the coordination of care and then also where the care is provided in the home. And those 2 strategies really have given us more confidence in the ability to manage these patients. As Brian said, the patients will continue to be costly and continue to be at no margin or very, very low margin business for us going forward. So again, I think we're in a great shape from where we were a year ago when we began talking about this. And as Brian also said, is that we do see this will be years in the making to see the penetration to the average penetration of MA overall."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","And Bruce, do you think that the pandemic itself has much impact on this population? I don't know if some of the providers you have talked given some updates recently, just thinking about that population as it relates to the pandemic itself?",42,"And Bruce, do you think that the pandemic itself has much impact on this population? I don't know if some of the providers you have talked given some updates recently, just thinking about that population as it relates to the pandemic itself?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. Typical to any vulnerable population, whether it's ESRD or other chronic conditions, you do have a higher likelihood of having more severe cases in those populations. And for us, we are very active in managing the populations that have those vulnerab",107,"Yes. Typical to any vulnerable population, whether it's ESRD or other chronic conditions, you do have a higher likelihood of having more severe cases in those populations. And for us, we are very active in managing the populations that have those vulnerable conditions. So I would say, they are different than the average population because of their conditions, but they are not different than our other chronic members and how we effectively reach out to them and manage them, and they are reflected, obviously, in the results that Brian was talking about in our -- in where we look at COVID being more costly in our forecast."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Matt Borsch from BMO Capital Markets.",14,"Our next question comes from the line of Matt Borsch from BMO Capital Markets."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Maybe I could ask about on Medicaid. What you are assuming or how you're thinking about the Medicaid rate process, given the action states took in the second half of last year? And then maybe also what you're assuming on the resumption of redeterminations",50,"Maybe I could ask about on Medicaid. What you are assuming or how you're thinking about the Medicaid rate process, given the action states took in the second half of last year? And then maybe also what you're assuming on the resumption of redeterminations, if you can just address that?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Sure. I'm happy to take that. So just on the rate side, we're waiting to see, and our major states are Kentucky and Florida. I think we expect some rate adjustments, and we're waiting to see, and we certainly bake what our expectations might be into our -",220,"Sure. I'm happy to take that. So just on the rate side, we're waiting to see, and our major states are Kentucky and Florida. I think we expect some rate adjustments, and we're waiting to see, and we certainly bake what our expectations might be into our -- sort of into our Medicaid budget. And so we're waiting to see the impact there. With respect to redeterminations, you see -- we've given a pretty wide guidance range on Medicaid membership. Effectively, the assumption is the public health emergency ends in April. We'll -- if that happens, then we expect to lose some lives because we saw a nice increase this past year, but as the redeterminations happen, that will cause that membership to decline. 
And so I would say that's sort of our base case expectation as we think about our overall guidance and revenue, et cetera. To the extent that the public health emergency is extended, redeterminations don't happen, that will cause the increase in membership to continue, which -- again, I think, would be relatively immaterial to the overall enterprise, but would cause us to have a higher membership at the end of the year. And that, of course, excludes anything from South Carolina or Oklahoma, which will kick in later this year, and our guide excludes that."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Steven Valiquette from Barclays.",12,"Our next question comes from the line of Steven Valiquette from Barclays."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Maybe just a question for Bruce, just on the COVID cost risk. As we do think about your ability to control the medical cost in '21 versus 2020, specifically for COVID, has there been any evolution on the provider side for '21 where value-based providers t",94,"Maybe just a question for Bruce, just on the COVID cost risk. As we do think about your ability to control the medical cost in '21 versus 2020, specifically for COVID, has there been any evolution on the provider side for '21 where value-based providers that want to go at risk for any sort of episodic bundled payments related to COVID patients? Or is that not really evolved? And if not, are there any other evolving payment arrangements with providers you can talk about, specifically tied to COVID that's different for '21 versus '20?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. Good question. We don't have a bundled type of payment model for COVID. I mean we have many bundles in other conditions and -- but not for COVID. And we haven't seen that really any uptake with physicians on that. Keep in mind, a lot of the COVID cos",179,"Yes. Good question. We don't have a bundled type of payment model for COVID. I mean we have many bundles in other conditions and -- but not for COVID. And we haven't seen that really any uptake with physicians on that. Keep in mind, a lot of the COVID cost is on a DRG basis and incorporated in the DRG side. The testing is something of a lesser magnitude here. So going at risk for that, I think, is fairly small and immaterial kind. I think to broaden your question a little bit, what we do see is that when we do have value-based relationships, the proactiveness of really helping the member in this time is so important for us, especially as you think about downstream cost and other conditions that could occur, if not properly maintained and traded. So to answer your question, we don't see much in COVID bundling in the type of payment, but we do see very different proactive care models in our value-based payment relationships in this time, especially with the more vulnerable populations."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of George Hill from Deutsche Bank.",13,"Our next question comes from the line of George Hill from Deutsche Bank."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Bruce, I just wanted to circle back and make sure I heard you right to say that pharmacy mail penetration was 37%. Was that for the quarter or for the year? I assume, it was for the quarter. And I guess, is it your expectation that, that kind of comes dow",86,"Bruce, I just wanted to circle back and make sure I heard you right to say that pharmacy mail penetration was 37%. Was that for the quarter or for the year? I assume, it was for the quarter. And I guess, is it your expectation that, that kind of comes down a bit as things return to normal? And would love to hear you talk a little bit more about the strategies that you guys have used to drive mail penetration to such a high level."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Okay. Great. Yes, that's right. I would -- that is actually for the year. We did see an increase in mail penetration as we looked for the -- in the early part of the COVID pandemic. We saw it in the March and April time frame as people were really concern",397,"Okay. Great. Yes, that's right. I would -- that is actually for the year. We did see an increase in mail penetration as we looked for the -- in the early part of the COVID pandemic. We saw it in the March and April time frame as people were really concerned about the lockdown that was happening, and therefore, were taking 90-day prescriptions and really utilizing the mail order along with the fact that they couldn't get to the drug stores if they were normal users and became more active users of the mail order. 
What we have seen is as a result of the convenience of mail order and really, I would say, as a result of our service improvement, we've seen more and more people really converting to mail order as a result of that. And so the pandemic, we have seen, has helped educate individuals of the benefit of mail order and the ability to continue to utilize it on an ongoing basis as opposed to just through the pandemic and some of the shutdown periods. So we look at it first as really an accelerator for us in that. 
The second thing is that we have a very active investment going in into making it much more consumer friendly on the mail order side, all the way from the digital platforms that are being used to the turnaround time of delivery, to be able to ensure that we can meet the expectations and the changing expectations of customers today on when they expect deliveries to happen. And I would say that our goal is to really grow the penetration of mail order in our existing book of business. 
You asked why sort of high the penetration. I would say it's been a very concentrated effort by our management team and really all the way from our service centers on the insurance side to our providers that we have relationships with to our specialty pharmacy area of continuing to remind our members of the benefits of the mail order. And that continued use throughout the organization of being -- bringing the mail order conversation in at the appropriate period of time has really assisted in us being able to increase that rate from a much different rate that is the average in the industry to really a superior rate that you see Humana having."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Dave Windley from Jefferies.",12,"Our next question comes from the line of Dave Windley from Jefferies."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I wanted to ask about telehealth, Bruce. You've mentioned it a couple of times during the call. How is Humana incentivizing telehealth? How are you looking at it as a facilitator to whether it's the primary care effort that you're putting forth, home heal",67,"I wanted to ask about telehealth, Bruce. You've mentioned it a couple of times during the call. How is Humana incentivizing telehealth? How are you looking at it as a facilitator to whether it's the primary care effort that you're putting forth, home health and extension there. I guess, I'm just wondering where are you using it aggressively? And how are you incentivizing and reimbursing its use."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","We're big believers in telehealth for -- all the way from the convenience of the member to really being able to have a channel that is actively engaging with the member at -- especially, the more vulnerable members where transportation is always a limiter",300,"We're big believers in telehealth for -- all the way from the convenience of the member to really being able to have a channel that is actively engaging with the member at -- especially, the more vulnerable members where transportation is always a limiter for them. To answer your question about how do we incentivize them, we're really doing it on 2 sides: First on, we did carry over the copay, the 0 copay this year to telehealth and carried that on going forward; and then the second thing that we've also done is, we continued to pay equal to our member -- I mean, our providers visit versus a telehealth visit. And both of those have been, I think, reducing the barriers and really creating, as you said, some incentives to use telehealth. 
We really have a few different strategies of using telehealth. I mean one is around really helping our providers if they don't have telehealth and providing them some technology that would offer them to utilize it. That's in a small need for external providers as they have all sort of become very acquainted with telehealth and being able to use it. Our internal -- our own providers, we offer them a very sophisticated telehealth platform that they can outreach on the telehealth side. And then the third area that we look at is continuing to work with hospital systems, especially in the specialty area, where we can have an outreach where specialists might be in short supply in certain markets and being able to offer that at a convenience in the local marketplace. So we do see it to help members -- I mean health providers, but more importantly, we do see us partnering with especially the hospital systems to offer specialty in remote areas."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","Can I clarify real quickly, is that reimbursement at parity, is that in your commercial book as well as Medicare?",20,"Can I clarify real quickly, is that reimbursement at parity, is that in your commercial book as well as Medicare?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","I don't know if we are different -- Amy, are we different? Are we giving the different payment by the different divisions? I don't think we're providing that. I would just say, in general, I know, in general, we're providing, but I wouldn't want to get in",50,"I don't know if we are different -- Amy, are we different? Are we giving the different payment by the different divisions? I don't think we're providing that. I would just say, in general, I know, in general, we're providing, but I wouldn't want to get into the specifics."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","I think the distinction is also, if it's in the office that we're -- we can follow-up, but if it's in the office, we're doing full reimbursement. If it's not, then it gets more of a reduced rate, but we can get you all the details.",46,"I think the distinction is also, if it's in the office that we're -- we can follow-up, but if it's in the office, we're doing full reimbursement. If it's not, then it gets more of a reduced rate, but we can get you all the details."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Gary Taylor from JPMorgan.",12,"Our next question comes from the line of Gary Taylor from JPMorgan."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I just want to maybe just go back big picture just for a second. Brian, you had talked about a lot of the MRA, COVID-related headwinds normalizing as you move into 2022, using the $21.50 as a jumping off point. So when we think about '22, given we've got",85,"I just want to maybe just go back big picture just for a second. Brian, you had talked about a lot of the MRA, COVID-related headwinds normalizing as you move into 2022, using the $21.50 as a jumping off point. So when we think about '22, given we've got an early and known final rate notice above historic rate increase, is there any reason from this distance that we shouldn't be thinking about the long-term 11% to 15% growth off of that $21.50 in 2022."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Well, again, I really don't want to be giving guidance on this call for 2022. I would say, at the highest level, certainly, our goal is to deliver that 11% to 15% growth. And that's a long-term growth rate, and sometimes we're above, there have been times",87,"Well, again, I really don't want to be giving guidance on this call for 2022. I would say, at the highest level, certainly, our goal is to deliver that 11% to 15% growth. And that's a long-term growth rate, and sometimes we're above, there have been times when we've been below. But certainly, our goal is to hit that 11% to 15%, and we always have to take the facts and circumstances at the time when we price. So hopefully that, I think, gives you the answer."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Charles Rhyee from Cowen.",12,"Our next question comes from the line of Charles Rhyee from Cowen."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","I just wanted to follow-up about telehealth. I think in the prepared comments, you spoke about how documentation with using telehealth created some uncertainty around coding. I think, later on, Bruce, you talked about, number one, issues, trying to get pe",131,"I just wanted to follow-up about telehealth. I think in the prepared comments, you spoke about how documentation with using telehealth created some uncertainty around coding. I think, later on, Bruce, you talked about, number one, issues, trying to get people back into the health care system itself. It sounds like -- is there a disconnect then that when telehealth is used to accurately kind of code people to understand sort of their actual health status? And is that a fundamental problem with the way telehealth is set up today? I know in just the previous question, you talked about how you're trying to incentivize your -- or, all providers to use it. Is this an integration issue? Or is this an issue itself with how telehealth is being deployed?"
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","No, it's really more on the member side what we find. First, telehealth, if you use audio and video today, can support documentation. So that is possible and regulatorily came into place the latter part of last year. So it is a way to be able to bring doc",225,"No, it's really more on the member side what we find. First, telehealth, if you use audio and video today, can support documentation. So that is possible and regulatorily came into place the latter part of last year. So it is a way to be able to bring documentation. The problem is that what we see is, once there is -- when someone uses telehealth, they then use it more frequently. And so we see a significant use of telehealth, but the members that are using it are more contained, I should say, or more refined, and it's not across all our membership. So we could see a significant increase in telehealth, but that increase in telehealth will be over a confined membership base as opposed to across our membership base. And that really comes to one of the barriers we're working with in the communities we serve, is that not everyone that accesses either feels comfortable with telehealth as a result of some of the technology limitations there or just needs to be educated more. They might have the technology, but it might not be integrated. And that's where we see a lot of work needs to be had, is the ability for telehealth to be used in a more broad membership base as opposed to the narrower membership base that it has today."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Analysts","If I could follow-up, does that mean when you guys talked earlier then about going into 2021, is it that just the usage of telehealth itself. You're uncertain whether the coding that your -- the documentation that you're getting is going to persist at tha",52,"If I could follow-up, does that mean when you guys talked earlier then about going into 2021, is it that just the usage of telehealth itself. You're uncertain whether the coding that your -- the documentation that you're getting is going to persist at that kind of level? Was that more..."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Yes. And Brian can add to this, but the -- really, the telehealth is -- let me give you an example. We have members today that are using telehealth. We are receiving documentation from -- on those members. The next visit could be a telehealth visit, and t",164,"Yes. And Brian can add to this, but the -- really, the telehealth is -- let me give you an example. We have members today that are using telehealth. We are receiving documentation from -- on those members. The next visit could be a telehealth visit, and therefore, we're not going -- that's not going to improve our documentation any better. We would love to see another member that hasn't been documented as being able to receive telehealth, but they're not comfortable with using telehealth for whatever the reasons I attributed to. So our penetration is more in a narrower membership base. We are working hard to try to broaden that, but there is a lot of barriers that require that, whether it's access to the technology itself or the ability to educate people on how to use telehealth. And that's really what we're talking about. It's a barrier because it is narrowing the membership, we only are penetrating a smaller membership for documentation."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","And we have no questions at this time. I will now turn the call back to Bruce Broussard. Sir, please go ahead.",22,"And we have no questions at this time. I will now turn the call back to Bruce Broussard. Sir, please go ahead."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Executives","Well, thanks, everyone. Again, we continue to thank you for your support and our -- and especially in this time of complexity and through the pandemic and through 2021. As you can see, the organization is performing quite well and -- at all levels, strate",103,"Well, thanks, everyone. Again, we continue to thank you for your support and our -- and especially in this time of complexity and through the pandemic and through 2021. As you can see, the organization is performing quite well and -- at all levels, strategically, from our consumer point of view and from our financial performance there. And as we end 2020, I think it's a great thank you to our 50,000 employees that have been dedicated to really delivering these results on behalf of all our constituencies. So thank you again, and I hope everyone is safe, and have a great day."
29618,700196136,2190067,"Humana Inc., Q4 2020 Earnings Call, Feb 03, 2021",2021-02-03,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, that does conclude our conference for today. Thank you all for participating, and you may now disconnect. Have a great day.",24,"Ladies and gentlemen, that does conclude our conference for today. Thank you all for participating, and you may now disconnect. Have a great day."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Good day, and thank you for standing by. Welcome to the Humana First Quarter 2021 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] With that, I would now like to hand the confere",58,"Good day, and thank you for standing by. Welcome to the Humana First Quarter 2021 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] 
With that, I would now like to hand the conference over to your speaker today, Amy Smith, Vice President of Investor Relations. Thank you, and please go ahead."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Chief Financial Officer, will discuss our first quarter 2021 results and our updated financial outlook for 2021. Following these pre",381,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Chief Financial Officer, will discuss our first quarter 2021 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Joe Ventura, our Chief Legal Officer, will also be joining Bruce and Brian for the Q&A session. We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. 
Additionally, we have posted supporting materials to our Investor Relations page related to the Kindred at Home transaction announced last night. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. 
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission and our first quarter 2021 earnings press release as they relate to forward-looking statements and, to note in particular, that these forward-looking statements could be impacted by risks related to the spread of and response to the COVID-19 pandemic. 
Our forward-looking statements should, therefore, be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements and future filings or communications regarding our business or results. 
Today's press release, our historical financial news releases and our filings with the SEC are also available on our Investor Relations site. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. 
Finally, any references to earnings per share, or EPS, made during this conference call refer to diluted earnings per common share. With that, I'll turn the call over to Bruce Broussard."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Thank you, Amy, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $7.67 for the first quarter of 2021, and  reaffirmed our full year 2021 and adjusted EPS guidance of $21.25 to $21.75. Our first quarter resu",1698,"Thank you, Amy, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $7.67 for the first quarter of 2021, and  reaffirmed our full year 2021 and adjusted EPS guidance of $21.25 to $21.75. Our first quarter results reflect solid performance across each of the company's segments, fueled by strong individual Medicare Advantage and state-based membership growth, and improved profitability in the group and specialty and Healthcare Services segments. 
As we continue to navigate the pandemic, we also meaningfully advanced our strategy during the quarter. I want to congratulate our Medicaid organization on the significant contract award in Ohio, which when combined with recent additions of Oklahoma, South Carolina and Wisconsin, brings our Medicaid footprint to 7 states. These additions affirm our capital efficient, organic growth strategy and further demonstrates the strength of our Medicaid capabilities built on our Medicare Advantage chassis. 
We also continue to deliver compelling dual special needs plan membership growth. These net membership increased approximately 23% in the quarter, and we now serve more than 0.5 million D-SNP members. We remain committed to proactively addressing disparities in health care for underserved populations and recognize that Medicare Advantage and Medicaid plans are uniquely positioned to address the needs of these members. 
Data shows that Medicare Advantage is continuing to grow as the preferred option for those who are low income and for racial and ethnic minorities with more than 28% of Medicare Advantage beneficiaries being racial and ethnic minorities as compared to 21% in traditional Medicare. Currently, 55% of Latino and 39% of African-American beneficiaries have actively chosen to enroll in MA, and there is growing diversity in enrollment because of the value provided to beneficiaries. The ability of MA plans to adapt to change and drive innovation and better clinical outcomes is why today nearly 27 million seniors have chosen MA over original Medicare. 
Our ability to drive innovation and improve clinical outcomes is enabled by our strong integrated care delivery platform. And in recent years, we have significantly expanded our health care services capabilities, from primary care to pharmacy to home care and more, in order to better serve our medical members and to significantly strengthen our payer-agnostic care offerings. These services help deliver on the promise of better quality and health outcomes, lower cost and a simpler, more personalized experience for the people they touch. 
These advancements also provide a solid foundation to ultimately serve individuals beyond our MA membership base, including original Medicare fee-for-service members as we continue to evolve and expand beyond managed care to a broader clinical services orientation with the ability to manage risk and coordinate care outside of MA. 
During the quarter, we took the next step in this evolution, introducing CenterWell as the new brand to unite our broad range of payer-agnostic health care service offerings. The CenterWell brand speaks to how we put our members and patients at the center of everything we do. The first Humana-owned services to adopt the brand, our partners in primary care and family physician group, named CenterWell senior primary care. We are also accelerating our strategy around the home. And as I will discuss in a moment, the home will be the next service to adopt the CenterWell brand. 
We see the home, coupled with our primary care strategy, has the mix meaningful opportunity to improve access to quality, proactive care for a broader senior population. As such, we continue to invest in assets that allow us to better manage the holistic needs of our members and patients by expanding care in the home, including primary care, telehealth and emergency room care while also addressing social determinants of health. 
The home health industry is among the fastest-growing health care industry in the U.S. as a result of an aging population, the prevalence of chronic disease and growing physician acceptance of care in the home. This need has only been accelerated by COVID-19. However, we recognized for some time that the current volume-based fee-for-service model has limited the innovation in home health. 
Accordingly, in 2018, we acquired a 40% interest in Kindred at Home, embarking on a journey to test and learn innovative clinical models in the home with the goal of evolving home health to value-based payment models. Today, Kindred at Home employs approximately 43,000 caregivers providing home health, hospice and community care services to over 550,000 patients annually. They have locations in 40 states, providing extensive geographic coverage, with approximately 65% overlap with Humana's individual Medicare Advantage membership. 
Yesterday, we announced that we signed a definitive agreement to acquire the remaining 60% interest in Kindred at Home. As detailed in the press release we issued last night, the Kindred at Home transaction represents an enterprise value of $8.1 billion, including the value of Humana's existing 40% equity interest. This acquisition, which is expected to close in the third quarter of this year, is the largest in Humana's history and comes at a pivotal time in health care, when a worldwide epidemic has exasperated the existing disparities in health care for underserved populations and highlighted the power of telehealth and in-home care and addressing those disparities. 
Further, the pandemic has reinforced patients' increasing desire for convenient and personalized delivery channels, requiring innovative home care offerings. The acquisition of Kindred at Home will provide us with an extensive network of nurses, a critical distribution channel for delivering care in the home. However, we recognize the need for innovative home care offering at scale. 
Through our successful partnership with Kindred's management team and our private equity partners, over the last few years, we have proved that altering the nurses' clinical interaction in the home improves care. We've demonstrated that we can reduce the cost of care and provide value to shareholders through additional referrals to Kindred, advancing effective clinical interventions in the home, and supporting higher acuity patients by leveraging other home-based assets we've assembled. 
When at home health episodes served by Kindred at Home has increased from 8% to 19% overall in markets with geographic overlap, reaching penetration as high as 49% in certain key markets. In addition, Kindred at Home continues to demonstrate superior patient outcomes, including reduced hospitalizations, admissions and ER utilization. 
Management's successful transition of Kindred at Home to an independent home health and hospice company, the strong and growing core business is reflected in Kindred's solid historical EBITDA compounded annual growth rate of approximately 20% since 2017, our demonstrated ability to deliver savings to health plans through reduced hospitalizations and the ability to drive increased referrals to Kindred at Home provides us the confidence to accelerate our 100% ownership of Kindred. Full ownership allows us to move from market testing to full-scale implementation over time. 
We recognize the significant value we can deliver to members and patients by integrating this asset into our holistic approach to care. Fully integrating at home -- Kindred at Home will enable us to more closely align incentives to focus on improving patient outcomes and on reducing the total cost of care. This is critical to deploying at scale, a value-based advanced home health model that makes it easier for patients and providers to benefit from our full continuum of home-based capabilities. By leveraging the best channel to deliver the right care needed at the right time, we believe we can deliver outcomes and value beyond what is possible and traditional fee-for-service models. 
As shown on the slide deck that we posted to our Investor Relations website this morning, home health utilizers are 5x more likely to have an inpatient admission within 120 days of the start of their home health episode as compared to an individual MA member that does not utilize home health. This speaks to the significant opportunity we have to continue to improve outcomes and lower costs for this population. 
We look forward to sharing additional details about the value creation we plan to drive with our home health strategy at our Investor Day in June. While the acquisition includes the operations of Kindred's hospice and community care operations, our intent is to ultimately only maintain a minority interest in this portion of the asset. Our experience with hospice demonstrates the integration of pallative and traditional hospice care, improves the quality of life for patients transitioning from restorative care to hospice. 
However, we have been successful delivering the desired patient experience and outcomes through partnership models, demonstrating we do not need to own a majority interest in the hospice asset long term. Kindred at Home will be integrated into Humana's Home Solutions business under the leadership of Susan Diamond. When combined, our Home Solutions geographic scale and clinical breadth will provide the opportunity to offer care beyond Humana members. And as a result, we will transition to our CenterWell brand as CenterWell home health. 
Luckily, Kindred Care services will be integrated and coordinated with other care offerings, including CenterWell's senior primary care and convenience VBID as well as our primary care and emerging care offerings in the home via our investment in heal and dispatch health. 
Before turning the call over to Brian, I want to acknowledge that this will be his last earnings call at Humana and thank him for his invaluable contribution to Humana over the last several years. Among his many contributions, Brian brought rigor to his role in the creation of a strong financial capability, not only through sophisticated physical and ongoing operational discipline, but also by developing a deep bench of talent within our finance organization to drive this discipline forward. 
We wish Brian the very best in his next chapter. As previously announced, Brian will remain in his current role through June 1 and then serve in an advisory role through the end of the year. On June 1, Susan Diamond will assume the role of interim CFO while we complete our search for a permanent replacement. Given Susan's strong knowledge of our business and financial expertise, I have great confidence in her ability to lead the finance team as we recruit a new CFO. Susan will also continue to lead the Home Solutions business. 
With that, I'll turn the call over to Brian."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. Today, we reported adjusted EPS of $7.67, reflecting a positive start to the year across our segments, particularly in light of the impacts that the pandemic has had on our results, which we outlined on our fo",1897,"Thank you, Bruce, and good morning, everyone. Today, we reported adjusted EPS of $7.67, reflecting a positive start to the year across our segments, particularly in light of the impacts that the pandemic has had on our results, which we outlined on our fourth quarter 2020 earnings call in February. While the first quarter came in modestly ahead of our previous expectations, it is early and we are continuing to work through uncertainty related both to our revenue and claims due to pandemic. 
Specifically as it relates to revenue, given our significant exposure to Medicare Advantage, we are disproportionately affected by COVID's impact on Medicare risk adjustment, or MRA. Our risk-adjusted revenue is determined by 2020 dates of service, medical utilization and resulting documentation, which as previously discussed, was materially depressed last year. In particular, we are focused on monitoring the impacts on utilization from the late surge of COVID cases in 4Q, which occurred following the communication of high-level 2021 guidance on our third quarter earnings call. 
While the extension of sequestration helps mitigate any potential pressure against our estimates, I would remind investors that a critical indicator of 2021 revenue relative to our initial expectations will be the midyear MRA payment, which we expect from CMS anytime in the next 1 to 3 months. The mid-year payment, which effectively rolls forward the dates of service used for 2021 payment to year-end 2020 from mid-year 2020 and incorporates the impact on risk-adjusted revenue of our new members is meaningfully more uncertain this year given the 4Q dynamics I mentioned, as this payment requires significant estimation even in normal times. 
As it relates to benefits expense, non-COVID utilization is running largely in line with our previous expectations and, as anticipated, is still depressed relative to baseline. The first 3 months of in-patient admissions were down approximately 20%, 15% and 10% in January, February and March, respectively, relative to baseline, with the first few weeks of April, seeing non-COVID inpatient trends moderate to around 5% depressed. 
Separately, non inpatient spend is also depressed, although it appears to be rebounding a bit faster than previously expected, with the caveat that the completion on non inpatient claims is much slower, and therefore, there is significantly more uncertainty around these service categories in terms of exactly where we stand. Finally, COVID admissions, which tend to have higher unit costs than those of non-COVID, came down more quickly than expected in the quarter. The COVID case deceleration moderated in late March and seems to be holding flat in early April, as certain geographic locations have become hotspots. We expect utilization to continue to rebound at par as we move through the second quarter and to slightly exceed baseline towards the end of the year. 
Given that we remain in a period of heightened uncertainty, we are reaffirming our full year 2021 adjusted EPS guide of $21.25 to $21.75 as well as the benefit expense and operating cost ratios notwithstanding the favorable first quarter results. This represents adjusted EPS growth of 16% above the 2020 baseline of $18.50 at the midpoint of our guide, nicely above the high end of our long-term EPS growth target of 11% to 15%. 
I would note that we have been consistent in our expectation of adjusted EPS growth above our long-term target since we provided our initial 2021 commentary on our third quarter 2020 earnings call in November. Additionally, we expect our second quarter adjusted EPS to reflect a low 30s percentage of our full year adjusted EPS. 
As we look ahead to 2022, we are pleased that our members appear to be engaging in more routine interactions with their providers, which we anticipate will result in more normalized Medicare Advantage revenue next year as providers are able to ensure that our members are receiving an appropriate level of care and that their conditions are being documented. While it is, of course, too early to provide 2022 guidance, I would note that as we think about our Medicare Advantage bids for 2022, our intention is to reflect the continued uncertainty associated with COVID-19 in our premium and claims assumptions. 
In addition, I would like to reiterate that the appropriate baseline for calculating 2022 adjusted EPS growth is $21.50, the midpoint of our 2021 guidance range. I will now briefly discuss each of our segment's performance in the quarter. 
In the retail segment, in addition to the revenue and claims dynamics I discussed, our Medicare Advantage growth remains comfortably on track and consistent with our previous expectations, with individual MA growing solidly above the market at an expected 11% to 12% increase. As Bruce indicated in his remarks, we experienced robust growth in D-SNP membership, adding 95,000 members in the first quarter with an additional 12,400 added effective April 1. I also want to echo Bruce's congratulations to our Medicaid team on their state contract awards in Ohio and Oklahoma, along with our application approval in South Carolina during the quarter. An incredible achievement, demonstrating the strength of our Medicaid capabilities. 
In our group and specialty segment, consistent with our commentary on our last earnings call in February, medical membership declines on account of COVID were less severe than initially expected coming into the year. The segment performance continues to improve, and we continue to execute on the first phase of a multiyear plan to grow our group commercial and specialty products, bringing in strong new talent, increasing our local presence in certain key markets, and deepening our partnerships with innovative companies. 
Our dental network expansion is proceeding ahead of plan. Our small group commercial medical pipeline volume is back in line with pre-COVID levels. And our Net Promoter Scores for our large group medical accounts were at a record high for first quarter performance. 
Finally, our healthcare services operations remain on track with our previous expectations. In our pharmacy operations, we continue to pursue pharmacy initiatives that we expect to further increase mail order penetration as the year progresses. I would note that this anticipated spend to accelerate growth, coupled with labor-related overtime and shipping costs due to weather-related disruptions in February, did modestly impact the pharmacy business results in the quarter. CenterWell's senior primary care in Conviva are performing well and we continue to execute on our clinic expansion with [indiscernible]. 
Kindred at Home is also delivering solid results. And as Bruce indicated in his remarks, we are accelerating our full acquisition of Kindred at Home. With respect to Kindred, last night, we announced that we signed a definitive agreement to acquire the remaining 60% interest in Kindred at Home for a total enterprise value of $8.1 billion, including $2.4 billion associated with our current 40% equity interest. We do not anticipate a material impact to non-GAAP or adjusted earnings in 2021. 
We expect the transaction to provide modest additional financial flexibility as we set targets for 2022 earnings, although I would note that buying in Kindred has long been a part of our financial planning process, which has included providing capability to build out our clinical capabilities and value-based care model. 
In addition, we intend to exclude onetime transaction and integrated costs related to the acquisition from non-GAAP earnings. Key financial terms are outlined in the slides available on our website accompanying today's earnings call. 
The innovative partnership we created with Welsh, Carson and TPG will deliver significant strategic and financial value to Humana. Executing on the Kindred at Home transaction now versus waiting for the contracted sponsor put option that would likely not be exercised until mid-2022, given the asset's strong EBITDA growth not only accelerates the strategic benefits, as Bruce described, but importantly, allows us to acquire the nation's largest home health and hospice company for a multiple meaningfully lower than where comparable public companies are trading today. 
Additionally, we expect that we will be able to capitalize on a robust market for hospice assets by divesting a majority stake in that portion of the business and what we anticipate will be an attractive valuation. 
As to the EBITDA multiple we are paying for Kindred at Home, investors should consider the $5.7 billion purchase price for the remaining 60% interest, plus our initial investment of $1.1 billion for our 40% stake in 2018, which when grown at a reasonable 8% weighted average cost of capital for a present value of $1.4 billion, equates to a total cash purchase price of approximately $7.1 billion all in. When using a normalized full year 2021 estimated EBITDA for Kindred at Home, inclusive of Hospice and Community Care, the transaction EBITDA multiple is approximately 11x. 
It is important to note that the normalized EBITDA excludes expected home care and hospice investments in clinical capabilities and value-based care models, onetime costs, including transaction and integration expenses and any potential synergies. The expected synergies will primarily result from the meaningfully enhanced clinical capabilities Bruce has described, which will materialize over time, in addition to the EBITDA benefit of in-sourcing further home health episodes from other home health providers. 
One other important note regarding the financial value created that I would mention. After adjusting for our intended divestiture of a majority interest in the hospice and community care assets at a reasonable market valuation, the implied transaction EBITDA multiple for acquiring the nation's largest home health business would be in the mid- to high-single digits, based on the roughly 50-50 split of the EBITDA between the Home and Hospice Community Care segments. 
As far as the transaction financing is concerned, we expect to fund the $5.7 billion purchase price, which again is net of our existing equity interest with a mix of parent company cash and debt financing. The transaction is expected to close in the third quarter of 2021, subject to customary state and federal regulatory approvals. Immediately following the closing of the transaction, we expect our consolidated debt-to-capital ratio to be in the low 40s, with significant deleveraging expected post divestiture of the majority stake in Hospice and Community Care. 
We expect the debt-to-capital ratio, including assuming a customary level of share repurchase to return to a more normalized target leverage level during 2022, freeing up the balance sheet for further capital deployment. We anticipate maintaining our investment-grade credit rating as a result of this transaction. 
Before we open the line up for questions, I want to take a moment to thank our associates, shareholders and sell-side analysts for their support over the last 7 years, as this will be my final Humana earnings call. I'm very proud of what the company has accomplished in a period of rapid transformation. And I know that under Bruce's leadership and with the support of the outstanding team across the organization, the company is well positioned to execute on its strategic plan and deliver significant shareholder value in the years ahead. It's been a true honor to serve the millions of Humana members, and I'm grateful to have worked with so many talented colleagues. I remain fully committed to a seamless transition in the coming weeks and months. And I'm very excited that Susan Diamond will serve as interim CFO. Susan is someone I've worked with extensively over the last 7 years and is one of the most talented people I know. 
With that, we will open the lines up for your questions. [Operator Instructions]. Operator, please introduce the first caller."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] We have our first question comes from the line of Matthew Borsch from BMO Capital Markets.",18,"[Operator Instructions] We have our first question comes from the line of Matthew Borsch from BMO Capital Markets."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I was hoping maybe you could elaborate a bit on the increased competition that you're seeing in the group Medicare Advantage area of what you think is driving that? And how you think that might settle out?",38,"I was hoping maybe you could elaborate a bit on the increased competition that you're seeing in the group Medicare Advantage area of what you think is driving that? And how you think that might settle out?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Sure. I'll take that. Well, just as we mentioned really on several calls, the group M&A market, particularly on the large-scale accounts has continually become more competitive. There are several players who you know well, who are pursuing these accounts,",195,"Sure. I'll take that. Well, just as we mentioned really on several calls, the group M&A market, particularly on the large-scale accounts has continually become more competitive. There are several players who you know well, who are pursuing these accounts, and they're obviously attractive pieces of business. They're large membership, significant revenue. And there are positive knock-on effects as well to winning these accounts in the local markets in which we operate with respect to providers, et cetera, and visibility. 
And so there's a lot of competition for these accounts. We remain very well positioned there. Our group MA team has really been very smart about how they've underwritten these accounts. We're not going to chase accounts down to profitability levels that we don't think are sustainable. And so we're being prudent and thoughtful as we pursue these opportunities. But again, feel very good about how we're positioned in group MA, notwithstanding the competition there. 
I would note one thing, though, that at the sort of smaller group account size, sort of mid- level accounts and small level accounts, the profit margins are better and more -- more attractive from a pure for profitability perspective."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","We are trying to -- just to add to Brian's comment, we are trying to differentiate through the service component of that. And we do find as a result of employers being responsible for the selection of this, that's an important differentiation. It's not al",63,"We are trying to -- just to add to Brian's comment, we are trying to differentiate through the service component of that. And we do find as a result of employers being responsible for the selection of this, that's an important differentiation. It's not always going to win over price, but we found on a number of accounts that has won over price."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Robert Jones from Goldman Sachs.",15,"We have our next question comes from the line of Robert Jones from Goldman Sachs."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I guess maybe just one on the headwinds and tailwinds, and I appreciate the qualitative commentary around utilization and COVID testing and treatment. I just wanted to see if those ranges you had laid out last quarter around those headwinds are still ki",103,"I guess maybe just one on the headwinds and tailwinds, and I appreciate the qualitative commentary around utilization and COVID testing and treatment. 
I just wanted to see if those ranges you had laid out last quarter around those headwinds are still kind of how you're seeing the world 1 quarter in. And then on the tailwind side, I know you were looking at sequestration relief of, I think, just 1 quarter last quarter and now with it being pushed out to the end of the year. Just wanted to get your latest thoughts on how that's being contemplated within the updated guidance."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, I would say that the ranges that we laid out in the fourth quarter call are consistent with what we're seeing today. And so we remain within those ranges. And again, that's, I think why we're comfortable, obviously, reiterating the guide that we put",120,"Well, I would say that the ranges that we laid out in the fourth quarter call are consistent with what we're seeing today. And so we remain within those ranges. And again, that's, I think why we're comfortable, obviously, reiterating the guide that we put forth today. 
The sequestration clearly is positive from an earnings perspective. But I think we have to consider that in the context of the overall headwinds and tailwinds that we see over the coming 9 months. And so while that certainly, as we mentioned in our remarks, is a positive tailwind to offset any potential pressure that we might see over the coming months, it's still very early. And so that's why we reaffirm today."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Justin Lake from Wolfe Research.",15,"We have our next question comes from the line of Justin Lake from Wolfe Research."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","First, let me wish Brian, good luck as he moves on, and thanks for everything over the last 7 years, Brian, it's been a pleasure. And then my -- I wanted to follow-up, based on Bob's question here, just kind of to narrow it down a little bit. My read of",141,"First, let me wish Brian, good luck as he moves on, and thanks for everything over the last 7 years, Brian, it's been a pleasure. 
And then my -- I wanted to follow-up, based on Bob's question here, just kind of to narrow it down a little bit. My read of kind of your updated view on 2021 is that you feel more comfortable about offsetting the headwinds that you kind of lined out in January, given where trends are coming in plus that benefit of sequestration. And that the remaining swing factor here is that risk adjustment true-up in June. Am I thinking about that correctly first? And then if so, any thoughts on how wide the outcome could be on that true up? And then lastly, can you tell us how you're doing with recapturing risk scores for 2022?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, first of all, Justin, thank you for the comments. With respect to -- let's start with risk adjustment. Obviously, there are ranges of outcomes, and they could be material. And so I would say as we think about the potential headwinds and tailwinds, t",352,"Well, first of all, Justin, thank you for the comments. With respect to -- let's start with risk adjustment. Obviously, there are ranges of outcomes, and they could be material. And so I would say as we think about the potential headwinds and tailwinds, that is one that we're very mindful of and it's something that, as I said to the last question, the sequestration is helpful, but it's still early. 
And so I would say that we're sort of in a similar posture as we were last quarter at this time. There are headwinds and tailwinds that we look at. And we want to be, I think, pretty cautious as we head into the last 9 months of the year because there's still a lot of uncertainty. And clearly, MRA is an important element of that, but there's also the claims side, which we have to see unfold over the next 9 months. 
And we obviously have assumptions about how claims are reverting to baseline levels, which they seem to be doing, sort of, in line with what largely as we expected. I would say not inpatient, maybe a little bit faster, but sort of in the range and patient in line, with COVID coming down faster. So that's obviously a positive. So there are a few puts and takes in those numbers. But I think there's a bit of a ways to go before, obviously, we're fully comfortable there. 
As it relates to the documentation for 2022, we as I mentioned, we are feeling reasonably good about what we're seeing so far, it still is early. But the documentation codes do seem to be coming in a way that makes us feel good about 2022. We've been effective in getting into the home through our in-home assessments program. We ramped those up pretty meaningfully. And so that I think is a positive side for 2022. 
But we also will be cautious as we price 2022 and run a range of scenarios to understand what the various eventualities may be on both revenue and claims as a result of the pandemic."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. Just -- maybe I can just reiterate what Brian is saying. We obviously had a good quarter. And -- but I would say that we -- as Brian has said, as we're early into this, we are looking at the assumptions we made and setting out the year. And this is -",139,"Yes. Just -- maybe I can just reiterate what Brian is saying. We obviously had a good quarter. And -- but I would say that we -- as Brian has said, as we're early into this, we are looking at the assumptions we made and setting out the year. And this is -- this is a good growth year for us. It's going to be in excess of 15%. 
And we just want to make sure that we see how the rest of the year plays out more before we adjust any of our -- any of our estimates there. And I think that's probably the best thing that investors should take away from is that we still are confident in what we've put out there as an assumption side, but it's the first quarter of 4 quarters here."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of A.J. Rice from Credit Suisse.",16,"We have our next question comes from the line of A.J. Rice from Credit Suisse."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Best wishes, Brian, as well. It's been great working with you. Just maybe I'll go and ask about the Kindred asset. As you described the way you're calculating that 11x purchase price, I may not be thinking about it rightly. But if it's $3.2 billion of rev",137,"Best wishes, Brian, as well. It's been great working with you. Just maybe I'll go and ask about the Kindred asset. As you described the way you're calculating that 11x purchase price, I may not be thinking about it rightly. But if it's $3.2 billion of revenues, and it's 11 multiple that you've paid, given your purchase price, which imply a sort of operating -- an EBITDA of about $645 million. I wondered if that was the right way to think about it. 
And then have you got clarity on how you're going to get rid of the hospice business? Is it open for sale? Is it a spin off? And will that hospice business then be able to get back into adult home care and compete with Kindred? Or is there limitations on that hospice business?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","A.J., I'll take the latter question, and then Brian can certify the multiple side. We are in the early stages of spinning it off. So there is definitely a commitment of us to spin it off. Our intentions would be to move down the road of possibly an IPO. B",221,"A.J., I'll take the latter question, and then Brian can certify the multiple side. We are in the early stages of spinning it off. So there is definitely a commitment of us to spin it off. Our intentions would be to move down the road of possibly an IPO. But there's a long ways between here and there, and we understand that this is a -- this is a great asset. It's an asset. It's a leading hospice asset in the marketplace. It is the -- it's got great operations from an operating point of view. Strong management team. And so I think it is going to be an asset that is going to have a lot of interest from multiple different buyers, so to speak. 
We haven't worked out the contractual terms of can they reenter into the home business, I think, even if they were to do that. It is a fragmented industry. But it is also an industry that, as you all know, because of legalities of licensure issues and being able to get home health license isn't the easiest thing in the world, especially both in CON states and to get a Medicare reimbursement side. So we do believe that there's barriers to entry in just getting into the business. So we're less worried about that."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. And I would say, A.J., on the EBITDA, that's -- you're broadly thinking about it right in terms of the numbers.",22,"Yes. And I would say, A.J., on the EBITDA, that's -- you're broadly thinking about it right in terms of the numbers."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Kevin Fischbeck from Bank of America.",16,"We have our next question comes from the line of Kevin Fischbeck from Bank of America."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Okay. Great. And thanks, Brian, for all your help over the years. But I guess -- I'm still struggling a little bit with this guidance number. The -- we were coming up with the sequestration benefit being maybe as much as $1.50 or so. And so I guess this l",176,"Okay. Great. And thanks, Brian, for all your help over the years. But I guess -- I'm still struggling a little bit with this guidance number. The -- we were coming up with the sequestration benefit being maybe as much as $1.50 or so. And so I guess this lower visibility, I guess, today than when you had last year or we provided guidance for Q4, is a little bit surprising me. 
It's not necessarily something that I'm hearing from the other managed care companies. I just want to hear a little bit more about why you think there is still so much lack of visibility in that number at this point, even though Q1 came in better. Like there was good PPD, and now you've got a big sequestration tailwind. It seems like that uncertainty would have to be significant. 
And then if it is significant, you're still reaffirming this number as your base for thinking about 2022. How can you feel comfortable that you would be able to fully reprice that into next year?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, I guess -- there's a lot in that question. I would say, first off, in terms of our confidence for pricing next year, I mean we as I said in my remarks, we're going to reflect any uncertainty that we see in our bids to ensure that there are any issue",482,"Well, I guess -- there's a lot in that question. I would say, first off, in terms of our confidence for pricing next year, I mean we as I said in my remarks, we're going to reflect any uncertainty that we see in our bids to ensure that there are any issues that we can contemplate here with respect to various scenarios that may play out, we would have considered in our bid. So I think that's the first thing. So $21.50, from a pricing perspective, we feel very good about. 
We also feel good about the reiterated guidance that we provided today. I would say relative to perhaps some of our peers, we have a much higher concentration of Medicare revenue and Medicare claims, which I think in many respects, particularly on the revenue side, have more volatility. But on the claims side as well, you're making assumptions about how seniors who have not used the health care system for a long time, how they're going to respond in the next, call it, back half of the year. And in that regard, we just want to -- and we think it's appropriate to be cautious about how they might use the system in the back half of the year. 
Especially as we saw again, the depressed utilization in the fourth quarter, how does that all play through. And so that's, I think, appropriate caution. As we said, the sequester benefit is beneficial for obvious reasons. So that is clearly a tailwind. But I think understanding how impactful on our revenue numbers, the last -- the fourth quarter was, is still out there. 
In particular, because the way the midyear payment works as it rolls forward to the last 6 months of the year in terms of how we get paid and understanding the documentation codes that were collected is something that we really need to understand, both on existing members as well as frankly, new members. 
We get a lot of new members every year. Remember, it's not just the net growth, but it's just the number of new sales that we have. And so from that perspective, there's uncertainty there. Again, I feel pretty good about where we are today. But we don't think it would be appropriate to change our guide. 
The last point I'd make is we came into the year committed to our 16% growth rate, which was above our target. And that's where we continue to be. We -- versus perhaps some of our other peers. Those numbers have not modified. And we actually obviously put out a number of ranges on a number of variables here, which are -- there was a reasonable amount of uncertainty starting from the fourth quarter. And as I mentioned, that continues.  But again, I think the first quarter is a good quarter, but there's still a ways to go."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Okay. Great. Actually, just real quickly, you say that you'll know the number when you get the payment from CMS midyear. Does that mean with Q2 results we should kind of have the answer? The coding benefit will be known and then sequestration would come i",63,"Okay. Great. Actually, just real quickly, you say that you'll know the number when you get the payment from CMS midyear. Does that mean with Q2 results we should kind of have the answer? The coding benefit will be known and then sequestration would come in, and we would expect an updated guidance for Q2 then? Is that how to think about it?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, it depends. I mean, possibly. I mean, CMS changes each year, exactly when they give them the midyear payment. My guess is we will have visibility by the second quarter call. But there's no guarantees. But I would say, most likely by the second quart",58,"Well, it depends. I mean, possibly. I mean, CMS changes each year, exactly when they give them the midyear payment. My guess is we will have visibility by the second quarter call. But there's no guarantees. But I would say, most likely by the second quarter call, we will have some visibility into our midyear MRA payment. Yes."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Josh Raskin from Nephron.",14,"We have our next question comes from the line of Josh Raskin from Nephron."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I'll let go of the congratulations as well and thanks to Brian as well. So my question is just on the segmentation. And what does it look like? What is the segments for Humana look like if we think sort of 3 years out? I'm interested in both sort of organ",111,"I'll let go of the congratulations as well and thanks to Brian as well. So my question is just on the segmentation. And what does it look like? What is the segments for Humana look like if we think sort of 3 years out? I'm interested in both sort of organizational operational structure of the company. 
But also reporting, and I'm really concentrating on kind of what businesses are going to be included in, I don't know what you'll call, sort of, the non-insurance segment. It sounds like most of the branding is going towards CareWell? And sort of what sort of disclosures and thoughts you guys have on that?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Let me start and then ask Brian to add, as we are building a health care service division. And I think at a simplest component, which we'll have -- start out with our pharmacy business, which is the largest part of the business. Our primary care business",254,"Let me start and then ask Brian to add, as we are building a health care service division. And I think at a simplest component, which we'll have -- start out with our pharmacy business, which is the largest part of the business. Our primary care business will be part of that. And our home health business will be part of that. And then we'll have some other health care services here and there over time. 
But those would be the 3 primarily large driving profitable arms of the organization there. They will serve multiple different markets. They will serve our existing members and be integrated with our existing members through technology and the service component of that. They will also serve when in the appropriate area, Medicare fee-for-service areas, such as direct contracting would be an example of that. 
And they will serve other providers, I mean, other payers as we do today in value-based payment models, and we'll take full risk. And so the opportunity we have is to take advantage of the -- the organic growth of each of those markets, to be able to then integrate those together and take advantage of offering a value-based offering to different payment mechanisms, whether it's within MA to other payers or within a direct contracting area. And then in addition, it's also the opportunity for us to serve our existing members there. 
And so I think you'll see the  CenterWell segment be just evolving to be the -- our health care service segment."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","And are there short-term thoughts on increased disclosures or rebranding or resegmentation?",13,"And are there short-term thoughts on increased disclosures or rebranding or resegmentation?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","I think with the entry on to with Kindred, I think we'll have to bring in other discussions there. And I think that probably, as we close on Kindred, you'll probably see it enter the 2022, you'll probably see more enhanced statistical side of the operatio",53,"I think with the entry on to with Kindred, I think we'll have to bring in other discussions there. And I think that probably, as we close on Kindred, you'll probably see it enter the 2022, you'll probably see more enhanced statistical side of the operational aspects of our health care services division."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. And I would just add that just in terms of what we disclosed today on the health care services side, as Bruce said, a lot of our revenue today is in our company, because of the pharmacy segment. And obviously, CenterWell primary care has a prognostic",137,"Yes. And I would just add that just in terms of what we disclosed today on the health care services side, as Bruce said, a lot of our revenue today is in our company, because of the pharmacy segment. And obviously, CenterWell primary care has a prognostic business and has external revenue. 
Which you'll see in Kindred though because it's not only pay agnostic, but also obviously serves the fee-for-service program. There will be a lot of about $3.2 billion of revenue. A good portion of that is obviously not Humana. So you'll see more disclosures there. And we'll provide more operating metrics around that as well. So I think you will get enhanced disclosure. 
We try to be very transparent with investors on our various businesses, and I think you'll continue to see that going forward."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Dave Windley from Jefferies.",14,"We have our next question comes from the line of Dave Windley from Jefferies."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Question I wanted to focus on, utilization. Looking specifically in the retail segment, we're estimating that maybe the impact of the HIF and the net increase in PYD this year or maybe about the same size. And so if I neutralize those out, your MLR on kin",115,"Question I wanted to focus on, utilization. Looking specifically in the retail segment, we're estimating that maybe the impact of the HIF and the net increase in PYD this year or maybe about the same size. And so if I neutralize those out, your MLR on kind of apples-to-apples basis for the first quarter would have also been up about 100 basis points. Is that right? 
And then as you think across the balance of the year, how are you thinking about utilization coming back in terms of acuity? And then any permanency in terms of site of service shifts and things like that, that would impact intensity and medical costs as the year progresses."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. So let me start with the MER question. The way I would think about it, year-over-year, is we're about 110 basis points above last year. The difference in PYD was about 110. Coincidentally, also 110 basis points. So call that 220. The HIF, and remem",428,"Yes. So let me start with the MER question. The way I would think about it, year-over-year, is we're about 110 basis points above last year. The difference in PYD was about 110. Coincidentally, also 110 basis points. So call that 220. 
The HIF, and remember, you have to tax effect it, because we did give some of that back to members, encompasses a good portion of that 220. And I would say the group phenomena that we called out and the PDP mix, is not insignificant in terms of impacting the MER. 
So I would -- if you want to do on an apples-to-apples incurred basis, I would actually say the MER got better year-over-year if you exclude prior periods and you just do it on an incurred basis. Other than, like I said, the group MER, as we expected, and as we as we price for it, I think that does have an impact on the overall margin in the retail segment, as I think we discussed on the last call. 
With respect to utilization bouncing back, we do assume, as we mentioned, that there will be -- we expect a bounce back in utilization. We are starting to see that again in line with what we what we've expected, particularly on the inpatient side, as more people are using the hospital facilities, in particular, but they're still below par. 
We do expect the utilization of the systems run at or perhaps a little bit above par as the year continues. We are not seeing increased acuity as yet, although as I mentioned with respect to both 2021 but also 2022, we just want to be mindful of how acuity or ""long haulers"" might play into our cost base, particularly for later this year and next year. And so we are definitely mindful of that as well as any just general bounce back in utilization in the system. 
And then on the side of service side, we'll see where it goes. We have seen a decline in D-SNP usage, and that's moved into the home, which I think also, frankly, helps validate the thesis behind the Kindred transaction just as more and more care is taking place into the home. And as Bruce outlined in his remarks, doing everything we can to make the home a much more comprehensive setting where care can be delivered. And so I think our belief is that, that will continue. 
Whether members are more shy -- shy away from the institutional setting. We're [indiscernible]. I would say that 
[Technical Difficulty]"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Still with you.",3,"Still with you."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Excuse me is the operator. I apologize that there will be a slight delay in today's conference. Please hold as the conference will resume shortly. Thank you for your patience. Once again, ladies and gentlemen. I apologize that there will be a slight del",60,"Excuse me is the operator. I apologize that there will be a slight delay in today's conference. Please hold as the conference will resume shortly. Thank you for your patience. 
Once again, ladies and gentlemen. I apologize that there will be a slight delay in today's conference. Please hold and the conference will resume shortly. Thank you for your patience."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","David, are you still there? Are we on the call?",10,"David, are you still there? Are we on the call?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I was on, yes, I am still here.",8,"I was on, yes, I am still here."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Sorry about that. We're in a conference room here, and something just happened. We don't know what it is. So I'm not sure where I got cut off. I hear a little beep. I think it was right around where, we're talking about side of service, site of care is",56,"Sorry about that. We're in a conference room here, and something just happened. We don't know what it is. 
So I'm not sure where I got cut off. I hear a little beep. I think it was right around where, we're talking about side of service, site of care is that where we got cut off?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Outside of service? Yes, you were.",6,"Outside of service? Yes, you were."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Okay. I tell you what I said was actually very profound. So I'm going to see if I can repeat it again, this time with feeling.",26,"Okay. I tell you what I said was actually very profound. So I'm going to see if I can repeat it again, this time with feeling."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","You're on a roll.",5,"You're on a roll."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Okay. I'm going out with a bang here. So on the side of service side, it's -- we'll see what happens in terms of whether seniors are less comfortable about using the institutional setting. We think it's possible that, that could happen. It's certainly not",65,"Okay. I'm going out with a bang here. So on the side of service side, it's -- we'll see what happens in terms of whether seniors are less comfortable about using the institutional setting. We think it's possible that, that could happen. It's certainly not something that we're going to underwrite in our either assumptions this year or bid assumptions next year, but it's possible."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Did you hear the SNP comment? I just wanted to make sure that wasn't cut off.",16,"Did you hear the SNP comment? I just wanted to make sure that wasn't cut off."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. What I said was about, we are seeing -- and I think you would have heard the SNF comment again, I was talking about. We are seeing lower skilled nursing claims, and that people are using the home in that regard, that validated. I think one of the val",62,"Yes. What I said was about, we are seeing -- and I think you would have heard the SNF comment again, I was talking about. We are seeing lower skilled nursing claims, and that people are using the home in that regard, that validated. I think one of the validation points of the Kindred transaction. Hopefully, you heard that part as well."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Scott Fidel from Stephens.",12,"Your next question comes from the line of Scott Fidel from Stephens."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","And I'll just echo my best wishes and thanks to Brian as well. And a question -- I know it's been a theme throughout the call just around some of the trends that you saw in the first quarter, and then keeping the guidance unchanged. But did want to just d",159,"And I'll just echo my best wishes and thanks to Brian as well. And a question -- I know it's been a theme throughout the call just around some of the trends that you saw in the first quarter, and then keeping the guidance unchanged. But did want to just drill in a bit to group in specialty, since it looks like you actually achieved considerably more earnings in the segment in the first quarter relative to the full year, reaffirmed guidance for that segment. So I think that, in particular, looks just pretty conservative right now. 
So -- and obviously, that's a segment that's not really exposed to this uncertainty around the risk-adjusted dynamic in Medicare. So just maybe a little insight into that in terms of if you still just wanted to see how utilization will ultimately develops? Or are you planning on sort of leading into that tailwind to increase your investments within that segment?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, thanks for the question, Scott. Thanks for the comments. I mean, I think you're reading it right. I mean, we're pretty bullish on how group and specialty is going this year. It is early. They do not have the same types of headwinds that Medicare doe",138,"Well, thanks for the question, Scott. Thanks for the comments. I mean, I think you're reading it right. I mean, we're pretty bullish on how group and specialty is going this year. It is early. They do not have the same types of headwinds that Medicare does, certainly on the revenue side. But it is early. 
The prior year development was a positive note. The incurred results that we've seen, we feel good about. The specialty results are also doing well, specialty meaning dental. And I think the military business is having a good start to the year. So really, all elements of our strategy are on course. And the financial performance, I think, is showing. But as you rightly point out, it's still very, very early. And so we want to see a few more quarters develop."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Got it. And Brian, just are there targeted investments that you would look to lean in on that? Or is this an area where the trends continue to look like, that's where you could ultimately revise the guidance around that for the year?",43,"Got it. And Brian, just are there targeted investments that you would look to lean in on that? Or is this an area where the trends continue to look like, that's where you could ultimately revise the guidance around that for the year?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","I would say that we're probably more lean towards more earnings in this segment than investments. We've built in investments into our guide already. I mean there are things around the edges that we would always do in a good year, just to shore up the segm",135,"I would say that we're probably more lean towards more earnings in this segment than investments. We've built in investments into our guide already. I mean there are things around the edges that we would always do in a good year, just to shore up the segment for future success. And it's something that we really want to do, because we think there's -- we think there's really a lot of growth in this segment potential, and really an opportunity to disrupt the current market as it exists. 
There's a lot of appetite to do that among our customer base. And so we will be prudent as we look to make investments. But I think to the extent there are meaningful outperformance in the earnings side, we would imagine that, that would flow through."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Ralph Giacobbe from Citi.",14,"We have our next question comes from the line of Ralph Giacobbe from Citi."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I was hoping to just flesh out the group MA commentary a little bit more, hoping you could frame the magnitude of the pressure from that alone. Because if I heard right, Brian, I think you said that core MLR was actually better year-over-year. So a pretty",78,"I was hoping to just flesh out the group MA commentary a little bit more, hoping you could frame the magnitude of the pressure from that alone. Because if I heard right, Brian, I think you said that core MLR was actually better year-over-year. So a pretty sizable jump in group MA. 
And then it sounds like that's more of a premium issue than a cost issue. So I guess, how does that get fixed at this point?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Okay, I wouldn't characterize it as a problem. I would just say, to Matt's initial question, that the market is more competitive at the high end of the range and these are large accounts. So -- and just given the high PMPM premiums, you could have a prett",275,"Okay, I wouldn't characterize it as a problem. I would just say, to Matt's initial question, that the market is more competitive at the high end of the range and these are large accounts. So -- and just given the high PMPM premiums, you could have a pretty significant revenue dollars here at lower margins. 
And so I wouldn't call it a problem. I would just say, you look at the overall retail -- overall retail segment, MER, I think it's important to normalize for some of the impacts there. And so if you sort of strip that out and you look at sort of year-over-year, I think we're -- from an MER perspective, in a pretty good position. 
And so I wouldn't want to quantify it specifically. Or am I then to say, I think anything not made up by the sort of hits, including the tax benefit, some of which we pass-through with the group MER impact because of the lower -- bidding on the lower margin levels for these large accounts. 
As well as frankly, the continued decline of PDP, which also as we've talked about, has the way the MER dynamics works would, I think, impact the first quarter in a way that would also effectively more, quote rate the 2 year-over-year. So we feel good about the year-over-year MER comparison. 
But again, I wouldn't get too caught up in the group, MER specifically, but rather just an overall commentary on the competitiveness in that one segment of the market. And so it's just something that we're mindful of, and we continue to be very thoughtful about how we price there."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of Ricky Goldwasser from Morgan Stanley.",15,"We have our next question comes from the line of Ricky Goldwasser from Morgan Stanley."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","So question around sort of how you think about build versus partner. At home is clearly closely aligned with telehealth and remote monitoring. So when you step back and you think about company investment that you need to make in that area, do you think th",66,"So question around sort of how you think about build versus partner. At home is clearly closely aligned with telehealth and remote monitoring. So when you step back and you think about company investment that you need to make in that area, do you think the telehealth is an asset that you should buy? Or that's, sort of, something that you can partner with someone on?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. On the telehealth side, we -- first, we won't buy or technology. I think the technology side, we would be leasing and/or, be someone would vend it to us. We feel that, that technology is, frankly, will be a commodity over time. So I just want to sort",219,"Yes. On the telehealth side, we -- first, we won't buy or technology. I think the technology side, we would be leasing and/or, be someone would vend it to us. We feel that, that technology is, frankly, will be a commodity over time. So I just want to sort of break down the different parts of telehealth. 
The second aspect is from who the providers are in that. And we really see there's different channels there, one, the partners and our provider value-based relationships that we have. Most of them already have telehealth, and so we don't need to provide that to them. 
In our clinics, we today have telehealth, and we are utilizing a few different technology platforms. And so we are offering that. And that's -- so we're in that business, but it's through our provider-based businesses. 
And then providers that are needing telehealth we will partner on a vended basis with some technology company to offer that. That's probably less than a minority part of our telehealth business. The first 2 will be the majority. And so I would answer the question that we don't need to partner. It would be more of a vended solution to offer the technology where we will offer or our partners will offer through our contractual relationships, the provider side."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","And my second follow-up question is on the synergies for the acquisition. I think you talked in one of the areas is the in-sourcing, the home health episodes from other providers. I know that in the deck, you talked about $1.1 billion in spend for Humana",101,"And my second follow-up question is on the synergies for the acquisition. I think you talked in one of the areas is the in-sourcing, the home health episodes from other providers. I know that in the deck, you talked about $1.1 billion in spend for Humana MA members. And that overall, it's kind of 19% of episodes, are currently managed by Kindred then 45% in some select market. 
So should we think about the opportunity of in-sourcing kind of like going from kind of like the 19% overall to 45%? Is that sort of a good proxy to think about?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","That could be a proxy. I would say that we're not putting any estimates out there, but our intention is to continue to penetrate in the markets that we operate. And the nice thing about the Kindred asset is that it has 65% overlap for the organization. So",86,"That could be a proxy. I would say that we're not putting any estimates out there, but our intention is to continue to penetrate in the markets that we operate. And the nice thing about the Kindred asset is that it has 65% overlap for the organization. So we have a lot of markets that we can go into. 
But your math is an estimate, but I would also just look at the our capacity to cover that because we're not in 100% of our markets."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question comes from the line of George Hill from Deutsche Bank.",15,"We have our next question comes from the line of George Hill from Deutsche Bank."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Brian, I'm excited to see where you pop up in your next endeavor and I want to wish you well. I guess, just as we think about the Kindred and CenterWell initiatives stepping back, can you guys talk about your outlook for the regulatory environment and pro",89,"Brian, I'm excited to see where you pop up in your next endeavor and I want to wish you well. I guess, just as we think about the Kindred and CenterWell initiatives stepping back, can you guys talk about your outlook for the regulatory environment and provider risk caring. And simplistically speaking, it seems to be a more benevolent regulatory environment, in the core MA business and it should create a better opportunity for returns in the near or medium term? Excuse me, am I thinking about that right?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","I would say from a customer point of view, the regulatory side, because just there's a significant amount of regulation around how we approach the customer and certain rules and compliance around how we service the customer. So I would say from the insura",111,"I would say from a customer point of view, the regulatory side, because just there's a significant amount of regulation around how we approach the customer and certain rules and compliance around how we service the customer. So I would say from the insurance component, you would be right. 
But within each of the care models, there is regulatory. I mean there's compliance regulatory. There's -- there's obviously licensure requirements, billing and et cetera. So I would say, it follows a more traditional provider-oriented fashion regulatory environment. 
But I would say that I wouldn't say it's a free range here. I would say that it has the proper caveats around it."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Lance Wilkes from Bernstein.",12,"Our next question comes from the line of Lance Wilkes from Bernstein."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Yes. I certainly wanted to thank Brian as well. And on the home health business, could you just talk a little bit about how you're looking at the home care delivery models with physicians like the heal and dispatch sorts of models? And would that be the s",96,"Yes. I certainly wanted to thank Brian as well. And on the home health business, could you just talk a little bit about how you're looking at the home care delivery models with physicians like the heal and dispatch sorts of models? And would that be the sort of thing if you expanded into that, that would be integrated into that business? 
Or would it be separate? And I guess, similarly, is frail elderly and programs like pace, kind of something you contemplate within this home health segment? Or are those other sorts of business lines?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, the nice thing about the home channel that we're developing, they have multiple different markets to go into. They're just so if at the appropriate time, pace makes sense, and then we can make that market, I think go into that market. Our big focu",188,"Well, the nice thing about the home channel that we're developing, they have multiple different markets to go into. They're just so if at the appropriate time, pace makes sense, and then we can make that market, I think go into that market. 
Our big focus was how do we get geographic coverage. And obviously, the Kindred distribution of nurses really provides us that opportunity in certain in different markets. Where they reside in the organization today, heal and dispatch relationship resides within our Home Solution group. But it is closely aligned with both from the plan and closely aligned with our primary care strategy. Because what we find is the best solution are the ones that are integrated together, where the plan is integrated with the provider side, the provider or the primary care is integrated with both going into the home, the clinics, in the home care offerings that we have. 
So I would say that it does reside in the Home Solutions area. But the way we operate it is really, and the goal is to have it integrated in the markets that we serve."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Frank Morgan from RBC.",12,"Our next question comes from the line of Frank Morgan from RBC."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Just curious as part of your capital strategy around this spinoff, would you contemplate placing leverage on the spin? I mean, it looks like if you're $300-and-some-odd million of EBITDA in the hospice side of the business, you could put quite a bit of de",110,"Just curious as part of your capital strategy around this spinoff, would you contemplate placing leverage on the spin? I mean, it looks like if you're $300-and-some-odd million of EBITDA in the hospice side of the business, you could put quite a bit of debt on a couple of turns of debt. So just curious your philosophy about how you would capitalize the spinco? 
And then secondly, what is it about the Hospice and Personal Care business that makes it more suitable for a partnership arrangement as opposed to ownership? Is it just geographic overlap? Is it just valuation? Just what specifically could you say about the reason for that?"
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Why don't I take the first one, and Brian can talk about the capitalization side. What we find is the pallative -- the integration of pallative in hospice is very powerful, and being able to offer both of those in an integrated fashion, really creates the",294,"Why don't I take the first one, and Brian can talk about the capitalization side. What we find is the pallative -- the integration of pallative in hospice is very powerful, and being able to offer both of those in an integrated fashion, really creates the opportunity for us to partner across the hospice business as opposed to having 1 vendor, so to speak in that. 
The second thing, hospice is much more fragmented than home health. Although home health is quite fragmented, hospice is much more fragmented. So our ability to offer hospice in multiple markets, you're going to have to partner anyway. And so what we've -- I think we found a very dainty solution here where we can still be -- have a significant relationship with Kindred hospice through a minority ownership and be able to then utilize that as an opportunity to integrate in the markets that they're at and integrate pallative in as part of that, but still have the flexibility to offer it in a broader fashion. 
Obviously, as we think about where our priorities of capital and where we put capital, we were going to put it in the areas that have the most impact and where we can have the most opportunity for growth. And we see home having a platform that has multiple different platforms to grow. And so when we think about capital deployment and efficiency of capital, I know, Frank, you've been following us a long time. I think you can see that, that is an area that we're constantly looking at, as not only the businesses that we're in, but also how do we continue to generate above-average returns. And the way where we deploy that capital is important to that."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. And just to add on the capital question, there's no doubt that hospice is a company that we can leverage. And so it's not something we'll disclose today. But we do intend to put that on the hospice co before we spin it. And so stay tuned for that. Bu",54,"Yes. And just to add on the capital question, there's no doubt that hospice is a company that we can leverage. And so it's not something we'll disclose today. But we do intend to put that on the hospice co before we spin it. And so stay tuned for that. But you are correct."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","And there are no further questions at this time. I'll turn back the call over to Bruce Broussard. Sir, please continue.",21,"And there are no further questions at this time. I'll turn back the call over to Bruce Broussard. Sir, please continue."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Just to conclude the call, I'd like to just make a few comments. I think, first, there's been a consistent question around basically, why didn't we raise earnings to be completely honest with you, to be direct here. We have had a strong first quarter, b",275,"Just to conclude the call, I'd like to just make a few comments. I think, first, there's been a consistent question around basically, why didn't we raise earnings to be completely honest with you, to be direct here. 
We have had a strong first quarter, but we are early in the year. I just want to reemphasize that we continue to see the trends that we put in the first quarter as being continuing, but we want to make sure that we are able to see those trends through a longer time frame before we make any kind of adjustments in our estimates there. And I hope the investors take that away. It's much more around it's just earlier, as Brian has said early in the game here. 
The second thing, as many of you have said, and thank Brian, for just his wonderful contribution over the 7 years he's been here, and I know he'll show up some place in health care. And I think you'll -- I'm sure that each one of you will invest in what he does is if and his next goal there. So because he has delivered a lot of value to our shareholders and to our members and to our associates there. 
And then third, the quality of our earnings, our strategic advancement this quarter and over many quarters previous to this couldn't have been accomplished without our 50,000 associates that are working every day on behalf of each one of you and our providers and our customers there, and I want to thank them for that. So thank you, and I hope everyone has a great day."
29618,709205934,2260486,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","This concludes today's conference call. Thank you all for participating, and you may now disconnect. Have a great day.",20,"This concludes today's conference call. Thank you all for participating, and you may now disconnect. Have a great day."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Good day, and thank you for standing by. Welcome to the Humana First Quarter 2021 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] With that, I would now like to hand the confere",58,"Good day, and thank you for standing by. Welcome to the Humana First Quarter 2021 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] 
With that, I would now like to hand the conference over to your speaker today, Amy Smith, Vice President of Investor Relations. Thank you, and please go ahead."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Chief Financial Officer, will discuss our first quarter 2021 results and our updated financial outlook for 2021. Following these pre",381,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Brian Kane, Chief Financial Officer, will discuss our first quarter 2021 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Joe Ventura, our Chief Legal Officer, will also be joining Bruce and Brian for the Q&A session. We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. 
Additionally, we have posted supporting materials to our Investor Relations page related to the Kindred at Home transaction announced last night. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. 
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission and our first quarter 2021 earnings press release as they relate to forward-looking statements, and to note in particular, that these forward-looking statements could be impacted by risks related to the spread of and response to the COVID-19 pandemic. 
Our forward-looking statements should, therefore, be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements and future filings or communications regarding our business or results. 
Today's press release, our historical financial news releases and our filings with the SEC are also available on our Investor Relations site. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Finally, any references to earnings per share, or EPS, made during this conference call refer to diluted earnings per common share. 
With that, I'll turn the call over to Bruce Broussard."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Thank you, Amy, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $7.67 for the first quarter of 2021, and reaffirmed our full year 2021 adjusted EPS guidance of $21.25 to $21.75. Our first quarter results r",1695,"Thank you, Amy, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $7.67 for the first quarter of 2021, and reaffirmed our full year 2021 adjusted EPS guidance of $21.25 to $21.75. Our first quarter results reflect solid performance across each of the company's segments, fueled by strong individual Medicare Advantage and state-based membership growth, and improved profitability in the Group and Specialty and Healthcare Services segments. 
As we continue to navigate the pandemic, we also meaningfully advanced our strategy during the quarter. I want to congratulate our Medicaid organization on the significant contract award in Ohio, which when combined with recent additions of Oklahoma, South Carolina and Wisconsin, brings our Medicaid footprint to 7 states. These additions affirm our capital-efficient organic growth strategy and further demonstrates the strength of our Medicaid capabilities built on our Medicare Advantage chassis. 
We also continue to deliver compelling dual Special Needs Plan membership growth. These net membership increased approximately 23% in the quarter, and we now serve more than 0.5 million D-SNP members. We remain committed to proactively addressing disparities in health care for underserved populations and recognize that Medicare Advantage and Medicaid plans are uniquely positioned to address the needs of these members. 
Data shows that Medicare Advantage is continuing to grow as the preferred option for those who are low income and for racial and ethnic minorities, with more than 28% of Medicare Advantage beneficiaries being racial and ethnic minorities as compared to 21% in traditional Medicare. Currently, 55% of Latino and 39% of African-American beneficiaries have actively chosen to enroll in MA, and there is growing diversity in enrollment because of the value provided to beneficiaries. The ability of MA plans to adapt to change and drive innovation and better clinical outcomes is why today nearly 27 million seniors have chosen MA over original Medicare. 
Our ability to drive innovation and improve clinical outcomes is enabled by our strong integrated care delivery platform. And in recent years, we have significantly expanded our Healthcare Services capabilities, from primary care to pharmacy to home care and more, in order to better serve our medical members and to significantly strengthen our payer-agnostic care offerings. 
These services help deliver on the promise of better quality and health outcomes, lower cost and a simpler, more personalized experience for the people they touch. These advancements also provide a solid foundation to ultimately serve individuals beyond our MA membership base, including original Medicare fee-for-service members, as we continue to evolve and expand beyond managed care to a broader clinical services orientation with the ability to manage risk and coordinate care outside of MA. 
During the quarter, we took the next step in this evolution, introducing CenterWell as the new brand to unite our broad range of payer-agnostic Healthcare Service offerings. The CenterWell brand speaks to how we put our members and patients at the center of everything we do. The first Humana-owned services to adopt the brand are Partners in Primary Care and Family Physician Group, named CenterWell Senior Primary Care. We are also accelerating our strategy around the home. And as I will discuss in a moment, the home will be the next service to adopt the CenterWell brand. 
We see the home coupled with our primary care strategy as the mix meaningful opportunity to improve access to quality, proactive care for a broader senior population. As such, we continue to invest in assets that allow us to better manage the holistic needs of our members and patients by expanding care in the home, including primary care, telehealth and emergency room care while also addressing social determinants of health. 
The home health industry is among the fastest-growing health care industry in the U.S. as a result of an aging population, the prevalence of chronic disease and growing physician acceptance of care in the home. This need has only been accelerated by COVID-19. However, we recognized for some time that the current volume-based fee-for-service model has limited the innovation in home health. 
Accordingly, in 2018, we acquired a 40% interest in Kindred at Home, embarking on a journey to test and learn innovative clinical models in the home with the goal of evolving home health to value-based payment models. Today, Kindred at Home employs approximately 43,000 caregivers providing home health, hospice and community care services to over 550,000 patients annually. They have locations in 40 states, providing extensive geographic coverage, with approximately 65% overlap with Humana's individual Medicare Advantage membership. 
Yesterday, we announced that we signed a definitive agreement to acquire the remaining 60% interest in Kindred at Home. As detailed in the press release we issued last night, the Kindred at Home transaction represents an enterprise value of $8.1 billion, including the value of Humana's existing 40% equity interest. This acquisition, which is expected to close in the third quarter of this year, is the largest in Humana's history and comes at a pivotal time in health care, when a worldwide epidemic has exasperated the existing disparities in health care for underserved populations and highlighted the power of telehealth and in-home care and addressing those disparities. 
Further, the pandemic has reinforced patients' increasing desire for convenient and personalized delivery channels, requiring innovative home care offerings. The acquisition of Kindred at Home will provide us with an extensive network of nurses, a critical distribution channel for delivering care in the home. 
However, we recognize the need for innovative home care offering at scale. Through our successful partnership with Kindred's management team and our private equity partners over the last few years, we have proved that altering the nurses' clinical interaction in the home improves care. We've demonstrated that we can reduce the cost of care and provide value to shareholders through additional referrals to Kindred, advancing effective clinical interventions in the home and supporting higher acuity patients by leveraging other home-based assets we've assembled. 
[ Created ] at home health episodes served by Kindred at Home has increased from 8% to 19% overall in markets with geographic overlap, reaching penetration as high as 49% in certain key markets. In addition, Kindred at Home continues to demonstrate superior patient outcomes, including reduced hospitalizations, admissions and ER utilization. 
Management's successful transition of Kindred at Home to an independent home health and hospice company, the strong and growing core business as reflected in Kindred's solid historical EBITDA compounded annual growth rate of approximately 20% since 2017, our demonstrated ability to deliver savings to health plans through reduced hospitalizations and the ability to drive increased referrals to Kindred at Home provides us the confidence to accelerate our 100% ownership of Kindred. Full ownership allows us to move from market testing to full-scale implementation over time. 
We recognize the significant value we can deliver to members and patients by integrating this asset into our holistic approach to care. Fully integrating at home -- Kindred at Home will enable us to more closely align incentives to focus on improving patient outcomes and on reducing the total cost of care. This is critical to deploying at scale a value-based advanced home health model that makes it easier for patients and providers to benefit from our full continuum of home-based capabilities. By leveraging the best channel to deliver the right care needed at the right time, we believe we can deliver outcomes and value beyond what isn't possible in traditional fee-for-service models. 
As shown on the slide deck that we posted to our Investor Relations website this morning, home health utilizers are 5x more likely to have an inpatient admission within 120 days of the start of their home health episode as compared to an individual MA member that does not utilize home health. This speaks to the significant opportunity we have to continue to improve outcomes and lower costs for this population. We look forward to sharing additional details about the value creation we plan to drive with our home health strategy at our Investor Day in June. 
While the acquisition includes the operations of Kindred's hospice and community care operations, our intent is to ultimately only maintain a minority interest in this portion of the asset. Our experience with hospice demonstrates the integration of palliative and traditional hospice care improves the quality of life for patients transitioning from restorative care to hospice. However, we have been successful delivering the desired patient experience and outcomes through partnership models, demonstrating we do not need to own a majority interest in a hospice asset long term. 
Kindred at Home will be integrated into Humana's Home Solutions business under the leadership of Susan Diamond. When combined, our Home Solutions' geographic scale and clinical breadth will provide the opportunity to offer care beyond Humana members. And as a result, we will transition to our CenterWell brand as CenterWell Home Health. 
Luckily, Kindred Care services will be integrated and coordinated with other care offerings, including CenterWell's Senior Primary Care and convenience VBID as well as our primary care and emerging care offerings in the home via our investment in Heal and DispatchHealth. 
Before turning the call over to Brian, I want to acknowledge that this will be his last earnings call at Humana and thank him for his invaluable contribution to Humana over the last several years. Among his many contributions, Brian brought rigor to his role in the creation of a strong financial capability, not only through sophisticated physical and ongoing operational discipline, but also by developing a deep bench of talent within our financial organization to drive this discipline forward. 
We wish Brian the very best in his next chapter. As previously announced, Brian will remain in his current role through June 1 and then serve in an advisory role through the end of the year. On June 1, Susan Diamond will assume the role of interim CFO while we complete our search for a permanent replacement. Given Susan's strong knowledge of our business and financial expertise, I have great confidence in her ability to lead the finance team as we recruit a new CFO. Susan will also continue to lead the Home Solutions business. 
With that, I'll turn the call over to Brian."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. Today, we reported adjusted EPS of $7.67, reflecting a positive start to the year across our segments, particularly in light of the impacts that the pandemic has had on our results, which we outlined on our fo",1898,"Thank you, Bruce, and good morning, everyone. Today, we reported adjusted EPS of $7.67, reflecting a positive start to the year across our segments, particularly in light of the impacts that the pandemic has had on our results, which we outlined on our fourth quarter 2020 earnings call in February. While the first quarter came in modestly ahead of our previous expectations, it is early and we are continuing to work through uncertainty related both to our revenue and claims due to pandemic. 
Specifically as it relates to revenue, given our significant exposure to Medicare Advantage, we are disproportionately affected by COVID's impact on Medicare Risk Adjustment, or MRA. Our risk-adjusted revenue is determined by 2020 dates of service, medical utilization and resulting documentation, which as previously discussed, was materially depressed last year. In particular, we are focused on monitoring the impacts on utilization from the late surge of COVID cases in 4Q, which occurred following the communication of high-level 2021 guidance on our third quarter earnings call. 
While the extension of sequestration helps mitigate any potential pressure against our estimates, I would remind investors that a critical indicator of 2021 revenue relative to our initial expectations will be the midyear MRA payment, which we expect from CMS anytime in the next 1 to 3 months. The mid-year payment, which effectively rolls forward the dates of service used for 2021 payment to year-end 2020 from mid-year 2020 and incorporates the impact on risk-adjusted revenue of our new members is meaningfully more uncertain this year given the 4Q dynamics I mentioned, as this payment requires significant estimation even in normal times. 
As it relates to benefits expense, non-COVID utilization is running largely in line with our previous expectations and, as anticipated, is still depressed relative to baseline. The first 3 months of in-patient admissions were down approximately 20%, 15% and 10% in January, February and March, respectively, relative to baseline, with the first few weeks of April, seeing non-COVID inpatient trends moderate to around 5% depressed. 
Separately, non-inpatient spend is also depressed, although it appears to be rebounding a bit faster than previously expected, with the caveat that the completion on non-inpatient claims is much slower, and therefore, there is significantly more uncertainty around these service categories in terms of exactly where we stand. 
Finally, COVID admissions, which tend to have higher unit costs than those of non-COVID, came down more quickly than expected in the quarter. The COVID case deceleration moderated in late March and seems to be holding flat in early April, as certain geographic locations have become hotspots. We expect utilization to continue to rebound at par as we move through the second quarter and to slightly exceed baseline towards the end of the year. 
Given that we remain in a period of heightened uncertainty, we are reaffirming our full year 2021 adjusted EPS guide of $21.25 to $21.75 as well as the benefit expense and operating cost ratios notwithstanding the favorable first quarter results. This represents adjusted EPS growth of 16% above the 2020 baseline of $18.50 at the midpoint of our guide, nicely above the high end of our long-term EPS growth target of 11% to 15%. 
I would note that we have been consistent in our expectation of adjusted EPS growth above our long-term target since we provided our initial 2021 commentary on our third quarter 2020 earnings call in November. Additionally, we expect our second quarter adjusted EPS to reflect a low 30s percentage of our full year adjusted EPS. 
As we look ahead to 2022, we are pleased that our members appear to be engaging in more routine interactions with their providers, which we anticipate will result in more normalized Medicare Advantage revenue next year as providers are able to ensure that our members are receiving an appropriate level of care and that their conditions are being documented. 
While it is, of course, too early to provide 2022 guidance, I would note that as we think about our Medicare Advantage bids for 2022, our intention is to reflect the continued uncertainty associated with COVID-19 in our premium and claims assumptions. In addition, I would like to reiterate that the appropriate baseline for calculating 2022 adjusted EPS growth is $21.50, the midpoint of our 2021 guidance range. 
I will now briefly discuss each of our segment's performance in the quarter. In the Retail segment, in addition to the revenue and claims dynamics I discussed, our Medicare Advantage growth remains comfortably on track and consistent with our previous expectations, with individual MA growing solidly above the market at an expected 11% to 12% increase. 
As Bruce indicated in his remarks, we experienced robust growth in D-SNP membership, adding 95,000 members in the first quarter, with an additional 12,400 added effective April 1. I also want to echo Bruce's congratulations to our Medicaid team on their state contract awards in Ohio and Oklahoma, along with our application approval in South Carolina during the quarter. An incredible achievement, demonstrating the strength of our Medicaid capabilities. 
In our Group and Specialty segment, consistent with our commentary on our last earnings call in February, medical membership declines on account of COVID were less severe than initially expected coming into the year. The segment performance continues to improve, and we continue to execute on the first phase of a multiyear plan to grow our group commercial and specialty products, bringing in strong new talent, increasing our local presence in certain key markets and deepening our partnerships with innovative companies. 
Our dental network expansion is proceeding ahead of plan. Our small group commercial medical pipeline volume is back in line with pre-COVID levels. And our Net Promoter Scores for our large group medical accounts were at a record high for first quarter performance. 
Finally, our Healthcare Services operations remain on track with our previous expectations. In our pharmacy operations, we continue to pursue pharmacy initiatives that we expect to further increase mail order penetration as the year progresses. I would note that this anticipated spend to accelerate growth, coupled with labor-related overtime and shipping costs due to weather-related disruptions in February, did modestly impact the pharmacy business results in the quarter. CenterWell's Senior Primary Care and Conviva are performing well and we continue to execute on our clinic expansion with Welsh, Carson. 
Kindred at Home is also delivering solid results. And as Bruce indicated in his remarks, we are accelerating our full acquisition of Kindred at Home. With respect to Kindred, last night we announced that we signed a definitive agreement to acquire the remaining 60% interest in Kindred at Home for a total enterprise value of $8.1 billion, including $2.4 billion associated with our current 40% equity interest. We do not anticipate a material impact to non-GAAP or adjusted earnings in 2021. 
We expect the transaction to provide modest additional financial flexibility as we set targets for 2022 earnings, although I would note that buying in Kindred has long been a part of our financial planning process, which has included providing capability to build out our clinical capabilities and value-based care model. In addition, we intend to exclude onetime transaction and integrated costs related to the acquisition from non-GAAP earnings. Key financial terms are outlined in the slides available on our website accompanying today's earnings call. 
The innovative partnership we created with Welsh, Carson and TPG will deliver significant strategic and financial value to Humana. Executing on the Kindred at Home transaction now versus waiting for the contracted sponsor put option that would likely not be exercised until mid-2022, given the asset's strong EBITDA growth, not only accelerates the strategic benefits as Bruce described, but importantly, allows us to acquire the nation's largest home health and hospice company for a multiple meaningfully lower than where comparable public companies are trading today. 
Additionally, we expect that we will be able to capitalize on a robust market for hospice assets by divesting a majority stake in that portion of the business at what we anticipate will be an attractive valuation. 
As to the EBITDA multiple we are paying for Kindred at Home, investors should consider the $5.7 billion purchase price for the remaining 60% interest, plus our initial investment of $1.1 billion for our 40% stake in 2018, which when grown at a reasonable 8% weighted average cost of capital for a present value of $1.4 billion, equates to a total cash purchase price of approximately $7.1 billion all in. When using a normalized full year 2021 estimated EBITDA for Kindred at Home, inclusive of hospice and community care, the transaction EBITDA multiple is approximately 11x. 
It is important to note that the normalized EBITDA excludes expected home care and hospice investments in clinical capabilities and value-based care models, onetime costs including transaction and integration expenses and any potential synergies. The expected synergies will primarily result from the meaningfully enhanced clinical capabilities Bruce has described, which will materialize over time, in addition to the EBITDA benefit of in-sourcing further home health episodes from other home health providers. 
One other important note regarding the financial value created that I would mention, after adjusting for our intended divestiture of a majority interest in the hospice and community care assets at a reasonable market valuation, the implied transaction EBITDA multiple for acquiring the nation's largest home health business would be in the mid- to high-single digits, based on the roughly 50-50 split of the EBITDA between the home and hospice community care segments. 
As far as the transaction financing is concerned, we expect to fund the $5.7 billion purchase price, which again is net of our existing equity interest, with a mix of parent company cash and debt financing. The transaction is expected to close in the third quarter of 2021 subject to customary state and federal regulatory approvals. 
Immediately following the closing of the transaction, we expect our consolidated debt-to-capital ratio to be in the low 40s, with significant deleveraging expected post divestiture of the majority stake in hospice and community care. We expect the debt-to-capital ratio, including assuming a customary level of share repurchase, to return to a more normalized target leverage level during 2022, freeing up the balance sheet for further capital deployment. We anticipate maintaining our investment-grade credit rating as a result of this transaction. 
Before we open the line up for questions, I want to take a moment to thank our associates, shareholders and sell-side analysts for their support over the last 7 years, as this will be my final Humana earnings call. I'm very proud of what the company has accomplished in a period of rapid transformation. And I know that under Bruce's leadership and with the support of the outstanding team across the organization, the company is well positioned to continue to execute on its strategic plan and deliver significant shareholder value in the years ahead. 
It's been a true honor to serve the millions of Humana members, and I'm grateful to have worked with so many talented colleagues. I remain fully committed to a seamless transition in the coming weeks and months. And I'm very excited that Susan Diamond will serve as interim CFO. Susan is someone I've worked with extensively over the last 7 years and is one of the most talented people I know. 
With that, we will open the lines up for your questions. [Operator Instructions]. Operator, please introduce the first caller."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] We have our first question comes from the line of Matthew Borsch from BMO Capital Markets.",18,"[Operator Instructions] We have our first question comes from the line of Matthew Borsch from BMO Capital Markets."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I was hoping maybe you could elaborate a bit on the increased competition that you're seeing in the group Medicare Advantage area, what you think is driving that and how you think that might settle out.",37,"I was hoping maybe you could elaborate a bit on the increased competition that you're seeing in the group Medicare Advantage area, what you think is driving that and how you think that might settle out."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Sure. I'll take that. Well, just as we mentioned really on several calls, the group M&A market, particularly on the large-scale accounts, has continually become more competitive. There are several players who you know well, who are pursuing these accounts",191,"Sure. I'll take that. Well, just as we mentioned really on several calls, the group M&A market, particularly on the large-scale accounts, has continually become more competitive. There are several players who you know well, who are pursuing these accounts. And they're obviously attractive pieces of business. They're large membership, significant revenue. And there are positive knock-on effects as well to winning these accounts in the local markets in which we operate with respect to providers, et cetera, and visibility. 
And so there's a lot of competition for these accounts. We remain very well positioned there. Our group MA team has really been very smart about how they've underwritten these accounts. We're not going to chase accounts down to profitability levels that we don't think are sustainable. And so we're being prudent and thoughtful as we pursue these opportunities. But again, feel very good about how we're positioned in group MA, notwithstanding the competition there. 
I would note one thing, though, that at the sort of smaller group account size, sort of mid- level accounts and small-level accounts, the profit margins are better and more attractive from a pure profitability perspective."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","We are trying to -- just to add to Brian's comment, we are trying to differentiate through the service component of that. And we do find as a result of employers being responsible for the selection of this, that's an important differentiation. It's not al",63,"We are trying to -- just to add to Brian's comment, we are trying to differentiate through the service component of that. And we do find as a result of employers being responsible for the selection of this, that's an important differentiation. It's not always going to win over price, but we found on a number of accounts that has won over price."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, it comes from the line of Robert Jones from Goldman Sachs.",16,"We have our next question, it comes from the line of Robert Jones from Goldman Sachs."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I guess maybe just one on the headwinds and tailwinds, and I appreciate the qualitative commentary around utilization and COVID testing and treatment. Just wanted to see if those ranges you had laid out last quarter around those headwinds are still kind o",102,"I guess maybe just one on the headwinds and tailwinds, and I appreciate the qualitative commentary around utilization and COVID testing and treatment. Just wanted to see if those ranges you had laid out last quarter around those headwinds are still kind of how you're seeing the world 1 quarter in. And then on the tailwinds side, I know you were looking at sequestration relief of, I think, just 1 quarter last quarter and now with it being pushed out to the end of the year. Just wanted to get your latest thoughts on how that's being contemplated within the updated guidance."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Sure. Well, I would say that the ranges that we laid out in the fourth quarter call are consistent with what we're seeing today. And so we remain within those ranges. And again, that's, I think why we're comfortable, obviously, reiterating the guide that",121,"Sure. Well, I would say that the ranges that we laid out in the fourth quarter call are consistent with what we're seeing today. And so we remain within those ranges. And again, that's, I think why we're comfortable, obviously, reiterating the guide that we put forth today. The sequestration clearly is positive from an earnings perspective. But I think we have to consider that in the context of the overall headwinds and tailwinds that we see over the coming 9 months. And so while that certainly, as we mentioned in our remarks, is a positive tailwind to offset any potential pressure that we might see over the coming months, it's still very early. And so that's why we reaffirm today."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Got it. Best of luck, Brian.",6,"Got it. Best of luck, Brian."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","You bet.",2,"You bet."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, it comes from the line of Justin Lake from Wolfe Research.",16,"We have our next question, it comes from the line of Justin Lake from Wolfe Research."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","First, let me wish Brian good luck as he moves on, and thanks for everything over the last 7 years, Brian, it's been a pleasure. And then my -- I wanted to follow-up, based on Bob's question here, just kind of to narrow it down a little bit. My read of",140,"First, let me wish Brian good luck as he moves on, and thanks for everything over the last 7 years, Brian, it's been a pleasure. 
And then my -- I wanted to follow-up, based on Bob's question here, just kind of to narrow it down a little bit. My read of kind of your updated view on 2021 is that you feel more comfortable about offsetting the headwinds that you kind of lined out in January given where trends are coming in plus that benefit of sequestration, and that the remaining swing factor here is that risk adjustment true-up in June. Am I thinking about that correctly, first? And then if so, any thoughts on how wide the outcome could be on that true-up? And then lastly, can you tell us how you're doing with recapturing risk scores for 2022?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, first of all, Justin, thank you for the comments. With respect to -- let's start with risk adjustment. Obviously, there are ranges of outcomes and they could be material. And so I would say as we think about the potential headwinds and tailwinds, th",351,"Well, first of all, Justin, thank you for the comments. With respect to -- let's start with risk adjustment. Obviously, there are ranges of outcomes and they could be material. And so I would say as we think about the potential headwinds and tailwinds, that is one that we're very mindful of and it's something that, as I said to the last question, the sequestration is helpful, but it's still early. 
And so I would say that we're sort of in a similar posture as we were last quarter at this time. There are headwinds and tailwinds that we look at. And we want to be, I think, pretty cautious as we head into the last 9 months of the year because there's still a lot of uncertainty. And clearly, MRA is an important element of that, but there's also the claims side which we have to see unfold over the next 9 months. 
And we obviously have assumptions about how claims are reverting to baseline levels, which they seem to be doing sort of in line with -- largely as we expected. I would say non-inpatient maybe a little bit faster but sort of in the range, and inpatient in line, with COVID coming down faster. So that's obviously a positive. So there are a few puts and takes in those numbers. But I think there's a bit of a ways to go before, obviously, we're fully comfortable there. 
As it relates to the documentation for 2022, as I mentioned, we are feeling reasonably good about what we're seeing so far. It still is early, but the documentation codes do seem to be coming in, in a way that makes us feel good about 2022. We've been effective in getting into the home through our in-home assessments program. We ramped those up pretty meaningfully. And so that I think is a positive side for 2022. But we also will be cautious as we price 2022 and run a range of scenarios to understand what the various eventualities may be on both revenue and claims as a result of the pandemic."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. Just -- maybe I can just reiterate what Brian is saying. We obviously had a good quarter. And -- but I would say that we -- as Brian has said, is we're early into this, we are looking at the assumptions we made and setting out the year. And this is -",135,"Yes. Just -- maybe I can just reiterate what Brian is saying. We obviously had a good quarter. And -- but I would say that we -- as Brian has said, is we're early into this, we are looking at the assumptions we made and setting out the year. And this is -- this is a good growth year for us. It's going to be in excess of 15%. And we just want to make sure that we see how the rest of the year plays out more before we adjust any of our estimates there. And I think that's probably the best thing that investors should take away from is that we still are confident in what we've put out there as an assumption side, but it's the first quarter of 4 quarters here."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, it comes from the line of A.J. Rice from Crdit Suisse.",16,"We have our next question, it comes from the line of A.J. Rice from Crdit Suisse."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Best wishes, Brian, as well. It's been great working with you. Just maybe I'll go and ask about the Kindred asset. As you described the way you're calculating that 11x purchase price, I may not be thinking about it rightly. But if it's $3.2 billion of rev",138,"Best wishes, Brian, as well. It's been great working with you. Just maybe I'll go and ask about the Kindred asset. As you described the way you're calculating that 11x purchase price, I may not be thinking about it rightly. But if it's $3.2 billion of revenues and it's an 11 multiple that you've paid given your purchase price, it would imply a sort of operating -- an EBITDA of about $645 million. I wondered if that was the right way to think about it. 
And then have you got clarity on how you're going to get rid of the hospice business? Is it open for sale? Is it a spin-off? And will that hospice business then be able to get back into adult home care and compete with Kindred? Or is there limitations on that hospice business?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","A.J., I'll take the latter question and then Brian can [ talk about ] the multiple side. We are in the early stages of spinning it off. So there is definitely a commitment of us to spin it off. Our intentions would be to move down the road of possibly an",221,"A.J., I'll take the latter question and then Brian can [ talk about ] the multiple side. We are in the early stages of spinning it off. So there is definitely a commitment of us to spin it off. Our intentions would be to move down the road of possibly an IPO. But there's a long ways between here and there, and we understand that this is a great asset. It's an asset -- it's a leading hospice asset in the marketplace. It is the -- it's got great operations from an operating point of view. Strong management team. And so I think it is going to be an asset that is going to have a lot of interest from multiple different buyers, so to speak. 
We haven't worked out the contractual terms of can they reenter into the home business, I think, even if they were to do that. It is a fragmented industry. But it is also an industry that, as you all know, because of legalities of licensure issues and being able to get home health license isn't the easiest thing in the world, especially both in CON states and to get a Medicare reimbursement side. So we do believe that there's barriers to entry in just getting into the business. So we're less worried about that."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. And I would say, A.J., on the EBITDA, that's -- you're broadly thinking about it right in terms of the numbers.",22,"Yes. And I would say, A.J., on the EBITDA, that's -- you're broadly thinking about it right in terms of the numbers."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, comes from the line of Kevin Fischbeck from Bank of America.",16,"We have our next question, comes from the line of Kevin Fischbeck from Bank of America."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Okay. Great. And thanks, Brian, for all your help over the years. But I guess -- I'm still struggling a little bit with this guidance number. The -- we were coming up with the sequestration benefit being maybe as much as $1.50 or so. And so I guess this l",177,"Okay. Great. And thanks, Brian, for all your help over the years. But I guess -- I'm still struggling a little bit with this guidance number. The -- we were coming up with the sequestration benefit being maybe as much as $1.50 or so. And so I guess this lower visibility, I guess, today than when you had last year or when you provided guidance for Q4, is a little bit surprising me. 
It's not necessarily something that I'm hearing from the other managed care companies. I just want to hear a little bit more about why you think there is still so much lack of visibility in that number at this point, even though Q1 came in better. Like there was good PPD, and now you've got a big sequestration tailwind. It seems like that uncertainty would have to be significant. And then if it is significant, you're still reaffirming this number as your base for thinking about 2022. How can you feel comfortable that you would be able to fully reprice that into next year?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, I guess -- there's a lot in that question. I would say, first off, in terms of our confidence for pricing next year, I mean we -- as I said in my remarks, we're going to reflect any uncertainty that we see in our bids to ensure that there are any is",483,"Well, I guess -- there's a lot in that question. I would say, first off, in terms of our confidence for pricing next year, I mean we -- as I said in my remarks, we're going to reflect any uncertainty that we see in our bids to ensure that there are any issues that we can contemplate here with respect to various scenarios that may play out, we would have considered in our bid. So I think that's the first thing. So $21.50, from a pricing perspective, we feel very good about. 
We also feel good about the reiterated guidance that we provided today. I would say relative to perhaps some of our peers, we have a much higher concentration of Medicare revenue and Medicare claims, which I think in many respects, particularly on the revenue side, have more volatility. But on the claims side as well, you're making assumptions about how seniors who have not used the health care system for a long time, how they're going to respond in the next, call it, back half of the year. 
And in that regard, we just want to -- and we think it's appropriate to be cautious about how they might use the system in the back half of the year. Especially as we saw, again, the depressed utilization in the fourth quarter, how does that all play through. And so that's, I think, appropriate caution. As we said, the sequester benefit is beneficial for obvious reasons. So that is clearly a tailwind. 
But I think understanding how impactful on our revenue numbers the last -- the fourth quarter was, is still out there, in particular, because the way the midyear payment works as it rolls forward to the last 6 months of the year in terms of how we get paid and understanding the documentation codes that were collected is something that we really need to understand both on existing members as well as, frankly, new members. We get a lot of new members every year. 
Remember, it's not just the net growth, but it's just the number of new sales that we have. And so from that perspective, there's uncertainty there. Again, I feel pretty good about where we are today. But we don't think it would be appropriate to change our guide. 
The last point I'd make is we came into the year committed to our 16% growth rate, which was above our target. And that's where we continue to be. We -- versus perhaps some of our other peers, those numbers have not modified. And we actually obviously put out a number of ranges on a number of variables here, which are -- there was a reasonable amount of uncertainty starting from the fourth quarter. And as I mentioned, that continues. But again, I think the first quarter is a good quarter, but there's still a ways to go."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Okay. Great. Actually, just real quickly, you say that you'll know the number when you get the payment from CMS midyear. Does that mean with Q2 results, we should kind of have the answer? The coding benefit will be known and then sequestration would come",63,"Okay. Great. Actually, just real quickly, you say that you'll know the number when you get the payment from CMS midyear. Does that mean with Q2 results, we should kind of have the answer? The coding benefit will be known and then sequestration would come in and we would expect an updated guidance for Q2 then. Is that how to think about it?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, it depends. I mean, possibly. I mean CMS changes each year, exactly when they give them the midyear payment. My guess is we will have visibility by the second quarter call. But there's no guarantees. But I would say, most likely by the second quarte",58,"Well, it depends. I mean, possibly. I mean CMS changes each year, exactly when they give them the midyear payment. My guess is we will have visibility by the second quarter call. But there's no guarantees. But I would say, most likely by the second quarter call, we will have some visibility into our midyear MRA payment, yes."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, it comes from the line of Josh Raskin from Nephron.",15,"We have our next question, it comes from the line of Josh Raskin from Nephron."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I'll let go of the congratulations as well, so thanks to Brian as well. So my question is just on the segmentation and what does it look like. What is the segments for Humana look like if we think sort of 3 years out? I'm interested in both sort of organi",114,"I'll let go of the congratulations as well, so thanks to Brian as well. So my question is just on the segmentation and what does it look like. What is the segments for Humana look like if we think sort of 3 years out? I'm interested in both sort of organizational or operational structure of the company. But also reporting. And I'm really concentrating on kind of what businesses are going to be included in, I don't know what you'll call, sort of the non-insurance segment. It sounds like most of the branding is going towards [ CareWell ]. And sort of what sort of disclosures and thoughts you guys have on that."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Let me start and then ask Brian to add. As we -- we are building a Healthcare Services division, and I think of it as the simplest component, which we'll now have. Start out with our pharmacy business, which is the largest part of the business. Our primar",255,"Let me start and then ask Brian to add. As we -- we are building a Healthcare Services division, and I think of it as the simplest component, which we'll now have. Start out with our pharmacy business, which is the largest part of the business. Our primary care business will be part of that. And our home health business will be part of that. And then we'll have some other Healthcare Services here and there over time. 
But those would be the 3 primarily large driving profitable arms of the organization there. They will serve multiple different markets. They will serve our existing members and be integrated with our existing members through technology and the service component of that. They will also serve when -- in the appropriate area, Medicare fee-for-service areas such as direct contracting would be an example of that. And they will serve other providers -- I mean, other payers as we do today in value-based payment models and will take full risk. 
And so the opportunity we have is to take advantage of the organic growth of each of those markets to be able to then integrate those together and take advantage of offering a value-based offering to different payment mechanisms, whether it's within MA to other payers or within a direct contracting area. And then in addition, it's also the opportunity for us to serve our existing members there. And so I think you'll see the  CenterWell segment be just evolving to be the -- our Healthcare Services segment."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","And are there short-term thoughts on increased disclosures or rebranding or resegmentation?",13,"And are there short-term thoughts on increased disclosures or rebranding or resegmentation?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","I think with the entry on to with Kindred, I think we'll have to bring in other discussions there. And I think that probably, as we close on Kindred, you'll probably see -- enter the 2022, you'll probably see more enhanced statistical side of the operatio",52,"I think with the entry on to with Kindred, I think we'll have to bring in other discussions there. And I think that probably, as we close on Kindred, you'll probably see -- enter the 2022, you'll probably see more enhanced statistical side of the operational aspects of our Healthcare Services division."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. And I would just add that just in terms of what we disclosed today on the Healthcare Services, as Bruce said, a lot of our revenue today is in our company because of the pharmacy segment. And obviously, CenterWell primary care is a payer-agnostic bus",134,"Yes. And I would just add that just in terms of what we disclosed today on the Healthcare Services, as Bruce said, a lot of our revenue today is in our company because of the pharmacy segment. And obviously, CenterWell primary care is a payer-agnostic business and has external revenue. 
What you'll see in Kindred though, because it's not only payer-agnostic but also obviously serves the fee-for-service program, there will be a lot of about $3.2 billion of revenue. A good portion of that is obviously not Humana. So you'll see more disclosures there. And we'll provide more operating metrics around that as well. So I think you will get enhanced disclosure. We try to be very transparent with investors on our various businesses, and I think you'll continue to see that going forward."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, it comes from the line of Dave Windley from Jefferies.",15,"We have our next question, it comes from the line of Dave Windley from Jefferies."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Question I wanted to focus on, utilization. Looking specifically in the Retail segment, we're estimating that maybe the impact of the HIF and the net increase in PYD this year are maybe about the same size. And so if I neutralize those out, your MLR on ki",115,"Question I wanted to focus on, utilization. Looking specifically in the Retail segment, we're estimating that maybe the impact of the HIF and the net increase in PYD this year are maybe about the same size. And so if I neutralize those out, your MLR on kind of apples-to-apples basis for the first quarter would have also been up about 100 basis points. Is that right? 
And then as you think across the balance of the year, how are you thinking about utilization coming back in terms of acuity? And then any permanency in terms of site of service shifts and things like that, that would impact intensity and medical costs as the year progresses."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. So let me start with the MER question. The way I would think about it year-over-year is we're about 110 basis points above last year. The difference in PYD was about 110 -- coincidentally, also 110 basis points, so call that 220. The HIF -- and remem",428,"Yes. So let me start with the MER question. The way I would think about it year-over-year is we're about 110 basis points above last year. The difference in PYD was about 110 -- coincidentally, also 110 basis points, so call that 220. The HIF -- and remember, you have to tax effect it, because we did give some of that back to members, encompasses a good portion of that 220. And I would say the group phenomena that we called out and the PDP mix, is not insignificant in terms of impacting the MER. 
So I would -- if you want to do on an apples-to-apples incurred basis, I would actually say the MER got better year-over-year if you exclude prior periods and you just do it on an incurred basis. Other than, like I said, the group MER, as we expected and as we as we priced for it, I think that does have an impact on the overall margin in the Retail  segment, as I think we discussed on the last call. 
With respect to utilization bouncing back, we do assume, as we mentioned, that there will be -- we expect a bounce back in utilization. We are starting to see that again in line with what we what we've expected, particularly on the inpatient side as more people are using the hospital facilities in particular, but they're still below par. 
We do expect the utilization of the systems run at or perhaps a little bit above par as the year continues. We are not seeing increased acuity as yet, although as I mentioned with respect to both 2021 but also 2022, we just want to be mindful of how acuity or ""long haulers"" might play into our cost base, particularly for later this year and next year. And so we are definitely mindful of that as well as any just general bounce back in utilization in the system. 
And then on the site of service side, we'll see where it goes. We have seen a decline in SNF usage, and that's moved into the home, which I think also, frankly, helps validate the thesis behind the Kindred transaction just as more and more care is taking place into the home. And as Bruce outlined in his remarks, doing everything we can to make the home a much more comprehensive setting where care can be delivered. And so I think our belief is that, that will continue. 
Whether members are more shy -- shy away from the institutional setting. We're [indiscernible]. I would say that"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Still with you. [Technical Difficulty]",5,"Still with you. 
[Technical Difficulty]"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","David, are you still there? Are we on the call?",10,"David, are you still there? Are we on the call?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I was on, yes, I am still here.",8,"I was on, yes, I am still here."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Sorry about that. We're in a conference room here, and something just happened. We don't know what it is. So I'm not sure where I got cut off. I hear a little beep. I think it was right around where, we're talking about site of service, site of care. Is t",56,"Sorry about that. We're in a conference room here, and something just happened. We don't know what it is. So I'm not sure where I got cut off. I hear a little beep. I think it was right around where, we're talking about site of service, site of care. Is that where we got cut off?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","On site of service. Yes, you were.",7,"On site of service. Yes, you were."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Okay. All right. I tell you what I said was actually very profound. So I'm going to see if I can repeat it again, this time with feeling. So...",29,"Okay. All right. I tell you what I said was actually very profound. So I'm going to see if I can repeat it again, this time with feeling. So..."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","You were on a roll.",5,"You were on a roll."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Okay. I'm going out with a bang here. So on the site of service side, it's -- we'll see what happens in terms of whether seniors are less comfortable about using the institutional setting. We think it's possible that, that could happen. It's certainly not",65,"Okay. I'm going out with a bang here. So on the site of service side, it's -- we'll see what happens in terms of whether seniors are less comfortable about using the institutional setting. We think it's possible that, that could happen. It's certainly not something that we're going to underwrite in our either assumptions this year or bid assumptions next year, but it's possible."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Did you hear the SNF comment? I just wanted to make sure that wasn't cut off.",16,"Did you hear the SNF comment? I just wanted to make sure that wasn't cut off."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. What I said was about -- we are seeing -- I think you would have heard the SNF comment. Again, I was talking about we are seeing lower skilled nursing claims and that people are using the home in that regard. That validated -- I think one of the vali",63,"Yes. What I said was about -- we are seeing -- I think you would have heard the SNF comment. Again, I was talking about we are seeing lower skilled nursing claims and that people are using the home in that regard. That validated -- I think one of the validation points of the Kindred transaction. Hopefully, you heard that part as well."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Got it. Very good. Best of luck, Brian.",8,"Got it. Very good. Best of luck, Brian."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Thanks, Dave. Appreciate it.",4,"Thanks, Dave. Appreciate it."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Scott Fidel from Stephens.",12,"Your next question comes from the line of Scott Fidel from Stephens."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","And I'll just echo my best wishes and thanks to Brian as well. And a question, and I know it's been a theme throughout the call, just around some of the trends that you saw in the first quarter and then keeping the guidance unchanged. But did want to just",158,"And I'll just echo my best wishes and thanks to Brian as well. And a question, and I know it's been a theme throughout the call, just around some of the trends that you saw in the first quarter and then keeping the guidance unchanged. But did want to just drill in a bit to Group and Specialty, since it looks like you actually achieved considerably more earnings in the segment in the first quarter relative to the full year, reaffirmed guidance for that segment. So I think that, in particular, looks just pretty conservative right now. 
So -- and obviously, that's a segment that's not really exposed to this uncertainty around the risk-adjusted dynamic in Medicare. So just maybe a little insight into that in terms of if it's still just wanted to see how utilization ultimately develops? Or are you planning on sort of leading into that tailwind to increase your investments within that segment?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, thanks for the question, Scott. Thanks for the comments. I mean, I think you're reading it right. I mean we're very -- we're pretty bullish on how Group and Specialty is growing this year. It is early. They do not have the same types of headwinds th",141,"Well, thanks for the question, Scott. Thanks for the comments. I mean, I think you're reading it right. I mean we're very -- we're pretty bullish on how Group and Specialty is growing this year. It is early. They do not have the same types of headwinds that Medicare does, certainly on the revenue side. 
But it is early. The prior year development was a positive note. The incurred results that we've seen, we feel good about. The Specialty results are also doing well, Specialty meaning dental. And I think the military business is having a good start to the year. So really, all elements of our strategy are on course. And the financial performance, I think, is showing. But as you rightly point out, it's still very, very early and so we want to see a few more quarters develop."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Got it. And Brian, just are there targeted investments that you would look to lean in on that? Or is this an area where the trends continue to look like that's where you could ultimately revise the guidance around that for the year?",43,"Got it. And Brian, just are there targeted investments that you would look to lean in on that? Or is this an area where the trends continue to look like that's where you could ultimately revise the guidance around that for the year?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","I would say that we're probably more leaning towards more earnings in this segment than investments. We've built in investments into the -- into our guide already. I mean there are things around the edges that we would always do in a good year, just to sh",134,"I would say that we're probably more leaning towards more earnings in this segment than investments. We've built in investments into the -- into our guide already. I mean there are things around the edges that we would always do in a good year, just to shore up the segment for future success. 
And it's something that we really want to do, because we think there's  really a lot of growth in this segment, potential, and really an opportunity to disrupt the current market as it exists. There's a lot of appetite to do that among our customer base. And so we will be prudent as we look to make investments. But I think to the extent there are meaningful outperformance in the earnings side, we would imagine that, that would flow through."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, comes from the line of Ralph Giacobbe from Citi.",14,"We have our next question, comes from the line of Ralph Giacobbe from Citi."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","I was hoping to just flesh out the group MA commentary a little bit more, hoping you could frame the magnitude of the pressure from that alone. Because if I heard right, Brian, I think you said that core MLR was actually better year-over-year. So a pretty",78,"I was hoping to just flesh out the group MA commentary a little bit more, hoping you could frame the magnitude of the pressure from that alone. Because if I heard right, Brian, I think you said that core MLR was actually better year-over-year. So a pretty sizable jump in group MA. And then it sounds like that's more of a premium issue than a cost issue. So I guess, how does that get fixed at this point?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Okay. I wouldn't characterize it as a problem. I would just say, to Matt's initial question, that the market is more competitive at the high end of the range and these are large accounts. So -- and just given the high PMPM premiums, you could have a prett",281,"Okay. I wouldn't characterize it as a problem. I would just say, to Matt's initial question, that the market is more competitive at the high end of the range and these are large accounts. So -- and just given the high PMPM premiums, you could have a pretty significant revenue dollars here at lower margins. 
And so I wouldn't call it a problem. I would just say, when you look at the over Retail -- overall Retail segment MER, I think it's important to normalize for some of the impacts there. And so if you sort of strip that out and you look at sort of year-over-year, I think we're -- from an MER perspective, in a pretty good position. 
And so I wouldn't want to quantify it specifically. [ What I'm going ] to say I think anything not made up by the sort of HIF, including the tax benefit, some of which we passed through with the group MER impact because of the lower -- bidding on the lower margin levels for these large accounts. As well as frankly, the continued decline of PDP, which also as we've talked about has -- the way the MER dynamics works would, I think, impact the first quarter in a way that would also effectively more [ corroborate ] the 2 year-over-year. 
So we feel good about the year-over-year MER comparison. But again, I wouldn't get too caught up in the group MA MER specifically, but rather just an overall commentary on the competitiveness in that one segment of the market. And so it's just something that we're mindful of, and we continue to be very thoughtful about how we price there."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, comes from the line of Ricky Goldwasser from Morgan Stanley.",15,"We have our next question, comes from the line of Ricky Goldwasser from Morgan Stanley."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","So question around sort of how you think about build versus partner. At home is clearly closely aligned with telehealth and remote monitoring. So when you step back and you think about the investment that you need to make in that area, do you think the te",66,"So question around sort of how you think about build versus partner. At home is clearly closely aligned with telehealth and remote monitoring. So when you step back and you think about the investment that you need to make in that area, do you think the telehealth is an asset that you should buy? Or that's, sort of, something that you can partner with someone on?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. On the telehealth side, we -- first, we won't buy or -- technology. I think the technology side, we would be leasing it or be it someone would vend it to us. We feel that, that technology is, frankly, will be a commodity over time. So I just want to",222,"Yes. On the telehealth side, we -- first, we won't buy or -- technology. I think the technology side, we would be leasing it or be it someone would vend it to us. We feel that, that technology is, frankly, will be a commodity over time. So I just want to sort of break down the different parts of telehealth. 
The second aspect is from who the providers are in that. And we really see there's different channels there, one, the partners and our provider value-based relationships that we have. Most of them already have telehealth, and so we don't need to provide that to them. In our clinics, we today have telehealth, and we are utilizing a few different technology platforms. And so we are offering that. And that's -- so we're in that business, but it's through our provider-based businesses. 
And then providers that are needing telehealth we will partner on a vended basis with some technology company to offer that. That's probably less than a minority part of our telehealth business. The first 2 will be the majority. And so I would answer the question that we don't need to partner, it would be more of a vended solution to offer the technology where we will offer or our partners will offer through our contractual relationships, the provider side."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","And my second follow-up question is on the synergies for the acquisition. I think you talked in one of the areas as the in-sourcing, the home health episodes from other providers. I note that in the deck, you talked about $1.1 billion in spend for Humana",100,"And my second follow-up question is on the synergies for the acquisition. I think you talked in one of the areas as the in-sourcing, the home health episodes from other providers. I note that in the deck, you talked about $1.1 billion in spend for Humana MA members. And that overall, kind of 19% of episodes are currently managed by Kindred and then 45% in some select market. So should we think about the opportunity of in-sourcing kind of like going from kind of like 19% overall to 45%? Is that sort of a good proxy to think about?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","That could be a proxy. I would say that we're not putting any estimates out there, but our intention is to continue to penetrate in the markets that we operate. And the nice thing about the Kindred asset is that it has 65% overlap with the organization. S",87,"That could be a proxy. I would say that we're not putting any estimates out there, but our intention is to continue to penetrate in the markets that we operate. And the nice thing about the Kindred asset is that it has 65% overlap with the organization. So we have a lot of markets that we can go into. But your math is an estimate, but I would also just look at the -- our capacity to cover that because we're not in 100% of our markets."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","We have our next question, comes from the line of George Hill from Deutsche Bank.",15,"We have our next question, comes from the line of George Hill from Deutsche Bank."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Brian, I'm excited to see where you pop up in your next endeavor and I want to wish you well. I guess just as we think about the Kindred and CenterWell initiatives stepping back, can you guys talk about your outlook for the regulatory environment and prov",86,"Brian, I'm excited to see where you pop up in your next endeavor and I want to wish you well. I guess just as we think about the Kindred and CenterWell initiatives stepping back, can you guys talk about your outlook for the regulatory environment and provider with caring? And simplistically speaking, it seems to be a more benevolent regulatory environment than the core MA business and should create a better opportunity for returns in the near or medium term? Am  I thinking about that right?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","I would say from a customer point of view, the regulatory side, because just there's a significant amount of regulation around how we approach the customer, and certain rules and compliance around how we service the customer. So I would say from the insur",110,"I would say from a customer point of view, the regulatory side, because just there's a significant amount of regulation around how we approach the customer, and certain rules and compliance around how we service the customer. So I would say from the insurance component, you would be right. 
But within each of the care models, there is regulatory. I mean there's compliance regulatory. There's obviously licensure requirements, billing and et cetera. So I would say it follows a more traditional provider-oriented fashion regulatory environment. But I would say that -- I wouldn't say it's a free rein here, I would say that it has the proper caveats around it."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Lance Wilkes from Bernstein.",12,"Our next question comes from the line of Lance Wilkes from Bernstein."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Yes. I certainly wanted to thank Brian as well. And on the home health business, could you just talk a little bit about how you're looking at the home care delivery models with physicians like the Heal and Dispatch sorts of models? And would that be the s",96,"Yes. I certainly wanted to thank Brian as well. And on the home health business, could you just talk a little bit about how you're looking at the home care delivery models with physicians like the Heal and Dispatch sorts of models? And would that be the sort of thing if you expanded into that, they would be integrated into that business? Or would it be separate? And I guess similarly, is frail elderly and programs like PACE, kind of something you contemplate within this home health segment? Or are those other sorts of business lines?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Well, the nice thing about the home channel that we're developing, they have multiple different markets to go into. They're just -- so if at the appropriate time, PACE makes sense and we can make that market, I think I'd go into that market. Our big focus",189,"Well, the nice thing about the home channel that we're developing, they have multiple different markets to go into. They're just -- so if at the appropriate time, PACE makes sense and we can make that market, I think I'd go into that market. Our big focus was how do we get geographic coverage. And obviously, the Kindred distribution of nurses really provides us that opportunity in certain -- in different markets. 
Where they reside in the organization today, Heal and Dispatch relationship, relies within our Home Solution group. But it is closely aligned with both the plan and closely aligned with our primary care strategy. Because what we find is the best solution are the ones that are integrated together, where the plan is integrated with the provider side, the provider or the primary care is integrated with both going into the home, the clinics and the home care offerings that we have. So I would say that it does reside in the Home Solutions area. But the way we operate it is really, and the goal, is to have it integrated in the markets that we serve."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","Our next question comes from the line of Frank Morgan from RBC.",12,"Our next question comes from the line of Frank Morgan from RBC."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Analysts","Just curious as part of your capital strategy around this spinoff, would you contemplate placing leverage on the spin? I mean it looks like if you're $300-and-some-odd million of EBITDA in the hospice side of the business, you could put quite a bit of deb",109,"Just curious as part of your capital strategy around this spinoff, would you contemplate placing leverage on the spin? I mean it looks like if you're $300-and-some-odd million of EBITDA in the hospice side of the business, you could put quite a bit of debt on a couple turns of debt. So just curious your philosophy about how you would capitalize the spinco.
And then secondly, what is it about the hospice and personal care business that makes it more suitable for a partnership arrangement as opposed to ownership? Is it just geographic overlap? Is it just valuation? Just what specifically could you say about the reason for that?"
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Why don't I take the first one and Brian can talk about the capitalization side. What we find is the palliative -- the integration of palliative in hospice is very powerful. And being able to offer both of those in an integrated fashion, really creates th",295,"Why don't I take the first one and Brian can talk about the capitalization side. What we find is the palliative -- the integration of palliative in hospice is very powerful. And being able to offer both of those in an integrated fashion, really creates the opportunity for us to partner across the hospice business as opposed to having one vendor, so to speak, in that. 
The second thing, hospice is much more fragmented than home health. Although home health is quite fragmented, hospice is much more fragmented. So our ability to offer hospice in multiple markets, you're going to have to partner anyway. And so what we've -- I think we found a very [ dainty ] solution here where we can still be -- have a significant relationship with Kindred hospice through a minority ownership and be able to then utilize that as an opportunity to integrate in the markets that they're at and integrate palliative as part of that, but still have the flexibility to offer it in a broader fashion. 
Obviously, as we think about where our priorities of capital and where we put capital, we were going to put it in the areas that have the most impact and where we can have the most opportunity for growth. And we see home having a platform that has multiple different platforms to grow. And so when we think about capital deployment and efficiency of capital -- I know, Frank, you've been following us a long time, I think you can see that, that is an area that we're constantly looking at, not only the businesses that we're in but also how do we continue to generate above-average returns. And the way where we deploy that capital is important to that."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Yes. And just to add on the capital question, there's no doubt that hospice is a company that we can leverage. And so it's not something we'll disclose today. But we do intend to put that on the hospice co before we spin it. And so stay tuned for that. Bu",54,"Yes. And just to add on the capital question, there's no doubt that hospice is a company that we can leverage. And so it's not something we'll disclose today. But we do intend to put that on the hospice co before we spin it. And so stay tuned for that. But you are correct."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","And there are no further questions at this time. I'll turn back the call over to Bruce Broussard. Sir, please continue.",21,"And there are no further questions at this time. I'll turn back the call over to Bruce Broussard. Sir, please continue."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Executives","Thank you. Just to conclude the call, I'd like to just make a few comments. I think, first, there's been a consistent question around basically why didn't we raise earnings, to be completely honest with you, to be direct here. We have had a strong first",277,"Thank you. Just to conclude the call, I'd like to just make a few comments. 
I think, first, there's been a consistent question around basically why didn't we raise earnings, to be completely honest with you, to be direct here. We have had a strong first quarter, but we are early in the year. I just want to reemphasize that we continue to see the trends that we put in the first quarter as being -- continuing, but we want to make sure that we are able to see those trends through a longer time frame before we make any kind of adjustments in our estimates there. And I hope the investors take that away. It's much more around it's just earlier. As Brian has said, early in the game here. 
The second thing, as many of you have said, I thank Brian for just his wonderful contribution over the 7 years he's been here. And I know he'll show up some place in health care. And I think you'll -- I'm sure that each one of you will invest in what he does on his next goal there, so -- because he has delivered a lot of value to our shareholders and to our members and to our associates there. 
And then third, the quality of our earnings, our strategic advancement this quarter and over many quarters previous to this couldn't have been accomplished without our 50,000 associates that are working every day on behalf of each one of you and our providers and our customers there, and I want to thank them for that. 
So thank you, and I hope everyone has a great day."
29618,709205934,2261098,"Humana Inc., Q1 2021 Earnings Call, Apr 28, 2021",2021-04-28,"Earnings Calls","Humana Inc.","Operator","This concludes today's conference call. Thank you all for participating and you may now disconnect. Have a great day.",20,"This concludes today's conference call. Thank you all for participating and you may now disconnect. Have a great day."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to Humana Second Quarter 2021 Earnings Call. [Operator Instructions] Thank you. Now I would like to welcome Ms. Amy Smith, Vice President of Investor Relations. Ma'am, please go ahead.",39,"Ladies and gentlemen, thank you for standing by, and welcome to Humana Second Quarter 2021 Earnings Call. [Operator Instructions] Thank you. 
Now I would like to welcome Ms. Amy Smith, Vice President of Investor Relations. Ma'am, please go ahead."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our second quarter 2021 results and our updated financial outlook for 2021. Following these",361,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our second quarter 2021 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Joe Ventura, our Chief Legal Officer, will also be joining Bruce and Susan for the Q&A session. We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. 
This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. 
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission and our second quarter 2021 earnings press release as they relate to forward-looking statements and to note in particular that these forward-looking statements could be impacted by risks related to the spread of and response to the COVID-19 pandemic. 
Our forward-looking statements should therefore be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements and future filings or communications regarding our business or results. Today's press release, our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site. 
Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Finally, any references to earnings per share or EPS made during this conference call refer to diluted earnings per common share. 
With that, I'll turn the call over to Bruce Broussard."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Amy, thank you. Good morning, everyone, and thank you for joining us. Today, we reported adjusted earnings per share of $6.89 for the second quarter of 2021, in line with our previous expectations. We continue to focus on delivering strong operating res",1015,"Amy, thank you. Good morning, everyone, and thank you for joining us. 
Today, we reported adjusted earnings per share of $6.89 for the second quarter of 2021, in line with our previous expectations. We continue to focus on delivering strong operating results while navigating a dynamic environment due to the ongoing COVID-19 pandemic, all while staying true to our commitment to delivering the highest quality health care experience for members and patients. Well, we are maintaining our full year 2021 adjusted EPS guidance of approximately $21.5 to $21.75 at the midpoint, representing full year adjusted EPS growth of 16% above the 2020 baseline of $18.50 in excess of our long-term growth target while acknowledging the continued uncertainty driven by COVID-19 hospitalization trends and the rate at which non-COVID costs normalized. 
As Susan will describe in more detail, our full year adjusted EPS guidance now assumes a $600 million COVID-19-related headwind that is expected to be largely offset by favorable operating items. In addition, this guidance assumes no COVID costs will run -- non-COVID costs will run approximately 2.5% below baseline in the back half of the year, including an assumption of minimum COVID testing and treatment costs for the remaining of the year. 
I'd like to reiterate that our core fundamentals are performing well, and 2021 is a year of COVID-19 transition with various pandemic-related financial impacts, including reduced Medicare Advantage revenue resulting from the significant temporary deferral of utilization in 2020 as well as the lingering near-term uncertainties regarding the pace and level of the return of utilization for the balance of the year. We also acknowledge that we are seeing increase in COVID utilization in recent weeks, which we will continue to watch closely. 
While we continue to navigate this pandemic-related uncertainties in 2021, as Susan will lay out in detail, we expect 2022 to be a more normal year. The health care system has been open for several months, and we have seen vaccination rates in the seniors reach approximately 80% nationally. Accordingly, our members continue to engage in more routine interactions with their providers, which we anticipate will result in more normalized Medicare Advantage revenue next year as providers are able to ensure that our members are receiving appropriate care and that their conditions are being fully documented. 
I would reiterate our remarks from the last quarter regarding our Medicare Advantage bids for 2022, which reflected the continued uncertainty associated with COVID-19 in our premium and claims assumption, with a focus on maintaining benefit stability in 2023. While it is still too early to provide 2022 guidance, we believe our operating discipline in 2021, combined with the depth of our planning for 2022 Medicare Advantage AEP, puts us in a strong position for financial growth in 2022. 
I will now turn to an operational and strategic update. Importantly, our underlying core businesses continue to deliver strong results on solid fundamentals, with individual Medicare Advantage membership growth outpacing the industry. As we highlighted at our recent Investor Day, this growth is balanced across various product lines, including HMO and PPO and dual special need plans, or D-SNPs. Our Medicaid business continues to perform well in 2021, and our South Carolina plant is now operational. We are diligently preparing for the Ohio contract go-live date in early 2022 and are continuing to improve our operating model, building off of our core Medicare Advantage capabilities. We've also experienced slightly better-than-expected results in our home and provider businesses and increased mail order rates in our pharmacy business. 
Finally, as announced last quarter, we've entered into an agreement to acquire the remaining 60% interest in Kindred at Home, and we expect the transaction to close mid-August, which we've included in our revised estimates for the year. Our strong operating performance this year is in part a tribute to our strong partnerships with providers who are delivering high-quality care to our members. We are currently seeing 87% of our provider partners and value-based arrangements in surplus. 
Further, our relentless focus on consumer centricity has led to an all-time high Net Promoter Scores for our retail organization, contributing to Medicare Advantage membership growth and resulted in an external recognition of Humana as an industry leader in customer satisfaction, including the announcement this morning that we received the highest ranking in mail order pharmacy customer satisfaction for the fourth year in a row in the J.D. Power 2021 U.S. Pharmacy study. 
On the public policy front, as policymakers explore changes to Medicare, including adding dental, vision and hearing as part of the Medicare benefit, we stand ready to both innovate for the more than 12 million of our members who already have these benefits, including 7 million dental and vision policies in our MA group as well as offer ideas, a public-private collaboration to leverage our deep capabilities in Medicare and specialty markets so that beneficiaries could quickly see benefits go from a proposed law to a tangible benefit. 
Before turning the call over to our new Chief Financial Officer, Susan Diamond, I'd like to take a moment to speak about Susan's experience at Humana over the last 15 years. She has served in various leadership roles across the company during our tenure, spending 8 years as part of the Medicare leadership team with various financial and operational and line of business responsibilities. She also spent 2 years on the finance team, leading enterprise planning and forecasting and overseeing the company's line of business, CFOs and controllers. 
Most recently, she led our home business, growing it to the largest offering of its kind. Her strong financial background and extensive knowledge of our business made her uniquely positioned to step into the CFO role. The board and I have great confidence in our abilities and the contribution she will make in the next chapter for Humana as we execute on our strategic plan and deliver shareholder value. In addition, given the strategic nature of the CFO role, Susan will continue to contribute in a meaningful way to our home health business. 
With that, I'll turn the call over to Susan."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce. And good morning, everyone. Today, we reported adjusted EPS of $6.89 for the second quarter, in line with our previous expectations. Our underlying core business fundamentals remain strong, and we experienced a positive start to the ye",1583,"Thank you, Bruce. And good morning, everyone. 
Today, we reported adjusted EPS of $6.89 for the second quarter, in line with our previous expectations. Our underlying core business fundamentals remain strong, and we experienced a positive start to the year across our segments with the first quarter coming in modestly ahead of our previous expectations. Our results moderated back to expected levels in the second quarter albeit with variation in the way specific underlying assumptions emerged, with COVID treatment costs coming in lower than expected, offset by non-inpatient utilization continuing to bounce back faster than originally anticipated. 
As I will describe in further detail in a moment, uncertainty remains for the balance of the year due to the pandemic, specifically as it respects COVID hospitalizations and the rate at which non-COVID costs normalize, inclusive of both volume and unit costs. 
Recognizing the majority of today's call will focus on our emerging experience and our 2021 guidance, I want to quickly touch on operating performance across our segments before diving into that detail. Our Medicare Advantage growth remains on track and consistent with our previous expectations, with individual MA growing solidly above the market and an expected 11.4% at the midpoint. Our Medicaid business results are exceeding our initial expectations, given membership increases largely attributable to the extension of the public health emergency as well as higher-than-expected favorable prior period development. 
In our Group and Specialty segment, consistent with our commentary on our last earnings call, medical membership declines are lower than we expected coming into the year. Our specialty business results are exceeding expectations as utilization, particularly for dental services, has been slower to bounce back than initially expected. 
Finally, within our Healthcare Services operations, pharmacy continues to see increased mail order penetration as a result of customer experience improvements and additional marketing initiatives. The Home business, CenterWell Senior Primary Care and Conviva are performing slightly ahead of expectations, and we remain on track to open 20 new clinics this year with Wells Carson. In addition, as Bruce indicated in his remarks, we now expect the Kindred at Home acquisition to close in mid-August, subject to customary state and federal regulatory approvals. 
Before I go into more detail on our 2021 guide, I want to reiterate that the uncertainty we are seeing in 2021 relates solely to the difficulty estimating the impact of the pandemic and is not expected to carry forward into 2022. We remain comfortable with how we approach 2022 pricing, which I will expand on later in my remarks. 
Turning to full year 2021 guidance. I would remind you our adjusted EPS guidance represents growth at or above the top end of our long-term target of 11% to 15%. Our philosophy regarding 2021 guidance has been to provide transparency into the uncertainty caused by COVID-19 and the ability to deliver our targeted earnings growth with solid underlying core business performance and largely offsetting COVID-19-related headwinds and tailwinds. We have been consistent in and remain committed to this philosophy. 
There is a reasonable path to achieving adjusted EPS within our initial guidance range. And accordingly, today, we are maintaining our full year adjusted EPS guidance of $21.25 to $21.75, while acknowledging the continued uncertainty as it respects COVID hospitalization trends as well as the pace at which non-COVID costs bounce back and at what level they ultimately normalize. Additionally, we expect our third quarter adjusted EPS to reflect a low 20s percentage of our full year adjusted EPS. 
As Bruce indicated, given our experience to date, together with our current estimates for the back half of 2021, we have effectively recognized a $600 million COVID-related headwind for Medicare Advantage in our full year guidance, offset by favorable operating items. These favorable items include, among others, higher than initially expected prior year development, the previously discussed better-than-expected specialty and Medicaid results and the expected contribution from Kindred at Home given the transaction is expected to close in the coming weeks. 
Now let me provide an update on the underlying changes since our initial detailed guide in February, articulate key assumptions regarding utilization in the back half of 2021 and expand on the continued pandemic-related uncertainties I described. 
I will begin with Medicare Advantage revenue. As discussed last quarter, given our significant exposure to Medicare Advantage, we are disproportionately affected by COVID's impact on Medicare risk adjustment, or MRA. Recall, our risk-adjusted revenue for 2021 is determined by 2020 dates of service, medical utilization and resulting documentation, which, as previously discussed, was materially depressed in 2020. As we have indicated since the beginning of the year, the MRA headwind that we are facing in 2021 is significant, and we have closely monitored it over the course of the year. Our April guide recognized we had $300 million of additional pressure from MRA relative to our initial expectations for the full year, which was offset by the net benefit of the extension of sequester relief. 
In July, we received the mid-year MRA payment, and it came in modestly lower than expected. We are, however, taking operational steps now to be able to recover some of the MRA revenue and the final payment for 2021. Accordingly, our MA premium estimates, net of capitation, remain largely in line with our initial expectations when factoring in the net sequestration benefit. 
Now turning to benefit expense. At the beginning of the year, we indicated that we expected non-COVID costs for our Medicare business to run 3.6% to 5.5% below baseline. We defined baseline as 2019 experience trended forward based on a normalized trending factor excluding the effects of COVID. In the first quarter, we acknowledge that non-inpatient costs were bouncing back faster than initially expected. However, that was offset by COVID utilization, decelerating faster than expected. We also recognize, however, visibility into non-inpatient claims was significantly less than inpatient and therefore, we acknowledge that there was more uncertainty around non-inpatient service categories in terms of exactly where we stood. However, at that time, we could still tolerate overall utilization returning to baseline late in the year if the non-inpatient acceleration we were seeing was due to pent-up demand and leveled off in the second and third quarters. 
In the first and second quarters, non-COVID costs ran approximately 7% and 3% below baseline, respectively, with the bounce back outpacing expectations in the second quarter. Non-inpatient utilization did not lever loss and instead continue to increase in the second quarter and was offset by lower-than-expected COVID costs and other business outperformance. 
As the health care system has been opened for several months and a high rate of the senior population has been vaccinated, our current guidance now assumes that non-COVID costs level off and run approximately 2.5% below baseline levels in the back half of the year. Consistent with our original forecast, our current guidance assumes minimal COVID testing and treatment costs in the back half of the year. That said, we do acknowledge that we are seeing increases in COVID admissions in recent weeks, although it's too early to determine if there will be offsetting declines in non-COVID utilization, and we will continue to monitor this recent development. Finally, as it respects our 2021 guide for our commercial business, we expect all-in utilization for COVID and non-COVID to continue to run above baseline as anticipated. 
In summary, I want to emphasize that 2021 as a COVID transition year. There is a reasonable path to deliver against our guidance expectations. However, as non-COVID utilization or COVID treatment costs increased beyond our expectations in the back half of the year, it will present a headwind to our guide, absent offsetting tailwinds. 
I also want to reiterate that the $21.50 midpoint of our original guide continues to be the right jumping off point for 2022 adjusted EPS growth. Our members continue to engage in routine interactions with their providers, which we anticipate will result in more normalized Medicare Advantage revenue next year as providers are able to ensure that our members are receiving appropriate care and if their conditions are fully documented. 
During the first half of 2021, provider interactions and documentation of clinical diagnosis that will impact 2022 revenue outpaced those experienced in the first half of 2020 and are approximately 80% complete, in line with the estimated completion of the same time period in 2019. Lastly, I would remind you that our Medicare managed bid for 2022 reflected the continued uncertainty associated with COVID-19 as it relates to our premium and baseline non-COVID claims trend assumptions, with a focus on maintaining benefit stability into 2023. 
Before we open up the line for questions, I'm excited to announce 2 finance leadership changes that will promote the growth and versatility of our finance leadership team. First, with the expected integration of Kindred at Home, our Home business is growing significantly, and Amy has accepted the role of Vice President and CFO of Home Solutions. She will be a key member of the Home Solutions leadership team, responsible for the financial oversight and planning and forecasting for the segment. Lisa Studer will succeed Amy, accepting the role of Vice President, Investor Relations. Lisa has worked with Amy over the last 4 years and is well-known and respected by our investors. We are excited about the opportunity this affords both Amy and Lisa, and Lisa's continuity in Investor Relations will allow for a seamless transition. 
With that, we will open up the lines for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your first question is from the line of Justin Lake from Wolfe Research.",13,"Your first question is from the line of Justin Lake from Wolfe Research."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Obviously, a lot to cover. I'll try to keep it to 1 question here. But the -- I'm hoping you could give us a few numbers. One is the MRA. Can you tell us what the full year impact is of the negative MRA? And I think there's a lot of confusion around 2 thi",187,"Obviously, a lot to cover. I'll try to keep it to 1 question here. But the -- I'm hoping you could give us a few numbers. One is the MRA. Can you tell us what the full year impact is of the negative MRA? And I think there's a lot of confusion around 2 things. One, it sounds like the first half or the second quarter, I should say, was worse than expected, and yet you still kind of came in line with -- from an MOR perspective. So you're telling us the back half has -- needs to be more optimistic. So what happened in the second quarter beyond that allowed you to make the MLR, but still have higher medical costs that need the back half? And then I guess the -- around that, the $600 million specifically, can you flush that out in as much detail as you can? Because is that comparable to the old COVID estimate? Or is that a new COVID headwind that you've kind of thrown in there for the back half of the year for us to think about?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take these 1 at a time. I'll start with your last question around the $600 million. So just to clarify, the $600 million represents our full year estimate of the Medicare Advantage-only net headwinds and tailwinds and related to the COVID pa",382,"Sure. So I'll take these 1 at a time. I'll start with your last question around the $600 million. So just to clarify, the $600 million represents our full year estimate of the Medicare Advantage-only net headwinds and tailwinds and related to the COVID pandemic. And if you recall back to our initial guidance earlier this year, we provided a schedule that laid out the specific line items that were considered in that and a range of estimates at the time. So the $600 million represents our current view and what is contemplated in our guide related to those items on a net basis, so the net of all the various headwinds and tailwinds based on our current expectations. 
As it respects to the first half and second half, as we described in the call, what we continue to see throughout the first half of the year was COVID costs coming down faster than initially expected, but non-COVID outpatient, in particular, rebounding faster than expected, and that continued through the second quarter. And we anticipate that, that will extend some into the third quarter before it levels off. In the first half of the year, the benefits we saw from COVID-related costs as well as some lower inpatient -- non-COVID inpatient costs, we do not expect to continue at the same rate because our expectation has always been that those costs on the Home side would come down as a result of the rollout of vaccinations and that utilization would rebound to more normal levels such that there is less positive upside that can offset those costs in the second half of the year, which is why we are now estimating a net 2.5% decline in non-COVID utilization in the back half of the year to meet our guide. 
As it respects to MRA, I think we provided the net detail in terms of what our current estimates really are. I know we provided the line item in the initial guide in terms of the beginning of the year. And what we're saying is on a net basis net of capitation, there's about a $300 million additional headwind. And in the context of the overall guide, that is largely offset or fully offset by the net impact of the positive sequestration benefit."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Okay. And then just quick follow-up on the $600 million, that was all really helpful. The $600 million, can you just tell us what that compares to specifically? Because you had like a $400 million to $700 million COVID number thrown into the original sche",99,"Okay. And then just quick follow-up on the $600 million, that was all really helpful. The $600 million, can you just tell us what that compares to specifically? Because you had like a $400 million to $700 million COVID number thrown into the original schedule, is that the comparable now? And then have you said that that's all eaten away in the first half of the year, so effectively, that updated $600 million is comparable to the $400 to $700, and it's completely gone effectively, so you don't have any -- none of that's assumed in the back half?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Just to be clear, this is in the full year estimate, so inclusive of first half and back half. But I also want to clarify, it is not meant to be specific to the line item that's labeled COVID testing and treatment on that initial schedule. That was 1 line",146,"Just to be clear, this is in the full year estimate, so inclusive of first half and back half. But I also want to clarify, it is not meant to be specific to the line item that's labeled COVID testing and treatment on that initial schedule. That was 1 line item. When we refer to the $600 million, it is the net impact of all of the line items that were represented on the schedule. 
And the other thing I would add as well in terms of your question about how did you offset that, there was a lower COVID and other inpatient costs. But also recall, we had other business outperformance that we mentioned in the discussion around the prior period development, commercial Medicaid that also offset some of that headwind we experienced in the first half of the year as well. Next question, please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Kevin Fischbeck from Bank of America.",14,"Your next question is from the line of Kevin Fischbeck from Bank of America."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I wanted to, I guess, follow up on the assumption for trends in the back half of the year. I guess you're saying core utilization, 2.5% below. I guess if you could maybe provide a little more color on that? I mean how do you get there? Are some things abo",123,"I wanted to, I guess, follow up on the assumption for trends in the back half of the year. I guess you're saying core utilization, 2.5% below. I guess if you could maybe provide a little more color on that? I mean how do you get there? Are some things above average, some things below average? If I understood what you were saying, I think you said that when you exclude COVID coast, total trend is above average, just want to make sure I heard that, but just color on how you get to the minus 2.5% for the back half of the year and why there isn't more of an assumption of ""core back to normal"" by the end of the year?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So just to provide a little more detail. So as we mentioned, the second quarter ran about 3% below baseline for that non-COVID utilization. Our third and fourth quarter now, on average, are estimated to run 2.5% below baseline. And recall that, that",235,"Sure. So just to provide a little more detail. So as we mentioned, the second quarter ran about 3% below baseline for that non-COVID utilization. Our third and fourth quarter now, on average, are estimated to run 2.5% below baseline. And recall that, that's inclusive of both utilization as well as unit cost. So as I mentioned, we do expect, given that the country has been largely open, our population is largely vaccinated, that we will see those non-COVID utilization start to normalize, and so we've allowed for some additional return to baseline relative to what we've experienced in the second quarter. 
I would also say that as we see that utilization come back, we also see that the average cost per hospitalization will come down because lower severity cases are reintroduced. And so the combination of leveling off of utilization and continued reductions in the unit cost contribute to that 2.5% below baseline. 
I think you've suggested that overall utilization might be above baseline. I think you might be referring to my comments about commercial where we had planned to see in total COVID -- non-COVID slightly above baseline as we were beginning to see that at the end of 2020. But for our Medicare business, because we're including limited COVID costs in our forecast in the back half of the year, it's not contributing significantly, so that would not take it over baseline."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Okay. But when you say it's the low baseline inpatient, outpatient physician, drugs, I guess, those 4 categories, are they all kind of there or some above, some below?",29,"Okay. But when you say it's the low baseline inpatient, outpatient physician, drugs, I guess, those 4 categories, are they all kind of there or some above, some below?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. We are seeing variations in some of the service categories as you can imagine. One of the reasons we believe that some of the tenant demand has been worked through the system is things like surgical procedures, colonoscopies and things like that. We",75,"Sure. We are seeing variations in some of the service categories as you can imagine. One of the reasons we believe that some of the tenant demand has been worked through the system is things like surgical procedures, colonoscopies and things like that. We did for a period of time to see go slightly above baseline, but other traditional normal course ER and observations and other activities continue below baseline. Thank you. Next question, please?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Matthew Borsch from BMO Capital Markets.",14,"Your next question is from the line of Matthew Borsch from BMO Capital Markets."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Maybe I could just continue on this theme of trying to understand with the Medicaid baseline through the end of the year. Do you think that -- what is sort of thought of is deferred care or the health care that didn't happen, but would have happened, I gu",117,"Maybe I could just continue on this theme of trying to understand with the Medicaid baseline through the end of the year. Do you think that -- what is sort of thought of is deferred care or the health care that didn't happen, but would have happened, I guess, really over the last 5 quarters? Is a lot of that just not going to -- that isn't something that is going to flow through as pent-up demand? It's sort of embedded in there is that assumption that -- and seniors, I guess, are going to still have some avoidance of the health care system even in the back half of this year. Just trying to understand that."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. I would say that our view would be that given the pace at which the non-inpatient utilization, in particular, bounced back, which was faster than we anticipated, that we are seeing -- and a lot of that, you'll see they're reengaging with their physic",143,"Yes. I would say that our view would be that given the pace at which the non-inpatient utilization, in particular, bounced back, which was faster than we anticipated, that we are seeing -- and a lot of that, you'll see they're reengaging with their physicians and specialists more than normal rate. And so I think we do believe that some of the pent-up demand as a result of the deferred here in 2020 has been reflected in our first half of the year results. And that, again, because of the length of time the country has largely been open, that pent-up demand has worked through. And therefore, while we will -- we are expecting a little bit more return to baseline relative to our second quarter performance that, that will stabilize through the back half of the year. Thank you. Next question, please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of A.J. Rice from Credit Suisse.",14,"Your next question is from the line of A.J. Rice from Credit Suisse."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Just to put a fine point on some of the discussion and then 2 other data points. The 2.5% for the back half, I think in the beginning guidance, you said that the underutilization for the full year will be 3.6% to 5.5% deferred relative to baseline. If you",176,"Just to put a fine point on some of the discussion and then 2 other data points. The 2.5% for the back half, I think in the beginning guidance, you said that the underutilization for the full year will be 3.6% to 5.5% deferred relative to baseline. If you got an updated number, how much are you at the lower end of that or are you even the overall range when you think about that original number? And then I would also ask you about the operating expense. Obviously, you've updated that. Is that mainly related to Kindred? Are you expecting more investments in the back half of the year in other areas? 
And then if I could squeeze in 1 more. Your comment about the offset of sequestration versus the MRA headwind this year, does that, in your mind, reverse next year? So if we lose sequestration, you -- the MRA catch-up by having fully coded all the people from last year and this year offsets that? Is that the way to think about it?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take these 1 at a time. So the first, to your question, based on our experience for first half of the year and our 2.5% expectation in the back half of the year, if you do all that math, it suggests that for the full year, our non-COVID util",258,"Sure. So I'll take these 1 at a time. So the first, to your question, based on our experience for first half of the year and our 2.5% expectation in the back half of the year, if you do all that math, it suggests that for the full year, our non-COVID utilization will end up at about 3.75% below baseline, so effectively at the low end of the range we had given you at the start of the year. 
On OpEx, as you said, you're exactly right. The reason for the change in the guide and the increase that is directly attributable to incorporating the Kindred performance into our guidance points, and so that is largely the reason for that increase. We do, however, I would say, in terms of our core business and even within Kindred anticipate some investment like we would in normal course. Kindred, as you can imagine, by integrating it, there are some investments we might want to make there as a respect to the value-based operating model that we've described at Investor Day. And so that is contemplated in there as well. 
On your second question on sequestration, we do expect that to reverse in 2022. That would have been contemplated in our bids and pricing. And our MRA assumptions as we think about 2022 would not be impacted by that explicitly. They are independently calculating what we believe the risk adjustment will be based on the diagnosis submissions that we would expect in a more normal environment. Thank you. Next question, please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Rivka Goldwasser from Morgan Stanley.",13,"Your next question is from the line of Rivka Goldwasser from Morgan Stanley."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I want to clarify a utilization and then another question. Just to clarify, Susan, is basically what you're saying is that the 2.5% below baseline really encompasses the fact that care is happening outside the 4 walls of the hospital? I think you mentione",131,"I want to clarify a utilization and then another question. Just to clarify, Susan, is basically what you're saying is that the 2.5% below baseline really encompasses the fact that care is happening outside the 4 walls of the hospital? I think you mentioned lower ER visits. You're also mentioning that you don't expect 2022 risk adjusters to be impacted by the lower utilization. So is it that just you're seeing a shift in where care is being provided, i.e. the telehealth primary care, and that's what's impacting that below baseline, it's a dollar number? And then my second question, if you can give us just some color and context around the announcement that we saw last week on the investment that you're making with them on -- into new PBM?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Okay. So to your first question on the 2.5%, so again, that is related to non-COVID utilization and all inclusive of inpatient and non-inpatient, again, both rate and volume. And so I wouldn't say that we're necessarily seeing shifts in the site of servic",250,"Okay. So to your first question on the 2.5%, so again, that is related to non-COVID utilization and all inclusive of inpatient and non-inpatient, again, both rate and volume. And so I wouldn't say that we're necessarily seeing shifts in the site of service or the site of care, but rather just as utilization returns to normal, there is some level of utilization that hasn't just hasn't come back on an absolute basis. But really, we are seeing, with the exception of some of those specific service categories I mentioned like surgical, other categories are largely still running below baseline across the board. 
As far as MRA impact, as we said, what we are seeing in terms of the normal routine interactions with our providers, our income assessment activity and other annual wellness programs, those are all trending exactly as we would expect to see in order to deliver against our 2022 revenue estimates contemplated in pricing. And so we feel really good about our trajectory there. Should we see somewhat depressed utilization in the back half of the year, given the way risk adjustment works, generally speaking, we feel good that so long as there's not sort of a full shutdown like we saw in 2020, which is not what we anticipate currently, we feel confident that we should be on pace to deliver against what we need for MRA, again, based on what we're currently seeing. I don't know, Bruce, would you like to address the Anthem partnership?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Similar to what we've done in the past and other more utility-oriented areas, I think availability would be an example of that, where we've tried to find partners within the industry that can help build a longer-term utility. And we look at the particular",118,"Similar to what we've done in the past and other more utility-oriented areas, I think availability would be an example of that, where we've tried to find partners within the industry that can help build a longer-term utility. And we look at the particular partnership with Anthem as the opportunity to update and really give more both increased productivity and, at the same time, increase the experience for members in the area of the PBM side, we, for a number of years, have been using SS&C as a vendor to help in the -- with the existing technology. But now I've been able to take it and really enhance it through this partnership with Anthem and SS&C."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you. Next question please.",5,"Thank you. Next question please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Stephen Baxter from Wells Fargo.",13,"Your next question is from the line of Stephen Baxter from Wells Fargo."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I was hoping that you could talk in a little bit greater detail about why the risk adjustment revenue ended up coming in below where you expected it for this year? I guess you had a lot of visibility into certain inputs and not others. To the extent you c",73,"I was hoping that you could talk in a little bit greater detail about why the risk adjustment revenue ended up coming in below where you expected it for this year? I guess you had a lot of visibility into certain inputs and not others. To the extent you could flesh those out, I think it would help give us a better sense of how comfortable we can be around next year's assumptions."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So as it respects the $300 million that we referenced that was contemplated in our April guide, so just for context, our January payment in 2021 would reflect claims that were submitted through the September submission deadline. And then that requir",326,"Sure. So as it respects the $300 million that we referenced that was contemplated in our April guide, so just for context, our January payment in 2021 would reflect claims that were submitted through the September submission deadline. And then that requires us to estimate the submissions that will come in organically as well as a result of our activities around chart review and prospective programs for the remainder of the year. 
At that time, we were not anticipating the significant surge that we saw across the country in the fourth quarter due to COVID and the resulting reduction in non-COVID utilization. What that led to was lower -- what we refer to as organic diagnosis submissions, so those are not related to the campaigns that we initiated, but rather organic submissions across the provider community based on the utilization that's happening. And those ultimately prove to come in lower than we had anticipated. And generally speaking, I think we've mentioned before that those organic submissions are more difficult to estimate, obviously, than the initiatives that we are executing. So that was reflected in our April guide at the time. 
In terms of the midyear adjustment, as we've said on previous calls, the adjustment there was solely related to new members or members who were only enrolled for a partial year in 2020, where we don't have full visibility to their claims. And so while we made an estimate of what we thought the impact would be based on what we were seeing within our concurrent population, ultimately, that midyear payment came in, it reflected a lower level of contribution for those new members and our estimates had originally anticipated. 
I would say that going into 2022, because those impacts were directly related to the COVID pandemic and impacts the utilization, I would not expect to see that continued uncertainty carry into 2022 based on what we're seeing so far this year. Thank you. Next question."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Josh Raskin from Nephron Research.",13,"Your next question is from the line of Josh Raskin from Nephron Research."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I understand we're coming out of the second quarter with non-COVID utilization running 3% below baseline. But how do you see that continuing to run 2.5% baseline for the second half of the year if you're also assuming that you're not going to see any COVI",118,"I understand we're coming out of the second quarter with non-COVID utilization running 3% below baseline. But how do you see that continuing to run 2.5% baseline for the second half of the year if you're also assuming that you're not going to see any COVID -- direct COVID cost for testing and treatment? I sort of think of those as related. And then would a rise in direct COVID costs, so if we did see this increase that you guys mentioned that you're seeing in the last couple of weeks, if that did continue, would that end up being a net negative now because you've got all the direct costs, but you're already assuming lower utilization?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I would say that our view of non-COVID is not influenced by what the recent activity and uptick we've seen in COVID cases. That is not why we're assuming that it runs below baseline. Our view is, again, just based on the trajectory we've seen tha",223,"Sure. So I would say that our view of non-COVID is not influenced by what the recent activity and uptick we've seen in COVID cases. That is not why we're assuming that it runs below baseline. Our view is, again, just based on the trajectory we've seen that given the level of utilization increase we've seen that we were at a point where it will be in the plateau and level off as sort of just a new baseline for the back half of the year. 
As it respects COVID, as we mentioned, it's just very early in terms of the increase we've seen is literally just in the last couple of weeks. It is still a bit too early to determine whether or not we will see offsetting non-COVID utilization impacts like we have seen in all previous surges. I will say, just this last week, we just began to see some level of reduction in inpatient -- non-COVID inpatient as the COVID cases increase. It's simply just too early to really assess the duration that we might see in terms of an uptake and the offsetting utilization. But should we see offsetting utilization in the non-COVID space, in order for that not to present a headwind, it would be incremental to the 2.5% that we are currently forecasting. Next question, please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Lance Wilkes from Bernstein.",12,"Your next question is from the line of Lance Wilkes from Bernstein."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes. Let's see, my primary question is on the pricing environment. You called out a little bit of a pricing environment in, I think, in group MA. Can you talk a little bit about that pricing environment impacts and magnitude in '21 outlook for '22? And th",104,"Yes. Let's see, my primary question is on the pricing environment. You called out a little bit of a pricing environment in, I think, in group MA. Can you talk a little bit about that pricing environment impacts and magnitude in '21 outlook for '22? And then in general for pricing, both individual and group, how does this work towards your return to kind of target margins here? And then on the utilization, the 1 extra thing I'd just ask on that 2.5% below baseline, just if you're getting any indications on impacts of delta variant on utilization in any of your own clinics?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. Just [indiscernible]. The first is the respect to pricing, U.S. industry about the group MA. And I think as we've said before, the group MA space, particularly for larger group accounts, continues to be highly competitive, and we would expect that t",394,"Sure. Just [indiscernible]. The first is the respect to pricing, U.S. industry about the group MA. And I think as we've said before, the group MA space, particularly for larger group accounts, continues to be highly competitive, and we would expect that to continue. And so the margins that we would see on those accounts to continue to be competitive and pressured. I think though, as we think about group MA, there are a lot of other benefits to winning those large accounts in terms of the impact they can have in a local geography on the network and our ability to work with provider partnerships, et cetera. But we expect that to be -- continue to be competitive. 
On the individual side, this is always a process we go through every year to understand sort of the rate environment, the competitive environment, other business performance. We always strive to maintain benefit stability, knowing how important that is to our members as well as our sales and distribution channels. So that's always our goal. And there's always a number of puts and takes that we will consider, including the broader enterprise performance as it respects, first and foremost, delivering against our overall growth target of 11% to 15%. 
And after considering sort of strategic investments, other business performance and then understanding what's required of our Medicare business and what we're trying to achieve, balancing both growth and margin in the long term. All of those are taken into account. We remain committed to achieving long-term, our targeted individual margin of 4.5% to 5%, and that will vary each year based on those things that I mentioned. But we expect this to continue to progress towards that goal. 
On utilization, I would say really it's too early, I think, for us to really see anything specific at the clinic level. That information is not as real time available to us as there are hopefully information. So to date, I have not seen anything that would provide us any visibility. I will say, there are some concentrations geographically. As you've seen probably in the press, Florida is a state that is seeing higher rates given we have a concentration of some of our clinics there. I imagine that they would see some, but we actually don't have detailed information on that just yet. Next question, please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Ralph Giacobbe from Citi.",12,"Your next question is from the line of Ralph Giacobbe from Citi."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I guess going back to the 2.5%, if your assumption is that 2.5% below baseline, I think your original guidance was to run above baseline towards the end of the year. So why wouldn't that represent upside? Or where is the offset there? And then can you giv",69,"I guess going back to the 2.5%, if your assumption is that 2.5% below baseline, I think your original guidance was to run above baseline towards the end of the year. So why wouldn't that represent upside? Or where is the offset there? And then can you give us how much COVID cost you've seen sort of through the first half against that $600 million full year estimate?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Okay. As it respects to 2.5%, as you mentioned, I think in earlier calls during the first quarter, did mention that our original forecast did contemplate over the course of the second half of the year that we would begin to approach baseline and potential",224,"Okay. As it respects to 2.5%, as you mentioned, I think in earlier calls during the first quarter, did mention that our original forecast did contemplate over the course of the second half of the year that we would begin to approach baseline and potentially for a short period of time see above baseline utilization related to pent-up demand. So we just projected that to occur later in the year. Our view is that given the rate at which we've seen it bounce back more quickly, that we have seen that in the first half of the year instead. And so at the time, I don't think we've given specifics on sort of the monthly trajectory. But in general, our original forecast going into the year did anticipate a slower return to baseline and could tolerate it getting to baseline by the end of the year. 
But as I described in my remarks, because we saw the faster bounce-back in non-inpatient and in the first half, that was, again, largely offset by the reductions in COVID and inpatient. Those trends will not continue at the same level and therefore, we will need to see below baseline utilization on the nonpoinside in order to achieve that full year estimate of 3.75%. And then could you repeat your second question, I'm sorry, about the COVID costs?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes, just trying to get a sense of what it ran in the first half of the year relative to the updated sort of $600 million. Are you fully through the $600 million at this point, is that what you're trying to imply? And there's nothing baked into the back h",60,"Yes, just trying to get a sense of what it ran in the first half of the year relative to the updated sort of $600 million. Are you fully through the $600 million at this point, is that what you're trying to imply? And there's nothing baked into the back half? Just trying to get a sense of magnitude there."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","No. So again, that $600 million is a full year estimate. It does, just to be clear, include in the assumption that the non-COVID utilization will run 2.5% in the back half of the year, so that's contemplated in that. But I don't think we had intended to p",74,"No. So again, that $600 million is a full year estimate. It does, just to be clear, include in the assumption that the non-COVID utilization will run 2.5% in the back half of the year, so that's contemplated in that. But I don't think we had intended to provide any quarterly detail of how that's emerging, but that is a full year number. It would not represent just the first half of the year."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Just to highlight on the $600 million, that is if you were to go to the first quarter or the February earnings release for the fourth quarter, we put together some lows and highs all the way from MRA, COVID testing, depressed utilization and sequestration",121,"Just to highlight on the $600 million, that is if you were to go to the first quarter or the February earnings release for the fourth quarter, we put together some lows and highs all the way from MRA, COVID testing, depressed utilization and sequestration. And what the $600 million is if you were to take that and roll that forward now, all the ins and outs from that would be the net number of the $600 million. The operational aspects of our business, as Susan has talked about, has offset all of that $600 million. But included in that $600 million net number is an assumption that 2.5% below baseline will be remaining for the remaining part of the year."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Next question, please.",3,"Next question, please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Scott Fidel from Stephens.",12,"Your next question is from the line of Scott Fidel from Stephens."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","First, I think you just clarified part of the question that I was going to have, which is just confirming that the net headwind and tailwind that had been 0 in that 4Q '25 deck, that's now $600 million, right? And then also just on the MRA piece in that s",181,"First, I think you just clarified part of the question that I was going to have, which is just confirming that the net headwind and tailwind that had been 0 in that 4Q '25 deck, that's now $600 million, right? And then also just on the MRA piece in that same slide deck, you had called that out at $700 million to $1 billion of expected headwind. I guess given the update that you guys have given us around the $300 million incremental impact a couple of months ago and then how things came out in the midyear claims review, Just interested if you have an updated estimate that we can compare now against that $700 million to $1 billion number? 
And then sort of, I guess, just putting this all together, just how this sort of nets out to -- for 2021? And putting all the pieces together, what that sort of implies and what you're assuming for your MA pretax margin so we can think about sort of the earnings run rate now relative to the long-term target margin?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","So what I would say, we never, at the time, as you mentioned, the schedule that we gave you, which provided a range of $700 million to $1 billion, I don't think at the time we ever said exactly where we were in that range in terms of our internal estimate",107,"So what I would say, we never, at the time, as you mentioned, the schedule that we gave you, which provided a range of $700 million to $1 billion, I don't think at the time we ever said exactly where we were in that range in terms of our internal estimate. I think what we just wanted to clarify was that we had seen $300 million of net pressure incremental to that, which is, again, in terms of the schedule offset then by the sequestration. And then can you repeat your second question? I'm sorry, I think it was '21 -- oh, the '21 question, I'm sorry."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes. Basically, it's just trying to take all these different pieces together. And what they net out to what sort of the underlying pretax MA margin assumption is for 2021 so we can think about that relative to the long-term target?",41,"Yes. Basically, it's just trying to take all these different pieces together. And what they net out to what sort of the underlying pretax MA margin assumption is for 2021 so we can think about that relative to the long-term target?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. So what I would say is, as you see in our guidance points, our MER target or MER range and our -- hasn't really changed. Because of the offsets and the nature of those offsets, there are many within the retail segment and Medicare in particular. So I",103,"Yes. So what I would say is, as you see in our guidance points, our MER target or MER range and our -- hasn't really changed. Because of the offsets and the nature of those offsets, there are many within the retail segment and Medicare in particular. So I would say, in general, there's no material movement in the individual MA margin because the headwind -- net headwind is largely offset by other positivity. And as we mentioned, the positive prior period development as an example as well as the sequestration would be attributable to the retail segment. Thank you. Next question, please?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of George Hill from Deutsche Bank.",13,"Your next question is from the line of George Hill from Deutsche Bank."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I'm going to try to put in 2 very quick ones. I guess, Bruce, as I think about the JV investment with Anthem, that's much more of an infrastructure and back-end investment as opposed to more of a PBM JV, if I understand that, right? And then just kind of",88,"I'm going to try to put in 2 very quick ones. I guess, Bruce, as I think about the JV investment with Anthem, that's much more of an infrastructure and back-end investment as opposed to more of a PBM JV, if I understand that, right? And then just kind of net-net of everything, am I hearing things right that the $21.25 to $21.75 is the right jumping off point as we think about fiscal '22 EPS, inclusive of all the moving pieces basically that they're all offsetting?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes, to answer your first question, you're exactly right. It is an infrastructural investment. And again, it's a utility for the industry. And actually, we would enjoy  others to join that joint venture over a period of time. In regards to your second que",63,"Yes, to answer your first question, you're exactly right. It is an infrastructural investment. And again, it's a utility for the industry. And actually, we would enjoy  others to join that joint venture over a period of time. In regards to your second question, you're exactly right, the midpoint is $21.50. And that is what we would base our '22 growth of off."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Next question, please.",3,"Next question, please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your last question is -- I'm sorry, your next question is from the line of David Windley from Jefferies.",19,"Your last question is -- I'm sorry, your next question is from the line of David Windley from Jefferies."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","You touched on this a little bit, but I want to try to bring a finer point to it. The 2.5% baseline in the second half, would you expect that -- not standing time frame, but would you expect that to return to baseline? Or are you seeing some permanent shi",92,"You touched on this a little bit, but I want to try to bring a finer point to it. The 2.5% baseline in the second half, would you expect that -- not standing time frame, but would you expect that to return to baseline? Or are you seeing some permanent shifts like ER utilization that would cause you to stay below baseline beyond 2021? And then what are you seeing in terms of member acuity as the bounce back utilization has come? Are you seeing higher acuity as patients represent for services?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. Great question. So as we said, the 2.5% represents an average for the back half of the year. I think it remains to be seen at what rate it ultimately settles in. It could come in more depressed in the third quarter and then get closer to baseline. T",260,"Sure. Great question. So as we said, the 2.5% represents an average for the back half of the year. I think it remains to be seen at what rate it ultimately settles in. It could come in more depressed in the third quarter and then get closer to baseline. There's obviously a range of scenarios that could emerge, some of which could be that by the end of the year, it gets closer to baseline. So I think that until we get to the plateau and see that sustained, I think it will be hard to assess the long-term, whether that's a long-term new normal or not. So we'll continue to watch that. 
As for acuity, I would say so far, we are not seeing indicators that there is a higher acuity or there has been impact from the deferred care in 2020. We are continuing to watch it. But so far, we have not seen any sort of systemic indicators of that. And in fact, some of the things that we were able to initiate along with our provider partners to ensure members received needed preventative care through telemedicine were quite hopeful during the pandemic. 
And 1 data point as an example, was that we saw higher medication adherence through the pandemic than we actually did pre-pandemic, so a nice indication that members were receiving the needed preventative care, receiving their medications and hopefully staying on top of their conditions. But so far, we are watching it, but we're not seeing any indications of higher acuity. Next question, please."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Rob Cottrell from Cleveland Research.",13,"Your next question is from the line of Rob Cottrell from Cleveland Research."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Wanted to revisit the operating cost guidance, and how should we think about that for future years, absorbing the full year cost of Kindred and also any potential synergies that could offset that into 2022 and beyond?",37,"Wanted to revisit the operating cost guidance, and how should we think about that for future years, absorbing the full year cost of Kindred and also any potential synergies that could offset that into 2022 and beyond?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. As I said, the current year guidance revision was a direct -- is directly attributable to incorporating Kindred in the guide. To be quite honest, we're going to need to do some work post-closing and integration to revisit our forward -- probably mor",217,"Sure. As I said, the current year guidance revision was a direct -- is directly attributable to incorporating Kindred in the guide. To be quite honest, we're going to need to do some work post-closing and integration to revisit our forward -- probably more in 2022, what our guidance points look like and whether they need to change. Obviously, within Kindred, they have direct cost of care. Those are -- all of their costs are included in that OpEx ratio. It's not showing up anywhere else in the guide. So that's something we'll look at, so we'll need to see whether there's anything we should break out separately, specific to the Kindred business. 
As it respect synergies, the Kindred transaction was not really a traditional synergy play. We obviously don't have a Home Health business to integrate into. The operations will be largely standalone. We are certainly looking at opportunities to see where we can create some synergies based on the capabilities we have and they have, but I would not expect those to be significant. The real value is going to be on the new products and models that we intend to introduce, particularly the value-based model we shared during Investor Day that will be the source of value creation as a result of that transaction."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","And just to reemphasize, we don't see net or operating costs going up as a result of the transaction outside of some investments we're making in the short term as a result of the integration. We continue to maintain a long-term orientation to continuing t",132,"And just to reemphasize, we don't see net or operating costs going up as a result of the transaction outside of some investments we're making in the short term as a result of the integration. We continue to maintain a long-term orientation to continuing to increase our productivity. You've seen that over the last number of years, and that has not changed. And the investors shouldn't walk away from that. This is increasing costs, we continue to keep that as a discipline. 
I think what you do see is it's just sort of taking 1 organization that has a different margin, a different operating structure and bringing it into our operating structure. And as we bring the 2 together, we'll have that same emphasis of continue to improve productivity on the organization."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","And I think that was our last question. So Bruce, if you have any closing comments?",16,"And I think that was our last question. So Bruce, if you have any closing comments?"
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. And we really appreciate everyone's support. We recognize that this quarter as a result of the transition year of COVID is a difficult one. We are very oriented to continuing to have the transparency between what is COVID and what's operationally, an",197,"Yes. And we really appreciate everyone's support. We recognize that this quarter as a result of the transition year of COVID is a difficult one. We are very oriented to continuing to have the transparency between what is COVID and what's operationally, and I hope you guys can discern between those 2 as we continue to have further questions on the operational performance. 
That being said, I do want to leave the investors with the understanding that we continue to believe that the organization's operational performance in '21 has been very strong as a result of what you see and just some of the offsets, operational offsets of some of the headwinds from COVID. And then secondarily, as we see 2022 we did take a very conservative view into pricing in our planning for both AEP and as we start to enter the season. I think you guys will see that thoughtfulness and reflect some of the uncertainties that maybe continue into 2022. 
So as always, we appreciate your support, and we also appreciate our teammates' continue to drive to both improve our operating performance and serve our customers in the best we can. So thank you."
29618,1671861870,2352665,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","And with that, this concludes today's conference call. Thank you for attending. You may now disconnect.",16,"And with that, this concludes today's conference call. Thank you for attending. You may now disconnect."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to Humana Second Quarter 2021 Earnings Call. [Operator Instructions] Thank you. Now I would like to welcome Ms. Amy Smith, Vice President of Investor Relations. Ma'am, please go ahead.",39,"Ladies and gentlemen, thank you for standing by, and welcome to Humana Second Quarter 2021 Earnings Call. [Operator Instructions] Thank you. 
Now I would like to welcome Ms. Amy Smith, Vice President of Investor Relations. Ma'am, please go ahead."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our second quarter 2021 results and our updated financial outlook for 2021. Following these",361,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our second quarter 2021 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Joe Ventura, our Chief Legal Officer, will also be joining Bruce and Susan for the Q&A session. We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. 
This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. 
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission and our second quarter 2021 earnings press release as they relate to forward-looking statements and to note in particular that these forward-looking statements could be impacted by risks related to the spread of and response to the COVID-19 pandemic. 
Our forward-looking statements should therefore be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements and future filings or communications regarding our business or results. Today's press release, our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site. 
Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Finally, any references to earnings per share or EPS made during this conference call refer to diluted earnings per common share. 
With that, I'll turn the call over to Bruce Broussard."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Amy, thank you. Good morning, everyone, and thank you for joining us. Today, we reported adjusted earnings per share of $6.89 for the second quarter of 2021, in line with our previous expectations. We continue to focus on delivering strong operating res",1015,"Amy, thank you. Good morning, everyone, and thank you for joining us. 
Today, we reported adjusted earnings per share of $6.89 for the second quarter of 2021, in line with our previous expectations. We continue to focus on delivering strong operating results while navigating a dynamic environment due to the ongoing COVID-19 pandemic, all while staying true to our commitment to delivering the highest quality health care experience for members and patients. Well, we are maintaining our full year 2021 adjusted EPS guidance of approximately $21.5 to $21.75 at the midpoint, representing full year adjusted EPS growth of 16% above the 2020 baseline of $18.50 in excess of our long-term growth target while acknowledging the continued uncertainty driven by COVID-19 hospitalization trends and the rate at which non-COVID costs normalized. 
As Susan will describe in more detail, our full year adjusted EPS guidance now assumes a $600 million COVID-19-related headwind that is expected to be largely offset by favorable operating items. In addition, this guidance assumes no COVID costs will run -- non-COVID costs will run approximately 2.5% below baseline in the back half of the year, including an assumption of minimum COVID testing and treatment costs for the remaining of the year. 
I'd like to reiterate that our core fundamentals are performing well, and 2021 is a year of COVID-19 transition with various pandemic-related financial impacts, including reduced Medicare Advantage revenue resulting from the significant temporary deferral of utilization in 2020 as well as the lingering near-term uncertainties regarding the pace and level of the return of utilization for the balance of the year. We also acknowledge that we are seeing increase in COVID utilization in recent weeks, which we will continue to watch closely. 
While we continue to navigate this pandemic-related uncertainties in 2021, as Susan will lay out in detail, we expect 2022 to be a more normal year. The health care system has been open for several months, and we have seen vaccination rates in the seniors reach approximately 80% nationally. Accordingly, our members continue to engage in more routine interactions with their providers, which we anticipate will result in more normalized Medicare Advantage revenue next year as providers are able to ensure that our members are receiving appropriate care and that their conditions are being fully documented. 
I would reiterate our remarks from the last quarter regarding our Medicare Advantage bids for 2022, which reflected the continued uncertainty associated with COVID-19 in our premium and claims assumption, with a focus on maintaining benefit stability in 2023. While it is still too early to provide 2022 guidance, we believe our operating discipline in 2021, combined with the depth of our planning for 2022 Medicare Advantage AEP, puts us in a strong position for financial growth in 2022. 
I will now turn to an operational and strategic update. Importantly, our underlying core businesses continue to deliver strong results on solid fundamentals, with individual Medicare Advantage membership growth outpacing the industry. As we highlighted at our recent Investor Day, this growth is balanced across various product lines, including HMO and PPO and dual special need plans, or D-SNPs. Our Medicaid business continues to perform well in 2021, and our South Carolina plant is now operational. We are diligently preparing for the Ohio contract go-live date in early 2022 and are continuing to improve our operating model, building off of our core Medicare Advantage capabilities. We've also experienced slightly better-than-expected results in our home and provider businesses and increased mail order rates in our pharmacy business. 
Finally, as announced last quarter, we've entered into an agreement to acquire the remaining 60% interest in Kindred at Home, and we expect the transaction to close mid-August, which we've included in our revised estimates for the year. Our strong operating performance this year is in part a tribute to our strong partnerships with providers who are delivering high-quality care to our members. We are currently seeing 87% of our provider partners and value-based arrangements in surplus. 
Further, our relentless focus on consumer centricity has led to an all-time high Net Promoter Scores for our retail organization, contributing to Medicare Advantage membership growth and resulted in an external recognition of Humana as an industry leader in customer satisfaction, including the announcement this morning that we received the highest ranking in mail order pharmacy customer satisfaction for the fourth year in a row in the J.D. Power 2021 U.S. Pharmacy study. 
On the public policy front, as policymakers explore changes to Medicare, including adding dental, vision and hearing as part of the Medicare benefit, we stand ready to both innovate for the more than 12 million of our members who already have these benefits, including 7 million dental and vision policies in our MA group as well as offer ideas, a public-private collaboration to leverage our deep capabilities in Medicare and specialty markets so that beneficiaries could quickly see benefits go from a proposed law to a tangible benefit. 
Before turning the call over to our new Chief Financial Officer, Susan Diamond, I'd like to take a moment to speak about Susan's experience at Humana over the last 15 years. She has served in various leadership roles across the company during our tenure, spending 8 years as part of the Medicare leadership team with various financial and operational and line of business responsibilities. She also spent 2 years on the finance team, leading enterprise planning and forecasting and overseeing the company's line of business, CFOs and controllers. 
Most recently, she led our home business, growing it to the largest offering of its kind. Her strong financial background and extensive knowledge of our business made her uniquely positioned to step into the CFO role. The board and I have great confidence in our abilities and the contribution she will make in the next chapter for Humana as we execute on our strategic plan and deliver shareholder value. In addition, given the strategic nature of the CFO role, Susan will continue to contribute in a meaningful way to our home health business. 
With that, I'll turn the call over to Susan."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce. And good morning, everyone. Today, we reported adjusted EPS of $6.89 for the second quarter, in line with our previous expectations. Our underlying core business fundamentals remain strong, and we experienced a positive start to the ye",1583,"Thank you, Bruce. And good morning, everyone. 
Today, we reported adjusted EPS of $6.89 for the second quarter, in line with our previous expectations. Our underlying core business fundamentals remain strong, and we experienced a positive start to the year across our segments with the first quarter coming in modestly ahead of our previous expectations. Our results moderated back to expected levels in the second quarter albeit with variation in the way specific underlying assumptions emerged, with COVID treatment costs coming in lower than expected, offset by non-inpatient utilization continuing to bounce back faster than originally anticipated. 
As I will describe in further detail in a moment, uncertainty remains for the balance of the year due to the pandemic, specifically as it respects COVID hospitalizations and the rate at which non-COVID costs normalize, inclusive of both volume and unit costs. 
Recognizing the majority of today's call will focus on our emerging experience and our 2021 guidance, I want to quickly touch on operating performance across our segments before diving into that detail. Our Medicare Advantage growth remains on track and consistent with our previous expectations, with individual MA growing solidly above the market and an expected 11.4% at the midpoint. Our Medicaid business results are exceeding our initial expectations, given membership increases largely attributable to the extension of the public health emergency as well as higher-than-expected favorable prior period development. 
In our Group and Specialty segment, consistent with our commentary on our last earnings call, medical membership declines are lower than we expected coming into the year. Our specialty business results are exceeding expectations as utilization, particularly for dental services, has been slower to bounce back than initially expected. 
Finally, within our Healthcare Services operations, pharmacy continues to see increased mail order penetration as a result of customer experience improvements and additional marketing initiatives. The Home business, CenterWell Senior Primary Care and Conviva are performing slightly ahead of expectations, and we remain on track to open 20 new clinics this year with Wells Carson. In addition, as Bruce indicated in his remarks, we now expect the Kindred at Home acquisition to close in mid-August, subject to customary state and federal regulatory approvals. 
Before I go into more detail on our 2021 guide, I want to reiterate that the uncertainty we are seeing in 2021 relates solely to the difficulty estimating the impact of the pandemic and is not expected to carry forward into 2022. We remain comfortable with how we approach 2022 pricing, which I will expand on later in my remarks. 
Turning to full year 2021 guidance. I would remind you our adjusted EPS guidance represents growth at or above the top end of our long-term target of 11% to 15%. Our philosophy regarding 2021 guidance has been to provide transparency into the uncertainty caused by COVID-19 and the ability to deliver our targeted earnings growth with solid underlying core business performance and largely offsetting COVID-19-related headwinds and tailwinds. We have been consistent in and remain committed to this philosophy. 
There is a reasonable path to achieving adjusted EPS within our initial guidance range. And accordingly, today, we are maintaining our full year adjusted EPS guidance of $21.25 to $21.75, while acknowledging the continued uncertainty as it respects COVID hospitalization trends as well as the pace at which non-COVID costs bounce back and at what level they ultimately normalize. Additionally, we expect our third quarter adjusted EPS to reflect a low 20s percentage of our full year adjusted EPS. 
As Bruce indicated, given our experience to date, together with our current estimates for the back half of 2021, we have effectively recognized a $600 million COVID-related headwind for Medicare Advantage in our full year guidance, offset by favorable operating items. These favorable items include, among others, higher than initially expected prior year development, the previously discussed better-than-expected specialty and Medicaid results and the expected contribution from Kindred at Home given the transaction is expected to close in the coming weeks. 
Now let me provide an update on the underlying changes since our initial detailed guide in February, articulate key assumptions regarding utilization in the back half of 2021 and expand on the continued pandemic-related uncertainties I described. 
I will begin with Medicare Advantage revenue. As discussed last quarter, given our significant exposure to Medicare Advantage, we are disproportionately affected by COVID's impact on Medicare risk adjustment, or MRA. Recall, our risk-adjusted revenue for 2021 is determined by 2020 dates of service, medical utilization and resulting documentation, which, as previously discussed, was materially depressed in 2020. As we have indicated since the beginning of the year, the MRA headwind that we are facing in 2021 is significant, and we have closely monitored it over the course of the year. Our April guide recognized we had $300 million of additional pressure from MRA relative to our initial expectations for the full year, which was offset by the net benefit of the extension of sequester relief. 
In July, we received the mid-year MRA payment, and it came in modestly lower than expected. We are, however, taking operational steps now to be able to recover some of the MRA revenue and the final payment for 2021. Accordingly, our MA premium estimates, net of capitation, remain largely in line with our initial expectations when factoring in the net sequestration benefit. 
Now turning to benefit expense. At the beginning of the year, we indicated that we expected non-COVID costs for our Medicare business to run 3.6% to 5.5% below baseline. We defined baseline as 2019 experience trended forward based on a normalized trending factor excluding the effects of COVID. In the first quarter, we acknowledge that non-inpatient costs were bouncing back faster than initially expected. However, that was offset by COVID utilization, decelerating faster than expected. We also recognize, however, visibility into non-inpatient claims was significantly less than inpatient and therefore, we acknowledge that there was more uncertainty around non-inpatient service categories in terms of exactly where we stood. However, at that time, we could still tolerate overall utilization returning to baseline late in the year if the non-inpatient acceleration we were seeing was due to pent-up demand and leveled off in the second and third quarters. 
In the first and second quarters, non-COVID costs ran approximately 7% and 3% below baseline, respectively, with the bounce back outpacing expectations in the second quarter. Non-inpatient utilization did not lever loss and instead continue to increase in the second quarter and was offset by lower-than-expected COVID costs and other business outperformance. 
As the health care system has been opened for several months and a high rate of the senior population has been vaccinated, our current guidance now assumes that non-COVID costs level off and run approximately 2.5% below baseline levels in the back half of the year. Consistent with our original forecast, our current guidance assumes minimal COVID testing and treatment costs in the back half of the year. That said, we do acknowledge that we are seeing increases in COVID admissions in recent weeks, although it's too early to determine if there will be offsetting declines in non-COVID utilization, and we will continue to monitor this recent development. Finally, as it respects our 2021 guide for our commercial business, we expect all-in utilization for COVID and non-COVID to continue to run above baseline as anticipated. 
In summary, I want to emphasize that 2021 as a COVID transition year. There is a reasonable path to deliver against our guidance expectations. However, as non-COVID utilization or COVID treatment costs increased beyond our expectations in the back half of the year, it will present a headwind to our guide, absent offsetting tailwinds. 
I also want to reiterate that the $21.50 midpoint of our original guide continues to be the right jumping off point for 2022 adjusted EPS growth. Our members continue to engage in routine interactions with their providers, which we anticipate will result in more normalized Medicare Advantage revenue next year as providers are able to ensure that our members are receiving appropriate care and if their conditions are fully documented. 
During the first half of 2021, provider interactions and documentation of clinical diagnosis that will impact 2022 revenue outpaced those experienced in the first half of 2020 and are approximately 80% complete, in line with the estimated completion of the same time period in 2019. Lastly, I would remind you that our Medicare managed bid for 2022 reflected the continued uncertainty associated with COVID-19 as it relates to our premium and baseline non-COVID claims trend assumptions, with a focus on maintaining benefit stability into 2023. 
Before we open up the line for questions, I'm excited to announce 2 finance leadership changes that will promote the growth and versatility of our finance leadership team. First, with the expected integration of Kindred at Home, our Home business is growing significantly, and Amy has accepted the role of Vice President and CFO of Home Solutions. She will be a key member of the Home Solutions leadership team, responsible for the financial oversight and planning and forecasting for the segment. Lisa Studer will succeed Amy, accepting the role of Vice President, Investor Relations. Lisa has worked with Amy over the last 4 years and is well-known and respected by our investors. We are excited about the opportunity this affords both Amy and Lisa, and Lisa's continuity in Investor Relations will allow for a seamless transition. 
With that, we will open up the lines for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your first question is from the line of Justin Lake from Wolfe Research.",13,"Your first question is from the line of Justin Lake from Wolfe Research."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Obviously, a lot to cover. I'll try to keep it to 1 question here. But the -- I'm hoping you could give us a few numbers. One is the MRA. Can you tell us what the full year impact is of the negative MRA? And I think there's a lot of confusion around 2 thi",187,"Obviously, a lot to cover. I'll try to keep it to 1 question here. But the -- I'm hoping you could give us a few numbers. One is the MRA. Can you tell us what the full year impact is of the negative MRA? And I think there's a lot of confusion around 2 things. One, it sounds like the first half or the second quarter, I should say, was worse than expected, and yet you still kind of came in line with -- from an MOR perspective. So you're telling us the back half has -- needs to be more optimistic. So what happened in the second quarter beyond that allowed you to make the MLR, but still have higher medical costs that need the back half? And then I guess the -- around that, the $600 million specifically, can you flush that out in as much detail as you can? Because is that comparable to the old COVID estimate? Or is that a new COVID headwind that you've kind of thrown in there for the back half of the year for us to think about?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take these 1 at a time. I'll start with your last question around the $600 million. So just to clarify, the $600 million represents our full year estimate of the Medicare Advantage-only net headwinds and tailwinds and related to the COVID pa",382,"Sure. So I'll take these 1 at a time. I'll start with your last question around the $600 million. So just to clarify, the $600 million represents our full year estimate of the Medicare Advantage-only net headwinds and tailwinds and related to the COVID pandemic. And if you recall back to our initial guidance earlier this year, we provided a schedule that laid out the specific line items that were considered in that and a range of estimates at the time. So the $600 million represents our current view and what is contemplated in our guide related to those items on a net basis, so the net of all the various headwinds and tailwinds based on our current expectations. 
As it respects to the first half and second half, as we described in the call, what we continue to see throughout the first half of the year was COVID costs coming down faster than initially expected, but non-COVID outpatient, in particular, rebounding faster than expected, and that continued through the second quarter. And we anticipate that, that will extend some into the third quarter before it levels off. In the first half of the year, the benefits we saw from COVID-related costs as well as some lower inpatient -- non-COVID inpatient costs, we do not expect to continue at the same rate because our expectation has always been that those costs on the Home side would come down as a result of the rollout of vaccinations and that utilization would rebound to more normal levels such that there is less positive upside that can offset those costs in the second half of the year, which is why we are now estimating a net 2.5% decline in non-COVID utilization in the back half of the year to meet our guide. 
As it respects to MRA, I think we provided the net detail in terms of what our current estimates really are. I know we provided the line item in the initial guide in terms of the beginning of the year. And what we're saying is on a net basis net of capitation, there's about a $300 million additional headwind. And in the context of the overall guide, that is largely offset or fully offset by the net impact of the positive sequestration benefit."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Okay. And then just quick follow-up on the $600 million, that was all really helpful. The $600 million, can you just tell us what that compares to specifically? Because you had like a $400 million to $700 million COVID number thrown into the original sche",99,"Okay. And then just quick follow-up on the $600 million, that was all really helpful. The $600 million, can you just tell us what that compares to specifically? Because you had like a $400 million to $700 million COVID number thrown into the original schedule, is that the comparable now? And then have you said that that's all eaten away in the first half of the year, so effectively, that updated $600 million is comparable to the $400 to $700, and it's completely gone effectively, so you don't have any -- none of that's assumed in the back half?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Just to be clear, this is in the full year estimate, so inclusive of first half and back half. But I also want to clarify, it is not meant to be specific to the line item that's labeled COVID testing and treatment on that initial schedule. That was 1 line",146,"Just to be clear, this is in the full year estimate, so inclusive of first half and back half. But I also want to clarify, it is not meant to be specific to the line item that's labeled COVID testing and treatment on that initial schedule. That was 1 line item. When we refer to the $600 million, it is the net impact of all of the line items that were represented on the schedule. 
And the other thing I would add as well in terms of your question about how did you offset that, there was a lower COVID and other inpatient costs. But also recall, we had other business outperformance that we mentioned in the discussion around the prior period development, commercial Medicaid that also offset some of that headwind we experienced in the first half of the year as well. Next question, please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Kevin Fischbeck from Bank of America.",14,"Your next question is from the line of Kevin Fischbeck from Bank of America."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I wanted to, I guess, follow up on the assumption for trends in the back half of the year. I guess you're saying core utilization, 2.5% below. I guess if you could maybe provide a little more color on that? I mean how do you get there? Are some things abo",123,"I wanted to, I guess, follow up on the assumption for trends in the back half of the year. I guess you're saying core utilization, 2.5% below. I guess if you could maybe provide a little more color on that? I mean how do you get there? Are some things above average, some things below average? If I understood what you were saying, I think you said that when you exclude COVID coast, total trend is above average, just want to make sure I heard that, but just color on how you get to the minus 2.5% for the back half of the year and why there isn't more of an assumption of ""core back to normal"" by the end of the year?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So just to provide a little more detail. So as we mentioned, the second quarter ran about 3% below baseline for that non-COVID utilization. Our third and fourth quarter now, on average, are estimated to run 2.5% below baseline. And recall that, that",235,"Sure. So just to provide a little more detail. So as we mentioned, the second quarter ran about 3% below baseline for that non-COVID utilization. Our third and fourth quarter now, on average, are estimated to run 2.5% below baseline. And recall that, that's inclusive of both utilization as well as unit cost. So as I mentioned, we do expect, given that the country has been largely open, our population is largely vaccinated, that we will see those non-COVID utilization start to normalize, and so we've allowed for some additional return to baseline relative to what we've experienced in the second quarter. 
I would also say that as we see that utilization come back, we also see that the average cost per hospitalization will come down because lower severity cases are reintroduced. And so the combination of leveling off of utilization and continued reductions in the unit cost contribute to that 2.5% below baseline. 
I think you've suggested that overall utilization might be above baseline. I think you might be referring to my comments about commercial where we had planned to see in total COVID -- non-COVID slightly above baseline as we were beginning to see that at the end of 2020. But for our Medicare business, because we're including limited COVID costs in our forecast in the back half of the year, it's not contributing significantly, so that would not take it over baseline."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Okay. But when you say it's the low baseline inpatient, outpatient physician, drugs, I guess, those 4 categories, are they all kind of there or some above, some below?",29,"Okay. But when you say it's the low baseline inpatient, outpatient physician, drugs, I guess, those 4 categories, are they all kind of there or some above, some below?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. We are seeing variations in some of the service categories as you can imagine. One of the reasons we believe that some of the tenant demand has been worked through the system is things like surgical procedures, colonoscopies and things like that. We",75,"Sure. We are seeing variations in some of the service categories as you can imagine. One of the reasons we believe that some of the tenant demand has been worked through the system is things like surgical procedures, colonoscopies and things like that. We did for a period of time to see go slightly above baseline, but other traditional normal course ER and observations and other activities continue below baseline. Thank you. Next question, please?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Matthew Borsch from BMO Capital Markets.",14,"Your next question is from the line of Matthew Borsch from BMO Capital Markets."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Maybe I could just continue on this theme of trying to understand with the Medicaid baseline through the end of the year. Do you think that -- what is sort of thought of is deferred care or the health care that didn't happen, but would have happened, I gu",117,"Maybe I could just continue on this theme of trying to understand with the Medicaid baseline through the end of the year. Do you think that -- what is sort of thought of is deferred care or the health care that didn't happen, but would have happened, I guess, really over the last 5 quarters? Is a lot of that just not going to -- that isn't something that is going to flow through as pent-up demand? It's sort of embedded in there is that assumption that -- and seniors, I guess, are going to still have some avoidance of the health care system even in the back half of this year. Just trying to understand that."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. I would say that our view would be that given the pace at which the non-inpatient utilization, in particular, bounced back, which was faster than we anticipated, that we are seeing -- and a lot of that, you'll see they're reengaging with their physic",143,"Yes. I would say that our view would be that given the pace at which the non-inpatient utilization, in particular, bounced back, which was faster than we anticipated, that we are seeing -- and a lot of that, you'll see they're reengaging with their physicians and specialists more than normal rate. And so I think we do believe that some of the pent-up demand as a result of the deferred here in 2020 has been reflected in our first half of the year results. And that, again, because of the length of time the country has largely been open, that pent-up demand has worked through. And therefore, while we will -- we are expecting a little bit more return to baseline relative to our second quarter performance that, that will stabilize through the back half of the year. Thank you. Next question, please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of A.J. Rice from Credit Suisse.",14,"Your next question is from the line of A.J. Rice from Credit Suisse."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Just to put a fine point on some of the discussion and then 2 other data points. The 2.5% for the back half, I think in the beginning guidance, you said that the underutilization for the full year will be 3.6% to 5.5% deferred relative to baseline. If you",176,"Just to put a fine point on some of the discussion and then 2 other data points. The 2.5% for the back half, I think in the beginning guidance, you said that the underutilization for the full year will be 3.6% to 5.5% deferred relative to baseline. If you got an updated number, how much are you at the lower end of that or are you even the overall range when you think about that original number? And then I would also ask you about the operating expense. Obviously, you've updated that. Is that mainly related to Kindred? Are you expecting more investments in the back half of the year in other areas? 
And then if I could squeeze in 1 more. Your comment about the offset of sequestration versus the MRA headwind this year, does that, in your mind, reverse next year? So if we lose sequestration, you -- the MRA catch-up by having fully coded all the people from last year and this year offsets that? Is that the way to think about it?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take these 1 at a time. So the first, to your question, based on our experience for first half of the year and our 2.5% expectation in the back half of the year, if you do all that math, it suggests that for the full year, our non-COVID util",258,"Sure. So I'll take these 1 at a time. So the first, to your question, based on our experience for first half of the year and our 2.5% expectation in the back half of the year, if you do all that math, it suggests that for the full year, our non-COVID utilization will end up at about 3.75% below baseline, so effectively at the low end of the range we had given you at the start of the year. 
On OpEx, as you said, you're exactly right. The reason for the change in the guide and the increase that is directly attributable to incorporating the Kindred performance into our guidance points, and so that is largely the reason for that increase. We do, however, I would say, in terms of our core business and even within Kindred anticipate some investment like we would in normal course. Kindred, as you can imagine, by integrating it, there are some investments we might want to make there as a respect to the value-based operating model that we've described at Investor Day. And so that is contemplated in there as well. 
On your second question on sequestration, we do expect that to reverse in 2022. That would have been contemplated in our bids and pricing. And our MRA assumptions as we think about 2022 would not be impacted by that explicitly. They are independently calculating what we believe the risk adjustment will be based on the diagnosis submissions that we would expect in a more normal environment. Thank you. Next question, please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Rivka Goldwasser from Morgan Stanley.",13,"Your next question is from the line of Rivka Goldwasser from Morgan Stanley."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I want to clarify a utilization and then another question. Just to clarify, Susan, is basically what you're saying is that the 2.5% below baseline really encompasses the fact that care is happening outside the 4 walls of the hospital? I think you mentione",131,"I want to clarify a utilization and then another question. Just to clarify, Susan, is basically what you're saying is that the 2.5% below baseline really encompasses the fact that care is happening outside the 4 walls of the hospital? I think you mentioned lower ER visits. You're also mentioning that you don't expect 2022 risk adjusters to be impacted by the lower utilization. So is it that just you're seeing a shift in where care is being provided, i.e. the telehealth primary care, and that's what's impacting that below baseline, it's a dollar number? And then my second question, if you can give us just some color and context around the announcement that we saw last week on the investment that you're making with them on -- into new PBM?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Okay. So to your first question on the 2.5%, so again, that is related to non-COVID utilization and all inclusive of inpatient and non-inpatient, again, both rate and volume. And so I wouldn't say that we're necessarily seeing shifts in the site of servic",250,"Okay. So to your first question on the 2.5%, so again, that is related to non-COVID utilization and all inclusive of inpatient and non-inpatient, again, both rate and volume. And so I wouldn't say that we're necessarily seeing shifts in the site of service or the site of care, but rather just as utilization returns to normal, there is some level of utilization that hasn't just hasn't come back on an absolute basis. But really, we are seeing, with the exception of some of those specific service categories I mentioned like surgical, other categories are largely still running below baseline across the board. 
As far as MRA impact, as we said, what we are seeing in terms of the normal routine interactions with our providers, our income assessment activity and other annual wellness programs, those are all trending exactly as we would expect to see in order to deliver against our 2022 revenue estimates contemplated in pricing. And so we feel really good about our trajectory there. Should we see somewhat depressed utilization in the back half of the year, given the way risk adjustment works, generally speaking, we feel good that so long as there's not sort of a full shutdown like we saw in 2020, which is not what we anticipate currently, we feel confident that we should be on pace to deliver against what we need for MRA, again, based on what we're currently seeing. I don't know, Bruce, would you like to address the Anthem partnership?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Similar to what we've done in the past and other more utility-oriented areas, I think availability would be an example of that, where we've tried to find partners within the industry that can help build a longer-term utility. And we look at the particular",118,"Similar to what we've done in the past and other more utility-oriented areas, I think availability would be an example of that, where we've tried to find partners within the industry that can help build a longer-term utility. And we look at the particular partnership with Anthem as the opportunity to update and really give more both increased productivity and, at the same time, increase the experience for members in the area of the PBM side, we, for a number of years, have been using SS&C as a vendor to help in the -- with the existing technology. But now I've been able to take it and really enhance it through this partnership with Anthem and SS&C."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you. Next question please.",5,"Thank you. Next question please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Stephen Baxter from Wells Fargo.",13,"Your next question is from the line of Stephen Baxter from Wells Fargo."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I was hoping that you could talk in a little bit greater detail about why the risk adjustment revenue ended up coming in below where you expected it for this year? I guess you had a lot of visibility into certain inputs and not others. To the extent you c",73,"I was hoping that you could talk in a little bit greater detail about why the risk adjustment revenue ended up coming in below where you expected it for this year? I guess you had a lot of visibility into certain inputs and not others. To the extent you could flesh those out, I think it would help give us a better sense of how comfortable we can be around next year's assumptions."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So as it respects the $300 million that we referenced that was contemplated in our April guide, so just for context, our January payment in 2021 would reflect claims that were submitted through the September submission deadline. And then that requir",326,"Sure. So as it respects the $300 million that we referenced that was contemplated in our April guide, so just for context, our January payment in 2021 would reflect claims that were submitted through the September submission deadline. And then that requires us to estimate the submissions that will come in organically as well as a result of our activities around chart review and prospective programs for the remainder of the year. 
At that time, we were not anticipating the significant surge that we saw across the country in the fourth quarter due to COVID and the resulting reduction in non-COVID utilization. What that led to was lower -- what we refer to as organic diagnosis submissions, so those are not related to the campaigns that we initiated, but rather organic submissions across the provider community based on the utilization that's happening. And those ultimately prove to come in lower than we had anticipated. And generally speaking, I think we've mentioned before that those organic submissions are more difficult to estimate, obviously, than the initiatives that we are executing. So that was reflected in our April guide at the time. 
In terms of the midyear adjustment, as we've said on previous calls, the adjustment there was solely related to new members or members who were only enrolled for a partial year in 2020, where we don't have full visibility to their claims. And so while we made an estimate of what we thought the impact would be based on what we were seeing within our concurrent population, ultimately, that midyear payment came in, it reflected a lower level of contribution for those new members and our estimates had originally anticipated. 
I would say that going into 2022, because those impacts were directly related to the COVID pandemic and impacts the utilization, I would not expect to see that continued uncertainty carry into 2022 based on what we're seeing so far this year. Thank you. Next question."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Josh Raskin from Nephron Research.",13,"Your next question is from the line of Josh Raskin from Nephron Research."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I understand we're coming out of the second quarter with non-COVID utilization running 3% below baseline. But how do you see that continuing to run 2.5% baseline for the second half of the year if you're also assuming that you're not going to see any COVI",118,"I understand we're coming out of the second quarter with non-COVID utilization running 3% below baseline. But how do you see that continuing to run 2.5% baseline for the second half of the year if you're also assuming that you're not going to see any COVID -- direct COVID cost for testing and treatment? I sort of think of those as related. And then would a rise in direct COVID costs, so if we did see this increase that you guys mentioned that you're seeing in the last couple of weeks, if that did continue, would that end up being a net negative now because you've got all the direct costs, but you're already assuming lower utilization?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I would say that our view of non-COVID is not influenced by what the recent activity and uptick we've seen in COVID cases. That is not why we're assuming that it runs below baseline. Our view is, again, just based on the trajectory we've seen tha",223,"Sure. So I would say that our view of non-COVID is not influenced by what the recent activity and uptick we've seen in COVID cases. That is not why we're assuming that it runs below baseline. Our view is, again, just based on the trajectory we've seen that given the level of utilization increase we've seen that we were at a point where it will be in the plateau and level off as sort of just a new baseline for the back half of the year. 
As it respects COVID, as we mentioned, it's just very early in terms of the increase we've seen is literally just in the last couple of weeks. It is still a bit too early to determine whether or not we will see offsetting non-COVID utilization impacts like we have seen in all previous surges. I will say, just this last week, we just began to see some level of reduction in inpatient -- non-COVID inpatient as the COVID cases increase. It's simply just too early to really assess the duration that we might see in terms of an uptake and the offsetting utilization. But should we see offsetting utilization in the non-COVID space, in order for that not to present a headwind, it would be incremental to the 2.5% that we are currently forecasting. Next question, please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Lance Wilkes from Bernstein.",12,"Your next question is from the line of Lance Wilkes from Bernstein."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes. Let's see, my primary question is on the pricing environment. You called out a little bit of a pricing environment in, I think, in group MA. Can you talk a little bit about that pricing environment impacts and magnitude in '21 outlook for '22? And th",104,"Yes. Let's see, my primary question is on the pricing environment. You called out a little bit of a pricing environment in, I think, in group MA. Can you talk a little bit about that pricing environment impacts and magnitude in '21 outlook for '22? And then in general for pricing, both individual and group, how does this work towards your return to kind of target margins here? And then on the utilization, the 1 extra thing I'd just ask on that 2.5% below baseline, just if you're getting any indications on impacts of delta variant on utilization in any of your own clinics?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. Just [indiscernible]. The first is the respect to pricing, U.S. industry about the group MA. And I think as we've said before, the group MA space, particularly for larger group accounts, continues to be highly competitive, and we would expect that t",394,"Sure. Just [indiscernible]. The first is the respect to pricing, U.S. industry about the group MA. And I think as we've said before, the group MA space, particularly for larger group accounts, continues to be highly competitive, and we would expect that to continue. And so the margins that we would see on those accounts to continue to be competitive and pressured. I think though, as we think about group MA, there are a lot of other benefits to winning those large accounts in terms of the impact they can have in a local geography on the network and our ability to work with provider partnerships, et cetera. But we expect that to be -- continue to be competitive. 
On the individual side, this is always a process we go through every year to understand sort of the rate environment, the competitive environment, other business performance. We always strive to maintain benefit stability, knowing how important that is to our members as well as our sales and distribution channels. So that's always our goal. And there's always a number of puts and takes that we will consider, including the broader enterprise performance as it respects, first and foremost, delivering against our overall growth target of 11% to 15%. 
And after considering sort of strategic investments, other business performance and then understanding what's required of our Medicare business and what we're trying to achieve, balancing both growth and margin in the long term. All of those are taken into account. We remain committed to achieving long-term, our targeted individual margin of 4.5% to 5%, and that will vary each year based on those things that I mentioned. But we expect this to continue to progress towards that goal. 
On utilization, I would say really it's too early, I think, for us to really see anything specific at the clinic level. That information is not as real time available to us as there are hopefully information. So to date, I have not seen anything that would provide us any visibility. I will say, there are some concentrations geographically. As you've seen probably in the press, Florida is a state that is seeing higher rates given we have a concentration of some of our clinics there. I imagine that they would see some, but we actually don't have detailed information on that just yet. Next question, please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Ralph Giacobbe from Citi.",12,"Your next question is from the line of Ralph Giacobbe from Citi."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I guess going back to the 2.5%, if your assumption is that 2.5% below baseline, I think your original guidance was to run above baseline towards the end of the year. So why wouldn't that represent upside? Or where is the offset there? And then can you giv",69,"I guess going back to the 2.5%, if your assumption is that 2.5% below baseline, I think your original guidance was to run above baseline towards the end of the year. So why wouldn't that represent upside? Or where is the offset there? And then can you give us how much COVID cost you've seen sort of through the first half against that $600 million full year estimate?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Okay. As it respects to 2.5%, as you mentioned, I think in earlier calls during the first quarter, did mention that our original forecast did contemplate over the course of the second half of the year that we would begin to approach baseline and potential",224,"Okay. As it respects to 2.5%, as you mentioned, I think in earlier calls during the first quarter, did mention that our original forecast did contemplate over the course of the second half of the year that we would begin to approach baseline and potentially for a short period of time see above baseline utilization related to pent-up demand. So we just projected that to occur later in the year. Our view is that given the rate at which we've seen it bounce back more quickly, that we have seen that in the first half of the year instead. And so at the time, I don't think we've given specifics on sort of the monthly trajectory. But in general, our original forecast going into the year did anticipate a slower return to baseline and could tolerate it getting to baseline by the end of the year. 
But as I described in my remarks, because we saw the faster bounce-back in non-inpatient and in the first half, that was, again, largely offset by the reductions in COVID and inpatient. Those trends will not continue at the same level and therefore, we will need to see below baseline utilization on the nonpoinside in order to achieve that full year estimate of 3.75%. And then could you repeat your second question, I'm sorry, about the COVID costs?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes, just trying to get a sense of what it ran in the first half of the year relative to the updated sort of $600 million. Are you fully through the $600 million at this point, is that what you're trying to imply? And there's nothing baked into the back h",60,"Yes, just trying to get a sense of what it ran in the first half of the year relative to the updated sort of $600 million. Are you fully through the $600 million at this point, is that what you're trying to imply? And there's nothing baked into the back half? Just trying to get a sense of magnitude there."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","No. So again, that $600 million is a full year estimate. It does, just to be clear, include in the assumption that the non-COVID utilization will run 2.5% in the back half of the year, so that's contemplated in that. But I don't think we had intended to p",74,"No. So again, that $600 million is a full year estimate. It does, just to be clear, include in the assumption that the non-COVID utilization will run 2.5% in the back half of the year, so that's contemplated in that. But I don't think we had intended to provide any quarterly detail of how that's emerging, but that is a full year number. It would not represent just the first half of the year."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Just to highlight on the $600 million, that is if you were to go to the first quarter or the February earnings release for the fourth quarter, we put together some lows and highs all the way from MRA, COVID testing, depressed utilization and sequestration",121,"Just to highlight on the $600 million, that is if you were to go to the first quarter or the February earnings release for the fourth quarter, we put together some lows and highs all the way from MRA, COVID testing, depressed utilization and sequestration. And what the $600 million is if you were to take that and roll that forward now, all the ins and outs from that would be the net number of the $600 million. The operational aspects of our business, as Susan has talked about, has offset all of that $600 million. But included in that $600 million net number is an assumption that 2.5% below baseline will be remaining for the remaining part of the year."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Next question, please.",3,"Next question, please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Scott Fidel from Stephens.",12,"Your next question is from the line of Scott Fidel from Stephens."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","First, I think you just clarified part of the question that I was going to have, which is just confirming that the net headwind and tailwind that had been 0 in that 4Q '25 deck, that's now $600 million, right? And then also just on the MRA piece in that s",181,"First, I think you just clarified part of the question that I was going to have, which is just confirming that the net headwind and tailwind that had been 0 in that 4Q '25 deck, that's now $600 million, right? And then also just on the MRA piece in that same slide deck, you had called that out at $700 million to $1 billion of expected headwind. I guess given the update that you guys have given us around the $300 million incremental impact a couple of months ago and then how things came out in the midyear claims review, Just interested if you have an updated estimate that we can compare now against that $700 million to $1 billion number? 
And then sort of, I guess, just putting this all together, just how this sort of nets out to -- for 2021? And putting all the pieces together, what that sort of implies and what you're assuming for your MA pretax margin so we can think about sort of the earnings run rate now relative to the long-term target margin?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","So what I would say, we never, at the time, as you mentioned, the schedule that we gave you, which provided a range of $700 million to $1 billion, I don't think at the time we ever said exactly where we were in that range in terms of our internal estimate",107,"So what I would say, we never, at the time, as you mentioned, the schedule that we gave you, which provided a range of $700 million to $1 billion, I don't think at the time we ever said exactly where we were in that range in terms of our internal estimate. I think what we just wanted to clarify was that we had seen $300 million of net pressure incremental to that, which is, again, in terms of the schedule offset then by the sequestration. And then can you repeat your second question? I'm sorry, I think it was '21 -- oh, the '21 question, I'm sorry."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes. Basically, it's just trying to take all these different pieces together. And what they net out to what sort of the underlying pretax MA margin assumption is for 2021 so we can think about that relative to the long-term target?",41,"Yes. Basically, it's just trying to take all these different pieces together. And what they net out to what sort of the underlying pretax MA margin assumption is for 2021 so we can think about that relative to the long-term target?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. So what I would say is, as you see in our guidance points, our MER target or MER range and our -- hasn't really changed. Because of the offsets and the nature of those offsets, there are many within the retail segment and Medicare in particular. So I",103,"Yes. So what I would say is, as you see in our guidance points, our MER target or MER range and our -- hasn't really changed. Because of the offsets and the nature of those offsets, there are many within the retail segment and Medicare in particular. So I would say, in general, there's no material movement in the individual MA margin because the headwind -- net headwind is largely offset by other positivity. And as we mentioned, the positive prior period development as an example as well as the sequestration would be attributable to the retail segment. Thank you. Next question, please?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of George Hill from Deutsche Bank.",13,"Your next question is from the line of George Hill from Deutsche Bank."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I'm going to try to put in 2 very quick ones. I guess, Bruce, as I think about the JV investment with Anthem, that's much more of an infrastructure and back-end investment as opposed to more of a PBM JV, if I understand that, right? And then just kind of",88,"I'm going to try to put in 2 very quick ones. I guess, Bruce, as I think about the JV investment with Anthem, that's much more of an infrastructure and back-end investment as opposed to more of a PBM JV, if I understand that, right? And then just kind of net-net of everything, am I hearing things right that the $21.25 to $21.75 is the right jumping off point as we think about fiscal '22 EPS, inclusive of all the moving pieces basically that they're all offsetting?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes, to answer your first question, you're exactly right. It is an infrastructural investment. And again, it's a utility for the industry. And actually, we would enjoy  others to join that joint venture over a period of time. In regards to your second que",63,"Yes, to answer your first question, you're exactly right. It is an infrastructural investment. And again, it's a utility for the industry. And actually, we would enjoy  others to join that joint venture over a period of time. In regards to your second question, you're exactly right, the midpoint is $21.50. And that is what we would base our '22 growth of off."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Next question, please.",3,"Next question, please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your last question is -- I'm sorry, your next question is from the line of David Windley from Jefferies.",19,"Your last question is -- I'm sorry, your next question is from the line of David Windley from Jefferies."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","You touched on this a little bit, but I want to try to bring a finer point to it. The 2.5% baseline in the second half, would you expect that -- not standing time frame, but would you expect that to return to baseline? Or are you seeing some permanent shi",92,"You touched on this a little bit, but I want to try to bring a finer point to it. The 2.5% baseline in the second half, would you expect that -- not standing time frame, but would you expect that to return to baseline? Or are you seeing some permanent shifts like ER utilization that would cause you to stay below baseline beyond 2021? And then what are you seeing in terms of member acuity as the bounce back utilization has come? Are you seeing higher acuity as patients represent for services?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. Great question. So as we said, the 2.5% represents an average for the back half of the year. I think it remains to be seen at what rate it ultimately settles in. It could come in more depressed in the third quarter and then get closer to baseline. T",260,"Sure. Great question. So as we said, the 2.5% represents an average for the back half of the year. I think it remains to be seen at what rate it ultimately settles in. It could come in more depressed in the third quarter and then get closer to baseline. There's obviously a range of scenarios that could emerge, some of which could be that by the end of the year, it gets closer to baseline. So I think that until we get to the plateau and see that sustained, I think it will be hard to assess the long-term, whether that's a long-term new normal or not. So we'll continue to watch that. 
As for acuity, I would say so far, we are not seeing indicators that there is a higher acuity or there has been impact from the deferred care in 2020. We are continuing to watch it. But so far, we have not seen any sort of systemic indicators of that. And in fact, some of the things that we were able to initiate along with our provider partners to ensure members received needed preventative care through telemedicine were quite hopeful during the pandemic. 
And 1 data point as an example, was that we saw higher medication adherence through the pandemic than we actually did pre-pandemic, so a nice indication that members were receiving the needed preventative care, receiving their medications and hopefully staying on top of their conditions. But so far, we are watching it, but we're not seeing any indications of higher acuity. Next question, please."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Rob Cottrell from Cleveland Research.",13,"Your next question is from the line of Rob Cottrell from Cleveland Research."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Wanted to revisit the operating cost guidance, and how should we think about that for future years, absorbing the full year cost of Kindred and also any potential synergies that could offset that into 2022 and beyond?",37,"Wanted to revisit the operating cost guidance, and how should we think about that for future years, absorbing the full year cost of Kindred and also any potential synergies that could offset that into 2022 and beyond?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. As I said, the current year guidance revision was a direct -- is directly attributable to incorporating Kindred in the guide. To be quite honest, we're going to need to do some work post-closing and integration to revisit our forward -- probably mor",217,"Sure. As I said, the current year guidance revision was a direct -- is directly attributable to incorporating Kindred in the guide. To be quite honest, we're going to need to do some work post-closing and integration to revisit our forward -- probably more in 2022, what our guidance points look like and whether they need to change. Obviously, within Kindred, they have direct cost of care. Those are -- all of their costs are included in that OpEx ratio. It's not showing up anywhere else in the guide. So that's something we'll look at, so we'll need to see whether there's anything we should break out separately, specific to the Kindred business. 
As it respect synergies, the Kindred transaction was not really a traditional synergy play. We obviously don't have a Home Health business to integrate into. The operations will be largely standalone. We are certainly looking at opportunities to see where we can create some synergies based on the capabilities we have and they have, but I would not expect those to be significant. The real value is going to be on the new products and models that we intend to introduce, particularly the value-based model we shared during Investor Day that will be the source of value creation as a result of that transaction."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","And just to reemphasize, we don't see net or operating costs going up as a result of the transaction outside of some investments we're making in the short term as a result of the integration. We continue to maintain a long-term orientation to continuing t",132,"And just to reemphasize, we don't see net or operating costs going up as a result of the transaction outside of some investments we're making in the short term as a result of the integration. We continue to maintain a long-term orientation to continuing to increase our productivity. You've seen that over the last number of years, and that has not changed. And the investors shouldn't walk away from that. This is increasing costs, we continue to keep that as a discipline. 
I think what you do see is it's just sort of taking 1 organization that has a different margin, a different operating structure and bringing it into our operating structure. And as we bring the 2 together, we'll have that same emphasis of continue to improve productivity on the organization."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","And I think that was our last question. So Bruce, if you have any closing comments?",16,"And I think that was our last question. So Bruce, if you have any closing comments?"
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. And we really appreciate everyone's support. We recognize that this quarter as a result of the transition year of COVID is a difficult one. We are very oriented to continuing to have the transparency between what is COVID and what's operationally, an",197,"Yes. And we really appreciate everyone's support. We recognize that this quarter as a result of the transition year of COVID is a difficult one. We are very oriented to continuing to have the transparency between what is COVID and what's operationally, and I hope you guys can discern between those 2 as we continue to have further questions on the operational performance. 
That being said, I do want to leave the investors with the understanding that we continue to believe that the organization's operational performance in '21 has been very strong as a result of what you see and just some of the offsets, operational offsets of some of the headwinds from COVID. And then secondarily, as we see 2022 we did take a very conservative view into pricing in our planning for both AEP and as we start to enter the season. I think you guys will see that thoughtfulness and reflect some of the uncertainties that maybe continue into 2022. 
So as always, we appreciate your support, and we also appreciate our teammates' continue to drive to both improve our operating performance and serve our customers in the best we can. So thank you."
29618,1671861870,2352667,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","And with that, this concludes today's conference call. Thank you for attending. You may now disconnect.",16,"And with that, this concludes today's conference call. Thank you for attending. You may now disconnect."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to Humana Second Quarter 2021 Earnings Call. [Operator Instructions] Thank you. Now I would like to welcome Ms. Amy Smith, Vice President of Investor Relations. Ma'am, please go ahead.",39,"Ladies and gentlemen, thank you for standing by, and welcome to Humana Second Quarter 2021 Earnings Call. [Operator Instructions] Thank you. 
Now I would like to welcome Ms. Amy Smith, Vice President of Investor Relations. Ma'am, please go ahead."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our second quarter 2021 results and our updated financial outlook for 2021. Following these",361,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our second quarter 2021 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the lines for a question-and-answer session with industry analysts. Joe Ventura, our Chief Legal Officer, will also be joining Bruce and Susan for the Q&A session. 
We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. 
This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. 
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. 
Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission and our second quarter 2021 earnings press release, as they relate to forward-looking statements and to note in particular that these forward-looking statements could be impacted by risks related to the spread of and response to the COVID-19 pandemic. 
Our forward-looking statements should therefore be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements and future filings or communications regarding our business or results. 
Today's press release, our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site. 
Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. 
Finally, any references to earnings per share, or EPS, made during this conference call refer to diluted earnings per common share. 
With that, I'll turn the call over to Bruce Broussard."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Amy, thank you. Good morning, everyone, and thank you for joining us. Today, we reported adjusted earnings per share of $6.89 for the second quarter of 2021, in line with our previous expectations. We continue to focus on delivering strong operating res",1013,"Amy, thank you. Good morning, everyone, and thank you for joining us. 
Today, we reported adjusted earnings per share of $6.89 for the second quarter of 2021, in line with our previous expectations. We continue to focus on delivering strong operating results, while navigating a dynamic environment due to the ongoing COVID-19 pandemic, all while staying true to our commitment to delivering the highest quality health care experience for members and patients. 
We are maintaining our full year 2021 adjusted EPS guidance of approximately $21.5 to $21.75 at the midpoint, representing full year adjusted EPS growth of 16% above the 2020 baseline of $18.50, in excess of our long-term growth target, while acknowledging the continued uncertainty driven by COVID-19 hospitalization trends and the rate at which non-COVID costs normalized. 
As Susan will describe in more detail, our full year adjusted EPS guidance now assumes a $600 million COVID-19-related headwind that is expected to be largely offset by favorable operating items. In addition, this guidance assumes no COVID costs will run -- non-COVID costs will run approximately 2.5% below baseline in the back half of the year, including an assumption of minimum COVID testing and treatment costs for the remaining of the year. 
I'd like to reiterate that our core fundamentals are performing well, and 2021 is a year of COVID-19 transition, with various pandemic-related financial impacts, including reduced Medicare Advantage revenue resulting from the significant temporary deferral of utilization in 2020, as well as the lingering near-term uncertainties regarding the pace and level of the return of utilization for the balance of the year. We also acknowledge that we are seeing increase in COVID utilization in recent weeks, which we will continue to watch closely. 
While we continue to navigate this pandemic-related uncertainties in 2021, as Susan will lay out in detail, we expect 2022 to be a more normal year. The health care system has been open for several months, and we have seen vaccination rates in the seniors reach approximately 80% nationally. 
Accordingly, our members continue to engage in more routine interactions with their providers, which we anticipate will result in more normalized Medicare Advantage revenue next year, as providers are able to ensure that our members are receiving appropriate care and that their conditions are being fully documented. 
I would reiterate our remarks from the last quarter regarding our Medicare Advantage bids for 2022, which reflected the continued uncertainty associated with COVID-19 in our premium and claims assumption, with a focus on maintaining benefit stability in 2023. While it is still too early to provide 2022 guidance, we believe our operating discipline in 2021, combined with the depth of our planning for 2022 Medicare Advantage AEP, puts us in a strong position for financial growth in 2022. 
I will now turn to an operational and strategic update. Importantly, our underlying core businesses continue to deliver strong results on solid fundamentals, with individual Medicare Advantage membership growth outpacing the industry. As we highlighted at our recent Investor Day, this growth is balanced across various product lines, including HMO, PPO and dual special need plans, or D-SNPs. 
Our Medicaid business continues to perform well in 2021, and our South Carolina plan is now operational. We are diligently preparing for the Ohio contract go-live date in early 2022 and are continuing to improve our operating model, building off of our core Medicare Advantage capabilities. 
We've also experienced slightly better-than-expected results in our home and provider businesses and increased mail order rates in our pharmacy business. 
Finally, as announced last quarter, we've entered into an agreement to acquire the remaining 60% interest in Kindred at Home, and we expect the transaction to close mid-August, which we've included in our revised estimates for the year. 
Our strong operating performance this year is in part a tribute to our strong partnerships with providers who are delivering high-quality care to our members. We are currently seeing 87% of our provider partners and value-based arrangements in surplus. 
Further, our relentless focus on consumer centricity has led to an all-time high Net Promoter Scores for our retail organization, contributing to Medicare Advantage membership growth and resulted in an external recognition of Humana as an industry leader in customer satisfaction, including the announcement this morning that we received the highest ranking in mail order pharmacy customer satisfaction for the fourth year in a row in the J.D. Power 2021 U.S. Pharmacy Study. 
On the public policy front, as policymakers explore changes to Medicare, including adding dental, vision and hearing as part of the Medicare benefit, we stand ready to both innovate for the more than 12 million of our members who already have these benefits, including 7 million dental and vision policies in our MA group, as well as offer ideas, a public-private collaboration to leverage our deep capabilities in Medicare and specialty markets, so that beneficiaries could quickly see benefits go from a proposed law to a tangible benefit. 
Before turning the call over to our new Chief Financial Officer, Susan Diamond, I'd like to take a moment to speak about Susan's experience at Humana over the last 15 years. She has served in various leadership roles across the company during her tenure, spending 8 years as part of the Medicare leadership team with various financial and operational and line of business responsibilities. She also spent 2 years on the finance team, leading enterprise planning and forecasting and overseeing the company's line of business, CFOs and controllers. 
Most recently, she led our home business, growing it to the largest offering of its kind. Her strong financial background and extensive knowledge of our business made her uniquely positioned to step into the CFO role. 
The Board and I have great confidence in her abilities and the contribution she will make in the next chapter for Humana as we execute on our strategic plan and deliver shareholder value. In addition, given the strategic nature of the CFO role, Susan will continue to contribute in a meaningful way to our home health business. 
With that, I'll turn the call over to Susan."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. Today, we reported adjusted EPS of $6.89 for the second quarter, in line with our previous expectations. Our underlying core business fundamentals remain strong, and we experienced a positive start to the ye",1587,"Thank you, Bruce, and good morning, everyone. 
Today, we reported adjusted EPS of $6.89 for the second quarter, in line with our previous expectations. Our underlying core business fundamentals remain strong, and we experienced a positive start to the year across our segments, with the first quarter coming in modestly ahead of our previous expectations. 
Our results moderated back to expected levels in the second quarter, albeit with variation in the way specific underlying assumptions emerged, with COVID treatment cost coming in lower than expected, offset by non-inpatient utilization continuing to bounce back faster than originally anticipated. 
As I will describe in further detail in a moment, uncertainty remains for the balance of the year due to the pandemic, specifically as it respects to COVID hospitalizations and the rate at which non-COVID costs normalize, inclusive of both volume and unit costs. 
Recognizing the majority of today's call will focus on our emerging experience and our 2021 guidance, I want to quickly touch on operating performance across our segments before diving into that detail. Our Medicare Advantage growth remains on track and consistent with our previous expectations, with individual MA growing solidly above the market and an expected 11.4% at the midpoint. 
Our Medicaid business results are exceeding our initial expectations given membership increases largely attributable to the extension of the public health emergency as well as higher-than-expected favorable prior period development. 
In our Group and Specialty segment, consistent with our commentary on our last earnings call, medical membership declines are lower than we expected coming into the year. Our specialty business results are exceeding expectations as utilization, particularly for dental services, has been slower to bounce back than initially expected. 
Finally, within our Healthcare Services operations, pharmacy continues to see increased mail order penetration as a result of customer experience improvements and additional marketing initiatives. 
The home business, CenterWell Senior Primary Care and Conviva, are performing slightly ahead of expectations, and we remain on track to open 20 new clinics this year with Welsh, Carson. 
In addition, as Bruce indicated in his remarks, we now expect the Kindred at Home acquisition to close in mid-August, subject to customary state and federal regulatory approvals. 
Before I go into more detail on our 2021 guide, I want to reiterate that the uncertainty we are seeing in 2021 relates solely to the difficulty estimating the impact of the pandemic and is not expected to carry forward into 2022. We remain comfortable with how we approach 2022 pricing, which I will expand on later in my remarks. 
Turning to full year 2021 guidance. I would remind you, our adjusted EPS guidance represents growth at or above the top end of our long-term target of 11% to 15%. Our philosophy regarding 2021 guidance has been to provide transparency into the uncertainty caused by COVID-19 and the ability to deliver our targeted earnings growth, with solid underlying core business performance and largely offsetting COVID-19-related headwinds and tailwinds. We have been consistent in and remain committed to this philosophy. 
There is a reasonable path to achieving adjusted EPS within our initial guidance range. And accordingly, today, we are maintaining our full year adjusted EPS guidance of $21.25 to $21.75, while acknowledging the continued uncertainty as it respects to COVID hospitalization trends as well as the pace at which non-COVID costs bounce back and at what level they ultimately normalize. Additionally, we expect our third quarter adjusted EPS to reflect a low 20s percentage of our full year adjusted EPS. 
As Bruce indicated, given our experience to date, together with our current estimates for the back half of 2021, we have effectively recognized a $600 million COVID-related headwind for Medicare Advantage in our full year guide, offset by favorable operating items. 
These favorable items include, among others, higher than initially expected prior period development, the previously discussed better-than-expected specialty and Medicaid results and the expected contribution from Kindred at Home given the transaction is expected to close in the coming weeks. 
Now let me provide an update on the underlying changes since our initial detailed guide in February, articulate key assumptions regarding utilization in the back half of 2021 and expand on the continued pandemic-related uncertainties I described. 
I will begin with Medicare Advantage revenue. As discussed last quarter, given our significant exposure to Medicare Advantage, we are disproportionately affected by COVID's impact on Medicare Risk Adjustment, or MRA. Recall, our risk-adjusted revenue for 2021 is determined by 2020 dates of service, medical utilization and resulting documentation, which, as previously discussed, was materially depressed in 2020. 
As we have indicated since the beginning of the year, the MRA headwind that we are facing in 2021 is significant, and we have closely monitored it over the course of the year. Our April guide recognized we had $300 million of additional pressure from MRA relative to our initial expectations for the full year, which was offset by the net benefit of the extension of sequester relief. 
In July, we received the mid-year MRA payment, and it came in modestly lower than expected. We are, however, taking operational steps now to be able to recover some of the MRA revenue and the final payment for 2021. Accordingly, our MA premium estimates, net of capitation, remain largely in line with our initial expectations when factoring in the net sequestration benefit. 
Now turning to benefit expense. At the beginning of the year, we indicated that we expected non-COVID costs for our Medicare business to run 3.6% to 5.5% below baseline. We define baseline as 2019 experience trended forward based on a normalized trending factor, excluding the effects of COVID. 
In the first quarter, we acknowledged that non-inpatient costs were bouncing back faster than initially expected. However, that was offset by COVID utilization decelerating faster than expected. We also recognize, however, visibility into non-inpatient claims was significantly less than inpatient and, therefore, we acknowledge that there was more uncertainty around non-inpatient service categories in terms of exactly where we stood. 
However, at that time, we could still tolerate overall utilization returning to baseline late in the year if the non-inpatient acceleration we were seeing was due to pent-up demand and leveled off in the second and third quarters. 
In the first and second quarters, non-COVID costs ran approximately 7% and 3% below baseline, respectively, with the bounce back outpacing expectations in the second quarter. Non-inpatient utilization did not level off and instead continue to increase in the second quarter and was offset by lower-than-expected COVID costs and other business outperformance. 
As the health care system has been open for several months, and a high rate of the senior population has been vaccinated, our current guidance now assumes that non-COVID cost level off and run approximately 2.5% below baseline levels in the back half of the year. 
Consistent with our original forecast, our current guidance assumes minimal COVID testing and treatment cost in the back half of the year. That said, we do acknowledge that we are seeing increases in COVID admissions in recent weeks, although it's too early to determine if there will be offsetting declines in non-COVID utilization, and we will continue to monitor this recent development. 
Finally, as it respects to our 2021 guide for our commercial business, we expect all-in utilization for COVID and non-COVID to continue to run above baseline as anticipated. 
In summary, I want to emphasize that 2021 is a COVID transition year. There is a reasonable path to deliver against our guidance expectations. However, as non-COVID utilization or COVID treatment cost increase beyond our expectations in the back half of the year, it will present a headwind to our guide, absent offsetting tailwinds. 
I also want to reiterate that the $21.50 midpoint of our original guide continues to be the right jumping off point for 2022 adjusted EPS growth. Our members continue to engage in routine interactions with their providers, which we anticipate will result in more normalized Medicare Advantage revenue next year, as providers are able to ensure that our members are receiving appropriate care and that their conditions are fully documented. 
During the first half of 2021, provider interactions and documentation of clinical diagnosis that will impact 2022 revenue outpaced those experienced in the first half of 2020 and are approximately 80% complete, in line with the estimated completion rate for the same time period in 2019. 
Lastly, I would remind you that our Medicare Advantage bid for 2022 reflected the continued uncertainty associated with COVID-19 as it relates to our premium and baseline non-COVID claims trend assumptions, with a focus on maintaining benefit stability into 2023. 
Before we open up the line for questions, I'm excited to announce 2 finance leadership changes that will promote the growth and versatility of our finance leadership team. First, with the expected integration of Kindred at Home, our Home business is growing significantly, and Amy has accepted the role of Vice President and CFO of Home Solutions. She will be a key member of the Home Solutions leadership team, responsible for the financial oversight and planning and forecasting for the segment. 
Lisa Stoner will succeed Amy, accepting the role of Vice President, Investor Relations. Lisa has worked with Amy over the last 4 years and is well-known and respected by our investors. We are excited about the opportunity this affords both Amy and Lisa, and Lisa's continuity in Investor Relations will allow for a seamless transition. 
With that, we will open up the lines for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your first question is from the line of Justin Lake from Wolfe Research.",13,"Your first question is from the line of Justin Lake from Wolfe Research."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Obviously, a lot to cover. I'll try to keep it to one question here. But I see -- I'm hoping you could give us a few numbers. One is the MRA. Can you tell us what the full year impact is of the negative MRA? And I think there's a lot of confusion around",190,"Obviously, a lot to cover. I'll try to keep it to one question here. But I see -- I'm hoping you could give us a few numbers. One is the MRA. Can you tell us what the full year impact is of the negative MRA? 
And I think there's a lot of confusion around 2 things. One, it sounds like the first half -- or the second quarter, I should say, was worse than expected. And yet, you still kind of came in line with -- from an MOR perspective. So you're telling us the back half has -- is -- needs to be more optimistic. 
So what happened in the second quarter beyond that allowed you to make the MLR, but still have higher medical costs beneath the back half? And then I guess the -- around that, the $600 million specifically, can you flesh that out in as much detail as you can because is that comparable to the old COVID estimate? Or is that a new COVID headwind that you've kind of thrown in there for the back half of the year for us to think about?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take these one at a time. I'll start with your last question around the $600 million. So just to clarify, the $600 million represents our full year estimate of the Medicare Advantage-only net headwinds and tailwinds related to the COVID pand",384,"Sure. So I'll take these one at a time. I'll start with your last question around the $600 million. So just to clarify, the $600 million represents our full year estimate of the Medicare Advantage-only net headwinds and tailwinds related to the COVID pandemic. And if you recall, back to our initial guidance earlier this year, we provided a schedule that laid out the specific line items that were considered in that and a range of estimates at the time. 
So the $600 million represents our current view and what is contemplated in our guide related to those items on a net basis, so the net of all the various headwinds and tailwinds based on our current expectations. 
As it respects to the first half and second half, as we described in the call, what we continue to see throughout the first half of the year was COVID cost coming down faster than initially expected, but non-COVID outpatient, in particular, rebounding faster than expected, and that continued through the second quarter. And we anticipate that, that will extend some into the third quarter before it levels off. 
In the first half of the year, the benefits we saw from COVID-related cost as well as some lower inpatient -- non-COVID inpatient cost, we do not expect to continue at the same rate because our expectation has -- had always been that those costs on the COVID side would come down as a result of the rollout of vaccinations and that utilization would rebound to more normal levels, such that there is less positive upside that can offset those costs in the second half of the year, which is why we are now estimating a net 2.5% decline in non-COVID utilization in the back half of the year to meet our guide. 
As it respects to MRA, I think we provided the net detail in terms of what our current estimates really are. I know we provided the line item in the initial guide in terms of the beginning of the year. And what we're saying is on a net basis, net of capitation, there's about a $300 million additional headwind. And in the context of the overall guide, that is largely offset -- or fully offset by the net impact of the positive sequestration benefit."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Okay. And then just quick follow-up on the $600 million, that was all really helpful. The $600 million, can you just tell us what that compares to specifically? Because you had like a $400 million to $700 million COVID number thrown into the original sche",106,"Okay. And then just quick follow-up on the $600 million, that was all really helpful. The $600 million, can you just tell us what that compares to specifically? Because you had like a $400 million to $700 million COVID number thrown into the original schedule. Is that the comparable now? 
And then have you said that, that's all eaten away in the first half of the year? So effectively, that updated $600 million is comparable to the $400 to $700, and it's completely gone effectively, so you don't have any -- none of that's assumed in the back half. Is that the way to read it?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. So just to be clear. The $600 million and full year estimate, so inclusive of first half and back half. But I also want to clarify, it is not meant to be specific to the line item that's labeled COVID testing and treatment on that initial schedule. T",144,"Yes. So just to be clear. The $600 million and full year estimate, so inclusive of first half and back half. But I also want to clarify, it is not meant to be specific to the line item that's labeled COVID testing and treatment on that initial schedule. That was one line item. When we refer to the $600 million, it is the net impact of all of the line items that were represented on the schedule. 
And the other thing I would add as well in terms of your question about how did you offset that, there was a lower COVID and other inpatient costs. But also recall, we had other business outperformance that we mentioned in the discussion around prior period development, commercial Medicaid that also offset some of that headwind we experienced in the first half of the year as well."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Kevin Fischbeck from Bank of America.",14,"Your next question is from the line of Kevin Fischbeck from Bank of America."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I wanted to, I guess, follow up on the assumption for trends in the back half of the year. I guess, you're saying core utilization, 2.5% below. I guess, if you could maybe provide a little more color on that. I mean, how do you get there? Are some things",123,"I wanted to, I guess, follow up on the assumption for trends in the back half of the year. I guess, you're saying core utilization, 2.5% below. I guess, if you could maybe provide a little more color on that. I mean, how do you get there? Are some things above average, some things below average? 
If I understood what you were saying, I think you said that when you include COVID cost, total trend is above average. Just want to make sure I heard that, but just color on how you get to the minus 2.5% for the back half of the year and why there isn't more of an assumption of ""core back to normal"" by the end of the year."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So just to provide a little more detail. So as we mentioned, the second quarter ran about 3% below baseline for that non-COVID utilization. Our third and fourth quarter now, on average, are estimated to run 2.5% below baseline. And recall that, that",236,"Sure. So just to provide a little more detail. So as we mentioned, the second quarter ran about 3% below baseline for that non-COVID utilization. Our third and fourth quarter now, on average, are estimated to run 2.5% below baseline. And recall that, that's inclusive of both utilization as well as unit cost. 
So as I mentioned, we do expect, given that the country has been largely open, our population is largely vaccinated, that we will see those non-COVID utilization start to normalize, and so we've allowed for some additional return to baseline relative to what we've experienced in the second quarter. 
I would also say that as we see that utilization come back, we also see that the average cost per hospitalization will come down because lower severity cases are reintroduced. And so the combination of leveling off of utilization and continued reductions in the unit cost contribute to that 2.5% below baseline. 
I think you've suggested that overall utilization might be above baseline. I think you might be referring to my comments about commercial, where we had planned to see in total COVID, non-COVID to run slightly above baseline as we were beginning to see that at the end of 2020. But for our Medicare business, because we're including limited COVID cost in our forecast in the back half of the year, it's not contributing significantly, so that would not take it over baseline."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Okay. But when you say it's the low baseline, inpatient, outpatient physician, drugs, I guess, those 4 categories, are they all kind of there or some above, some below?",29,"Okay. But when you say it's the low baseline, inpatient, outpatient physician, drugs, I guess, those 4 categories, are they all kind of there or some above, some below?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. We are seeing variations in some of the service categories as you can imagine. One of the reasons we believe that some of the tenant demand has been worked through the system is things like surgical procedures, colonoscopies and things like that. We",73,"Sure. We are seeing variations in some of the service categories as you can imagine. One of the reasons we believe that some of the tenant demand has been worked through the system is things like surgical procedures, colonoscopies and things like that. We did for a period of time see it go slightly above baseline. But other traditional -- normal course ER and observations and other activities continue below baseline. Thank you."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Matthew Borsch from BMO Capital Markets.",14,"Your next question is from the line of Matthew Borsch from BMO Capital Markets."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Maybe I could just continue on this theme of trying to understand with the Medicaid baseline through the end of the year. Do you think that -- what is sort of thought of this deferred care or the health care that didn't happen, but would have happened, I",118,"Maybe I could just continue on this theme of trying to understand with the Medicaid baseline through the end of the year. Do you think that -- what is sort of thought of this deferred care or the health care that didn't happen, but would have happened, I guess, really over the last 5 quarters? 
Is a lot of that just not going to -- that isn't something that is going to flow through as pent-up demand? It's sort of embedded in there is that assumption that -- and the seniors, I guess, are going to still have some avoidance of the health care system even in the back half of this year. Just trying to understand that."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. I would say that our view would be that given the pace at which the non-inpatient utilization, in particular, bounce back, which was faster than we anticipated, that we are seeing -- and a lot of that, you'll see they're reengaging with their physici",140,"Yes. I would say that our view would be that given the pace at which the non-inpatient utilization, in particular, bounce back, which was faster than we anticipated, that we are seeing -- and a lot of that, you'll see they're reengaging with their physicians and specialists more than normal rate. 
And so I think we do believe that some of the pent-up demand as a result of the deferred care in 2020 has been reflected in our first half of the year results. And that, again, because of the length of time the country has largely been open, that pent-up demand has worked through. And therefore, while we will -- we are expecting a little bit more return to baseline relative to our second quarter performance that, that will stabilize through the back half of the year. Thank you."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of A.J. Rice from Credit Suisse.",14,"Your next question is from the line of A.J. Rice from Credit Suisse."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Just to put a fine point on some of the discussion and then 2 other data points. The 2.5% for the back half, I think, in the beginning guidance, you said that the underutilization for the full year will be 3.6% to 5.5% deferred relative to baseline. If yo",177,"Just to put a fine point on some of the discussion and then 2 other data points. The 2.5% for the back half, I think, in the beginning guidance, you said that the underutilization for the full year will be 3.6% to 5.5% deferred relative to baseline. If you got an updated number, how much are you at the lower end of that? Or are you even the overall range when you think about that original number? 
And then I would also ask you about the operating expense. Obviously, you've updated that. Is that mainly related to Kindred? Are you expecting more investments in the back half of the year in other areas? 
And then if I could squeeze in one more. Your comment about the offset of sequestration versus the MRA headwind this year, does that, in your mind, reverse next year? So if we lose sequestration, you -- the MRA catch-up by having fully coded all of the people from last year and this year offsets that. Is that the way to think about it?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take these one at a time. So the first, to your question, based on our experience for first half of the year and our 2.5% expectation in the back half of the year, if you do all that math, it suggests that for the full year, our non-COVID ut",255,"Sure. So I'll take these one at a time. So the first, to your question, based on our experience for first half of the year and our 2.5% expectation in the back half of the year, if you do all that math, it suggests that for the full year, our non-COVID utilization will end up at about 3.75% below baseline, so effectively at the low end of the range we had given you at the start of the year. 
On OpEx, as you said, you're exactly right. The reason for the change in the guide and the increase that is directly attributable to incorporating the Kindred performance into our guidance points, and so that is largely the reason for that increase. 
We do, however, I would say, in terms of our core business, and even within Kindred, anticipate some investment like we would in normal course. Kindred, as you can imagine, by integrating it, there are some investments we might want to make there as it respect to the value-based operating model that we've described at Investor Day. And so that is contemplated in there as well. 
On your second question on sequestration, we do expect that to reverse in 2022. That would have been contemplated in our bids and pricing. And our MRA assumptions, as we think about 2022, would not be impacted by that explicitly. They are independently calculating. What we believe the risk adjustment will be based on the diagnosis submissions that we would expect in a more normal environment. Thank you."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Ricky Goldwasser from Morgan Stanley.",13,"Your next question is from the line of Ricky Goldwasser from Morgan Stanley."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","So one clarification on utilization and then another question. So just to clarify, Susan, is basically what you're saying is that the 2.5% below baseline really encompasses the fact that care is happening outside the 4 walls of the hospital? I think you",132,"So one clarification on utilization and then another question. So just to clarify, Susan, is basically what you're saying is that the 2.5% below baseline really encompasses the fact that care is happening outside the 4 walls of the hospital? 
I think you mentioned lower ER visits. You're also mentioning that you don't expect 2022 risk adjusters to be impacted by this lower utilization. So is it that just you're seeing a shift in where care is being provided, i.e. the telehealth primary care, and that's what's impacting that below baseline, that's a dollar number? 
And then my second question, if you can give us just some color and context around the announcement that we saw last week on the investment that you're making with Anthem on -- into a new PBM."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Okay. So to your first question on the 2.5%, so again, that is related to non-COVID utilization and all inclusive of inpatient and non-inpatient, again, both rate and volume. And so I wouldn't say that we're necessarily seeing shifts in the site of servic",251,"Okay. So to your first question on the 2.5%, so again, that is related to non-COVID utilization and all inclusive of inpatient and non-inpatient, again, both rate and volume. And so I wouldn't say that we're necessarily seeing shifts in the site of service or the site of care, but rather just, as utilization returns to normal, there is some level of utilization that hasn't -- just hasn't come back on an absolute basis. 
But really, we are seeing, with the exception of some of those specific service categories I mentioned like surgical, other categories are largely still running below baseline across the board. 
As far as MRA impact, as we said, what we are seeing in terms of the normal routine interactions with our providers, our in-home assessment activity and other annual wellness programs, those are all trending exactly as we would expect to see in order to deliver against our 2022 revenue estimates contemplated in pricing. And so we feel really good about our trajectory there. 
Should we see somewhat depressed utilization in the back half of the year, given the way risk adjustment works, generally speaking, we feel good that so long as there's not sort of a full shutdown like we saw in 2020, which is not what we anticipate currently, we feel confident that we should be on pace to deliver against what we need for MRA, again, based on what we're currently seeing. 
I don't know, Bruce. Would you like to address the Anthem partnership?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. The -- similar to what we've done in the past and other more utility-oriented areas, I think Availity would be an example of that, where we've tried to find partners within the industry that can help build a longer-term utility. And we look at the",120,"Sure. The -- similar to what we've done in the past and other more utility-oriented areas, I think Availity would be an example of that, where we've tried to find partners within the industry that can help build a longer-term utility. 
And we look at the particular partnership with Anthem as the opportunity to update and really give more both increased productivity and, at the same time, increase the experience for members in the area of the PBM side. We, for a number of years, have been using SS&C as a vendor to help in the -- with the existing technology, but now have been able to take it and really enhance it through this partnership with Anthem and SS&C."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Thank you.",2,"Thank you."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Stephen Baxter from Wells Fargo.",13,"Your next question is from the line of Stephen Baxter from Wells Fargo."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I was hoping that you could talk in a little bit greater detail about why the risk adjustment revenue ended up coming in below where you expected it for this year. I guess, you had a lot of visibility into certain inputs and not others. To the extent you",73,"I was hoping that you could talk in a little bit greater detail about why the risk adjustment revenue ended up coming in below where you expected it for this year. I guess, you had a lot of visibility into certain inputs and not others. To the extent you could flesh those out, I think it would help give us a better sense of how comfortable we can be around next year's assumptions."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So as it respects to the $300 million that we referenced that was contemplated in our April guide, so just for context, our January payment in 2021 would reflect claims that were submitted through the September submission deadline. And then that req",324,"Sure. So as it respects to the $300 million that we referenced that was contemplated in our April guide, so just for context, our January payment in 2021 would reflect claims that were submitted through the September submission deadline. And then that requires us to estimate the submissions that will come in organically as well as a result of our activities around chart review and prospective programs for the remainder of the year. 
At that time, we were not anticipating the significant surge that we saw across the country in the fourth quarter due to COVID and the resulting reduction in non-COVID utilization. What that led to was lower, what we refer to as, organic diagnosis submissions. So those are not related to the campaigns that we initiated, but rather organic submissions across the provider community based on the utilization that's happening, and those ultimately prove to come in lower than we had anticipated. 
And generally speaking, I think we've mentioned before that those organic submissions are more difficult to estimate, obviously, than the initiatives that we are executing. So that was reflected in our April guide at the time. 
In terms of the midyear adjustment, as we've said on previous calls, the adjustment there was solely related to new members or members who were only enrolled for a partial year in 2020, where we don't have full visibility to their claims. And so while we made an estimate of what we thought the impact would be based on what we were seeing within our concurrent population, ultimately, that midyear payment came in. It reflected a lower level of contribution for those new members than our estimates had originally anticipated. 
I would say that going into 2022, because those impacts were directly related to the COVID pandemic and impacts the utilization, I would not expect to see that continued uncertainty carry into 2022 based on what we're seeing so far this year. Thank you."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Joshua Raskin from Nephron Research.",13,"Your next question is from the line of Joshua Raskin from Nephron Research."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","So I understand we're coming out of the second quarter with non-COVID utilization running 3% below baseline, but how do you see that continuing to run 2.5% baseline for the second half of the year if you're also assuming that you're not going to see any C",119,"So I understand we're coming out of the second quarter with non-COVID utilization running 3% below baseline, but how do you see that continuing to run 2.5% baseline for the second half of the year if you're also assuming that you're not going to see any COVID -- direct COVID cost for testing and treatment? I sort of think of those as related. 
And then would a rise in direct COVID costs, so if we did see this increase that you guys mentioned that you're seeing in the last couple of weeks, if that did continue, would that end up being a net negative now because you've got all the direct costs, but you're already assuming lower utilization?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I would say that our view of non-COVID is not influenced by what the recent activity and uptick we've seen in COVID cases. That is not why we're assuming that it runs below baseline. Our view is, again, just based on the trajectory we've seen t",222,"Sure. So I would say that our view of non-COVID is not influenced by what the recent activity and uptick we've seen in COVID cases. That is not why we're assuming that it runs below baseline. 
Our view is, again, just based on the trajectory we've seen that, given the level of utilization increase we've seen that we were at a point where it will be in the plateau and level off as sort of just a new baseline for the back half of the year. 
As it respects to COVID, as we mentioned, it's just very early. In terms of the increase, what we've seen is literally just in the last couple of weeks. It is still a bit too early to determine whether or not we will see offsetting non-COVID utilization impacts like we have seen in all previous surges. 
I will say, just this last week, we just began to see some level of reduction in inpatient -- non-COVID inpatient, as the COVID cases increase. It's simply just too early to really assess the duration that we might see in terms of an uptake and the offsetting utilization. But should we see offsetting utilization in the non-COVID space, in order for that not to present a headwind, it would be incremental to the 2.5% that we are currently forecasting."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Lance Wilkes from Bernstein.",12,"Your next question is from the line of Lance Wilkes from Bernstein."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes. Let's see, my primary question is on the pricing environment. You called out a little bit of a pricing environment, I think, in group MA. Can you talk a little bit about that pricing environment impacts and magnitude in '21, outlook for '22? And th",103,"Yes. Let's see, my primary question is on the pricing environment. You called out a little bit of a pricing environment, I think, in group MA. Can you talk a little bit about that pricing environment impacts and magnitude in '21, outlook for '22? 
And then in general for pricing, both individual and group, how does this work towards your return to kind of target margins here? And then on the utilization, the one extra thing I'd just ask on that 2.5% below baseline, just if you're getting any indications on impacts of Delta variant on utilization in any of your own clinics."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take these one at a time. The first is with respect to pricing, you asked specifically about the group MA, and I think as we've said before, the group MA space, particularly for larger group accounts, continues to be highly competitive, and",402,"Sure. So I'll take these one at a time. The first is with respect to pricing, you asked specifically about the group MA, and I think as we've said before, the group MA space, particularly for larger group accounts, continues to be highly competitive, and we would expect that to continue, and so the margins that we would see on those accounts to continue to be competitive and pressured. 
I think, though, as we think about group MA, there are a lot of other benefits to winning those large accounts in terms of the impact they can have in a local geography on the network and our ability to work with provider partnerships, et cetera. But we expect that to be -- continue to be competitive. 
On the individual side, this is always a process we go through every year to understand sort of the rate environment, the competitive environment, other business performance. We always strive to maintain benefit stability, knowing how important that is to our members as well as our sales and distribution channels. 
So that's always our goal, and there's always a number of puts and takes that we will consider, including the broader enterprise performance as it respects to, first and foremost, delivering against our overall growth target of 11% to 15%. 
And after considering sort of strategic investments, other business performance and then understanding what's required of our Medicare business and what we're trying to achieve, balancing both growth and margin in the long term, all of those are taken into account. 
We remain committed to achieving, long term, our targeted individual margin of 4.5% to 5%, and that will vary each year based on those things that I mentioned. But we would expect this to continue to progress towards that goal. 
On utilization, I would say, really, it's too early, I think, for us to really see anything specific at the clinic level. That information is not as real time available to us as our health plan information. And so to date, I have not seen anything that would provide us any visibility. 
I will say, there are some concentrations geographically. As you've seen probably in the press, Florida is a state that is seeing higher rates. Given we have a concentration of some of our clinics there, I imagine that they would see some, but we actually don't have detailed information on that just yet."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Ralph Giacobbe from Citi.",12,"Your next question is from the line of Ralph Giacobbe from Citi."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I guess, going back to the 2.5%. If your assumption is that 2.5% below baseline, I think your original guidance was to run above baseline towards the end of the year. So why wouldn't that represent upside? Or where is the offset there? And then can you",68,"I guess, going back to the 2.5%. If your assumption is that 2.5% below baseline, I think your original guidance was to run above baseline towards the end of the year. 
So why wouldn't that represent upside? Or where is the offset there? And then can you give us how much COVID cost you've seen sort of through the first half against that $600 million full year estimate?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Okay. As it respects to 2.5%, as you mentioned, I think in earlier calls during the first quarter, we did mention that our original forecast did contemplate over the course of the second half of the year that we would begin to approach baseline and potent",226,"Okay. As it respects to 2.5%, as you mentioned, I think in earlier calls during the first quarter, we did mention that our original forecast did contemplate over the course of the second half of the year that we would begin to approach baseline and potentially for a short period of time see above baseline utilization related to pent-up demand. So we just projected that to occur later in the year. 
Our view is that, given the rate at which we've seen it bounce back more quickly, that we have seen that in the first half of the year instead. And so at the time, I don't think we've given specifics on sort of the monthly trajectory. But in general, our original forecast going into the year did anticipate a slower return to baseline and could tolerate it getting to baseline by the end of the year. 
But as I described in my remarks, because we saw the faster bounce-back in non-inpatient and in the first half, that was, again, largely offset by the reductions in COVID and inpatient, those trends will not continue at the same level. And therefore, we will need to see below baseline utilization on the non-COVID side in order to achieve that full year estimate of 3.75%. 
And then could you repeat your second question, I'm sorry, about the COVID cost?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes. Just trying to get a sense of what it ran in the first half of the year relative to the updated sort of $600 million. Are you fully through the $600 million at this point? Is that what you're trying to imply, and there's nothing baked into the back h",60,"Yes. Just trying to get a sense of what it ran in the first half of the year relative to the updated sort of $600 million. Are you fully through the $600 million at this point? Is that what you're trying to imply, and there's nothing baked into the back half? Just trying to get a sense of magnitude there."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","No. So again, that $600 million is a full year estimate. It does, just to be clear, include the assumption that the non-COVID utilization will run 2.5% in the back half of the year, so that's contemplated in that. But I don't think we had intended to pr",73,"No. So again, that $600 million is a full year estimate. It does, just to be clear, include the assumption that the non-COVID utilization will run 2.5% in the back half of the year, so that's contemplated in that. 
But I don't think we had intended to provide any quarterly detail of how that's emerging, but that is a full year number. It would not represent just the first half of the year."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Just to highlight on the $600 million. That is if you were to go to the first quarter or the February earnings release for the fourth quarter, we put together some lows and highs all the way from MRA, COVID testing, the depressed utilization and sequestra",122,"Just to highlight on the $600 million. That is if you were to go to the first quarter or the February earnings release for the fourth quarter, we put together some lows and highs all the way from MRA, COVID testing, the depressed utilization and sequestration. And what the $600 million is if you were to take that and roll that forward now, all the ins and outs from that would be the net number of the $600 million. 
The operational aspects of our business, as Susan has talked about, has offset all of that $600 million. But included in that $600 million net number is an assumption that 2.5% below baseline will be remaining for the remaining part of the year."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Scott Fidel from Stephens.",12,"Your next question is from the line of Scott Fidel from Stephens."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","First, I think you just clarified part of the question that I was going to have, which is just confirming that the net headwind and tailwind that had been 0 in that 4Q '25 deck, that's now $600 million, right? And then also just on the MRA piece in that s",180,"First, I think you just clarified part of the question that I was going to have, which is just confirming that the net headwind and tailwind that had been 0 in that 4Q '25 deck, that's now $600 million, right? And then also just on the MRA piece in that same slide deck, you had called that out at $700 million to $1 billion of expected headwind. 
I guess, given the update that you guys have given us around the $300 million incremental impact a couple of months ago and then how things came out in the midyear claims review, just interested if you have an updated estimate that we can compare now against that $700 million to $1 billion number.
And then sort of, I guess, just putting this all together, just how this sort of nets out to -- for 2021. Putting all the pieces together, what that sort of implies and what you're assuming for your MA pretax margin, so we can think about sort of the earnings run rate now relative to the long-term target margin?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","So what I would say, we never -- at the time, as you mentioned, the schedule that we gave you, which provided a range of $700 million to $1 billion, I don't think at the time we ever said exactly where we were in that range in terms of our internal estima",113,"So what I would say, we never -- at the time, as you mentioned, the schedule that we gave you, which provided a range of $700 million to $1 billion, I don't think at the time we ever said exactly where we were in that range in terms of our internal estimate. 
I think what we just wanted to clarify was that we had seen $300 million of net pressure incremental to that, which is, again, in terms of the schedule offset then by the sequestration. 
And then can you repeat your second question? I'm sorry, I think it was '21 -- oh, the '21 -- what was your '21 question? I'm sorry."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Yes. Susan, basically, it's just trying to take all these different pieces together, and what they net out to what sort of the underlying pretax MA margin assumption is for 2021, so we can think about that relative to the long-term target.",42,"Yes. Susan, basically, it's just trying to take all these different pieces together, and what they net out to what sort of the underlying pretax MA margin assumption is for 2021, so we can think about that relative to the long-term target."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. So what I would say is, as you see in our guidance points, our MER target -- or MER range and our -- hasn't really changed. So -- and because of the offsets and the nature of those offsets, there are many within the retail segment and Medicare, in pa",104,"Yes. So what I would say is, as you see in our guidance points, our MER target -- or MER range and our -- hasn't really changed. So -- and because of the offsets and the nature of those offsets, there are many within the retail segment and Medicare, in particular. 
So I would say, in general, there's not material movement in the individual MA margin because the headwind -- net headwind is largely offset by other positivity. And as we mentioned, the positive prior period development as an example as well as the sequestration would be attributable to the retail segment. Thank you."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of George Hill from Deutsche Bank.",13,"Your next question is from the line of George Hill from Deutsche Bank."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","I'm going to try to put in 2 very quick ones. I guess, Bruce, as I think about the JV investment with Anthem, that's much more of an infrastructure and back-end investment as opposed to more of a PBM JV, if I understand that right. And then just kind of",88,"I'm going to try to put in 2 very quick ones. I guess, Bruce, as I think about the JV investment with Anthem, that's much more of an infrastructure and back-end investment as opposed to more of a PBM JV, if I understand that right. 
And then just kind of net-net of everything, am I hearing things right that the $21.25 to $21.75 is the right jumping off point as we think about fiscal '22 EPS, inclusive of all the moving pieces basically that they're all offsetting?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. To answer your first question, you're exactly right. It is an infrastructural investment. And again, it's a utility for the industry. And actually, we would enjoy others to join that joint venture over a period of time. In regards to your second qu",63,"Yes. To answer your first question, you're exactly right. It is an infrastructural investment. And again, it's a utility for the industry. And actually, we would enjoy others to join that joint venture over a period of time. 
In regards to your second question, you're exactly right. The midpoint is $21.50, and that is what we would base our '22 growth of off."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your last question is -- I'm sorry, your next question is from the line of David Windley from Jefferies.",19,"Your last question is -- I'm sorry, your next question is from the line of David Windley from Jefferies."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","You touched on this a little bit, but I want to try to bring a finer point to it. The 2.5% baseline in the second half, would you expect that -- not withstanding time frame, but would you expect that to return to baseline? Or are you seeing some permanent",92,"You touched on this a little bit, but I want to try to bring a finer point to it. The 2.5% baseline in the second half, would you expect that -- not withstanding time frame, but would you expect that to return to baseline? Or are you seeing some permanent shifts, like ER utilization that would cause you to stay below baseline beyond 2021? 
And then what are you seeing in terms of member acuity as the bounce back utilization has come? Are you seeing higher acuity as patients represent for services?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. Great question. So as we said, the 2.5% represents an average for the back half of the year. I think it remains to be seen at what rate it ultimately settles in. It could come in more depressed in the third quarter and then get closer to baseline.",262,"Sure. Great question. So as we said, the 2.5% represents an average for the back half of the year. I think it remains to be seen at what rate it ultimately settles in. It could come in more depressed in the third quarter and then get closer to baseline. 
There's obviously a range of scenarios that could emerge, some of which could be that, by the end of the year, it gets closer to baseline. So I think that, until we get to the plateau and then see that sustained, I think it will be hard to assess the long term, whether that's a long-term new normal or not. So we'll continue to watch that. 
As for acuity, I would say, so far, we are not seeing indicators that there is a higher acuity, that there's -- or there has been impact from the deferred care in 2020. We are continuing to watch it. But so far, we have not seen any sort of systemic indicators of that. And in fact, some of the things that we were able to initiate along with our provider partners to ensure members receive the needed preventative care through telemedicine were quite hopeful during the pandemic. 
And one data point as an example was that we saw higher medication adherence through the pandemic than we actually did pre-pandemic. So a nice indication that members were receiving the needed preventative care, receiving their medications and hopefully staying on top of their conditions. But so far, we are watching it. We're not seeing any indications of higher acuity."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","Your next question is from the line of Rob Cottrell from Cleveland Research.",13,"Your next question is from the line of Rob Cottrell from Cleveland Research."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Analysts","Wanted to revisit the operating cost guidance and how should we think about that for future years, absorbing the full year cost of Kindred. And also any potential synergies that could offset that into 2022 and beyond?",37,"Wanted to revisit the operating cost guidance and how should we think about that for future years, absorbing the full year cost of Kindred. And also any potential synergies that could offset that into 2022 and beyond?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Sure. As I said, the current year guidance revision was a direct -- is directly attributable to incorporating Kindred in the guide. To be quite honest, we're going to need to do some work post closing and integration to revisit our forward -- probably mor",222,"Sure. As I said, the current year guidance revision was a direct -- is directly attributable to incorporating Kindred in the guide. To be quite honest, we're going to need to do some work post closing and integration to revisit our forward -- probably more in 2022, what our guidance points look like and whether they need to change. 
Obviously, within Kindred, they have direct cost of care. Those are -- all of their costs are included in that OpEx ratio. There's -- it's not showing up anywhere else in the guide. So that's something we'll look at, so we'll need to see whether there's anything we should break out separately, specific to the Kindred business. 
As it respect to synergies, the Kindred transaction was not really a traditional synergy play. We obviously don't have a Home Health business to integrate into, so the operations will be largely standalone. We are certainly looking at opportunities to see where we can create some synergies based on the capabilities we have and they have, but I would not expect those to be significant. 
The real value is going to be on the new products and models that we intend to introduce, particularly the value-based model we shared during Investor Day, that will be the source of value creation as a result of that transaction."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","And just to reemphasize, we don't see net our operating costs going up as a result of the transaction outside of some investments we're making in the short term as a result of the integration. We continue to maintain a long-term orientation to continuing",132,"And just to reemphasize, we don't see net our operating costs going up as a result of the transaction outside of some investments we're making in the short term as a result of the integration. We continue to maintain a long-term orientation to continuing to increase our productivity. 
You've seen that over the last number of years, and that has not changed. And the investors shouldn't walk away from that. This is increasing costs. We continue to keep that as a discipline. 
I think what you do see is it's just sort of taking one organization that has a different margin, a different operating structure and bringing it into our operating structure. And as we bring the 2 together, we'll have that same emphasis of continuing to improve productivity on the organization."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","And I think that was our last question. So Bruce, if you have any closing comments?",16,"And I think that was our last question. So Bruce, if you have any closing comments?"
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Executives","Yes. And we really appreciate everyone's support. We recognize that this quarter as a result of the transition year of COVID is a difficult one. We are very oriented to continuing to have the transparency between what is COVID and what's operationally, an",199,"Yes. And we really appreciate everyone's support. We recognize that this quarter as a result of the transition year of COVID is a difficult one. We are very oriented to continuing to have the transparency between what is COVID and what's operationally, and I hope you guys can discern between those 2 as we continue to have further questions on the operational performance. 
That being said, I do want to leave the investors with the understanding that we continue to believe that the organization's operational performance in '21 has been very strong as a result of what you see and just some of the offsets -- operational offsets of some of the headwinds from COVID. 
And then secondarily, as we see 2022, we did take a very conservative view into pricing in our planning for both AEP and as we start to enter the AEP season. I think you guys will see that thoughtfulness and reflect some of the uncertainties that maybe continue into 2022. 
So as always, we appreciate your support, and we also appreciate our teammates' continue to drive to both improve our operating performance and serve our customers in the best we can. So thank you."
29618,1671861870,2352889,"Humana Inc., Q2 2021 Earnings Call, Jul 28, 2021",2021-07-28,"Earnings Calls","Humana Inc.","Operator","And with that, this concludes today's conference call. Thank you for attending. You may now disconnect.",16,"And with that, this concludes today's conference call. Thank you for attending. You may now disconnect."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Good day, and thank you for standing by. Welcome to the Humana Inc. Quarterly Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference ov",54,"Good day, and thank you for standing by. Welcome to the Humana Inc. Quarterly Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, Ms. Lisa Stoner, Vice President of Investor Relations. Please go ahead."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our third quarter 2021 results and our updated financial outlook for 2021. Following these",360,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our third quarter 2021 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the line for a question-and-answer session with industry analysts. Joe Ventura, our Chief Legal Officer, will also be joining Bruce and Susan for the Q&A session. 
We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. 
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K and other filings with the Securities and Exchange Commission and our third quarter 2021 earnings press release as they relate to forward-looking statements and to note, in particular, that these forward-looking statements could be impacted by risks related to the spread of in response to the COVID-19 pandemic. Our forward-looking statements should therefore be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. 
We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results. Today's press release, our historical financial news releases and our filings with the SEC are also available on our Investor Relations website. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Finally, any references to earnings per share or EPS made during this conference call refer to diluted earnings per common share. 
With that, I'll turn the call over to Bruce Broussard."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Thank you, Lisa, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $4.83 for the third quarter of 2021, slightly above consensus estimates. Our year-to-date results reflect the strength of our core operati",383,"Thank you, Lisa, and good morning, and thank you for joining us. 
Today, we reported adjusted earnings per share of $4.83 for the third quarter of 2021, slightly above consensus estimates. Our year-to-date results reflect the strength of our core operations as we continue to see strong underlying fundamentals across all lines of business and have remained focused on ensuring our members receive the right care at the right time despite the continued disruption caused by the pandemic. 
While our underlying fundamentals are strong, 2021 financial results have been impacted by the ongoing pandemic, which has resulted in an adjustment to our full year adjusted EPS guidance. As detailed in our earnings press release, we have updated our guidance to approximately $20.50 from our previous guidance of $21.25 to $21.75. As Susan will share in more detail, this reduction of approximately $1 in adjusted EPS as a direct result of COVID and corresponds to our current expectation of the total Medicare Advantage utilization inclusive of COVID costs will run 1% below baseline in the fourth quarter, which is 150 basis points less than our previous assumption of 2.5% below baseline. 
This update reflects a more conservative posture going into the final months of the year. And notably, $21.50 remains the baseline of which to grow for 2022. 
As a reminder, prior to this guidance update, we had not recognized a COVID headwind in our '21 guidance as many of our peers did. Our adjusted EPS guidance has been above our long-term growth target at the midpoint throughout the year at 16% growth. This update results in an expected adjusted EPS growth at the lower end of our long-term range and importantly, is not reflective of any concerns with our core operations. 
I will now turn to our operational and strategic update. Our Medicare Advantage individual above-market growth in 2021 of 11% can be in part attributed to our industry-leading quality and consumer satisfaction scores. We are pleased to be recognized by CMS for having 97% of our members in 4-star or higher-rated contracts for 2022. We also increased the number of contracts that received a 5-star rating from one contract in 2021 to 4 contracts in 2022, the most in our history. And whilst we did make adjustments to the [indiscernible]
[Technical Difficulty]"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","This is the operator. Your conference will begin momentarily. Please stay on hold until the conference begins.",17,"This is the operator. Your conference will begin momentarily. Please stay on hold until the conference begins."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Well, welcome back, and we're sorry for the technical glitch here. Let me just maybe just go back to our guidance update here and ensure that the investors understand the guidance and in addition, how it reflects in the -- as we look at the future here.",1918,"Well, welcome back, and we're sorry for the technical glitch here. Let me just maybe just go back to our guidance update here and ensure that the investors understand the guidance and in addition, how it reflects in the -- as we look at the future here. 
First, the guidance reflects a much more conservative posture going into the final months of the year. And notably, $21.50 remains the baseline of which to grow for 2022. As a reminder, prior to the guidance update, we had not recognized a COVID headwind in our 2021 guidance as many of our peers did. Our adjusted EPS guidance has been above our long-term growth target at the midpoint throughout the year at 16% growth. This update results and expected adjusted EPS growth at the lower end of our long-term range and is importantly does not reflect any concern with our core operations. 
I will now turn to our operational and strategic update. Our Medicare Advantage individual above-market growth in 2021 of 11% can be in part attributed to our industry-leading quality and consumer satisfaction scores. We are pleased to be recognized by CMS for having 97% of our members in 4-star or higher contract for 2022. We also increased the number of contracts that received a 5-star rating from 1 contract in 2021 to 4 contracts in 2022, the most in our history. 
And while CMS did make adjustments to the 2022 star ratings due to the possible impact of the COVID-19 pandemic, these adjustments had minimal impact on our ratings. This further demonstrates our enterprise-wide focus on quality, clinical outcomes and best-in-class customer service, which has been recognized from notable organizations such as Forrester, J.D. Power and USAA. Importantly, the stars bonus allows us to maintain a strong value proposition for our members and provided value supplemental benefits that address social determinants of health and other barriers not addressed by fee-for-service Medicare. 
Looking ahead to 2022, we are pleased to be able to provide stable or enhanced benefits for the majority of our Medicare Advantage members, offering plans that support members' whole health needs while continuing to deliver the human care our members have come to expect from us. Our strong clinical and quality programs drive improved clinical outcomes and cost savings that allow our Medicare Advantage plans to continue to expand member benefits beyond those covered by fee-for-service Medicare. 
Our plans include highly valuable extra benefits, including dental, vision, hearing and over-the-counter medication allowance, transportation support, business program memberships and home delivered meals following an inpatient hospital stay. 
Over the last few years, we've made great progress in addressing social determinants of health and health equity by expanding our Medicare Advantage benefits. Examples of those impactful areas include respite care, distributing 1.5 million meals during COVID, sending fans to seniors with COPD during a heat wave and providing support for financial need impacting a senior's health and well-being. Given the increase in demand for health equity across America, we have aggressively expanded our efforts to address it. 
We continue to advance our consumer segmentation efforts, developing plans that are tailored to the unique needs of specific member populations. This has allowed us to provide benefits that enhance and complement an individual's existing coverage through programs like Medicaid or entities such as Veterans Affairs. 
This approach leads to disproportionate growth. As you've seen in our D-SNP plans designed for dual eligible members where we have grown our membership approximately 40% in both 2022 and 2021, we've expanded our D-SNP offerings for 2022 to cover nearly 65% of the dual eligible population nationally. 
To reduce food and security, 97% of our members enrolled in our D-SNP plans and will have a healthy food card which provides a monthly allowance to purchase approved food and beverages at various national chains. New for 2022, many of our D-SNP members will have reduced Part D drug co-pays as a result of the D-SNP prescription drug savings benefit, which will help address the financial barriers some members face when assessing needed prescriptions, leading to better medication adherence, an important driver of members health -- overall health outcomes. 
As previously shared, we took a more conservative approach to our 2022 bids recognizing the continued uncertainty associated with COVID-19 and potential impacts to premium and claims assumption, allowing us to prioritize long-term benefit stability for our members. While it is early in the selling season, we believe we've struck the right balance and are competitively positioned for our continued growth in Medicare Advantage. Our brand promise to deliver human care resonates with seniors given our comprehensive set of offerings and focus on providing a patient-centric experience based on their specific needs. Susan will provide more detailed 2022 commentary in our remarks, including high-level EPS and membership guidance. 
I now would like to highlight the continued progress of our strategy through the build-out of our health care service platform, starting with primary care business and then moving to our growing home solutions offerings. We have the largest senior-focused, value-based primary care organization in the country, which by year-end, will include approximately 200 clinics, serving 300,000 patients across 24 markets in 9 states. 
We are accelerating organic and inorganic growth nationally and plan to open a total of 30 de novo senior-focused centers in 2022, up from 24 in 2021. This will include launching in 2 new major metropolitan areas, Dallas and Phoenix, next year. This faster-paced expansion comes as we continue to gain conviction in our de novo center model with panel growth in centers launched in 2021, exceeding plan, and clinical performance in our more mature markets continuing to improve. 
In our more mature centers, hospitalizations and ER visits are down 12% year-to-date versus 2019 pre-COVID levels, with star performance tracking to 4.5 stars and NPS score of 90. We will also continue to expand through inorganic growth, completing 7 acquisitions through the third quarter of this year, bringing 21 newly wholly-owned centers to our portfolio. We plan to continue this pace of acquisitions, focused on the markets where we have established presence to provide more access and high-quality care to our patients. 
Turning to the home. We completed the acquisition of Kindred at Home in the third quarter and now the largest home health and hospice organization in the nation. As previously shared, we will be migrating Kindred at Home to Humana's payer-agnostic health care service brand, CenterWell. 
Our efforts to transform home health to a value-based model come at a pivotal time for the industry. As seniors increasingly choose Medicare Advantage, there is a meaningful opportunity for home health organizations to engage differently with patients and Medicare Advantage payers to more holistically address patient needs and improve health outcomes, reduce the total cost of care for health plans and share appropriately in this value creation. We've made substantial progress towards our goal of scaling and maturing a risk-bearing value-based model that manages the provision of home health, durable medical equipment and home infusion services. 
With the acquisition of One Home earlier in 2021, a delegated post-acute management services organization for the home, we have the capabilities to be a value-based convener, providing risk-based contracting and referral management and continue to develop technology, enabling us to coordinate other adjacent services. 
These services include gap in care, closure, primary or emergent care in the home as well as coordination of meals, transportation and other services to positively support social determinants of health. 
We currently care for approximately 270,000 Humana members under value-based home care models in South Florida and Southeast Texas, where we have seen improved outcomes, including emergency room usage being 100 basis points better than Humana's national average. We now are focused on expanding to select markets in North Carolina and Virginia, which we chose based on multiple criteria, including market density, opportunity to significantly reduce home care expense and a robust Kindred at Home footprint. We expect to begin the rollout in the second quarter of 2022 with the goal of covering nearly 50% of Humana Medicare Advantage members under this value-based home health model within the next 5 years. 
We are excited about the continued progress of our strategy in the home, but consistent with our home health peers, we recognize that the national nursing labor shortage poses a significant risk to the industry, and we are taking proactive steps to address it as part of our well-developed integration process with Kindred at Home. 
In some markets, the nursing shortages resulting inadequate capacity to meet demand negatively impacting our ability to grow the top line. We believe the Humana CenterWell brand, supported by our patient-centric culture, will bolster recruiting and retention efforts for nurses. 
We've seen increased nurse satisfaction and engagement in pilot markets where we have deployed value-based concepts with voluntary nursing turnover, improving nearly 10% among home health nurses in 2021. In addition to unlock sufficient capacity to meet our growth goals, we are implementing broader operational improvements and benefit enhancements while also making targeted investments in capacity-constrained areas to enhance nurse recruiting and retention. 
With respect to hospice, our intent remains to ultimately divest the majority interest in this portion of the asset. As our experience has demonstrated, we can deliver desired experiences and outcomes for patients transitioning from restorative care to hospice through partnership models. 
Since we closed the transaction in August, we have continued to explore alternatives for the long-term ownership structure for the business and have initiated steps to reorganize the hospice business for stand-alone operations while also ensuring business continuity and monitoring underlying trends. We do not have any further update on the specific transaction structure or expected transaction timing, but we will provide additional updates as appropriate moving forward. 
Given the continued expansion of interest in our health care service platform, we are committed to providing additional disclosure to give further transparency into the performance of these businesses, beginning with our first quarter 2022 reporting. 
Before closing, I want to touch on the current regulatory and legislative landscape. As you know, last week, the White House and Congressional leaders released their plan known as Build Back Better, which includes several proposed changes to the Medicare program, including establishing a hearing benefit starting in calendar year 2024, which will be included in the Medicare Advantage benchmark. 
Given that today, more than 40% of Medicare beneficiaries, over 27 million seniors and those with disabilities are enrolled in Medicare Advantage, we were encouraged to see that the package did not include any payment reductions to the program. As this legislation continues to advance and likely be modified and as we look ahead to the annual CMS call letter and rate notice period, we will continue to work with policymakers and the Biden administration to further improve Medicare Advantage, building on the program's innovation and significant progress in areas like value-based care, social determinants of health, affordability and financial protection for beneficiaries. as well as reducing the total cost of care. 
These attributes, along with the deep consumer popularity of Medicare Advantage are what have enabled it to have a strong bipartisan support with hundreds of members of Congress on the record supporting the program. With Medicare Advantage serving as a leading example of a successful private-public partnership, I am often missed it. We can continue to lead on important health care issues facing both individuals and society, including addressing health and equities, improving health outcomes and expanding value-based care. 
With that, I'll turn the call over to Susan."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. Today, we reported adjusted EPS of $4.83 for the third quarter and updated full year 2021 adjusted EPS guidance to approximately $20.50 to reflect a net unmitigated COVID headwind resulting from our current",1555,"Thank you, Bruce, and good morning, everyone. 
Today, we reported adjusted EPS of $4.83 for the third quarter and updated full year 2021 adjusted EPS guidance to approximately $20.50 to reflect a net unmitigated COVID headwind resulting from our current view of utilization levels for the balance of the year. Before beginning, I would point you to Page 4 of our earnings press release for detail of our previous assumptions for Medicare Advantage utilization in the second half of the year, actual third quarter utilization results as well as current projections for the fourth quarter. 
I will now walk you through the details, starting with a reminder of our previous commentary. As of our second quarter call, full year guidance assumed non-COVID Medicare Advantage utilization would run 2.5% below baseline in the second half of the year, with a further assumption of minimal COVID testing and treatment costs for the same period. In September 2021, as a result of the surge in COVID cases due to the Delta variant, we updated our commentary on full year guidance to indicate we expected non-COVID Medicare Advantage utilization to be 5.5% below baseline in the back half of the year, while being partially [indiscernible] by 3% of COVID costs. Therefore, again, assuming total utilization would be 2.5% below baseline in the back half of 2021. 
What we've seen developed for the third quarter is that total utilization is running 1% below baseline versus the previously anticipated 2.5%. COVID costs have been higher than initially anticipated as the Delta variant resulted in hospitalization levels on par with what we experienced in January of 2021 and were overwhelmingly driven by the 20% of our Medicare Advantage members believed to be unvaccinated. 
These higher-than-expected COVID costs were fully offset by depressed non-COVID utilization in the quarter. As COVID hospitalizations increase or decrease, we continue to see an approximate 1:1 offset in non-COVID hospitalization levels. We also continue to see significantly reduced non-inpatient utilization when surges occur, offsetting the higher average cost of a COVID admission. 
However, for the third quarter, in total, we saw 1% incremental reduction in utilization beyond the level needed to offset COVID costs versus a 2.5% contemplated in our previous guide. As a result, we have adjusted our full year guide to now reflect the fourth quarter running similarly with total Medicare Advantage utilization running 1% below baseline, inclusive of estimated COVID costs, consistent with what we experienced in the third quarter. 
We realized higher-than-expected positive current claims development in Medicare Advantage in the third quarter as well as other operating outperformance largely mitigating the lower-than-anticipated depressed Medicare Advantage utilization, allowing us to report results that were slightly favorable to the Street estimates. Our revised guidance does not assume that the higher levels of favorable current period development seen in the third quarter will continue. Taken together, our updated full year 2021 adjusted EPS guidance takes a more conservative posture going into the final months of 2021. 
And it's important to note, as we've consistently shared throughout the year, the midpoint of our original guidance range of $21.50 remains the correct baseline for 2022, given our approach to pricing. 
I will now briefly touch on operating results across our segments before sharing early thoughts on 2022 performance. Our Medicare Advantage growth remains on track and consistent with previous expectations. We have refined our full year individual Medicare Advantage membership guidance to up approximately 450,000 members, consistent with the midpoint of our previous guidance of up 425,000 to 475,000 members. This outlook represents above-market growth with an increase of 11.4% year-over-year. 
Our Medicaid results continue to exceed initial expectations due to higher-than-anticipated membership increases largely attributable to the extension of the public health emergency. We now expect to add 125,000 to 150,000 Medicaid members in 2021, up from our previous expectation of 100,000 to 125,000 members. 
Utilization trends continue to be favorable to initial expectations and the Medicaid team is working diligently toward a successful implementation in Ohio with go-live anticipated in July. 
In our Group and Specialty segment, fully insured medical results were impacted by higher-than-expected COVID costs in the quarter, while our specialty business results continue to exceed expectations as utilization particularly for dental services remained lower than previously anticipated. Recall that our guidance as of the second quarter did not contemplate significant COVID costs in the back half of the year and the commercial business is not seeing the same level of utilization offset experience in Medicare Advantage. 
From a membership perspective, we have increased our expected group medical membership losses from $100,000 to $125,000, reflecting the expectation of additional losses in the fourth quarter as the result of rating actions taken to account for the expected impact of COVID in 2022. 
Finally, within our Healthcare Services operations, the pharmacy and provider businesses continue to perform slightly better than expected, with pharmacy benefiting from increased mail order penetration as a result of customer experience improvements and marketing campaigns. And the provider business seeing continued operating improvements in our more mature centers which are now aligned under the same leadership is our de novo centers. 
As Bruce mentioned in his remarks, we are actively integrating the Kindred at Home operations and results post integration have largely been in line with expectations. Similar to home health and hospice peers, the business is being impacted by COVID and labor shortages. For the third quarter, home health admissions grew low single digits year-over-year while hospice experienced a low single-digit decline year-over-year. We will continue to closely monitor trends as we make targeted investments to sustainably improve the recruitment and retention of nurses. 
Now let me take a few moments to share an early outlook for 2022, starting with membership. As you're aware, the overall PDP market continues to decline as more and more beneficiaries, including dual eligibles, choose Medicare Advantage. In addition, as we have discussed previously, PDP plans to become a commodity with a low-price leader capturing disproportionate growth. 
Consistent with 2021, the Walmart value plan will offer competitive benefits but will not be the low premium leader in 2022. As a result, we expect a net decline in PDP membership of a few hundred thousand members in 2022. We continue to focus on creating enterprise value for our PDP plans by driving increased mail order penetration and conversions to Medicare Advantage. 
With respect to group Advanced Group Medicare Advantage, we expect membership to be generally flat for 2022 as we do not anticipate any large accounts will be gained or lost as we continue to maintain pricing discipline in a highly competitive market. 
Moving to individual Medicare Advantage. As previously shared, we took a more conservative approach to our 2022 bids, reflecting the continued uncertainty associated with the pandemic. We expect to grow our individual Medicare Advantage membership in a range of 325,000 to 375,000 members in 2022 or approximately 8% year-over-year, reflective of our prudent approach we took to pricing for 2022 and the competitive nature of the market. 
It is early in our AEP selling season and the outlook we are providing today could change depending on how sales and voluntary disenrollments ultimately come in. And consistent with prior years, we have very little member disenrollment data at this point in the AEP cycle. 
I will now turn to our expected 2022 financial performance. As previously mentioned, I want to reiterate that the $21.50 midpoint of our original 2021 guide continues to be the appropriate jumping off point for 2022 adjusted EPS growth given our approach to pricing. In addition, we feel comfortable that the risk adjustment assumptions in our 2022 pricing are appropriate, as providers have been actively engaging with our members to ensure their conditions are fully documented and that care plans are established to address gaps in care. 
Provider interactions and documentation of clinical diagnoses that we anticipate will impact 2022 revenue are approximately 92% complete to date, in line with both our expectations for 2021 as well as the estimated completion rate for the same time period in 2019. We also assumed a medical costs would return to baseline levels, reflective of pre-COVID historical trending. 
From an earnings perspective, we believe the conservative approach we took to 2022 pricing struck the appropriate balance between membership and earnings growth. Given the ongoing uncertainty surrounding the COVID-19 pandemic, we expect to enter the year with an appropriately conservative view of our initial 2022 financial outlook. Accordingly, we anticipate that our initial EPS guidance will target the low end of our long-term growth range of 11% to 15%. 
We expect that COVID will be net neutral to the Medicare business in 2022 as we do not anticipate a risk adjustment headwind and expect COVID utilization to be offset by a reduction in non-COVID utilization. However, our initial guide will allow for an explicit COVID-related headwind that we can tolerate, should it emerge, similar to the approach some of our peers took in 2021. We believe entering the year with this more conservative approach is prudent in the current environment and sets the company up for success in 2022. We look forward to providing more specific guidance on our fourth quarter earnings call in early February. 
With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] Your first question comes from the line of Kevin Fischbeck from Bank of America.",16,"[Operator Instructions] Your first question comes from the line of Kevin Fischbeck from Bank of America."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","All right. Great. I appreciate all the color on the 2022 guidance. I guess I think a lot of people are just wondering, the company has had a hard time forecasting where costs are going to be in the upcoming quarter for the last few quarters, obviously, to",109,"All right. Great. I appreciate all the color on the 2022 guidance. I guess I think a lot of people are just wondering, the company has had a hard time forecasting where costs are going to be in the upcoming quarter for the last few quarters, obviously, to some degree, understandable during the pandemic. But just wanted to see how you felt about your visibility into costs and how good of a handle you feel like that, that cost trend as you develop your pricing for next year has come in? I guess, how do you think about that visibility into the cost as you thought about next year?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure, Kevin. Happy to take that one. So to your point, estimating the impact of COVID has proven to be more challenging particularly given the environment that we were in, in 2020 is quite different than what we're experiencing, obviously, in 2021. In 202",369,"Sure, Kevin. Happy to take that one. So to your point, estimating the impact of COVID has proven to be more challenging particularly given the environment that we were in, in 2020 is quite different than what we're experiencing, obviously, in 2021. In 2020, no one was vaccinated, various states have lockdown throughout the year. As we acknowledged in our Q2 call, anticipating how behavior might emerge in an environment where largely people are back to normal and a large percentage of our Medicare population were vaccinated, we just recognized that it was difficult to anticipate whether we see the same level of offset through the surge. 
The good news is, as we saw the surge emerge in the third quarter, despite it being just as high as what we experienced the last time, we did continue to see a full offset. The hospitalization offsets have been pretty consistent throughout 2020 and 2021. It's on the non-inpatient side where we tend to see more variation. And as we explained in the second quarter, that claims service category is one where we don't have the same level of near-term visibility. 
Having said that, we've studied all of the historical patterns based on what we saw in the third quarter, and our estimates of the continued decline in the COVID curve in the fourth quarter, we feel very comfortable with the assumptions that are underlying our revised guide and feel like we have sufficient visibility to feel confident we can deliver against that. 
Your question about 2022 was a good one. As we've explained in all of our calls, given this late surge in 2021, getting visibility to where baseline trend is actually running, obviously, will be more challenging. However, given how we approach the pricing for 2022, meaning that we started with pre-COVID historical levels and assumed historical trending factors not anticipating any ongoing depressed utilization into 2022, we feel confident that, that's an appropriate baseline expectation. So we'll continue to watch it. And certainly, if we see something different emerge, if any of the depression continues, that would be positive for us, but we are not contemplating it, which is what gives us confidence about our approach to 2022."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Matt Borsch from BMO Capital Markets.",14,"Your next question comes from the line of Matt Borsch from BMO Capital Markets."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Yes. So I was just hoping that you could maybe comment on the competition in Medicare Advantage. I know you said it's competitive, but just relatively speaking, we've seen geographic expansions by really almost all of the major public companies over the l",101,"Yes. So I was just hoping that you could maybe comment on the competition in Medicare Advantage. I know you said it's competitive, but just relatively speaking, we've seen geographic expansions by really almost all of the major public companies over the last few years and a number of new entrants. And yet it doesn't seem like it's had a noticeable impact on profit margins. I guess I'm just wondering how you see the dynamic. Is the greater availability of products actually, in essence, expanding the Medicare Advantage market more than it's necessarily lead into competition that would push down margins?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes, Matt, maybe I'll take that. What we see is a few things. I mean, first, we do see more and more intensity in the local markets and similar to in the past, we see some players being more aggressive to try to gain market share while others are a little",267,"Yes, Matt, maybe I'll take that. What we see is a few things. I mean, first, we do see more and more intensity in the local markets and similar to in the past, we see some players being more aggressive to try to gain market share while others are a little more aligned with the pricing that -- and a little more stability in the marketplace. So we do see a bell curve in just how people are approaching it as their strategic plan is pushing them to make those decisions. 
We are seeing more awareness in the marketplace as a result of the amount of education that's going on through marketing and through the telesales efforts that are going on. And I think that is a positive for the industry because it really brings alive all the benefits that members receive. It creates more competitive nature for that for those members, but it does create, I think, more growth industry-wide. 
For us as an organization, we were one of the early adopters of the tele market -- the telesales area, and we have benefited from that, I think, in multiple different ways, benefited from it in the way of both our market growth and in addition our ability to reach a population that we haven't been able to reach in the past. So I do think it's a benefit for us. But to answer your question, more competitive in the local market, more awareness in the industry. That is a good thing in the industry, and I feel that we have been a beneficiary of that."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","And Matthew, one thing I would add to that as well as I think our focus on, as Bruce mentioned in his comments, the consumer segmentation efforts by designing products that more specifically address unique consumer needs, you've seen in our dual offerings",72,"And Matthew, one thing I would add to that as well as I think our focus on, as Bruce mentioned in his comments, the consumer segmentation efforts by designing products that more specifically address unique consumer needs, you've seen in our dual offerings as well as our veteran offerings that we can drive disproportionate growth. And so we do think that's a differentiator and something you'll see us continue to focus on."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Steve Baxter of Wells Fargo.",13,"Your next question comes from the line of Steve Baxter of Wells Fargo."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","I was hoping to come back to the commentary on assuming baseline utilization in 2022. Just to clarify, it seems pretty clear that there will be some level of ongoing COVID costs into 2022. So does that mean you're continuing to assume non-COVID costs to b",78,"I was hoping to come back to the commentary on assuming baseline utilization in 2022. Just to clarify, it seems pretty clear that there will be some level of ongoing COVID costs into 2022. So does that mean you're continuing to assume non-COVID costs to be below baseline in 2022? And then just any color or context you can provide on the magnitude of this EPS hedge that you're talking about in relation to baseline would be appreciated."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. Great question. So just to be clear, so what we -- right now, based on all of our experience, we would expect that to the degree we experienced additional COVID costs in 2022 that we would see an offsetting depression in non-COVID utilization, but t",218,"Sure. Great question. So just to be clear, so what we -- right now, based on all of our experience, we would expect that to the degree we experienced additional COVID costs in 2022 that we would see an offsetting depression in non-COVID utilization, but the net of that would be neutral, right? We're not expecting net favorability that we've seen this year, that 1% we're projecting for the fourth quarter, consistent what we saw in the third quarter. 
So what we would say is we are expecting that if we have COVID cost, they'll be offset, but that we would still be at baseline. But as I mentioned in my comments, what we intend to do with our initial guide, though, is despite the belief that, that's a reasonable assumption, we will allow for an explicit net COVID headwind, should it emerge, such that in we would run actually above baseline levels, should that emerge and our guide will contemplate and allow for some of that if it should emerge. 
And while not giving a specific amount, obviously, today, when we do give specific guidance on our fourth quarter call, we will be explicit about how much of a COVID headwind we can tolerate within the guide. So we will be explicit about that at that time."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Ricky Goldwasser of Morgan Stanley.",13,"Your next question comes from the line of Ricky Goldwasser of Morgan Stanley."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","So one for and then long-term question. Just to understand, Susan, if you think about 80% of your MA members are vaccinated based on your estimate. So just kind of trying to reconcile what you're saying versus what some of your peers are saying. What do y",125,"So one for and then long-term question. Just to understand, Susan, if you think about 80% of your MA members are vaccinated based on your estimate. So just kind of trying to reconcile what you're saying versus what some of your peers are saying. What do you think happened that drove COVID hospitalization to levels experienced back in January? Was that sort of a specific geography or anything else that can explain it? And then the longer-term question is really around sort of virtual. Many of your peers launched your virtual first offering on the commercial side for 2022. Do you see room for some sort of virtual first type offering in the Medicare population, especially when you consider sort of the Kindred capabilities?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","That'd be great. So to take your question, so with respect to the high COVID levels and you're right, and honestly, this was something that was a bit surprising to us as well that we did see levels on par with what we experienced in the last surge despite",410,"That'd be great. So to take your question, so with respect to the high COVID levels and you're right, and honestly, this was something that was a bit surprising to us as well that we did see levels on par with what we experienced in the last surge despite the high vaccination rate. And what we learned is to your point, some of that was a reflection of our geographic mix. Say like Florida and Texas and Louisiana did see higher levels than even the previous surge. It represents a new all-time high, and we have disproportionate share there. So that was part of it. 
But the main driver is that as we looked at the hospitalization rate between vaccinated and unvaccinated, the unvaccinated fairly consistently saw hospitalization rate that was 10 or more times the vaccinated population. And so that, again, as I mentioned in my comments, was the overwhelming driver. And because of the spread of the Delta variant through that vaccinated population and at much higher hospitalization rate, that is what drove the level on par with what we saw historically. 
To your second question about Virtual First in Medicare, we were pleased with the COVID pandemic to see that primary care providers and specialists really did adopt telemedicine at a higher rate to ensure that they could continue to support their patients and their permitted needs. I think as a result of that, frankly, providers gained a better appreciation of the range of care and the quality of care that they can provide through virtual, which, frankly, pre pandemic, they really didn't appreciate were adopting. 
So I think we will see some continued use of virtual technology to enhance the operating model and allow for more touch points with their patients than we did pre-pandemic. Your question about home health is definitely a good one. It's something we're looking at, particularly with the challenges we have in terms of nursing labor shortages. Virtual is one strategy we're looking at to see how it can be leveraged to, again, create more touch points with the patient and improve the efficiency of the operating model to just create more overall capacity. And so we'll be testing with Kindred appropriate uses of that and where we can implement it and still see the high-quality outcomes that we would expect. So we'll be testing that and the hope would be that you'll see expansion of that in the future."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Just a few other comments to that. We didn't launch a few years ago, a Virtual First with doctors on-demand product, and that was a success for us on the commercial side. But on the Medicare side, what we do find is that there's a great opportunity to see",156,"Just a few other comments to that. We didn't launch a few years ago, a Virtual First with doctors on-demand product, and that was a success for us on the commercial side. But on the Medicare side, what we do find is that there's a great opportunity to see the patient, both to understand the patient in a physical setting. And unlike more episodic of care versus a chronic care management there's a good -- there is an importance of being able to have a physical and encouraging a physical interaction. 
We see that telehealth as being an opportunity to have a complementary and more interaction. But I don't know if it would be a replacement or we would want to motivate highly chronic members to have a Virtual First interaction for a whole host of reasons, both from a care point of view and from the ability for us to establish the proper care plan."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Josh Raskin from Nephron Research.",13,"Your next question comes from the line of Josh Raskin from Nephron Research."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","I wanted to ask about sort of the shorter short term. So just the assumption that non-COVID utilization will be down in 4Q, I'm just curious, are you seeing script trends, pre-authorizations or anything that would indicate sort of that level of decline ju",89,"I wanted to ask about sort of the shorter short term. So just the assumption that non-COVID utilization will be down in 4Q, I'm just curious, are you seeing script trends, pre-authorizations or anything that would indicate sort of that level of decline just in light of what seems to be an abatement in COVID cases currently? And then specifically, are you seeing any different trends with members that are in your centers or with other value-based providers or the underlying trends underneath that capitation any different? 
[Technical Difficulty]"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Excuse me, participants. This is the operator. I'll just turn the music on for the speakers.",16,"Excuse me, participants. This is the operator. I'll just turn the music on for the speakers."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Hi, Josh, are you there?",5,"Hi, Josh, are you there?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Yes. Can you guys hear me okay?",7,"Yes. Can you guys hear me okay?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","We can, sorry about that.",5,"We can, sorry about that."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes, we can.",3,"Yes, we can."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Your question must have been so insightful that it just dropped off the line.",14,"Your question must have been so insightful that it just dropped off the line."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","I thought it was so scary that you ran for it. So -- so I'll ask my question again, sorry. So just in the very, very short term. My question is, why are you assuming that non-COVID utilization will be down as much as 4% in the fourth quarter, especially i",134,"I thought it was so scary that you ran for it. So -- so I'll ask my question again, sorry. So just in the very, very short term. My question is, why are you assuming that non-COVID utilization will be down as much as 4% in the fourth quarter, especially in light of what we're seeing in terms of the big reduction in COVID costs -- in COVID -- direct COVID cases in the fourth quarter? And is there script trends? Is there pre-authorization? Is there something that would indicate that level of decline that you're seeing today? And then long -- or sort of adjacent to that, are you seeing different trends with members that are in your centers or even with other value-based providers sort of the underlying trends underneath the capitation?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","So to your question, so with respect to the fourth quarter, as we said before, we have really analyzed all of the prior surges to understand the patterns coming out of a surge. And you might recall from our previous commentary, what you typically see is a",529,"So to your question, so with respect to the fourth quarter, as we said before, we have really analyzed all of the prior surges to understand the patterns coming out of a surge. And you might recall from our previous commentary, what you typically see is a tail of depressed utilization anytime you come off a curve, which is what allows you to sort of fully recapture the cost of that COVID peak. And so we've -- with this surge in particular, what's kind of interesting is different states, as I mentioned before, are seeing different levels of utilization relative to previous surges, Texas, Florida, were examples where we saw a very high peak and a very rapid decline. 
There are some other states like New York and Michigan, where we're actually seeing a much more moderate and sort of gradual increase without sort seeing the same start peak in decline. So as we've seen that in total that on a national basis, what we're seeing is the slope of the downturn from -- coming off of the peak isn't quite as sharp as what we've seen historically. 
We've drilled into each of those states and are consistently seeing irrespective of that difference in peak level, we are still seeing that 1:1 offset regardless. And so to some degree, we think there's just an overall capacity constraints, particularly on the inpatient side that comes into play. And the rest is just that behavior change in terms of providers and patients as they manage through it. 
So based on what we've seen emerge and particularly in the third quarter with that 1% offset, everything we've seen suggests that assuming the same level of offset as we continue to come off that third quarter peak is reasonable. To your point about early indicators, we do, as we've said before, have really good real-time information on inpatient activity. That continues to hold where as the COVID utilization comes down, we'll see a bounce back on a 1:1 offset in the non-COVID hospitalization. So that has been very consistent. And we'll continue to watch the non-inpatient, but again, based on everything we've seen, we believe that is a reasonable assumption. 
In terms of your question about value-based providers, interestingly enough, most of our -- both our own centers and some of our high-performing partners, they have indicated that they are not seeing the same sort of neutrality or even benefit from a COVID event that we do. And the theory there is that in general, they manage sort of the unnecessary hospitalization events as lower value out of the system more routinely. 
And so when you do see a surge, there's not as much utilization to manage to be depressed because they have already managed it out on a more run rate basis. And so we're still, frankly, trying to assess and use some analytics on that. I think they may take a little bit more time for their claims to fully develop and have a full view of that. But their belief is that they don't see the same level of net benefit that we do on the health plan side generally."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Got it. So they see the COVID cost, but not the offset you're saying?",14,"Got it. So they see the COVID cost, but not the offset you're saying?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Correct. Now on the flip side of that, though, they tend to do better on a revenue basis than our non-risk payers, and they were much better about making sure they got their patients in 2020, got their conditions documented. So on the revenue side, I'd sa",68,"Correct. Now on the flip side of that, though, they tend to do better on a revenue basis than our non-risk payers, and they were much better about making sure they got their patients in 2020, got their conditions documented. So on the revenue side, I'd say they would make some of that up. But on the utilization side, they typically are saying they're not seeing a benefit."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Kevin Caliendo of UBS.",12,"Your next question comes from the line of Kevin Caliendo of UBS."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","In thinking about '22, I appreciate all the color, but I just wanted to know if there was any other sort of onetime things we should be thinking about, any other headwinds or tailwinds whether it comes to investments or benefits that you might be making t",57,"In thinking about '22, I appreciate all the color, but I just wanted to know if there was any other sort of onetime things we should be thinking about, any other headwinds or tailwinds whether it comes to investments or benefits that you might be making that could impact the sort of EPS growth for the year?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","So I would say, obviously, as we mentioned, COVID is the main one that we continue to evaluate. We've been clear that based on history, we think it would be an offset, but we will take a more conservative initial approach and allow for a headwind should i",261,"So I would say, obviously, as we mentioned, COVID is the main one that we continue to evaluate. We've been clear that based on history, we think it would be an offset, but we will take a more conservative initial approach and allow for a headwind should it emerge. And that really is reflective of the fact that, again, the environment continues to shift, the level of vaccination, hopefully, will continue to increase. But now there's the introduction of the need for boosters. And so will people be as compliant with boosters is they were the initial vaccine, the emergency variance and all of those things will continue to monitor as well as the ability for people to have reinfection breakthrough cases. 
So that's the main one. I would say, obviously, with what comes out of the administrative priorities, certainly, the taxes are one that we continue to watch. It's not obviously an investment, but something that we'll have to watch if there's any '22 impact. But otherwise, as we said before, and Bruce mentioned in his remarks, we continue to support our primary care business. We certainly will continue to look for capital-efficient way to support that business. I would say we aren't expecting anything in 2022 that would have -- that we couldn't withstand within our guide. So obviously, right now, there's nothing that I would point to that's a looming concern that we have that gives us any concern that we can't manage through in our -- whatever we go out with in terms of our initial guidance."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Can I just maybe follow up, is the guidance inclusive or exclusive of the incremental headwind that you're discussing here? Meaning like is the sort of low end 11% net of the headwinds or not? I just -- I'm a little confused on how I should think about th",49,"Can I just maybe follow up, is the guidance inclusive or exclusive of the incremental headwind that you're discussing here? Meaning like is the sort of low end 11% net of the headwinds or not? I just -- I'm a little confused on how I should think about that?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. With what we do out in our initial guide, it will explicitly contemplate a net headwind should emerge that we could would create no net impact then beyond our guide. So it is inclusive of that. So if it does not emerge, then you would see that conser",63,"Yes. With what we do out in our initial guide, it will explicitly contemplate a net headwind should emerge that we could would create no net impact then beyond our guide. So it is inclusive of that. So if it does not emerge, then you would see that conservatism release throughout the year. But it will contemplate a potential headwind within the gun."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Got it. That's really helpful.",5,"Got it. That's really helpful."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Scott Fidel from Stephens.",12,"Your next question comes from the line of Scott Fidel from Stephens."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Just wanted to ask another question just on the Medicare Advantage annual enrollment period. And I know you already talked about the competitive dynamics. Just interested in terms of what you're seeing on the consumer behavior side. And in particular, jus",125,"Just wanted to ask another question just on the Medicare Advantage annual enrollment period. And I know you already talked about the competitive dynamics. Just interested in terms of what you're seeing on the consumer behavior side. And in particular, just whether you're seeing any types of shifts in distribution channels in terms of where more of the sales are occurring or not. Just thinking about, obviously, 2021 was an unusual year for the AEP as it was playing out a mixed COVID. So interesting whether -- interested whether you're seeing more of a continuation of that 2021 type dynamic in terms of consumer buying practices or whether we're seeing, I guess, more of a blended sort of post-pandemic and pre-pandemic dynamic more for 2022?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. And Scott, thanks for the question. We are continuing to see an increasing use of the telephonic channel [indiscernible] external -- our external partners. And as Matt had asked about just on the competitive side, their marketing and their aggressive",101,"Yes. And Scott, thanks for the question. We are continuing to see an increasing use of the telephonic channel [indiscernible] external -- our external partners. And as Matt had asked about just on the competitive side, their marketing and their aggressiveness in the marketing, I think, is bringing more individuals to that channel. As I mentioned also, it's also how we feel it's a benefit for the industry because the industry is getting significant awareness and education from that. But what we're seeing is a continuation of that trend even pre 2021 AEP, it was also happening in the 2020 AEP."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Ralph Giacobbe from Citi.",12,"Your next question comes from the line of Ralph Giacobbe from Citi."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Sorry to come back to this, but I guess what does the $21.50 baseline incorporate at this time? Is it what you would have earned with normal utilization and no COVID in it? Is it some level of COVID but lower than normal core? I guess I'm really just tryi",56,"Sorry to come back to this, but I guess what does the $21.50 baseline incorporate at this time? Is it what you would have earned with normal utilization and no COVID in it? Is it some level of COVID but lower than normal core? I guess I'm really just trying to understand what the $21.50 represents."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. So the $21.50 is probably the midpoint of our original guide. And if you remember, the way we approached our initial guide was a bit different than many of our peers in the sense that we did not contemplate a net COVID headwind. And so that initial g",218,"Yes. So the $21.50 is probably the midpoint of our original guide. And if you remember, the way we approached our initial guide was a bit different than many of our peers in the sense that we did not contemplate a net COVID headwind. And so that initial guide at the midpoint was actually above our more typical long-term growth range, recognizing some of the tailwinds that supported our pricing in -- for 2021. 
And by reaffirming that, that is the appropriate baseline really just reinforces that the way we approached our 2022 pricing acknowledge that despite, however, the results emerged in 2021, that our revenue assumptions would assume that Medicare risk adjustment return to more normalized levels for 2022. And that claims also returned to more normalized levels as if COVID cannot occur. And so again, for claims, we started with pre-pandemic levels in 2019 and using historical trend factors turned that forward. And so that's why we continue to reinforce given that approach, $21.50 is the appropriate jumping off point from which we would grow and expect to be in our long-term arrangement in 2022, recognizing, however, from an initial guide perspective, we do intend to take a more conservative approach to ensure we're set up for success and target the lower end of that range."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Justin Lake of Wolfe Research.",13,"Your next question comes from the line of Justin Lake of Wolfe Research."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","First, I had a quick numbers question. We're kind of putting to next year, Medicare Advantage yields probably being in the high single digits in the individual business. Just given the -- you have the strong rates and the bounce back in risk scores, offse",146,"First, I had a quick numbers question. We're kind of putting to next year, Medicare Advantage yields probably being in the high single digits in the individual business. Just given the -- you have the strong rates and the bounce back in risk scores, offset, I guess, by a bit of sequestration. Is that a reasonable number? And then, Bruce, can you tell us how to think about where you think the growth opportunity is within your physician management kind of center business? I know you said you're adding 30. I know also that your Welsh, Carson deal is up in the end of 2022, and you have to think about how to finance those again going forward. So how many do you think you can add post 2022? And how do you think you finance these things going forward post that Welsh, Carson deal expiry?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take the first one for premium and then Bruce can take the second. So we obviously haven't given specific detailed guidance points for 2022 yet. So I can't comment specifically, but certainly, as you think about the premium yield in '22, the",108,"Sure. So I'll take the first one for premium and then Bruce can take the second. So we obviously haven't given specific detailed guidance points for 2022 yet. So I can't comment specifically, but certainly, as you think about the premium yield in '22, there are some tailwinds, as you mentioned, is the favorable rate notice as well as the -- as I said, the expectation that risk adjustment will return to more normal levels and then the typical sort of dynamics from just member growth. So to your point, all of those should produce tailwinds. But at this point, we haven't given specific guidance, obviously, on premium."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","On the primary care, I'll answer the 2 questions on the growth side. I think, first, obviously, adding the number of organic units in the earlier years creates a drag as they mature, and we're seeing some great maturation in the cohorts that have been ope",609,"On the primary care, I'll answer the 2 questions on the growth side. I think, first, obviously, adding the number of organic units in the earlier years creates a drag as they mature, and we're seeing some great maturation in the cohorts that have been open a year or 2, both on a membership side from a point of view of revenue and in addition, on the cost side. So we feel very confident. And that's one of the reasons why we increased the number of cohorts this year as a result of our confidence and conviction in the business outcome. 
What we see over a longer period of time is as we call it the J curve, we'll start to become into profitability of the ones that we opened in the earlier years. And that will start to give us growth. So if you were to shut off the development, you actually see a pretty quick growth rate within the existing business. We are accenting that by 2 other opportunities for growth. One is the existing operations of the businesses that have been open for a while, the mature centers. And we're seeing some really great same-store growth in that area and they have done a great turnaround over the last few years in being able to approve that. 
And although it doesn't show up in the profitability because of the J curve override it a lot, we are seeing some really great improvement there with operationally and then also from a quality and experience point of view. And then the third area of growth for us as an organization is really in the inorganic area. As many of you know, we do have a relationship with a number of providers, especially in our more mature markets that we have the right of first refusal. And that offers us an advantage in being able to continue to densify markets that we're in and add additional sites and  we did that in 2021, we anticipate doing in 2022. And those are very synergistic inorganic opportunities from the standpoint that we're able to evolve the management of it into our existing management team. We're able to, in addition, bring some of our operating capabilities to those centers. 
So 3, the continuum advancement of our J curve and what we see there, the more mature centers continuing to improve that. And then the third, the inorganic growth and being able to leverage in some of the markets we have. I think over a period of time, we're going to see a 5 to 7 period of time, I think you're going to see a fairly sizable business come out of this as a result of the investments we're making today and both in the organic and inorganic area, really today is the leading size clinic or clinics oriented to senior business. I think we'll continue to maintain that leadership long term. 
Relative to financing, we don't have -- we haven't come to structure yet. And Justin, I think that will be an active conversation with the investors in probably the second quarter of 2022. We will come back to the investors and discuss how we will finance another cohort or number of clinics for the foreseeable future. We, today, have enough of the capital to invest from our off-balance sheet financing on Welsh, Carson to get us through to the 2022 openings. And so we -- this doesn't cause any slowdown into our openings. But we do and are looking at all the different alternatives for financing and the most cost effective for our shareholders as we think about the future."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Stephen Valiquette from Barclays.",12,"Your next question comes from the line of Stephen Valiquette from Barclays."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Great. A lot of questions already on Medicare Advantage, just to maybe throw another one out there. Just curious to hear more about the pace of your county expansion. And obviously, you already have -- you're in more counties than anybody else already. Ev",103,"Great. A lot of questions already on Medicare Advantage, just to maybe throw another one out there. Just curious to hear more about the pace of your county expansion. And obviously, you already have -- you're in more counties than anybody else already. Even some of your larger peers seem to be growing their county footprint by double digits for '22. I think you guys are somewhere around mid-single digits based on what we calculated. But just curious you more about your thoughts on pace of county expansion for next year, maybe just in general, kind of your strategy and thoughts around that."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. I'll take that. So as you mentioned, Humana really was ahead of many of our peers in terms of the rate of expansion we had a number of years ago. And so you don't see from an accounting perspective, the same level of growth for us, as you might see",214,"Sure. I'll take that. So as you mentioned, Humana really was ahead of many of our peers in terms of the rate of expansion we had a number of years ago. And so you don't see from an accounting perspective, the same level of growth for us, as you might see for some others, particularly those who have focused on Medicare Advantage in the last couple of years. 
What you'll typically instead see from us is product expansion within our existing geographies. That could be additional -- a couple of years ago, it was really focused on our $0 premium LTPO product, as an example. You see us continue to expand our dual eligible D-SNP footprint, and you will see county expansion there in 2022 as well as our veteran offering, both the duals and the veterans, as we said before, are great examples of where we focused on product and consumer segmentation and designing product that uniquely meets the needs of this consumers. 
And when we do that well, you see an opportunity for disproportionate growth. So we'll continue to evaluate opportunities to do that. But again, I think you'll see more product expansion from Humana versus county expansion just because to your point, we've already got pretty broad coverage with some products."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of A.J. Rice from Credit Suisse.",14,"Your next question comes from the line of A.J. Rice from Credit Suisse."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Two more, one on perspective, and more and more on just clarifying what you're saying about 2022. I guess I'm trying to understand, so is it fair to say that the MA bids were due early in the summer? Obviously, from your perspective, at least the way it's",182,"Two more, one on perspective, and more and more on just clarifying what you're saying about 2022. I guess I'm trying to understand, so is it fair to say that the MA bids were due early in the summer? Obviously, from your perspective, at least the way it's coming across us, there's been a lot of developments in the back half of 2021. It may be more different than what you would have said when those bids would do. Is the right way to interpret what you're saying today is that you are so conservative when you constructed those bids that even though the second half has turned out worse, you're still comfortable with the outlook? Is that the way to interpret what you're saying? 
And then would give us something on the Kindred. I assumed, I think that, that was going to be an incremental tailwind for next year. Obviously, home health business seems to have deteriorated a bit. Is that still a tailwind in your mind for next year? And any way to size how much that might help you?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure, Andrew. I can take that. So for your first question on 2022, recall that in 2021, when we came out with our second quarter commentary, we acknowledged that we had a net COVID headwind that had emerged. And as I mentioned a few minutes ago, we did no",488,"Sure, Andrew. I can take that. So for your first question on 2022, recall that in 2021, when we came out with our second quarter commentary, we acknowledged that we had a net COVID headwind that had emerged. And as I mentioned a few minutes ago, we did not contemplate that explicitly in our original guidance for 2021. So as we saw that emerge as we explained in the second quarter, we were able to mitigate a fair amount of that through other business outperformance, some favorable prior period development and other items. 
But in order to achieve our guide, it did require that utilization continued to run below baseline throughout the year. That is not what we're considering in our 2022 pricing. We assume that it will bounce back. And so it's really just a reflection -- the challenges in 2021 are just acknowledging that while we are seeing net utilization below baseline levels, it's running less than we had previously anticipated or needed in order to achieve the guide and overcome that net COVID headwind that we discussed in the second quarter. 
Again, given the way we approach '22 pricing, while our pricing didn't explicitly contemplate COVID costs beyond just sort of vaccination and testing, as we've consistently said, we did take a more overall conservative approach to pricing, recognizing there would be uncertainty that we would need to be able to navigate through and also recognizing that it was a favorable rate environment, we had the headwinds. We wanted to make sure that we could maintain long-term benefit stability for our members and contemplated there may be a less favorable rate environment in 2023. 
So again, those are all the reasons that we approach pricing the way we did and the reason we continue to have confidence because we did not anticipate any ongoing net benefit in respect to price utilization into 2022. On Kindred, and we've had this question a couple of times. I think we've addressed it both in the second quarter call and again, maybe at Morgan Stanley, is that we -- that was one of the items that helped us address the net COVID headwind in 2021, the contribution from the full integration. We knew at the time of bid that we would be integrating Kindred. So that was something we were able to consider as we aligned around our targets and our good pricing for 2022. 
We've always said the capital deployment is one of the levers we have available, and we'll use to sustainably deliver our long-term growth target of 11% to 15%, so that was something we specifically contemplated in pricing. So it wouldn't represent an incremental tailwind for 2022, but certainly expect the value that we expect to create from that value-based model and the continued growth of Kindred will certainly continue to contribute in the future to our sustainable ability to deliver against our long-term target."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Lisa Gill from JPMorgan.",12,"Your next question comes from the line of Lisa Gill from JPMorgan."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Susan, I just want to go back to your comment around PDP shift to MA. Can you talk about ability to retain any of those members and bring them over to MA? I think you talked about losing a couple of hundred thousand lives. And then secondly, I know it's s",87,"Susan, I just want to go back to your comment around PDP shift to MA. Can you talk about ability to retain any of those members and bring them over to MA? I think you talked about losing a couple of hundred thousand lives. And then secondly, I know it's still fluid of what's going on down in D.C. around transparency and direct negotiation on the drug pricing side, but just curious if that will have any impact or you anticipate any impact around your PBM business?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure, Lisa. I'll take the first one. So PDP MA, so that is something that we have been focused on for many years. And what we see is we actively work to educate our PDP members about the value proposition of Medicare Advantage. In recent years as we've ex",319,"Sure, Lisa. I'll take the first one. So PDP MA, so that is something that we have been focused on for many years. And what we see is we actively work to educate our PDP members about the value proposition of Medicare Advantage. In recent years as we've expanded our dual-eligible SNP offerings that increased our ability to drive those conversions because a large percentage of our PDP members are low-income or dual-eligible members. 
And so what we consistently see is that we will be able to generate a disproportionate share of our PDP members who ultimately choose Medicare Advantage. And so we will disproportionately capture share within a Humana plan relative to what you would see our share capture in just overall Medicare Advantage. So really pleased with that. 
Having said that, some of our members do use other competitor MA plans. And so we continue to focus on identifying if there are opportunities to enhance the product to attract more PDP members who ultimately are likely to migrate to MA, are there things we can do to enhance the marketing, product segmentation, all of those things we've talked about to continue to drive increased share capture for those PDP members who ultimately determine that MA provides a better value proposition for them. 
On your second question around some of the recent tax has come out, we certainly are watching it closely. We'd say it really represents a framework at this point. We'll have to see some of the detailed tax that ultimately comes through and what the final proposals are and certainly are certainly supportive of anything that can be done to reduce the cost of prescription drugs for our members. And it's something we would certainly contemplate and take into consideration in our pricing each year. But I think at this point, it's too early, we'll need to see what comes out of the final tax."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Just on that from our vantage point, we continue to put rebates back into our pricing. So I guess back directly to the customer, we do not retain those rebates. So any kind of opportunity to lower the cost of the drugs will directly benefit our members an",63,"Just on that from our vantage point, we continue to put rebates back into our pricing. So I guess back directly to the customer, we do not retain those rebates. So any kind of opportunity to lower the cost of the drugs will directly benefit our members and not have an impact on us as a result of just we pass it through."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Lance Wilkes from Bernstein.",12,"Your next question comes from the line of Lance Wilkes from Bernstein."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Great. Could you provide a little more color on the primary care centers? And what I was interested in is looking at the centers and the patients served, can you describe a little bit about the composition of patients, what percent are MA versus Medicare",94,"Great. Could you provide a little more color on the primary care centers? And what I was interested in is looking at the centers and the patients served, can you describe a little bit about the composition of patients, what percent are MA versus Medicare fee-for-service? And then how many of them are employer or other? What percent of those are in full risk contracts versus maybe stages of that? And then how much of the membership -- or how much of the patient base is Humana membership as opposed to with other payers?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Okay. A few things there. There's a lot in that question. So let me try to provide as much as I can here. They are built really for full-risk Medicare Advantage members. That's what they're built for. That's how the staffing is constructed. That's how the",308,"Okay. A few things there. There's a lot in that question. So let me try to provide as much as I can here. They are built really for full-risk Medicare Advantage members. That's what they're built for. That's how the staffing is constructed. That's how the recruiting of the physicians, that's how the business model is built. And so that sort of leads you to the conclusion the majority of them are going to be MA members. 
Now we have some Medicare fee-for-service side members in there. They are really oriented to how, over time, that can evolve to be a longer-term member for us through a Medicare Advantage relationship. They are agnostic platforms. And so there's a good composition of Humana members as well as other payers in the clinic. That's why it's really called CenterWell, it's to reinforce that agnostic nature, and we are very oriented to that being agnostic. And a number of our sites, there's probably more non-Humana members than there are Humana members on there.
So you do see us oriented to a much broader opportunity for Medicare Advantage. In addition, in a few of the sites, we do have direct contracting members as a result of that. And so we are in the opportunity to take Medicare fee-for-service relationships that then -- that are more oriented to value-based. Your last part of your question just was the relationship. Over time, they will take full risk. 
Now there might be an earlier part of the opening that they will take a path to risk orientation where they'll have some upside and downside limits, but they will, over time, convert to a full risk model. And that's really just as the panel size gets bigger and bigger, the ability to manage the risk is much easier because of the diversification of the panel size."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Great. And what's the time to breakeven in those de novo sites for you guys?",15,"Great. And what's the time to breakeven in those de novo sites for you guys?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. Breakeven is between 3 to 5 years and fill up. I'd say the earlier year is probably 3 years is more around profitability and contribution margin. The fifth year is more around return on capital, obtaining the return on capital aside.",42,"Yes. Breakeven is between 3 to 5 years and fill up. I'd say the earlier year is probably 3 years is more around profitability and contribution margin. The fifth year is more around return on capital, obtaining the return on capital aside."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of George Hill from Deutsche Bank.",13,"Your next question comes from the line of George Hill from Deutsche Bank."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Susan, I was just wondering if you'd be willing to provide a little bit more color on how you're thinking about medical cost trend as it relates to 2022? And I guess to provide some granularity about how I'm thinking about the question is, is 2019 kind of",157,"Susan, I was just wondering if you'd be willing to provide a little bit more color on how you're thinking about medical cost trend as it relates to 2022? And I guess to provide some granularity about how I'm thinking about the question is, is 2019 kind of the right baseline number from an MLR perspective, plus then adjustments for mix because we've seen so much growth in virtual and retail care clinics? And then if the -- if you've included some, what I'll call, some excess COVID headwind, but if we see a continued reversion of utilization, like could we see a number that looks like greater than 100% of that 2019 baseline from an MLR perspective? Are you thinking about utilization being higher offset by changing cost mix? I'm not asking for the hard number, but just would love how you're thinking about the moving pieces as it relates to the growth in medical costs."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","That'd be great, sure. Yes, lots of specificity. So I'll try to answer this as much as I can, maybe a little bit more generally. But as you said before, right now, in our '22 pricing, our approach to baseline trend was to go back to pre-COVID levels, use",403,"That'd be great, sure. Yes, lots of specificity. So I'll try to answer this as much as I can, maybe a little bit more generally. But as you said before, right now, in our '22 pricing, our approach to baseline trend was to go back to pre-COVID levels, use historical trend factors and roll that forward. Now we certainly -- our models have a lot of granularity to them. And so certainly, they would take into account any site of service shifts that we may be seeing and then our estimate of what those might do going forward. 
They also look at what we've referred to as health care pipeline technologies to anything else that we expect that may be coming to market that would impact trends differently than what we've seen historically. And that's just part of our consistent process. So all of that work was done to support our '22 pricing. 
We have not changed our view of that currently. Although as you can imagine, there is a lot of work being done across the enterprise to study as best we can what has emerged over the course of 2020 and 2021, how we can decipher COVID impacted utilization, depression versus what might be just lower baseline trend. I think our view and as you've seen us consistently be able to meet and beat earnings historically, would imply that our core sort of trend forecasting models may have a little bit of conservatism in that. We've not assumed that going forward. Trending off '19 is certainly more years of trending than we would typically like. And so that's why we're going to do a lot more analysis between now and issuing our final guidance points for 2022 to see if there's any additional information that would inform our perspective on 2022 baselines. 
But what we're considering now we think is an appropriately conservative view. To your point, is the COVID headwind that we will contemplate in that guide does emerge, then we would be seeing utilization above baseline levels -- or I'm sorry, hit that backwards -- that I heard -- yes. That we would be able to tolerate it running above baseline, even though we don't expect that to occur. If it does not occur, then that would obviously represent an additional tailwind for us that you should see unwind over the course of the year. Does that answer..."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Okay. And if I could go with a quick -- it does. And I guess my quick follow-up is it just where do you feel like the flexibility is for your ability to pull levers on the cost side should costs on the medical side run ahead so that you guys can deliver y",56,"Okay. And if I could go with a quick -- it does. And I guess my quick follow-up is it just where do you feel like the flexibility is for your ability to pull levers on the cost side should costs on the medical side run ahead so that you guys can deliver your earnings targets?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","I think, in general, I would say we continue to work on our trend initiatives and various utilization management and other strategies not -- no different than any other year to continue to work to reduce total cost of care. Some of the work that we're doi",146,"I think, in general, I would say we continue to work on our trend initiatives and various utilization management and other strategies not -- no different than any other year to continue to work to reduce total cost of care. Some of the work that we're doing with our value-based home health model as well as the use of our broader home set of capabilities or other examples of how we continue to work to see how we can use these capabilities to focus on patients who are disproportionately likely to see potentially avoidable hospitalization events and use those capabilities to redirect to an alternative site of service like the home or an outpatient setting. So we'll continue to do all of those things in support of not only 2022 trend mitigation, but then also longer term to support our value proposition in Medicare Advantage broadly."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","And just -- you had asked a question about administrative management. We constantly are managing the investments we make and our cost trends within the administrative side to ensure that they provide the adequate cushion for us as we think about earnings",44,"And just -- you had asked a question about administrative management. We constantly are managing the investments we make and our cost trends within the administrative side to ensure that they provide the adequate cushion for us as we think about earnings being set."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Whit Mayo from SVB Leerink.",13,"Your next question comes from the line of Whit Mayo from SVB Leerink."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","I had just a quick clarification question, Susan. I think you said that you would expect that reserve development in the fourth quarter would come in less favorably than you experienced in the third quarter? I just wanted to make sure that I heard that ri",75,"I had just a quick clarification question, Susan. I think you said that you would expect that reserve development in the fourth quarter would come in less favorably than you experienced in the third quarter? I just wanted to make sure that I heard that right. And of the membership growth that you expect in 2022, I think 350 at the midpoint, how much of that is coming from special need plans, duals, et cetera?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. To your first question on current period development, yes, you heard correctly that while we did see positive current period development in the third quarter, our guide does not assume that we continue to see those elevated levels. Our guide would a",163,"Sure. To your first question on current period development, yes, you heard correctly that while we did see positive current period development in the third quarter, our guide does not assume that we continue to see those elevated levels. Our guide would always have seen some level of normal course CPD in any given quarter. You can see that would take we defined through the year. But we are not assuming currently that, that same excess favorability we saw emerge in third quarter will continue. 
In terms of '22 growth, we obviously haven't given detailed guidance by product. What I can tell you though is while it's still early in the AEP, Bruce mentioned we saw 40% growth in 2020 and 2021. We do continue to see strong growth in 2022. So while we're not prepared to share any specific number so far, again, while it's early, ease growth is actually coming in better than we had originally expected for '22 so far."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Gary Taylor from Cowen.",12,"Your next question comes from the line of Gary Taylor from Cowen."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Just 2 quick questions I have remaining. In April, you upped your MRA headwind to $1 billion to $1.3 billion for the full year. I just want to make sure, is that still the right '21 headwind and most of that comes back next year, and that's part of how yo",57,"Just 2 quick questions I have remaining. In April, you upped your MRA headwind to $1 billion to $1.3 billion for the full year. I just want to make sure, is that still the right '21 headwind and most of that comes back next year, and that's part of how you're offsetting the return to baseline utilization?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","That's exactly right. Our estimate has not been changed since our previous update on the MRA headwind. As we said, we're tracking very closely the diagnosis code submissions in 2021. And that will support our 2022 reimbursement, and those are in line with",78,"That's exactly right. Our estimate has not been changed since our previous update on the MRA headwind. As we said, we're tracking very closely the diagnosis code submissions in 2021. And that will support our 2022 reimbursement, and those are in line with expectations and more similar to what we saw pre-COVID. So to your tech point, that headwind, we do not expect to recur and does provide mitigation from trend bouncing back to more normal levels."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","And just one more quick one. When you talked about -- as I was just mentioning less development in the 4Q. Your third quarter prior year development was very similar to last year. So I presume you were talking about intra-year development from the first h",79,"And just one more quick one. When you talked about -- as I was just mentioning less development in the 4Q. Your third quarter prior year development was very similar to last year. So I presume you were talking about intra-year development from the first half that you recognized in the 3Q that doesn't occur -- you're not assuming occurs. Is that correct? And could you just give us a little color on where that came from inpatient, outpatient?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes, you are correct. When we refer to current period development that developed in the quarter, that would refer to [indiscernible] first half of the year.[Technical Difficulty]Hi, Gary. Can you hear us?",34,"Yes, you are correct. When we refer to current period development that developed in the quarter, that would refer to [indiscernible] first half of the year.
[Technical Difficulty]
Hi, Gary. Can you hear us?"
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Speakers, you are now live.",5,"Speakers, you are now live."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Hi, Gary, I'm sorry, we dropped again, unfortunately. Can you hear me? All right. So just -- I'm not sure exactly where we dropped. But just to your last point, current period development does refer to how plans restated in the first half of the year. And",116,"Hi, Gary, I'm sorry, we dropped again, unfortunately. Can you hear me? All right. So just -- I'm not sure exactly where we dropped. But just to your last point, current period development does refer to how plans restated in the first half of the year. And as we said, we did see some favorable restatement. What I can say is, at a high level, relative to we gave you estimates as of Q2 and what we saw develop in the third quarter is that net of the COVID, any COVID costs that we saw positive restatement of about 50 basis points for both the first and second quarter of 2021 developed in the third quarter."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","And speakers, we don't have any questions on the line. I would like to turn the call to Mr. Bruce Broussard for closing remarks.",24,"And speakers, we don't have any questions on the line. I would like to turn the call to Mr. Bruce Broussard for closing remarks."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Well, first, I want to apologize for the technical  glitches here. I think we have a problem with our leader line, and we will definitely work on that to ensure that the service that we subscribe to is capable of keeping a consistent connection. Second,",155,"Well, first, I want to apologize for the technical  glitches here. I think we have a problem with our leader line, and we will definitely work on that to ensure that the service that we subscribe to is capable of keeping a consistent connection. 
Second, I hope you take away from our conversation today that we have been very thoughtful and conservative as we look into the fourth quarter and as we enter into 2022. As you can see from all the commentary, we do reflect the uncertainty of COVID and all the aspects of going into 2022. I do want to say thank you for our 90,000 associates that make this such a successful organization and their dedication to not only our customers, but also providing our shareholders the adequate return. And I want to thank you for your long-term support for us as an organization. So thank you, and have a great day."
29618,1683170079,2422902,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.",17,"Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Good day, and thank you for standing by. Welcome to the Humana Inc. quarterly earnings conference call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference ov",54,"Good day, and thank you for standing by. Welcome to the Humana Inc. quarterly earnings conference call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker today, Ms. Lisa Stoner, Vice President of Investor Relations. Please go ahead."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our third quarter 2021 results and our updated financial outlook for 2021. Following these",360,"Thank you, and good morning. In a moment, Bruce Broussard, Humana's President and Chief Executive Officer; and Susan Diamond, Chief Financial Officer, will discuss our third quarter 2021 results and our updated financial outlook for 2021. Following these prepared remarks, we will open up the line for a question-and-answer session with industry analysts. Joe Ventura, our Chief Legal Officer, will also be joining Bruce and Susan for the Q&A session. 
We encourage the investing public and media to listen to both management's prepared remarks and the related Q&A with analysts. This call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. 
Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K and other filings with the Securities and Exchange Commission and our third quarter 2021 earnings press release as they relate to forward-looking statements and to note, in particular, that these forward-looking statements could be impacted by risks related to the spread of in response to the COVID-19 pandemic. Our forward-looking statements should therefore be considered in light of these additional uncertainties and risks, along with other risks discussed in our SEC filings. 
We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results. Today's press release, our historical financial news releases and our filings with the SEC are also available on our Investor Relations website. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Finally, any references to earnings per share or EPS made during this conference call refer to diluted earnings per common share. 
With that, I'll turn the call over to Bruce Broussard."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Thank you, Lisa, and good morning, and thank you for joining us. Today, we reported adjusted earnings per share of $4.83 for the third quarter of 2021, slightly above consensus estimates. Our year-to-date results reflect the strength of our core operati",382,"Thank you, Lisa, and good morning, and thank you for joining us. 
Today, we reported adjusted earnings per share of $4.83 for the third quarter of 2021, slightly above consensus estimates. Our year-to-date results reflect the strength of our core operations as we continue to see strong underlying fundamentals across all lines of business and have remained focused on ensuring our members receive the right care at the right time despite the continued disruption caused by the pandemic. 
While our underlying fundamentals are strong, 2021 financial results have been impacted by the ongoing pandemic, which has resulted in an adjustment to our full year adjusted EPS guidance. As detailed in our earnings press release, we have updated our guidance to approximately $20.50 from our previous guidance of $21.25 to $21.75. As Susan will share in more detail, this reduction of approximately $1 in adjusted EPS, as a direct result of COVID and corresponds to our current expectation of the total Medicare Advantage utilization inclusive of COVID costs, will run 1% below baseline in the fourth quarter, which is 150 basis points less than our previous assumption of 2.5% below baseline. 
This update reflects a more conservative posture going into the final months of the year. And notably, $21.50 remains the baseline of which to grow for 2022. 
As a reminder, prior to this guidance update, we had not recognized a COVID headwind in our '21 guidance as many of our peers did. Our adjusted EPS guidance has been above our long-term growth target at the midpoint throughout the year at 16% growth. This update results in an expected adjusted EPS growth at the lower end of our long-term range and, importantly, is not reflective of any concerns with our core operations. 
I will now turn to our operational and strategic update. Our Medicare Advantage individual above-market growth in 2021 of 11% can be in part attributed to our industry-leading quality and consumer satisfaction scores. We are pleased to be recognized by CMS for having 97% of our members in 4-Star or higher-rated contracts for 2022. We also increased the number of contracts that received a 5-Star rating from one contract in 2021 to 4 contracts in 2022, the most in our history. And while CMS did make adjustments to the...
[Technical Difficulty]"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","This is the operator. Your conference will begin momentarily. Please stay on hold until the conference begin.",17,"This is the operator. Your conference will begin momentarily. Please stay on hold until the conference begin."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Well, welcome back, and we're sorry for the technical glitch here. Let me just maybe just go back to our guidance update here and ensure that the investors understand the guidance and in addition, how it reflects in the -- as we look at the future here.",1917,"Well, welcome back, and we're sorry for the technical glitch here. Let me just maybe just go back to our guidance update here and ensure that the investors understand the guidance and in addition, how it reflects in the -- as we look at the future here. 
First, the guidance reflects a much more conservative posture going into the final months of the year. And notably, $21.50 remains the baseline of which to grow for 2022. As a reminder, prior to the guidance update, we had not recognized a COVID headwind in our 2021 guidance as many of our peers did. Our adjusted EPS guidance has been above our long-term growth target, at the midpoint throughout the year at 16% growth. This update results and expected adjusted EPS growth at the lower end of our long-term range and is importantly does not reflect any concern with our core operations. 
I will now turn to our operational and strategic update. Our Medicare Advantage individual above-market growth in 2021 of 11% can be in part attributed to our industry-leading quality and consumer satisfaction scores. We are pleased to be recognized by CMS for having 97% of our members in 4-Star or higher contract for 2022. We also increased the number of contracts that received a 5-Star rating from 1 contract in 2021 to 4 contracts in 2022, the most in our history. 
And while CMS did make adjustments to the 2022 Star ratings due to the possible impact of the COVID-19 pandemic, these adjustments had minimal impact on our ratings. This further demonstrates our enterprise-wide focus on quality, clinical outcomes and best-in-class customer service, which has been recognized from notable organizations such as Forrester, J.D. Power and USAA. Importantly, the Stars bonus allows us to maintain a strong value proposition for our members and provided valuable supplemental benefits that address social determinants of health and other barriers not addressed by fee-for-service Medicare. 
Looking ahead to 2022, we are pleased to be able to provide stable or enhanced benefits for the majority of our Medicare Advantage members, offering plans that support members' whole health needs while continuing to deliver the human care our members have come to expect from us. Our strong clinical and quality programs drive improved clinical outcomes and cost savings that allow our Medicare Advantage plans to continue to expand member benefits beyond those covered by fee-for-service Medicare. 
Our plans include highly valuable extra benefits, including dental, vision, hearing and over-the-counter medication allowance, transportation support, business program memberships and home-delivered meals following an inpatient hospital stay. 
Over the last few years, we've made great progress in addressing social determinants of health and health equity by expanding our Medicare Advantage benefits. Examples of those impactful areas include respite care, distributing 1.5 million meals during COVID, sending fans to seniors with COPD during a heat wave and providing support for financial need impacting a senior's health and well-being. Given the increase in demand for health equity across America, we have aggressively expanded our efforts to address it. 
We continue to advance our consumer segmentation efforts, developing plans that are tailored to the unique needs of specific member populations. This has allowed us to provide benefits that enhance and complement an individual's existing coverage through programs like Medicaid or entities such as Veterans Affairs. 
This approach leads to disproportionate growth. As you've seen in our D-SNP plans designed for dual-eligible members, where we have grown our membership approximately 40% in both 2022 and 2021, we've expanded our D-SNP offerings for 2022 to cover nearly 65% of the dual-eligible population nationally. 
To reduce food and security, 97% of our members enrolled in our D-SNP plans and will have a healthy food card, which provides a monthly allowance to purchase approved food and beverages at various national chains. New for 2022, many of our D-SNP members will have reduced Part D drug co-pays as a result of the D-SNP prescription drug savings benefit, which will help address the financial barriers some members face when assessing needed prescriptions, leading to better medication adherence, an important driver of members health -- overall health outcomes. 
As previously shared, we took a more conservative approach to our 2022 bids, recognizing the continued uncertainty associated with COVID-19 and potential impacts to premium and claims assumption, allowing us to prioritize long-term benefit stability for our members. While it is early in the selling season, we believe we've struck the right balance and are competitively positioned for our continued growth in Medicare Advantage. Our brand promise to deliver human care resonates with seniors given our comprehensive set of offerings and focus on providing a patient-centric experience based on their specific needs. Susan will provide more detailed 2022 commentary in our remarks, including high-level EPS and membership guidance. 
I now would like to highlight the continued progress of our strategy through the build-out of our health care service platforms, starting with primary care business and then moving to our growing home solutions offerings. We have the largest senior-focused, value-based primary care organization in the country, which by year-end, will include approximately 200 clinics, serving 300,000 patients across 24 markets in 9 states. 
We are accelerating organic and inorganic growth nationally and plan to open a total of 30 de novo senior-focused centers in 2022, up from 24 in 2021. This will include launching in 2 new major metropolitan areas, Dallas and Phoenix, next year. This faster-paced expansion comes as we continue to gain conviction in our de novo center model with panel growth in centers launched in '20 and 2021 exceeding plan, and clinical performance in our more mature markets continuing to improve. 
In our more mature centers, hospitalizations and ER visits are down 12% year-to-date versus 2019 pre-COVID levels, with Stars performance tracking to 4.5 Stars and NPS score of 90. We will also continue to expand through inorganic growth, completing 7 acquisitions through the third quarter of this year, bringing 21 newly wholly-owned centers to our portfolio. We plan to continue this pace of acquisitions, focused on the markets where we have established presence to provide more access and high-quality care to our patients. 
Turning to the home. We completed the acquisition of Kindred at Home in the third quarter and now the largest home health and hospice organization in the nation. As previously shared, we will be migrating Kindred at Home to Humana's payer-agnostic health care service brand, CenterWell. 
Our efforts to transform home health to a value-based model come at a pivotal time for the industry. As seniors increasingly choose Medicare Advantage, there is a meaningful opportunity for home health organizations to engage differently with patients and Medicare Advantage payers to more holistically address patient needs and improve health outcomes, reduce the total cost of care for health plans and share appropriately in this value creation. We've made substantial progress towards our goal of scaling and maturing a risk-bearing value-based model that manages the provision of home health, durable medical equipment and home infusion services. 
With the acquisition of onehome earlier in 2021, a delegated post-acute management services organization for the home, we have the capabilities to be a value-based convener, providing risk-based contracting and referral management and continue to develop technology, enabling us to coordinate other adjacent services. 
These services include gap in care, closure, primary or emergent care in the home as well as coordination of meals, transportation and other services to positively support social determinants of health. 
We currently care for approximately 270,000 Humana members under value-based home care models in South Florida and Southeast Texas, where we have seen improved outcomes, including emergency room usage being 100 basis points better than Humana's national average. We now are focused on expanding to select markets in North Carolina and Virginia, which we chose based on multiple criteria, including market density, opportunity to significantly reduce home care expense and a robust Kindred at Home footprint. We expect to begin the rollout in the second quarter of 2022 with the goal of covering nearly 50% of Humana Medicare Advantage members under this value-based home health model within the next 5 years. 
We are excited about the continued progress of our strategy in the home. But consistent with our home health peers, we recognize that the national nursing labor shortage poses a significant risk to the industry, and we are taking proactive steps to address it as part of our well-developed integration process with Kindred at Home. 
In some markets, the nursing shortage is resulting inadequate capacity to meet demand, negatively impacting our ability to grow the top line. We believe the Humana CenterWell brand, supported by our patient-centric culture, will bolster recruiting and retention efforts for nurses. 
We've seen increased nurse satisfaction and engagement in pilot markets where we have deployed value-based concepts, with voluntary nursing turnover improving nearly 10% among home health nurses in 2021. In addition, to unlock sufficient capacity to meet our growth goals, we are implementing broader operational improvements and benefit enhancements while also making targeted investments in capacity-constrained areas to enhance nurse recruiting and retention. 
With respect to hospice, our intent remains to ultimately divest the majority interest in this portion of the asset. As our experience has demonstrated, we can deliver desired experiences and outcomes for patients transitioning from restorative care to hospice through partnership models. 
Since we closed the transaction in August, we have continued to explore alternatives for the long-term ownership structure for the business and have initiated steps to reorganize the hospice business for stand-alone operations while also ensuring business continuity and monitoring underlying trends. We do not have any further update on the specific transaction structure or expected transaction timing, but we will provide additional updates as appropriate moving forward. 
Given the continued expansion of interest in our health care service platform, we are committed to providing additional disclosure to give further transparency into the performance of these businesses, beginning with our first quarter 2022 reporting. 
Before closing, I want to touch on the current regulatory and legislative landscape. As you know, last week, the White House and Congressional leaders released their plan known as Build Back Better, which includes several proposed changes to the Medicare program, including establishing a hearing benefit starting in calendar year 2024, which will be included in the Medicare Advantage benchmark. 
Given that today, more than 40% of Medicare beneficiaries, over 27 million seniors and those with disabilities are enrolled in Medicare Advantage, we were encouraged to see that the package did not include any payment reductions to the program. As this legislation continues to advance and likely be modified and as we look ahead to the annual CMS call letter and rate notice period, we will continue to work with policymakers and the Biden administration to further improve Medicare Advantage, building on the program's innovation and significant progress in areas like value-based care, social determinants of health, affordability and financial protection for beneficiaries as well as reducing the total cost of care. 
These attributes, along with the deep consumer popularity of Medicare Advantage, are what have enabled it to have a strong bipartisan support with hundreds of members of Congress on the record supporting the program. With Medicare Advantage serving as a leading example of a successful private-public partnership, I am often missed it. We can continue to lead on important health care issues facing both individuals and society, including addressing health and equities, improving health outcomes and expanding value-based care. 
With that, I'll turn the call over to Susan."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Thank you, Bruce, and good morning, everyone. Today, we reported adjusted EPS of $4.83 for the third quarter and updated full year 2021 adjusted EPS guidance to approximately $20.50 to reflect a net unmitigated COVID headwind resulting from our current",1555,"Thank you, Bruce, and good morning, everyone. 
Today, we reported adjusted EPS of $4.83 for the third quarter and updated full year 2021 adjusted EPS guidance to approximately $20.50 to reflect a net unmitigated COVID headwind resulting from our current view of utilization levels for the balance of the year. Before beginning, I would point you to Page 4 of our earnings press release for detail of our previous assumptions for Medicare Advantage utilization in the second half of the year, actual third quarter utilization results as well as current projections for the fourth quarter. 
I will now walk you through this detail, starting with a reminder of our previous commentary. As of our second quarter call, full year guidance assumed non-COVID Medicare Advantage utilization would run 2.5% below baseline in the second half of the year, with a further assumption of minimal COVID testing and treatment costs for the same period. In September 2021, as a result of the surge in COVID cases due to the Delta variant, we updated our commentary on full year guidance to indicate we expected non-COVID Medicare Advantage utilization to be 5.5% below baseline in the back half of the year, while being partially [indiscernible] by 3% of COVID costs. Therefore, again, assuming total utilization would be 2.5% below baseline in the back half of 2021. 
What we've seen developed for the third quarter is that total utilization is running 1% below baseline versus the previously anticipated 2.5%. COVID costs have been higher than initially anticipated as the Delta variant resulted in hospitalization levels on par with what we experienced in January of 2021 and were overwhelmingly driven by the 20% of our Medicare Advantage members believed to be unvaccinated. 
These higher-than-expected COVID costs were fully offset by depressed non-COVID utilization in the quarter. As COVID hospitalizations increase or decrease, we continue to see an approximate 1:1 offset in non-COVID hospitalization levels. We also continue to see significantly reduced non-inpatient utilization when surges occur, offsetting the higher average cost of a COVID admission. 
However, for the third quarter, in total, we saw 1% incremental reduction in utilization beyond the level needed to offset COVID costs versus a 2.5% contemplated in our previous guide. As a result, we have adjusted our full year guide to now reflect the fourth quarter running similarly with total Medicare Advantage utilization running 1% below baseline, inclusive of estimated COVID costs, consistent with what we experienced in the third quarter. 
We realized higher-than-expected positive current period claims development in Medicare Advantage in the third quarter as well as other operating outperformance largely mitigating the lower-than-anticipated depressed Medicare Advantage utilization, allowing us to report results that were slightly favorable to the Street estimates. Our revised guidance does not assume that the higher levels of favorable current period development seen in the third quarter will continue. Taken together, our updated full year 2021 adjusted EPS guidance takes a more conservative posture going into the final months of 2021. 
And it's important to note, as we've consistently shared throughout the year, the midpoint of our original guidance range of $21.50 remains the correct baseline for 2022, given our approach to pricing. 
I will now briefly touch on operating results across our segments before sharing early thoughts on 2022 performance. Our Medicare Advantage growth remains on track and consistent with previous expectations. We have refined our full year individual Medicare Advantage membership guidance to up approximately 450,000 members, consistent with the midpoint of our previous guidance of up 425,000 to 475,000 members. This outlook represents above-market growth with an increase of 11.4% year-over-year. 
Our Medicaid results continue to exceed initial expectations due to higher-than-anticipated membership increases largely attributable to the extension of the public health emergency. We now expect to add 125,000 to 150,000 Medicaid members in 2021, up from our previous expectation of up 100,000 to 125,000 members. 
Utilization trends continue to be favorable to initial expectations, and the Medicaid team is working diligently toward a successful implementation in Ohio with go-live anticipated in July. 
In our Group and Specialty segment, fully insured medical results were impacted by higher-than-expected COVID costs in the quarter, while our specialty business results continued to exceed expectations as utilization, particularly for dental services remained lower than previously anticipated. Recall that our guidance as of the second quarter did not contemplate significant COVID costs in the back half of the year, and the commercial business is not seeing the same level of utilization offset experienced in Medicare Advantage. 
From a membership perspective, we have increased our expected group medical membership losses from $100,000 to $125,000, reflecting the expectation of additional losses in the fourth quarter as the result of rating actions taken to account for the expected impact of COVID in 2022. 
Finally, within our Healthcare Services operations, the pharmacy and provider businesses continue to perform slightly better than expected, with pharmacy benefiting from increased mail order penetration as a result of customer experience improvements and marketing campaigns. And the provider business seeing continued operating improvements in our more mature centers, which are now aligned under the same leadership as our de novo centers. 
As Bruce mentioned in his remarks, we are actively integrating the Kindred at Home operations, and results post integration have largely been in line with expectations. Similar to home health and hospice peers, the business is being impacted by COVID and labor shortages. For the third quarter, home health admissions grew low single digits year-over-year while hospice experienced a low single-digit decline year-over-year. We will continue to closely monitor trends as we make targeted investments to sustainably improve the recruitment and retention of nurses. 
Now let me take a few moments to share an early outlook for 2022, starting with membership. As you're aware, the overall PDP market continues to decline as more and more beneficiaries, including dual eligibles, choose Medicare Advantage. In addition, as we have discussed previously, PDP plans should become a commodity with a low-price leader capturing disproportionate growth. 
Consistent with 2021, the Walmart Value Plan will offer competitive benefits but will not be the low-premium leader in 2022. As a result, we expect a net decline in PDP membership of a few hundred thousand members in 2022. We continue to focus on creating enterprise value for our PDP plans by driving increased mail order penetration and conversions to Medicare Advantage. 
With respect to group advanced -- group Medicare Advantage, we expect membership to be generally flat for 2022 as we do not anticipate any large accounts will be gained or lost as we continue to maintain pricing discipline in a highly competitive market. 
Moving to individual Medicare Advantage. As previously shared, we took a more conservative approach to our 2022 bids, reflecting the continued uncertainty associated with the pandemic. We expect to grow our individual Medicare Advantage membership in a range of 325,000 to 375,000 members in 2022 or approximately 8% year-over-year, reflective of our prudent approach we took to pricing for 2022 and the competitive nature of the market. 
It is early in our AEP selling season and the outlook we are providing today could change depending on how sales and voluntary disenrollments ultimately come in. And consistent with prior years, we have very little member disenrollment data at this point in the AEP cycle. 
I will now turn to our expected 2022 financial performance. As previously mentioned, I want to reiterate that the $21.50 midpoint of our original 2021 guide continues to be the appropriate jumping-off point for 2022 adjusted EPS growth given our approach to pricing. In addition, we feel comfortable that the risk adjustment assumptions in our 2022 pricing are appropriate, as providers have been actively engaging with our members to ensure their conditions are fully documented and that care plans are established to address gaps in care. 
Provider interactions and documentation of clinical diagnoses that we anticipate will impact 2022 revenue are approximately 92% complete to date, in line with both our expectations for 2021 as well as the estimated completion rate for the same time period in 2019. We also assumed medical costs would return to baseline levels, reflective of pre-COVID historical trending. 
From an earnings perspective, we believe the conservative approach we took to 2022 pricing struck the appropriate balance between membership and earnings growth. Given the ongoing uncertainty surrounding the COVID-19 pandemic, we expect to enter the year with an appropriately conservative view of our initial 2022 financial outlook. Accordingly, we anticipate that our initial EPS guidance will target the low end of our long-term growth range of 11% to 15%. 
We expect that COVID will be net neutral to the Medicare business in 2022 as we do not anticipate a risk adjustment headwind and expect COVID utilization to be offset by a reduction in non-COVID utilization. However, our initial guide will allow for an explicit COVID-related headwind that we can tolerate, should it emerge, similar to the approach some of our peers took in 2021. We believe entering the year with this more conservative approach is prudent in the current environment and sets the company up for success in 2022. We look forward to providing more specific guidance on our fourth quarter earnings call in early February. 
With that, we will open the lines up for your questions. [Operator Instructions] Operator, please introduce the first caller."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","[Operator Instructions] Your first question comes from the line of Kevin Fischbeck from Bank of America.",16,"[Operator Instructions] Your first question comes from the line of Kevin Fischbeck from Bank of America."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","All right. Great. I appreciate all the color on the 2022 guidance. I guess I think a lot of people are just wondering, the company has had a hard time forecasting where costs are going to be in the upcoming quarter for the last few quarters, obviously, to",109,"All right. Great. I appreciate all the color on the 2022 guidance. I guess I think a lot of people are just wondering, the company has had a hard time forecasting where costs are going to be in the upcoming quarter for the last few quarters, obviously, to some degree, understandable during a pandemic. But just wanted to see how you felt about your visibility into costs and how good of a handle you feel like that, that cost trend as you develop your pricing for next year has come in? I guess how do you think about that visibility into the cost as you thought about next year?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure, Kevin. Happy to take that one. So to your point, estimating the impact of COVID has proven to be more challenging particularly given the environment that we were in, in 2020 is quite different than what we're experiencing, obviously, in 2021. In 202",370,"Sure, Kevin. Happy to take that one. So to your point, estimating the impact of COVID has proven to be more challenging particularly given the environment that we were in, in 2020 is quite different than what we're experiencing, obviously, in 2021. In 2020, no one was vaccinated, various states have lockdown throughout the year. And as we acknowledged in our Q2 call, anticipating how behavior might emerge in an environment where largely people were back to normal and a large percentage of our Medicare population were vaccinated, we just recognized that it was difficult to anticipate whether we see the same level of offset through the surge. 
The good news is, as we saw the surge emerge in the third quarter, despite it being just as high as what we experienced the last time, we did continue to see a full offset. The hospitalization offsets have been pretty consistent throughout 2020 and 2021. It's on the non-inpatient side where we tend to see more variation. And as we explained in the second quarter, that claims service category is one where we don't have the same level of near-term visibility. 
Having said that, we've studied all of the historical patterns based on what we saw in the third quarter, and our estimates of the continued decline in the COVID curve in the fourth quarter, we feel very comfortable with the assumptions that are underlying our revised guide and feel like we have sufficient visibility to feel confident we can deliver against that. 
Your question about 2022 was a good one. As we've explained in all of our calls, given this late surge in 2021, getting visibility to where baseline trend is actually running, obviously, will be more challenging. However, given how we approach the pricing for 2022, meaning that we started with pre-COVID historical levels and assumed historical trending factors not anticipating any ongoing depressed utilization into 2022, we feel confident that, that's an appropriate baseline expectation. So we'll continue to watch it. And certainly, if we see something different emerge, if any of the depression continues, that would be positive for us, but we are not contemplating it, which is what gives us confidence about our approach to 2022."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Matt Borsch from BMO Capital Markets.",14,"Your next question comes from the line of Matt Borsch from BMO Capital Markets."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Yes. So I was just hoping that you could maybe comment on the competition in Medicare Advantage. I know you said it's competitive, but just relatively speaking, we've seen geographic expansions by really almost all of the major public companies over the l",101,"Yes. So I was just hoping that you could maybe comment on the competition in Medicare Advantage. I know you said it's competitive, but just relatively speaking, we've seen geographic expansions by really almost all of the major public companies over the last few years and a number of new entrants. And yet it doesn't seem like it's had a noticeable impact on profit margins. I guess I'm just wondering how you see the dynamic. Is the greater availability of products actually, in essence, expanding the Medicare Advantage market more than it's necessarily lead into competition that would push down margins?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. Matt, maybe I'll take that. What we see is a few things. I mean first, we do see more and more intensity in the local markets. And similar to in the past, we see some players being more aggressive to try to gain market share while others are a little",268,"Yes. Matt, maybe I'll take that. What we see is a few things. I mean first, we do see more and more intensity in the local markets. And similar to in the past, we see some players being more aggressive to try to gain market share while others are a little more aligned with the pricing that -- and a little more stability in the marketplace. So we do see a bell curve in just how people are approaching it as their strategic plan is pushing them to make those decisions. 
We are seeing more awareness in the marketplace as a result of the amount of education that's going on through marketing and through the telesales efforts that are going on. And I think that is a positive for the industry because it really brings alive all the benefits that members receive. It creates more competitive nature for that, for those members, but it does create, I think, more growth industry-wide. 
For us as an organization, we were one of the early adopters of the tele market -- the telesales area, and we have benefited from that, I think, in multiple different ways, benefited from it in the way of both our market growth and in addition, our ability to reach a population that we haven't been able to reach in the past. So I do think it's a benefit for us. But to answer your question, more competitive in the local market, more awareness as in the industry. That is a good thing in the industry, and I feel that we have been a beneficiary of that."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","And Matthew, one thing I would add to that as well as I think our focus on, as Bruce mentioned in his comments, the consumer segmentation efforts by designing products that more specifically address unique consumer needs, you've seen in our dual offerings",72,"And Matthew, one thing I would add to that as well as I think our focus on, as Bruce mentioned in his comments, the consumer segmentation efforts by designing products that more specifically address unique consumer needs, you've seen in our dual offerings as well as our veteran offerings that we can drive disproportionate growth. And so we do think that's a differentiator and something you'll see us continue to focus on."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Steve Baxter of Wells Fargo.",13,"Your next question comes from the line of Steve Baxter of Wells Fargo."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","I was hoping to come back to the commentary on assuming baseline utilization in 2022. Just to clarify, it seems pretty clear that there will be some level of ongoing COVID costs into 2022. So does that mean you're continuing to assume non-COVID costs to b",78,"I was hoping to come back to the commentary on assuming baseline utilization in 2022. Just to clarify, it seems pretty clear that there will be some level of ongoing COVID costs into 2022. So does that mean you're continuing to assume non-COVID costs to be below baseline in 2022? And then just any color or context you can provide on the magnitude of this EPS hedge that you're talking about in relation to baseline would be appreciated."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. Great question. So just to be clear, so what we -- right now, based on all of our experience, we would expect that to the degree we experienced additional COVID costs in 2022, that we would see an offsetting depression in non-COVID utilization, but",220,"Sure. Great question. So just to be clear, so what we -- right now, based on all of our experience, we would expect that to the degree we experienced additional COVID costs in 2022, that we would see an offsetting depression in non-COVID utilization, but the net of that would be neutral, right? We're not expecting net favorability that we've seen this year, that 1% we're projecting for the fourth quarter, consistent to what we saw in the third quarter. 
So what we would say is we are expecting that if we have COVID cost, they'll be offset, but that we would still be at baseline. But as I mentioned in my comments, what we intend to do with our initial guide though is despite the belief that, that's a reasonable assumption, we will allow for an explicit net COVID headwind, should it emerge, such that and then we would run actually above baseline levels, should that emerge and our guide will contemplate and allow for some of that if it should emerge. 
And while not giving a specific amount, obviously, today, when we do give specific guidance on our fourth quarter call, we will be explicit about how much of a COVID headwind we can tolerate within the guide. So we will be explicit about that at that time."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Ricky Goldwasser of Morgan Stanley.",13,"Your next question comes from the line of Ricky Goldwasser of Morgan Stanley."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","So one for us and then a long-term question. Just to understand, Susan, if you think about 80% of your MA members are vaccinated based on your estimate. So just kind of trying to reconcile what you're saying versus what some of your peers are saying. What",124,"So one for us and then a long-term question. Just to understand, Susan, if you think about 80% of your MA members are vaccinated based on your estimate. So just kind of trying to reconcile what you're saying versus what some of your peers are saying. What do you think happened that drove COVID hospitalization to levels experienced back in January? Was that sort of a specific geography or anything else that can explain it? And then the longer-term question is really around sort of virtual. Many of your peers launched a virtual-first offering on the commercial side for 2022. Do you see room for some sort of virtual-first-type offering in the Medicare population, especially when you consider sort of the Kindred capabilities?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","That'd be great. So to take your question, so with respect to the high COVID levels and you're right, and honestly, this was something that was a bit surprising to us as well that we did see levels on par with what we experienced in the last surge despite",412,"That'd be great. So to take your question, so with respect to the high COVID levels and you're right, and honestly, this was something that was a bit surprising to us as well that we did see levels on par with what we experienced in the last surge despite the high vaccination rate. And what we learned is to your point, some of that was a reflection of our geographic mix. Say like Florida and Texas and Louisiana did see higher levels than even the previous surge. It represents a new all-time high, and we have disproportionate share there. So that was part of it. 
But the main driver is that as we looked at the hospitalization rate between vaccinated and unvaccinated, the unvaccinated fairly consistently saw hospitalization rate that was 10 or more times the vaccinated population. And so that, again, as I mentioned in my comments, was the overwhelming driver. And because of the spread of the Delta variant through that unvaccinated population and at much higher hospitalization rate, that is what drove the level on par with what we saw historically. 
To your second question about virtual first in Medicare, we were pleased with the COVID pandemic to see that primary care providers and specialists really did adopt telemedicine at a higher rate to ensure that they could continue to support their patients and their permitted needs. I think as a result of that, frankly, providers gained a better appreciation of the range of care and the quality of care that they can provide through virtual, which frankly, pre pandemic, they really didn't appreciate and weren't adopting. 
So I think we will see some continued use of virtual technology to enhance the operating model and allow for more touch points with their patients than we did pre pandemic. Your question about home health is definitely a good one. It's something we're looking at, particularly with the challenges we have in terms of nursing labor shortages. Virtual is one strategy we're looking at to see how it can be leveraged to, again, create more touch points with the patient and improve the efficiency of the operating model to just create more overall capacity. And so we'll be testing with Kindred appropriate uses of that and where we can implement it and still see the high-quality outcomes that we would expect. So we'll be testing that, and the hope would be that you'll see expansion of that in the future."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Just a few other comments to that. We did launch a few years ago, a virtual first with doctors on-demand product, and that was a success for us on the commercial side. But on the Medicare side, what we do find is that there's a great opportunity to see th",155,"Just a few other comments to that. We did launch a few years ago, a virtual first with doctors on-demand product, and that was a success for us on the commercial side. But on the Medicare side, what we do find is that there's a great opportunity to see the patient, both to understand the patient in a physical setting. And unlike more episodic of care versus a chronic care management, there's a good -- there is an importance of being able to have a physical and encouraging a physical interaction. 
We see that telehealth as being an opportunity to have a complementary and more interaction. But I don't know if it would be a replacement or we would want to motivate highly chronic members to have a virtual-first interaction for a whole host of reasons, both from a care point of view and from the ability for us to establish the proper care plan."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Josh Raskin from Nephron Research.",13,"Your next question comes from the line of Josh Raskin from Nephron Research."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","I wanted to ask about sort of the shorter short term. So just the assumption that non-COVID utilization will be down in 4Q, I'm just curious, are you seeing script trends, pre-authorizations or anything that would indicate sort of that level of decline ju",89,"I wanted to ask about sort of the shorter short term. So just the assumption that non-COVID utilization will be down in 4Q, I'm just curious, are you seeing script trends, pre-authorizations or anything that would indicate sort of that level of decline just in light of what seems to be an abatement in COVID cases currently? And then specifically, are you seeing any different trends with members that are in your centers or with other value-based providers? Or the underlying trends underneath that capitation any different? 
[Technical Difficulty]"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Hi, Josh. Are you there?",5,"Hi, Josh. Are you there?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Yes. Can you guys hear me okay?",7,"Yes. Can you guys hear me okay?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","We can. Sorry about that.",5,"We can. Sorry about that."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes, we can.",3,"Yes, we can."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Your question must have been so insightful that it just dropped off the line.",14,"Your question must have been so insightful that it just dropped off the line."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","I thought it was so scary that you ran for it. So I'll ask my question again, sorry. So just in the very, very short term, my question is, why are you assuming that non-COVID utilization will be down as much as 4% in the fourth quarter, especially in ligh",132,"I thought it was so scary that you ran for it. So I'll ask my question again, sorry. So just in the very, very short term, my question is, why are you assuming that non-COVID utilization will be down as much as 4% in the fourth quarter, especially in light of what we're seeing in terms of the big reduction in COVID costs -- in COVID -- direct COVID cases in the fourth quarter? And is there script trends? Is there pre-authorizations? Is there something that would indicate that level of decline that you're seeing today? And then long -- or sort of adjacent to that, are you seeing different trends with members that are in your centers or even with other value-based providers sort of the underlying trends underneath the capitation?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. So to your question, so with respect to the fourth quarter, as we said before, we have really analyzed all of the prior surges to understand the patterns coming out of a surge. And you might recall from our previous commentary, what you typically se",531,"Sure. So to your question, so with respect to the fourth quarter, as we said before, we have really analyzed all of the prior surges to understand the patterns coming out of a surge. And you might recall from our previous commentary, what you typically see is a tail of depressed utilization anytime you come off a curve, which is what allows you to sort of fully recapture the cost of that COVID peak. And so we've -- with this surge in particular, what's kind of interesting is different states, as I mentioned before, are seeing different levels of utilization relative to previous surges. Texas, Florida, were examples where we saw a very high peak and a very rapid decline. 
There are some other states like New York and Michigan, where we're actually seeing a much more moderate and sort of gradual increase without sort of seeing the same sharp peak in decline. So as we've seen that in total that on a national basis, what we're seeing is the slope of the downturn from -- coming off of the peak isn't quite as sharp as what we've seen historically. 
We've drilled into each of those states and are consistently seeing irrespective of that difference in peak level, we are still seeing that 1:1 offset regardless. And so to some degree, we think there's just an overall capacity constraints, particularly on the inpatient side that comes into play. And the rest is just that behavior change in terms of providers and patients as they manage through it. 
So based on what we've seen emerge and particularly in the third quarter with that 1% offset, everything we've seen suggests that assuming the same level of offset as we continue to come off that third quarter peak is reasonable. To your point about early indicators, we do, as we've said before, have really good real-time information on inpatient activity. That continues to hold, where as the COVID utilization comes down, we'll see a bounce back on a 1:1 offset in the non-COVID hospitalization. So that has been very consistent. And we'll continue to watch the non-inpatient, but again, based on everything we've seen, we believe that is a reasonable assumption. 
In terms of your question about value-based providers, interestingly enough, most of our -- both our own centers and some of our high-performing partners, they have indicated that they are not seeing the same sort of neutrality or even benefit from a COVID event that we do. And the theory there is that in general, they manage sort of the unnecessary hospitalization events as lower value out of the system more routinely. 
And so when you do see a surge, there's not as much utilization to manage to be depressed because they have already managed it out on a more run rate basis. And so we're still, frankly, trying to assess and use some analytics on that. I think they may take a little bit more time for their claims to fully develop and have a full view of that. But their belief is that they don't see the same level of net benefit that we do on the health plan side generally."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Got it. So they see the COVID cost, but not the offset you're saying?",14,"Got it. So they see the COVID cost, but not the offset you're saying?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Correct. Now on the flip side of that though, they tend to do better on a revenue basis than our non-risk payers, and they were much better about making sure they got their patients in, in 2020, got their conditions documented. So on the revenue side, I'd",69,"Correct. Now on the flip side of that though, they tend to do better on a revenue basis than our non-risk payers, and they were much better about making sure they got their patients in, in 2020, got their conditions documented. So on the revenue side, I'd say they would make some of that up. But on the utilization side, they typically are saying they're not seeing a benefit."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Kevin Caliendo of UBS.",12,"Your next question comes from the line of Kevin Caliendo of UBS."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","In thinking about '22, I appreciate all the color, but I just wanted to know if there was any other sort of onetime things we should be thinking about, any other headwinds or tailwinds whether it comes to investments or benefits that you might be making t",57,"In thinking about '22, I appreciate all the color, but I just wanted to know if there was any other sort of onetime things we should be thinking about, any other headwinds or tailwinds whether it comes to investments or benefits that you might be making that could impact the sort of EPS growth for the year?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","So I would say, obviously, as we mentioned, COVID is the main one that we continue to evaluate. We've been clear that based on history, we think it would be an offset, but we will take a more conservative initial approach and allow for a headwind should i",263,"So I would say, obviously, as we mentioned, COVID is the main one that we continue to evaluate. We've been clear that based on history, we think it would be an offset, but we will take a more conservative initial approach and allow for a headwind should it emerge. And that really is reflective of the fact that, again, the environment continues to shift, the level of vaccination, hopefully, will continue to increase. But now there's the introduction of the need for boosters. And so will people be as compliant with boosters as they were in the initial vaccine, the emergence of variants and all of those things we'll continue to monitor as well as the ability for people to have reinfection breakthrough cases. 
So that's the main one. I would say, obviously, with what comes out of the administrative priorities, certainly, the taxes are one that we continue to watch. It's not obviously an investment, but something that we'll have to watch if there's any '22 impact. But otherwise, as we said before, and Bruce mentioned in his remarks, we continue to support our primary care business. We certainly will continue to look for capital-efficient way to support that business. I would say we aren't expecting anything in 2022 that would have -- that we couldn't withstand within our guide. So obviously, right now, there's nothing that I would point to that's a looming concern that we have that gives us any concern that we can't manage through in our -- whatever we go out with in terms of our initial guidance."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Can I just maybe follow up? Is the guidance inclusive or exclusive of the incremental headwind that you're discussing here? Meaning like is the sort of low end or 11% net of the headwinds or not? I just -- I'm a little confused on how I should think about",50,"Can I just maybe follow up? Is the guidance inclusive or exclusive of the incremental headwind that you're discussing here? Meaning like is the sort of low end or 11% net of the headwinds or not? I just -- I'm a little confused on how I should think about that."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. With what we do out in our initial guide, it will explicitly contemplate a net headwind should it emerge that we could -- would create no net impact than beyond our guide. So it is inclusive of that. So if it does not emerge, then you would see that",65,"Yes. With what we do out in our initial guide, it will explicitly contemplate a net headwind should it emerge that we could -- would create no net impact than beyond our guide. So it is inclusive of that. So if it does not emerge, then you would see that conservatism release throughout the year. But it will contemplate a potential headwind within the guide."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Scott Fidel from Stephens.",12,"Your next question comes from the line of Scott Fidel from Stephens."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Just wanted to ask another question just on the Medicare Advantage annual enrollment period. And I know you already talked about the competitive dynamics. Just interested in terms of what you're seeing on the consumer behavior side. And in particular, jus",124,"Just wanted to ask another question just on the Medicare Advantage annual enrollment period. And I know you already talked about the competitive dynamics. Just interested in terms of what you're seeing on the consumer behavior side. And in particular, just whether you're seeing any types of shifts in distribution channels in terms of where more of the sales are occurring or not. Just thinking about, obviously, 2021 was an unusual year for the AEP as it was playing out a mixed COVID. So interesting whether -- interested whether you're seeing more of a continuation of that 2021-type dynamic in terms of consumer buying practices or whether we're seeing, I guess, more of a blended sort of post-pandemic and pre-pandemic dynamic more for 2022?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. And Scott, thanks for the question. We are continuing to see an increasing use of the telephonic channel, external, our external partners. And as Matt had asked about just on the competitive side, their marketing and their aggressiveness in the marke",98,"Yes. And Scott, thanks for the question. We are continuing to see an increasing use of the telephonic channel, external, our external partners. And as Matt had asked about just on the competitive side, their marketing and their aggressiveness in the marketing, I think, is bringing more individuals to that channel. As I mentioned also, it's also how we feel it's a benefit for the industry because the industry is getting significant awareness and education from that. But what we're seeing is a continuation of that trend even pre-2021 AEP, it was also happening in the 2020 AEP."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Ralph Giacobbe from Citi.",12,"Your next question comes from the line of Ralph Giacobbe from Citi."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Sorry to come back to this, but I guess what does the $21.50 baseline incorporate at this time? Is it what you would have earned with normal utilization and no COVID in it? Is it some level of COVID but lower than normal core? I guess I'm really just tryi",56,"Sorry to come back to this, but I guess what does the $21.50 baseline incorporate at this time? Is it what you would have earned with normal utilization and no COVID in it? Is it some level of COVID but lower than normal core? I guess I'm really just trying to understand what the $21.50 represents."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. So the $21.50 is probably the midpoint of our original guide. And if you remember, the way we approached our initial guide was a bit different than many of our peers in the sense that we did not contemplate a net COVID headwind. And so that initial g",218,"Yes. So the $21.50 is probably the midpoint of our original guide. And if you remember, the way we approached our initial guide was a bit different than many of our peers in the sense that we did not contemplate a net COVID headwind. And so that initial guide at the midpoint was actually above our more typical long-term growth range, recognizing some of the tailwinds that supported our pricing in -- for 2021. 
So by reaffirming that, that is the appropriate baseline really just reinforces that the way we approached our 2022 pricing acknowledge that despite however the results emerge in 2021, that our revenue assumptions would assume that Medicare risk adjustment return to more normalized levels for 2022. And that claims also return to more normalized levels as if COVID did not occur. And so again, for claims, we started with pre-pandemic levels in 2019 and using historical trend factors trended that forward. And so that's why we continue to reinforce given that approach, $21.50 is the appropriate jumping-off point from which we would grow and expect to be in our long-term arrangement in 2022, recognizing, however, from an initial guide perspective, we do intend to take a more conservative approach to ensure we're set up for success and target the lower end of that range."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Justin Lake of Wolfe Research.",13,"Your next question comes from the line of Justin Lake of Wolfe Research."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","First, I had a quick numbers question. We're kind of putting to next year, Medicare Advantage yields probably being in the high single digits in the individual business. Just given the -- you have the strong rates and the bounce back in risk scores, offse",146,"First, I had a quick numbers question. We're kind of putting to next year, Medicare Advantage yields probably being in the high single digits in the individual business. Just given the -- you have the strong rates and the bounce back in risk scores, offset, I guess, by a bit of sequestration. Is that a reasonable number? And then, Bruce, can you tell us how to think about where you think the growth opportunity is within your physician management kind of center business? I know you said you're adding 30. I know also that your Welsh, Carson deal is up in the end of 2022, and you have to think about how to finance those again going forward. So how many do you think you can add post 2022? And how do you think you finance these things going forward post that Welsh, Carson deal expiry?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. So I'll take the first around premium yield and then Bruce can take the second. So we obviously haven't given specific detailed guidance points for 2022 yet. So I can't comment specifically, but certainly, as you think about the premium yield in '22",108,"Sure. So I'll take the first around premium yield and then Bruce can take the second. So we obviously haven't given specific detailed guidance points for 2022 yet. So I can't comment specifically, but certainly, as you think about the premium yield in '22, there are some tailwinds, as you mentioned, is the favorable rate notice as well as the -- as I said, the expectation that risk adjustment will return to more normal levels and then the typical sort of dynamics from just member growth. So to your point, all of those should produce tailwinds. But at this point, we haven't given specific guidance, obviously, on premium."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","On the primary care, I'll answer the 2 questions on the growth side. I think, first, obviously, adding the number of organic units in the earlier years creates a drag as they mature, and we're seeing some great maturation in the cohorts that have been ope",611,"On the primary care, I'll answer the 2 questions on the growth side. I think, first, obviously, adding the number of organic units in the earlier years creates a drag as they mature, and we're seeing some great maturation in the cohorts that have been open a year or 2, both on a membership side from a point of view of revenue and in addition, on the cost side. So we feel very confident. And that's one of the reasons why we increased the number of cohorts this year as a result of our confidence and conviction in the business outcome. 
What we see over a longer period of time is as we call it the J-curve, we'll start to become into profitability of the ones that we opened in the earlier years. And that will start to give us growth. So if you were to shut off the development, you actually see a pretty quick growth rate within the existing business. We are accenting that by 2 other opportunities for growth. One is the existing operations of the businesses that have been open for a while, the mature centers. And we're seeing some really great same-store growth in that area, and they have done a great turnaround over the last few years in being able to approve that. 
And although it doesn't show up in the profitability because of the J-curve override it a lot, we are seeing some really great improvement there both operationally and then also from a quality and experience point of view. And then the third area of growth for us as an organization is really in the inorganic area. As many of you know, we do have a relationship with a number of providers, especially in our more mature markets that we have the right of first refusal. And that offers us an advantage in being able to continue to densify markets that we're in and add additional sites and  we did that in 2021, we anticipate doing that in 2022. And those are very synergistic inorganic opportunities from the standpoint that we're able to evolve the management of it into our existing management team. We're able to, in addition, bring some of our operating capabilities to those centers. 
So [ going 3 ], the continuum advancement of our J-curve and what we see there, the more mature centers continuing to improve that. And then the third, the inorganic growth and being able to leverage in some of the markets we have. I think over a period of time, you're going to see a 5 to 7 period of time, I think you're going to see a fairly sizable business come out of this as a result of the investments we're making today and both in the organic and inorganic area, really today is the leading size clinic or clinics oriented to senior business. I think we'll continue to maintain that leadership long term. 
And relative to financing, we don't have -- we haven't come to structure yet. And Justin, I think that will be an active conversation with the investors in probably the second quarter of 2022. We will come back to the investors and discuss how we will finance another cohort or number of clinics for the foreseeable future. We, today, have enough of the capital to invest from our off-balance sheet financing on Welsh, Carson to get us through to the 2022 openings. And so we -- this doesn't cause any slowdown into our openings. But we do and are looking at all the different alternatives for financing and the most cost effective for our shareholders as we think about the future."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Steven Valiquette from Barclays.",12,"Your next question comes from the line of Steven Valiquette from Barclays."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Great. A lot of questions already on Medicare Advantage, just to maybe throw another one out there. Just curious to hear more about the pace of your county expansion. And obviously, you already have -- you're in more counties than anybody else already. Ev",104,"Great. A lot of questions already on Medicare Advantage, just to maybe throw another one out there. Just curious to hear more about the pace of your county expansion. And obviously, you already have -- you're in more counties than anybody else already. Even some of your larger peers seem to be growing their county footprint by double digits for '22. I think you guys are somewhere around mid-single digits based on what we calculated. But just curious to hear more about your thoughts of pace of county expansion for next year, maybe just in general, kind of your strategy and thoughts around that."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. I'll take that. So as you mentioned, Humana really was ahead of many of our peers in terms of the rate of expansion we had a number of years ago. And so you don't see from an accounting perspective, the same level of growth for us, as you might see",213,"Sure. I'll take that. So as you mentioned, Humana really was ahead of many of our peers in terms of the rate of expansion we had a number of years ago. And so you don't see from an accounting perspective, the same level of growth for us, as you might see for some others, particularly those who have focused on Medicare Advantage in the last couple of years. 
What you'll typically instead see from us is product expansion within our existing geographies. That could be additional -- a couple of years ago, it was really focused on our $0 premium LPPO product, as an example. You see us continue to expand our dual-eligible SNP footprint, and you will see county expansion there in 2022 as well as our veteran offering. Both the duals and the veterans, as we said before, are great examples of where we focused on product and consumer segmentation and designing product that uniquely meets the needs of those consumers. 
And when we do that well, you see an opportunity for disproportionate growth. So we'll continue to evaluate opportunities to do that. But again, I think you'll see more product expansion from Humana versus county expansion just because to your point, we've already got pretty broad coverage with some products."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of A.J. Rice from Crdit Suisse.",14,"Your next question comes from the line of A.J. Rice from Crdit Suisse."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Two more, one on perspective, and more and more on just clarifying what you're saying about 2022. I guess I'm trying to understand, so is it fair to say that the MA bids were due early in the summer? Obviously, from your perspective, at least the way it's",183,"Two more, one on perspective, and more and more on just clarifying what you're saying about 2022. I guess I'm trying to understand, so is it fair to say that the MA bids were due early in the summer? Obviously, from your perspective, at least the way it's coming across to us, there's been a lot of developments in the back half of 2021. There may be more difference than what you would have said when those bids would do. Is the right way to interpret what you're saying today is that you are so conservative when you constructed those bids that even though the second half has turned out worse, you're still comfortable with the outlook? Is that the way to interpret what you're saying? 
And then give us something on the Kindred. I had assumed, I think that, that was going to be an incremental tailwind for next year. Obviously, home health business seems to have deteriorated a bit. Is that still a tailwind in your mind for next year? And any way to size how much that might help you?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure, A.J. I can take that. So for your first question on 2022, recall that in 2021, when we came out with our second quarter commentary, we acknowledged that we had a net COVID headwind that had emerged. And as I mentioned a few minutes ago, we did not c",489,"Sure, A.J. I can take that. So for your first question on 2022, recall that in 2021, when we came out with our second quarter commentary, we acknowledged that we had a net COVID headwind that had emerged. And as I mentioned a few minutes ago, we did not contemplate that explicitly in our original guidance for 2021. So as we saw that emerge as we explained in the second quarter, we were able to mitigate a fair amount of that through other business outperformance, some favorable prior period development and other items. 
But in order to achieve our guide, it did require that utilization continue to run below baseline throughout the year. That is not what we're considering in our 2022 pricing. We assume that it was bounce back. And so it's really just a reflection -- the challenges in 2021 are just acknowledging that while we are seeing net utilization below baseline levels, it's running less than we had previously anticipated or needed in order to achieve the guide and overcome that net COVID headwind that we discussed at the second quarter. 
Again, given the way we approach '22 pricing, while our pricing didn't explicitly contemplate COVID costs beyond just sort of vaccination and testing, as we've consistently said, we did take a more overall conservative approach to pricing, recognizing there would be uncertainty that we would need to be able to navigate through and also recognizing that it was a favorable rate environment, we had the MRA headwinds. We wanted to make sure that we could maintain long-term benefit stability for our members and contemplated there may be a less favorable rate environment in 2023. 
So again, those are all the reasons that we approach pricing the way we did and the reason we continue to have confidence, because we did not anticipate any ongoing net benefit in respect to price utilization into 2022. On Kindred, and we've had this question a couple of times. I think we've addressed it both in the second quarter call and again, maybe at Morgan Stanley, is that we -- that was one of the items that helped us address the net COVID headwind in 2021, the contribution from the full integration. We knew at the time of bid that we would be integrating Kindred. So that was something we were able to consider as we aligned around our targets and our good pricing for 2022. 
We've always said the capital deployment is one of the levers we have available, and we'll use to sustainably deliver our long-term growth target of 11% to 15%, so that was something we specifically contemplated in pricing. So it wouldn't represent an incremental tailwind for 2022, but certainly expect the value that we expect to create from that value-based model and the continued growth of Kindred will certainly continue to contribute in the future to our sustainable ability to deliver against our long-term target."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Lisa Gill from JPMorgan.",12,"Your next question comes from the line of Lisa Gill from JPMorgan."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Susan, I just want to go back to your comment around PDP shift to MA. Can you talk about your ability to retain any of those members and bring them over to MA? I think you talked about losing a couple of hundred thousand lives. And then secondly, I know i",88,"Susan, I just want to go back to your comment around PDP shift to MA. Can you talk about your ability to retain any of those members and bring them over to MA? I think you talked about losing a couple of hundred thousand lives. And then secondly, I know it's still fluid of what's going on down in D.C. around transparency and direct negotiation on the drug pricing side, but just curious if that will have any impact or you anticipate any impact around your PBM business."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure, Lisa. I'll take the first one. So PDP to MA, so that is something that we have been focused on for many years. And what we see is we actively work to educate our PDP members about the value proposition of Medicare Advantage. In recent years, as we'v",320,"Sure, Lisa. I'll take the first one. So PDP to MA, so that is something that we have been focused on for many years. And what we see is we actively work to educate our PDP members about the value proposition of Medicare Advantage. In recent years, as we've expanded our dual-eligible SNP offerings, that increased our ability to drive those conversions because a large percentage of our PDP members are low-income, dual-eligible members. 
And so what we consistently see is that we will be able to generate a disproportionate share of our PDP members who ultimately choose Medicare Advantage. And so we will disproportionately capture share within a Humana plan relative to what you would see our share capture in just overall Medicare Advantage. So really pleased with that. 
Having said that, some of our members do choose other competitor MA plans. And so we continue to focus on identifying if there are opportunities to enhance the product to attract more PDP members who ultimately are likely to migrate to MA, are there things we can do to enhance the marketing, product segmentation, all of those things we've talked about to continue to drive increased share capture for those PDP members who ultimately determine that MA provides a better value proposition for them. 
On your second question around some of the recent tax has come out, we certainly are watching it closely. We'd say it really represents a framework at this point. We'll have to see some of the detailed tax that ultimately comes through and what the final proposals are and certainly are -- certainly supportive of anything that can be done to reduce the cost of prescription drugs for our members. And it's something we would certainly contemplate and take into consideration in our pricing each year. But I think at this point, it's too early, we'll need to see what comes out of the final tax."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Just on that -- from our vantage point, we continue to put rebates back into our pricing. So I guess back directly to the customer, we do not retain those rebates. So any kind of opportunity to lower the cost of the drugs will directly benefit our members",64,"Just on that -- from our vantage point, we continue to put rebates back into our pricing. So I guess back directly to the customer, we do not retain those rebates. So any kind of opportunity to lower the cost of the drugs will directly benefit our members and not have an impact on us as a result of just we pass it through."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Lance Wilkes from Bernstein.",12,"Your next question comes from the line of Lance Wilkes from Bernstein."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Great. Could you provide a little more color on the primary care centers? And what I was interested in is looking at the centers and the patients served, can you describe a little bit about the composition of patients, what percent are MA versus Medicare",93,"Great. Could you provide a little more color on the primary care centers? And what I was interested in is looking at the centers and the patients served, can you describe a little bit about the composition of patients, what percent are MA versus Medicare fee-for-service? And then how many of them are employer or other? What percent of those are in full-risk contracts versus maybe stages of that? And then how much of the membership -- or how much of the patient base is Humana membership as opposed to with other payers?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Okay. A few things there. There's a lot in that question. So let me try to provide as much as I can here. They are built really for full-risk Medicare Advantage members. That's what they're built for. That's how the staffing is constructed. That's how the",309,"Okay. A few things there. There's a lot in that question. So let me try to provide as much as I can here. They are built really for full-risk Medicare Advantage members. That's what they're built for. That's how the staffing is constructed. That's how the recruiting of the physicians, that's how the business model is built. And so that sort of leads you to the conclusion the majority of them are going to be MA members. 
Now we have some Medicare fee-for-service side members in there. They are really oriented to how, over time, that can evolve to be a longer-term member for us through a Medicare Advantage relationship. They are agnostic platforms, and so there's a good composition of Humana members as well as other payers in the clinic. That's why it's really called CenterWell. It's to reinforce that agnostic nature, and we are very oriented to that being agnostic. And a number of our sites, there's probably more non-Humana members than there are Humana members on there.
So you do see us oriented to a much broader opportunity for Medicare Advantage. In addition, in a few of the sites, we do have direct contracting members as a result of that. And so we are in the opportunity to take Medicare fee-for-service relationships that then -- that are more oriented to value based. 
Your last part of your question just was the relationship. Over time, they will take full risk.  Now there might be an earlier part of the opening that they will take a path to risk orientation where they'll have some upside and downside limits, but they will, over time, convert to a full risk model. And that's really just as the panel size gets bigger and bigger, the ability to manage the risk is much easier because of the diversification of the panel size."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Great. And what's the time to break even in those de novo sites for you guys?",16,"Great. And what's the time to break even in those de novo sites for you guys?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes. Breakeven is between 3 to 5 years and fill up. I'd say the earlier year is probably 3 years is more around profitability and contribution margin. The fifth year is more around return on capital, obtaining the return on capital side.",42,"Yes. Breakeven is between 3 to 5 years and fill up. I'd say the earlier year is probably 3 years is more around profitability and contribution margin. The fifth year is more around return on capital, obtaining the return on capital side."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of George Hill from Deutsche Bank.",13,"Your next question comes from the line of George Hill from Deutsche Bank."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Susan, I was just wondering if you'd be willing to provide a little bit more color on how you're thinking about medical cost trend as it relates to 2022? And I guess to provide some granularity about how I'm thinking about the question is, is 2019 kind of",157,"Susan, I was just wondering if you'd be willing to provide a little bit more color on how you're thinking about medical cost trend as it relates to 2022? And I guess to provide some granularity about how I'm thinking about the question is, is 2019 kind of the right baseline number from an MLR perspective, plus then adjustments for mix because we've seen so much growth in virtual and retail care clinics? And then if the -- if you've included some, what I'll call, some excess COVID headwind, but if we see a continued reversion of utilization, like could we see a number that looks like greater than 100% of that 2019 baseline from an MLR perspective? Are you thinking about utilization being higher offset by changing cost mix? I'm not asking for the hard number, but just would love how you're thinking about the moving pieces as it relates to the growth in medical costs."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","That'd be great, sure. Yes, for lots of specificity. So I'll try to answer this as much as I can, maybe a little bit more generally. But as you said before, right now, in our '22 pricing, our approach to baseline trend was to go back to pre-COVID levels,",407,"That'd be great, sure. Yes, for lots of specificity. So I'll try to answer this as much as I can, maybe a little bit more generally. But as you said before, right now, in our '22 pricing, our approach to baseline trend was to go back to pre-COVID levels, use historical trend factors and roll that forward. Now we certainly -- our models have a lot of granularity to them. And so certainly, they would take into account any site of service shifts that we may be seeing and then our estimate of what those might be going forward. 
They'd also look at what we've referred to as health care pipeline technologies to anything else that we expect that may be coming to market that would impact trends differently than what we've seen historically. And that's just part of our consistent process. So all of that work was done to support our '22 pricing. 
We have not changed our view of that currently. Although as you can imagine, there is a lot of work being done across the enterprise to study as best we can what has emerged over the course of 2020 and 2021, how we can decipher COVID-impacted utilization, depression versus what might be just lower baseline trend. I think our view and as you've seen us consistently be able to meet and beat earnings historically, would imply that our core sort of trend forecasting models may have a little bit of conservatism in that. We've not assumed that going forward. Trending off '19 is certainly more years of trending than we would typically like. And so that's why we're going to do a lot more analysis between now and issuing our final guidance points for 2022 to see if there's any additional information that would inform our perspective on 2022 baselines. 
But what we're considering now we think is an appropriately conservative view. To your point, is the COVID headwind that we will contemplate in that guide does not emerge -- does emerge, then we would be seeing utilization above baseline levels -- or I'm sorry, hit that backwards, is that what I heard? Yes. That we would be able to tolerate it running above baseline even though we don't expect that to occur. If it does not occur, then that would obviously represent an additional tailwind for us that you should see unwind over the course of the year. Does that answer..."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Okay. And if I could go with a quick -- it does. And I guess my quick follow-up is just where do you feel like the flexibility is for your ability to pull levers on the cost side should costs on the medical side run ahead so that you guys can deliver your",55,"Okay. And if I could go with a quick -- it does. And I guess my quick follow-up is just where do you feel like the flexibility is for your ability to pull levers on the cost side should costs on the medical side run ahead so that you guys can deliver your earnings targets?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","I think in general, I would say we continue to work on our trend initiatives and various utilization management and other strategies not -- no different than any other year to continue to work to reduce total cost of care. Some of the work that we're doin",146,"I think in general, I would say we continue to work on our trend initiatives and various utilization management and other strategies not -- no different than any other year to continue to work to reduce total cost of care. Some of the work that we're doing with our value-based home health model as well as the use of our broader home set of capabilities or other examples of how we continue to work to see how we can use these capabilities to focus on patients who are disproportionately likely to see potentially avoidable hospitalization events and use those capabilities to redirect to an alternative site of service like the home or an outpatient setting. So we'll continue to do all of those things in support of not only 2022 trend mitigation, but then also longer term to support our value proposition in Medicare Advantage broadly."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","And just -- you had asked a question about administrative management. We constantly are managing the investments we make and our cost trends within the administrative side to ensure that they provide the adequate cushion for us as we think about earnings",44,"And just -- you had asked a question about administrative management. We constantly are managing the investments we make and our cost trends within the administrative side to ensure that they provide the adequate cushion for us as we think about earnings being set."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Whit Mayo from SVB Leerink.",13,"Your next question comes from the line of Whit Mayo from SVB Leerink."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","I had just a quick clarification question, Susan. I think you said that you would expect that reserve development in the fourth quarter would come in less favorably than you experienced in the third quarter? I just wanted to make sure that I heard that ri",75,"I had just a quick clarification question, Susan. I think you said that you would expect that reserve development in the fourth quarter would come in less favorably than you experienced in the third quarter? I just wanted to make sure that I heard that right. And of the membership growth that you expect in 2022, I think 350 at the midpoint, how much of that is coming from special need plans, duals, et cetera?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Sure. To your first question on current period development, yes, you heard correctly that while we did see positive current period development in the third quarter, our guide does not assume that we continue to see those elevated levels. Our guide would a",164,"Sure. To your first question on current period development, yes, you heard correctly that while we did see positive current period development in the third quarter, our guide does not assume that we continue to see those elevated levels. Our guide would always have seen some level of normal course CPD in any given quarter. You can see that [ we typically decline ] through the year. But we are not assuming currently that, that same excess favorability we saw emerge in third quarter will continue. 
In terms of '22 growth, we obviously haven't given detailed guidance by product. What I can tell you though is while it's still early in the AEP, Bruce mentioned we saw 40% growth in 2020 and 2021. We do continue to see strong growth in 2022. So while we're not prepared to share any specific number so far, again, while it's early, D-SNP growth is actually coming in better than we had originally expected for '22 so far."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Your next question comes from the line of Gary Taylor from Cowen.",12,"Your next question comes from the line of Gary Taylor from Cowen."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","Just two quick questions I have remaining. In April, you upped your MRA headwind to $1 billion to $1.3 billion for the full year. I just want to make sure, is that still the right '21 headwind and most of that comes back next year, and that's part of how",57,"Just two quick questions I have remaining. In April, you upped your MRA headwind to $1 billion to $1.3 billion for the full year. I just want to make sure, is that still the right '21 headwind and most of that comes back next year, and that's part of how you're offsetting the return to baseline utilization?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","That's exactly right. Our estimate has not been changed since our previous update on the MRA headwind. As we said, we're tracking very closely the diagnosis code submissions in 2021. That will support our 2022 reimbursement, and those are in line with exp",78,"That's exactly right. Our estimate has not been changed since our previous update on the MRA headwind. As we said, we're tracking very closely the diagnosis code submissions in 2021. That will support our 2022 reimbursement, and those are in line with expectations and more similar to what we saw pre COVID. So to your exact point, that headwind, we do not expect to recur and does provide mitigation from trend bouncing back to more normal levels."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Analysts","And just one more quick one. When you talked about -- as I was just mentioning less development in the 4Q. Your third quarter prior year development was very similar to last year. So I presume you were talking about intra-year development from the first h",78,"And just one more quick one. When you talked about -- as I was just mentioning less development in the 4Q. Your third quarter prior year development was very similar to last year. So I presume you were talking about intra-year development from the first half that you recognized in the 3Q that doesn't occur, you're not assuming occurs. Is that correct? And could you just give us a little color on where that came from inpatient, outpatient?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Yes, you are correct. When we refer to current period development that developed in the quarter, that would refer to [indiscernible] for the first half of the year.[Technical Difficulty]Hi, Gary. I'm sorry. Can you hear us?",38,"Yes, you are correct. When we refer to current period development that developed in the quarter, that would refer to [indiscernible] for the first half of the year.
[Technical Difficulty]
Hi, Gary. I'm sorry. Can you hear us?"
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Speakers, you are now live.",5,"Speakers, you are now live."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Okay. Hi, Gary, I'm sorry, we dropped again, unfortunately. Can you hear me? All right. So just -- I'm not sure exactly where we dropped. But just to your last point, current period development does refer to how claims restated in the first half of the ye",118,"Okay. Hi, Gary, I'm sorry, we dropped again, unfortunately. Can you hear me? All right. So just -- I'm not sure exactly where we dropped. But just to your last point, current period development does refer to how claims restated in the first half of the year. And as we said, we did see some favorable restatement. What I can say is, at a high level, relative to -- we gave you estimates as of Q2 and what we saw developed in the third quarter is that net of the COVID, any COVID costs that we saw positive restatement of about 50 basis points for both the first and second quarter of 2021 developed in the third quarter."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","And speakers, we don't have any questions on the line. I would like to turn the call to Mr. Bruce Broussard for closing remarks.",24,"And speakers, we don't have any questions on the line. I would like to turn the call to Mr. Bruce Broussard for closing remarks."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Executives","Well, first, I want to apologize for the technical glitches here. I think we have a problem with our leader line, and we will definitely work on that to ensure that the service that we subscribe to is capable of keeping a consistent connection. Second,",155,"Well, first, I want to apologize for the technical glitches here. I think we have a problem with our leader line, and we will definitely work on that to ensure that the service that we subscribe to is capable of keeping a consistent connection. 
Second, I hope you take away from our conversation today that we have been very thoughtful and conservative as we look into the fourth quarter and as we enter into 2022. As you can see from all the commentary, we do reflect the uncertainty of COVID and all the aspects of going into 2022. I do want to say thank you for our 90,000 associates that make this such a successful organization and their dedication to not only our customers, but also providing our shareholders the adequate return. And I want to thank you for your long-term support for us as an organization. So thank you, and have a great day."
29618,1683170079,2423517,"Humana Inc., Q3 2021 Earnings Call, Nov 03, 2021",2021-11-03,"Earnings Calls","Humana Inc.","Operator","Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.",17,"Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect."
